
<html lang="en"     class="pb-page"  data-request-id="e6cbb12c-6f3d-435f-9164-19fa2fefead0"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-13;requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.0c00694;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Temozolomide, Gemcitabine, and Decitabine Hybrid Nanoconjugates: From Design to Proof-of-Concept (PoC) of Synergies toward the Understanding of Drug Impact on Human Glioblastoma Cells" /></meta><meta name="dc.Creator" content="Ferdaous  Sahli" /></meta><meta name="dc.Creator" content="Manon  Courcelle" /></meta><meta name="dc.Creator" content="Tony  Palama" /></meta><meta name="dc.Creator" content="Nadia  Djaker" /></meta><meta name="dc.Creator" content="Philippe  Savarin" /></meta><meta name="dc.Creator" content="Jolanda  Spadavecchia" /></meta><meta name="dc.Description" content="This paper emphasizes the synthesis of novel hybrid drug nanoparticles (Hyb-D-AuNPs) based on gold-temozolomide (TMZ) complexes combined with gemcitabine (GEM) and decitabine (DAC) to improve the e..." /></meta><meta name="Description" content="This paper emphasizes the synthesis of novel hybrid drug nanoparticles (Hyb-D-AuNPs) based on gold-temozolomide (TMZ) complexes combined with gemcitabine (GEM) and decitabine (DAC) to improve the e..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 11, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00694" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00694" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00694" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00694" /></link>
        
    
    

<title>Temozolomide, Gemcitabine, and Decitabine Hybrid Nanoconjugates: From Design to Proof-of-Concept (PoC) of Synergies toward the Understanding of Drug Impact on Human Glioblastoma Cells | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00694" /></meta><meta property="og:title" content="Temozolomide, Gemcitabine, and Decitabine Hybrid Nanoconjugates: From Design to Proof-of-Concept (PoC) of Synergies toward the Understanding of Drug Impact on Human Glioblastoma Cells" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0012.jpeg" /></meta><meta property="og:description" content="This paper emphasizes the synthesis of novel hybrid drug nanoparticles (Hyb-D-AuNPs) based on gold-temozolomide (TMZ) complexes combined with gemcitabine (GEM) and decitabine (DAC) to improve the efficiency and reduce the resistance of U87 malignant glial cells against TMZ. All products were evaluated by several spectroscopic techniques (Raman, UV–Vis) and transmission electron microscopy (TEM). Besides, for therapeutic purposes, the effect of these nanoparticles on cell proliferation and toxicity was evaluated, which clearly showed a synergic action of TMZ and GEM. Through the analysis of the exometabolome by nuclear magnetic resonance (NMR), the metabolic changes in the culture medium were measured in glial cells. Moreover, these nanoparticles are especially appropriated to the thermal destruction of cancer in the case of photothermal therapy due to their photothermal heating properties. This study presents an original chemical approach that it could play a central role in the field of nanomedicine, with novel perspectives for the development of new drugs and active targeting in glioblastoma multiforme (GBM) cancer therapy." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00694"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00694">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00694&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00694&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00694&amp;href=/doi/10.1021/acs.jmedchem.0c00694" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 7410-7421</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00636" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00733" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Temozolomide, Gemcitabine, and Decitabine Hybrid Nanoconjugates: From Design to Proof-of-Concept (PoC) of Synergies toward the Understanding of Drug Impact on Human Glioblastoma Cells</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Ferdaous Sahli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ferdaous Sahli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratoire de Chimie, Structures et Propriétés de Biomatériaux et d’Agents Thérapeutiques, Université Sorbonne Paris Nord, CNRS, NBD-CSPBAT, UMR 7244, Bobigny 93000, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ferdaous++Sahli">Ferdaous Sahli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Manon Courcelle</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Manon Courcelle</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratoire de Chimie, Structures et Propriétés de Biomatériaux et d’Agents Thérapeutiques, Université Sorbonne Paris Nord, CNRS, NBD-CSPBAT, UMR 7244, Bobigny 93000, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Manon++Courcelle">Manon Courcelle</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tony Palama</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tony Palama</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratoire de Chimie, Structures et Propriétés de Biomatériaux et d’Agents Thérapeutiques, Université Sorbonne Paris Nord, CNRS, NBD-CSPBAT, UMR 7244, Bobigny 93000, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tony++Palama">Tony Palama</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nadia Djaker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nadia Djaker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratoire de Chimie, Structures et Propriétés de Biomatériaux et d’Agents Thérapeutiques, Université Sorbonne Paris Nord, CNRS, NBD-CSPBAT, UMR 7244, Bobigny 93000, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nadia++Djaker">Nadia Djaker</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7912-5436" title="Orcid link">http://orcid.org/0000-0001-7912-5436</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Philippe Savarin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Philippe Savarin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratoire de Chimie, Structures et Propriétés de Biomatériaux et d’Agents Thérapeutiques, Université Sorbonne Paris Nord, CNRS, NBD-CSPBAT, UMR 7244, Bobigny 93000, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Philippe++Savarin">Philippe Savarin</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jolanda Spadavecchia</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jolanda Spadavecchia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratoire de Chimie, Structures et Propriétés de Biomatériaux et d’Agents Thérapeutiques, Université Sorbonne Paris Nord, CNRS, NBD-CSPBAT, UMR 7244, Bobigny 93000, France</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#2943464548474d48075a59484d485f4c4a4a414048695c47405f0459485b405a181a074f5b"><span class="__cf_email__" data-cfemail="4923262528272d28673a39282d283f2c2a2a212028093c27203f6439283b203a787a672f3b">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jolanda++Spadavecchia">Jolanda Spadavecchia</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6697-1174" title="Orcid link">http://orcid.org/0000-0001-6697-1174</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00694&amp;href=/doi/10.1021%2Facs.jmedchem.0c00694" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 7410–7421</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 11, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>26 April 2020</li><li><span class="item_label"><b>Published</b> online</span>11 June 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 July 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00694" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00694</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7410%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DFerdaous%2BSahli%252C%2BManon%2BCourcelle%252C%2BTony%2BPalama%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D13%26contentID%3Dacs.jmedchem.0c00694%26title%3DTemozolomide%252C%2BGemcitabine%252C%2Band%2BDecitabine%2BHybrid%2BNanoconjugates%253A%2BFrom%2BDesign%2Bto%2BProof-of-Concept%2B%2528PoC%2529%2Bof%2BSynergies%2Btoward%2Bthe%2BUnderstanding%2Bof%2BDrug%2BImpact%2Bon%2BHuman%2BGlioblastoma%2BCells%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7421%26publicationDate%3DJuly%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00694"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">746</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">6</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00694" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Temozolomide, Gemcitabine, and Decitabine Hybrid Nanoconjugates: From Design to Proof-of-Concept (PoC) of Synergies toward the Understanding of Drug Impact on Human Glioblastoma Cells&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ferdaous&quot;,&quot;last_name&quot;:&quot;Sahli&quot;},{&quot;first_name&quot;:&quot;Manon&quot;,&quot;last_name&quot;:&quot;Courcelle&quot;},{&quot;first_name&quot;:&quot;Tony&quot;,&quot;last_name&quot;:&quot;Palama&quot;},{&quot;first_name&quot;:&quot;Nadia&quot;,&quot;last_name&quot;:&quot;Djaker&quot;},{&quot;first_name&quot;:&quot;Philippe&quot;,&quot;last_name&quot;:&quot;Savarin&quot;},{&quot;first_name&quot;:&quot;Jolanda&quot;,&quot;last_name&quot;:&quot;Spadavecchia&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;11&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;7410-7421&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00694&quot;},&quot;abstract&quot;:&quot;This paper emphasizes the synthesis of novel hybrid drug nanoparticles (Hyb-D-AuNPs) based on gold-temozolomide (TMZ) complexes combined with gemcitabine (GEM) and decitabine (DAC) to improve the efficiency and reduce the resistance of U87 malignant glial cells against TMZ. All products were evaluated by several spectroscopic techniques (Raman, UV–Vis) and transmission electron microscopy (TEM). Besides, for therapeutic purposes, the effect of these nanoparticles on cell proliferation and toxicity was evaluated, which clearly showed a synergic action of TMZ and GEM. Through the analysis of the exometabolome by nuclear magnetic resonance (NMR), the metabolic changes in the culture medium were measured in glial cells. Moreover, these nanoparticles are especially appropriated to the thermal destruction of cancer in the case of photothermal therapy due to their photothermal heating properties. This study presents an original chemical approach that it could play a central role in the field of nanomedicine, with no&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00694&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00694" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00694&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00694" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00694&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00694" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00694&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00694&amp;href=/doi/10.1021/acs.jmedchem.0c00694" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00694" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00694" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00694%26sid%3Dliteratum%253Aachs%26pmid%3D32524814%26genre%3Darticle%26aulast%3DSahli%26date%3D2020%26atitle%3DTemozolomide%252C%2BGemcitabine%252C%2Band%2BDecitabine%2BHybrid%2BNanoconjugates%253A%2BFrom%2BDesign%2Bto%2BProof-of-Concept%2B%2528PoC%2529%2Bof%2BSynergies%2Btoward%2Bthe%2BUnderstanding%2Bof%2BDrug%2BImpact%2Bon%2BHuman%2BGlioblastoma%2BCells%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D13%26spage%3D7410%26epage%3D7421%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291876" title="Drug release">Drug release</a>,</li><li><a href="/action/doSearch?ConceptID=291938" title="Metal nanoparticles">Metal nanoparticles</a>,</li><li><a href="/action/doSearch?ConceptID=291918" title="Gold">Gold</a>,</li><li><a href="/action/doSearch?ConceptID=290920" title="Nanoparticles">Nanoparticles</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/jmcmar.2020.63.issue-13/20200709/jmcmar.2020.63.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">This paper emphasizes the synthesis of novel hybrid drug nanoparticles (Hyb-D-AuNPs) based on gold-temozolomide (TMZ) complexes combined with gemcitabine (GEM) and decitabine (DAC) to improve the efficiency and reduce the resistance of U87 malignant glial cells against TMZ. All products were evaluated by several spectroscopic techniques (Raman, UV–Vis) and transmission electron microscopy (TEM). Besides, for therapeutic purposes, the effect of these nanoparticles on cell proliferation and toxicity was evaluated, which clearly showed a synergic action of TMZ and GEM. Through the analysis of the exometabolome by nuclear magnetic resonance (NMR), the metabolic changes in the culture medium were measured in glial cells. Moreover, these nanoparticles are especially appropriated to the thermal destruction of cancer in the case of photothermal therapy due to their photothermal heating properties. This study presents an original chemical approach that it could play a central role in the field of nanomedicine, with novel perspectives for the development of new drugs and active targeting in glioblastoma multiforme (GBM) cancer therapy.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02727" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02727" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Glioblastoma multiforme (GBM) is the most highly aggressive primary brain tumor, with a median survival of 12–15 months and a 5-year survival rate inferior to 3%.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The continuous tumor relapse can be demonstrated by the failure to eliminate some cells within the tumor, named cancer stem cells (CSCs). Indeed, CSCs are particularly resistant to chemotherapeutic agents and radiation compared to the bulk of the tumor cells.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Temozolomide (TMZ) is an imidazotetrazine and a chemotherapy agent for GBM that methylates the guanine and adenine bases of DNA with a consequent cell cycle arrest and cell death.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In high-grade gliomas, the chemotherapy treatment is restricted by the development of resistance, leaving no therapeutic option.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Nevertheless, TMZ is an unstable molecule sensible to rapid hydrolysis and consequent dose-limiting hematological toxicity.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Many efforts have been made to realize efficient and safe nanocarrier systems for chemotherapeutic drugs that suggest various advantages, including passive/active targeting, reduced side effects, improved maximum tolerated doses, and overcoming chemoresistance.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> For GBM, it has been proved that the irregular expression of the O-6-methylguanine-DNA-methyltransferase (MGMT) gene is due to a lower alkylation (i.e., temozolomide) treatment.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> A positive relationship between the gene body methylation and MGMT expression was recently refined. The use of DNA demethylating agents, such as decitabine (5-aza-2′-deoxycytidine, DAC), in myelodysplastic syndrome to combine traditional treatments, has shown better results in prognosis treatment.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p">Hence, pretreating MGMT-expressing cells with decitabine (DAC), a cytosine analogue with its 5-carbon substituted by nitrogen, can considerably sensitize the tumor cells to temozolomide.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> A nucleoside analogue of decitabine applied for several extracranial solid tumors is gemcitabine (GEM).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> GEM interferes with DNA synthesis through competition with the natural nucleotide deoxycytidine triphosphate.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> GEM has revealed efficiency against human glioma cell lines in vitro,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> in vivo,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and as a radiosensitizer.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> While GEM has been demonstrated to cross the blood–brain barrier (BBB) to a certain extent, its clinical efficacy in GBM treatment has been reduced by a very short half-life after systemic delivery due to fast metabolism that limits the optimal concentration of drug-to-brain tumor cells in the central nervous system due to the blood–brain barrier (BBB).</div><div class="NLM_p">The capacity of gold nanoparticles to cross the blood–brain barrier, after intravenous injection, has been reported.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14−16)</a> Anyway, each system is complex and requires intense and more efforts to accomplish and combine all issues.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a></div><div class="NLM_p">Another noninvasive approach is to study the metabolic profile to reflect the phenotype in biological processes. This knowledge may be the key for the development of the next generation of nanodevices with low toxicity and better efficiency.</div><div class="NLM_p">Herein, we demonstrate the conjugation of temozolomide alone and combined with gemcitabine (GEM) and decitabine (DAC) to the surface of gold nanoparticles (<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="095d4453244e4c4449594c4e24487c47597a">[email protected]</a>, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="37637a6d1a737674776772701a7642796744">[email protected]</a>) to uptake the drug in the perinuclear region of glioma stem cells with high efficiency. The polymer carboxyl groups (PEG diacid) reduced Au<sup>3+</sup> from tetrachloroauric acid (HAuCl<sub>4</sub>) salt to Au<sup>+1</sup>, and then Au<sup>+1</sup> was reduced to Au<sup>0</sup> in the presence of sodium borohydride (NaBH<sub>4</sub>). Then, the amine group of the drug (TMZ; GEM, DAC) was capped onto the nanoparticles. The drugs were organized into high-order hybrid nanostructures. The morphological, optical, and structural characteristics of the hybrid nanovectors were then investigated by UV–Visible (UV–Vis), transmission electron microscopy (TEM), and Raman spectroscopy. The thermoplasmonic properties of these hybrid nanostructures were evaluated, and especially high photothermal conversion was obtained in the case of complex-shaped nanoparticles (nanoflowers). In the second part of our work, the efficiency of the hybrid-TMZ vector on malignant glioma stem cells was tested using the MTT assay and the metabolic impact of the drugs was investigated by nuclear magnetic resonance (NMR) (see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Endotoxin Units Detected by Means of the LAL Chromogenic Endotoxin Quantitation Kit<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">sample</th><th class="colsep0 rowsep0" align="center">endotoxin units (EU/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PEG-AuNPs (control)</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="b6e2fbecf6e6f3f19bf7c3f8e6c5">[email protected]</a></td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="286c696b68786d6f05695d66785b">[email protected]</a></td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="c0948d9aed84818380908587ed81b58e90b3">[email protected]</a></td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="8adec7d0a7cdcfc7cadacfcda7cbffc4daf9">[email protected]</a></td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">ND = not detectable; >1 = above the detection limit of the assay.</p></div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32554" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32554" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our aim was to design four hybrid gold nanomaterials (Hyb-D-AuNPs), tuning the chemical–physical characteristics based on a better steric arrangement of TMZ on the gold surface of nanoparticles, combining the chelation process (Method IN) and electrostatic adsorption (EA).</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Formation Mechanism of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="cd9980978d9d888ae08cb8839dbe">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="40040103001005076d01350e1033">[email protected]</a></h3><div class="NLM_p">Previously, Spadavecchia et al. have developed an original methodology called “Method IN” in which drugs and biomolecules were chelated with gold salt and biocompatible polymers to form hybrid gold nanoparticles with high biological efficiency.<a onclick="showRef(event, 'ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26">(19−26)</a></div><div class="NLM_p">Based on these findings, we used similar chemical-synthetic protocols to form <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="2d7960776d7d686a006c58637d5e">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="bcf8fdfffcecf9fb91fdc9f2eccf92">[email protected]</a> When TMZ and/or DAC molecules were combined with the PEG-Au solution, the charged amino residues (−NH<sub class="stack">3</sub><sup class="stack">+</sup>) on the skeletal region of TMZ and DAC interacted with the polar surface of pegylated chains and the steric configuration of the drug was formed on the gold surface (see <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). This steric arrangement of TMZ and/or DAC during the synthesis of gold nanoparticles was evaluated by UV–Vis absorption spectroscopy, TEM, and Raman spectroscopy and will be reported in the <a class="ref internalNav" href="#sec2_2" aria-label="Formation Mechanism of TMZ-GEM@PEG-AuNPs and TMZ-DAC@PEG-AuNPs">Formation Mechanism of <span class="__cf_email__" data-cfemail="ebbfa6b1c6acaea6abbbaeacc6aa9ea5bb98">[email protected]</span> and <span class="__cf_email__" data-cfemail="c3978e99ee87828083938684ee82b68d93b0">[email protected]</span></a> section.</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="96c2dbccd6c6d3d1bbd7e3d8c6e5">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="1d595c5e5d4d585a305c68534d6e">[email protected]</a> via Chelation Process (Please Note that the Drawings Are Not to Scale)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Formation Mechanism of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="17435a4d3a50525a574752503a5662594764">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="e3b7aeb9cea7a2a0a3b3a6a4cea296adb390">[email protected]</a></h3><div class="NLM_p">In a previous study, Spadavecchia et al. have designed gemcitabine hybrid nanotherapeutics (<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="4106040c011104066c00340f1132">[email protected]</a>)<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> based on the modification of Method IN, in which the main difference with previously reported synthetic procedures based on the drug–gold complex<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> is that the drug participates in the stabilization of AuNPs via complexation and an electrostatic interaction between the ketone and the amino groups with chloride auric ions and dicarboxylic pegylated chains of the polymer. Based on this achievement, the same methodology was applied to chelate gemcitabine (GEM) and/or decitabine (DAC) by the Method IN and then conjugate temozolomide (TMZ) by electrostatic adsorption on the gold surface, as depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div><div class="NLM_p">The choice of GEM and DAC in the building of our hybrid nanosystem is related to their chemical structures (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c00694/suppl_file/jm0c00694_si_001.pdf" class="ext-link">Scheme S1</a> in the Supporting Information). Gemcitabine (-2′-deoxy-2′,2′-difluorocytidine) is an antimetabolite used as a chemotherapeutic agent in pancreatic cancer.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Indeed, GEM displays the hydroxyl and ketone functional groups responsible for anticancer activity.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The chemical characteristics of GEM do not enable electrostatic interaction with all nanoparticle surfaces. For this purpose, in previous works, GEM was conjugated onto iron-oxide nanoparticles by cycloaddition through the Diels Alder reaction.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Decitabine is also a cytidine molecule (5-aza-2′-deoxycytidine, DAC) used in myelodysplastic syndrome to complement traditional treatments.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> Previously, Cui et al.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> have encapsulated decitabine (DAC) into a PLGA-PEG-nanoconjugate to form nanomicelles with a highly efficient cell uptake. The efficiency of this drug was studied in solid tumors in the synergic effect with temozolomide to target human GBM.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> In our case, we complexed GEM and DAC with gold salt by the chelation process to form hybrid nanoparticles. Then, the conjugation of TMZ was carried out through a better ratio of concentration and electrostatic charges between the drugs onto AuNPs (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). It has to be underlined that the three drugs (TMZ, GEM, and DAC) have an amino group positively charged in aqueous solution (−NH<sub class="stack">3</sub><sup class="stack">+</sup>) that interacts electrostatically with the carboxylic group of the polymer (−COO<sup>–</sup>) embedded onto gold salt during the nucleation of the particles (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Procedure of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="abffe6f186eceee6ebfbeeec86eadee5fbd8">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="e3b7aeb9cea7a2a0a3b3a6a4cea296adb390">[email protected]</a> by Electrostatic Adsorption (Please Note that the Drawings Are Not to Scale)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0009.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Schematic Hypothesis of the Chelation Process and the Electrostatic Interaction between the Polymer (PEG Diacid)-Gold Salt and Drugs (TMZ, GEM, DAC)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Comparative Physical–Chemical Characterization</h3><div class="NLM_p">In our study, TMZ was conjugated onto the pegylated complex to AuCl<sub class="stack">4</sub><sup class="stack">–</sup> to obtain gold nanoflowers. TEM images of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="a7f3eafde7f7e2e08ae6d2e9f7d4">[email protected]</a> show a snowlike shape with a thin layer of PEG and a diameter of around 72 ± 3 nm (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A, panel 2), compared with PEG-AuNPs as the control<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> with an average size of 32 ± 2nm (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A, panel 1). Spadavecchia et al. have realized the synthesis of similar snowflake nanostructures using polymers,<a onclick="showRef(event, 'ref19 ref35'); return false;" href="javascript:void(0);" class="ref ref19 ref35">(19,35)</a> biomolecules, and drugs, obtained by their inclusion with gold salt.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> On the basis of these studies,<a onclick="showRef(event, 'ref19 ref24 ref37'); return false;" href="javascript:void(0);" class="ref ref19 ref24 ref37">(19,24,37)</a> we assume that when TMZ is mixed with PEG-AuCl<sub class="stack">4</sub><sup class="stack">–</sup>, the polymer changes its chemical conformation varying from the mushroom to brush mode. The UV–Vis spectra of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="ebbfa6b1abbbaeacc6aa9ea5bb98">[email protected]</a> and PEG-AuNPs showed a peak at 540 nm (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B, red line) for PEG-AuNPs (i.e., control) and 600 nm for <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="66322b3c263623214b2713283615">[email protected]</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B, black line). Dicarboxylic polymeric chains (PEG-COOH) coordinate Au ions with the ketone or amino groups of TMZ, consequently leading to the growth of AuNP-like flowers. This chemical behavior is due to the π–π* electronic transitions between the imidazole ring and PEG-AuCl<sub class="stack">4</sub><sup class="stack">–</sup> ions. The loading of TMZ on the gold nanoparticles was confirmed by the presence of the absorption peak at 328 nm<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> and the strong red-shift of the plasmon band at 600 nm. The bright violet-blue color obtained and the UV–Vis spectra remain unchanged after storage at room temperature. This confirms the formation of a stable colloidal solution. The steric and chemical configuration of TMZ on PEG-AuNPs was confirmed by Raman analysis (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C).</div><figure id="fig1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0001.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Normalized UV–Vis absorption of PEG-AuNPs (red line) and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="3561786f756570721874407b6546">[email protected]</a> (black line). (B) TEM images of PEG-AuNPs (panel 1) and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="abffe6f1eb">[email protected]</a> PEG-AuNPs (panel 2); 1′, 2′: histogram size distribution. (C) Raman spectra <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="d581988f95859092f894a09b85">[email protected]</a> products (black line) compared to free PEG-AuNPs as control (red line). Experimental conditions: λ<sub>exc</sub> = 785 nm; laser power 20 mW; accumulation time 180 s.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In detail, the Raman spectra of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="bbeff6e196fbebfefc96facef5ebc8">[email protected]</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C, black line) compared to PEG-AuNPs (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C, red line) in water exhibit some bands in the 500–3000 cm<sup>–1</sup> region.</div><div class="NLM_p">In particular, the peaks at 500 and 800 cm<sup>–1</sup> are characteristics of the aromatic hydrogens of C–N groups, the vibrations at 1269 cm<sup>–1</sup> are due to ν C–O–C stretching, and the vibration at 1655 cm<sup>–1</sup> is due to the protonated (−NH<sub class="stack">3</sub><sup class="stack">+</sup>) group. We observed a decrease of the peaks at 2837 and 2926 cm<sup>–1</sup> of the C–H vibrations after the grafting of TMZ onto the nanoparticles. In addition, we observed the disappearance of several bands at 469 and 514 cm<sup>–1</sup> when the TMZ was conjugated onto AuNPs due to the C–C–O vibration. Furthermore, the exaltation of the peaks at 250 and 358 cm<sup>–1</sup> confirmed the formation of the gold salt complex with the drug by chelation. In fact, these bands can be attributed to the gold chloride stretches, ν(Au–Cl) and δ(O–Au–O), in the nucleoside ring, confirming the formation of the AuCl<sub class="stack">2</sub><sup class="stack">–</sup>–TMZ complex. Based on the spectrochemical and previous theoretical results, we believe that TMZ assumes a specific chemical and steric arrangement on pegylated gold nanoparticles as discussed previously.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> When TMZ was grafted onto <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="24636169647461630965516a7457">[email protected]</a> to form <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="184c5542355f5d5558485d5f35596d56486b">[email protected]</a>, we observed a red shift of the plasmon peak from 640 nm (<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="5017151d100015177d11251e0023">[email protected]</a>) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A, blue line) to 670 nm (<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="4d190017600a08000d1d080a600c38031d3e">[email protected]</a>) with a decrease of the plasmon peak intensity (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A, green line). The success of grafting was also confirmed by the simultaneous presence of the peak at 260 nm, characteristic of GEM, and the peak at 328 nm, relative to the presence of TMZ.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> As observed previously,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="6126242c213124264c20142f3112">[email protected]</a> showed a characteristic flowerlike shape wrapped in a polymer layer (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B1,1′) due to the adsorption of GEM<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> onto the crystallographic gold facet during nucleation and growth processes. The TMZ grafting onto <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="5a1d1f171a0a1f1d771b2f140a29">[email protected]</a> (<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="84d0c9dea9c3c1c9c4d4c1c3a9c5f1cad4f7">[email protected]</a>) also modified the nanoparticle shape from flower to popcorn with a size superior to 85 nm due to the dual combination of TMZ and GEM on the gold facet of pegylated gold nanoparticles (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B2,2′). In the scientific literature, similar anisotropic popcorn-shaped gold nanoparticles have been obtained through a synthesis process among several proteins.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> Raman spectroscopy (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C) confirmed the successful synthesis of the dual chemotherapeutic nanodrugs, thanks to the common peaks due to the presence of GEM (1440–1660 cm<sup>–1</sup>) corresponding to the aromatic ring: 1639 cm<sup>–1</sup> (ν C–O); 1639 cm<sup>–1</sup> corresponding to the vibration of the N–H group, and TMZ (1360 cm<sup>–1</sup> (ν-NH<sub>2</sub>)), 1440 cm<sup>–1</sup> (aromatic ring; C═N), and 1722–1750 cm<sup>–1</sup> (ν C═O). However, in both cases, we observe the presence of the peak at 1292 cm<sup>–1</sup> due to the vibrations of the polymer COOH groups (PEG diacid). Note that the intensity of this peak has decreased for both <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="1750525a574752503a5662594764">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="82d6cfd8afc5c7cfc2d2c7c5afc3f7ccd2f1">[email protected]</a>; this decrease is more noticeable for <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="44030109041401036905310a14376a">[email protected]</a> This explains the direct exposure of the GEM molecule to the COO<sup>–</sup> group of PEG diacid. This seems obvious since the electrostatic grafting will involve the interaction between the −COO<sup>–</sup> group of PEG and the NH<sub class="stack">3</sub><sup class="stack">+</sup> group of GEM at pH 7. Indeed, the TMZ has a characteristic signal of the −NH<sub class="stack">3</sub><sup class="stack">+</sup> group at 1292 cm<sup>–1</sup>, which will also react with the remaining −COO<sup>–</sup> group of PEG. It can be concluded that the presence of both molecules affects the surface of the nanoparticle.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Normalized UV–Vis absorption of PEG-AuNPs (red line), <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="a1e6e4ece1f1e4e68ce0d4eff1d2">[email protected]</a> (blue line), and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="4f1b021562080a020f1f0a08620e3a011f3c">[email protected]</a> (green line). (B) TEM images (scale bars: 50 and 20 nm) of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="84c3c1c9c4d4c1c3a9c5f1cad4f7">[email protected]</a> (panels 1, 1′) and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="cf9b8295e2888a828f9f8a88e28eba819fbc">[email protected]</a> (panels 2, 2′). (C) <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="0c4b41564c5c494b214d79425c7f">[email protected]</a> (blue line) and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="6f3b223542282a222f3f2a28422e1a213f1c">[email protected]</a> (green line) products compared to free PEG-AuNPs as control (red line) Raman spectra. Experimental conditions: λ<sub>exc</sub> = 785 nm; laser power 20 mW; accumulation time 180 s.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The physical and chemical evaluation of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="92d6d3d1d2c2d7d5bfd3e7dcc2e1">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="a2f6eff88fe6e3e1e2f2e7e58fe3d7ecf2d1">[email protected]</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00694/suppl_file/jm0c00694_si_001.pdf" class="ext-link">S3</a> in the Supporting Information) confirms the success of the reactions and bioconjugation of dual hybrid nanovectors. Indeed, in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00694/suppl_file/jm0c00694_si_001.pdf" class="ext-link">Figure S3</a>A, we can see a red shift and a decrease of the plasmon peak band from 570 nm (<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="8cc8cdcfccdcc9cba1cdf9c2dcff">[email protected]</a>) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00694/suppl_file/jm0c00694_si_001.pdf" class="ext-link">Figure S3</a>A, purple line) to 579 nm after the TMZ grafting on the same pegylated nanoparticles (<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="a9fde4f384ede8eae9f9ecee84e8dce7f9da">[email protected]</a>) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00694/suppl_file/jm0c00694_si_001.pdf" class="ext-link">Figure S3</a>A, blue line). The simultaneous presence of both drugs (DAC-TMZ) on PEG-AuNPs was also confirmed by the presence of the band at 258 nm, characteristic of DAC, and the presence of the band at 328 nm, due to TMZ.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="86c2c7c5c6d6c3c1abc7f3c8d6f5">[email protected]</a> were characterized by Raman spectroscopy (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00694/suppl_file/jm0c00694_si_001.pdf" class="ext-link">Figure S3</a>B, purple line). Indeed, the characteristic peaks due to the vibrations at 1500–1600 cm<sup>–1</sup> relative to the aromatic ring and 1488 and 460 cm<sup>–1</sup> due to ν C═N confirm the presence of DAC on pegylated nanoparticles. After TMZ grafting onto <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="cd898c8e8d9d888ae08cb8839dbe">[email protected]</a>, we observed the presence of TMZ, thanks to the peak at 2900 cm<sup>–1</sup> due to C═N, and the disappearance of the peaks at 460 and 669 cm<sup>–1</sup> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00694/suppl_file/jm0c00694_si_001.pdf" class="ext-link">Figure S3</a>B, blue line). This spectroscopic behavior showed that the amino group plays a crucial role during the electrostatic reaction between TMZ and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="54101517140411137915211a04277a">[email protected]</a> The Hyb-D-AuNP sizes were confirmed by dynamic light scattering (DLS) measurements (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). ζ-Potential measurements show that all NPs were colloidally stable at physiological pH.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. ζ-Potential and Hydrodynamic Diameter of Hyb-D-AuNPs</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">synthetic product</th><th class="colsep0 rowsep0" align="center" char="±">ζ-potential (mV)</th><th class="colsep0 rowsep0" align="center" char="±">hydrodynamic diameter (nm)</th><th class="colsep0 rowsep0" align="center" char=".">“size PDI”</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PEG-AuNPs (i.e., control)</td><td class="colsep0 rowsep0" align="char" char="±">–25 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">32 ± 2</td><td class="colsep0 rowsep0" align="char" char=".">0.259</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="693d243329392c2e44281c27391a">[email protected]</a></td><td class="colsep0 rowsep0" align="char" char="±">–22 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">72 ± 2</td><td class="colsep0 rowsep0" align="char" char=".">0.257</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="74333139342431335935013a2407">[email protected]</a> (i.e., control)</td><td class="colsep0 rowsep0" align="char" char="±">–25 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">50 ± 2</td><td class="colsep0 rowsep0" align="char" char=".">0.242</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="40140d1a6d07050d001005076d01350e1033">[email protected]</a></td><td class="colsep0 rowsep0" align="char" char="±">10 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">85 ± 2</td><td class="colsep0 rowsep0" align="char" char=".">0.220</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="d094919390809597fd91a59e80a3">[email protected]</a></td><td class="colsep0 rowsep0" align="char" char="±">20 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">65 ± 2</td><td class="colsep0 rowsep0" align="char" char=".">0.257</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="aafee7f087eeebe9eafaefed87ebdfe4fad9">[email protected]</a></td><td class="colsep0 rowsep0" align="char" char="±">10 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">85 ± 2</td><td class="colsep0 rowsep0" align="char" char=".">0.247</td></tr></tbody></table></div></div><div class="NLM_p last">The <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="ebbfa6b1c6acaea6abbbaeacc6aa9ea5bb">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="a5f1e8ff88e1e4e6e5f5e0e288e4d0ebf5">[email protected]</a> charges were more positive than those of PEG-AuNPs and G<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="652028253520224824102b3516">[email protected]</a> as controls, confirming the complete neutralization of the negative charge of PEG diacid during the coupling of the two nucleoside analogue drugs (GEM; DAC).</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Photothermal Heating</h3><div class="NLM_p">The nanoparticle solutions at 10 mM concentration were exposed to 1 W/cm<sup>2</sup> excitation laser density to evaluate their photothermal properties in the case of the photothermal therapy application. The temperature elevation of 1 mL of each sample containing each type of nanoparticle and its solvent was measured during 15 min.</div><div class="NLM_p">PEG-AuNPs and solvents (free GEM, DAC, or TMZ in phosphate-buffered saline (PBS) without nanoparticles) showed a negligible temperature elevation below the limit of 4 °C (minimum temperature required for the photothermal effect). Otherwise, the temperature elevation in both <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="0f5b425522484a424f5f4a48224e7a415f7c">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="bde9f0e790f9fcfefdedf8fa90fcc8f3edce">[email protected]</a> exceeded this limit in a few seconds and increased gradually during 10 min until its stabilization at 15 min at a temperature of 36 and 20 °C in <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="b5e1f8ef98f2f0f8f5e5f0f298f4c0fbe5c6">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="5c08110671181d1f1c0c191b711d29120c2f">[email protected]</a>, respectively. It is already known that the heating efficiency depends on the nanoparticle plasmon resonance band position, the excitation wavelength, and the gold nanoparticle size and shape, which can be tuned to increase the temperature generation.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Herein, both <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="1e4a534433595b535e4e5b59335f6b504e6d">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="0f5b4255224b4e4c4f5f4a48224e7a415f7c">[email protected]</a> presented a complex shape, a bigger size, and a plasmon resonance band closer to the excitation wavelength (808 nm) than the PEG-AuNPs that have a smaller size with a smooth surface shape. All of these geometrical and optical properties make <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="e0b4adbacda7a5ada0b0a5a7cda195aeb093">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="36627b6c1b727775766673711b7743786645">[email protected]</a> good candidates for photon-heat conversion and hence for use in photothermal therapy applications (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Measurements of temperature elevation (Δ<i>T</i>) during 15 min in 1 mL nanoparticle solutions: <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="91c5dccbbcd6d4dcd1c1d4d6bcd0e4dfc1e2">[email protected]</a>, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="2571687f08616466657560620864506b7556">[email protected]</a>, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="d7839a8d97879290fa96a29987a4">[email protected]</a>, and PEG-AuNPs (A). Δ<i>T</i> measured in the same experimental conditions (1 mL) of GEM, DAC, and TMZ solutions without nanoparticles (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Drug Loading and Release</h3><div class="NLM_p">TMZ is insoluble in water molecules (5.0 mg/mL) and hardly encapsulated into nanoparticles.<a onclick="showRef(event, 'ref1 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref1 ref45 ref46">(1,45,46)</a></div><div class="NLM_p">Recently, Ananta et al. have demonstrated the delivery of TMZ by PLGA nanoparticles with a loading of 4.4% w/w.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> In another approach, Patil grafted TMZ in its hydrazide form with poly(β-<span class="smallcaps smallerCapital">l</span>-malic acid) with an anti-transferrin receptor (TfR) monoclonal antibody for tumor targeting.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Other authors have realized the conjugation between TMZ and chitosan to obtain nanoparticles with a size of 47.8 nm and TMZ loading of 4.9% w/w.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">In our hybrid nanoformulations (Hyb-D-AuNPs), after the chelation process, TMZ assumes a different chemical and steric conformation compared to the recent synthesis approach in which the drug molecules were encapsulated into pegylated nanoparticles<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> or conjugated onto the surface of NPs through the chemical step.<a onclick="showRef(event, 'ref28 ref34'); return false;" href="javascript:void(0);" class="ref ref28 ref34">(28,34)</a> The successful loading ratio of TMZ, GEM, and DAC onto PEG-AuNPs was evidenced by the characteristic absorption peaks at 328 nm for TMZ, 254 nm for GEM, and 258 nm for DAC (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00694/suppl_file/jm0c00694_si_001.pdf" class="ext-link">Figure S2</a>, Supporting Information). We also analyzed all synthesized Hyb-D_AuNPs: the standard absorption values of TMZ and DAC were plotted in the inset of the figure (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00694/suppl_file/jm0c00694_si_001.pdf" class="ext-link">Figure S2</a>, Supporting Information) according to the UV–Vis absorbance spectra of TMZ and DAC at various concentrations. In the case of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="e1b5acbbcca6a4aca1b1a4a6cca094afb192">[email protected]</a>, the drug release was carried out in the presence of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="a9eeece4e9f9ecee84e8dce7f9da">[email protected]</a>, as described above.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The loading efficiencies were estimated to be 90%, with 9.5 μg present in 2.8 × 10<sup>–7</sup> mol of NPs. TMZ-GEM releases were pH- and time-dependent (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). A sustained drug release was observed in the first 5 h for both drugs at pH 4 (blue line) and pH 7 (red line). We supposed that the release of TMZ-GEM as complex was due to a chemical equilibrium between the pegylated gold complex in the AuNPs and the hydrophobic interactions between the PEG chains and ionic drugs. As previously discussed, the chemical mechanism of drug release is due to the presence of diacid pegylated molecules. Each group becomes protonated at acidic pH. This decreases the electrostatic interactions between PEG and drugs that stabilize the <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="a6f2ebfc8be1e3ebe6f6e3e18be7d3e8f6">[email protected]</a> structure. Moreover, the loading efficiencies and release of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="edb9a0b7adbda8aac0ac98a3bd9e">[email protected]</a> (80%), <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="194d5443345d585a59495c5e34586c57496a">[email protected]</a> (75%), and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="387c797b78687d7f15794d76684b">[email protected]</a> (60%) were, respectively, carried out in the same experimental conditions, confirming the success of the combined drugs on the surface of the gold nanoparticles. We emphasize that the chemical and steric combination of TMZ with GEM and DAC improves the loading efficiency and release as complex due to a better ratio between the ionic charges of the drugs and the polymers (PEG diacid). The release spectra are presented at pH 5 and 6 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00694/suppl_file/jm0c00694_si_001.pdf" class="ext-link">Figure S4</a> in the Supporting Information). These data were very important for the present study. Indeed, tumor tissues are more acidic than normal tissues due to their particular vasculature architecture. For this reason, acid-promoted drug release is a very important mechanism that can be exploited to realize stimuli-triggered cancer nanomedicine products.<a onclick="showRef(event, 'ref49 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51">(49−51)</a> The mechanism by which acidic pH triggers drug release is probably associated with the presence of carboxylate groups in the chemical structure of the PEG molecules.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Drug release percentage (%) of Hyb-D-AuNPs in PBS (37 °C) at pH = 4.0 (blue line) or at pH = 7.0 (red line).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Behavior of U87 Cell Metabolism with Hyb-D-AuNPs</h3><div class="NLM_p">Like several cancers, GBM utilizes a constant source of energy for novel cell production.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Recently Kriel et al. have confirmed that both oxidative and glycolytic metabolic pathways are involved in glioma progression, depending on the level of malignancy.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> As previously demonstrated, the production of lactate in the glycolysis process reflects its activity.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Excessive conversion of glucose to lactate and a reduction of pyruvate oxidation are the features of many cancers, also in the presence of high oxygen levels. This metabolic phenomenon is known as the Warburg effect.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a> For this purpose, the targeting of the glycolytic metabolic pathway represents a promising approach for the treatment of GBM.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Moreover, previous studies have shown that glioma stem cells (GSCs) exhibit an improved rate of glycolysis and low mitochondrial respiratory activity.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> The metabolic impact of hybrid drug nanoparticles has been much less explored. Recently, Minafra et al. have reported the metabolic profile analysis of breast cancer cells in contact with curcumin nanoparticles.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Lactate dehydrogenase (LDH) checks the bidirectional conversion of pyruvate and lactate and constitutes a major checkpoint for the switch from oxidative phosphorylation (OXPHOS) to glycolysis.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><div class="NLM_p">Our first aim was to be able to follow the cell metabolism through the glycolysis pathway and lactate concentration in the medium of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="8fcbcecccfdfcac8a2cefac1dffc">[email protected]</a> and GEM @PEG-AuNPs. For this objective, we compared the lactate concentration before and after the exposition to nanoparticles. It can be seen in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> that <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="a5e1e4e6e5f5e0e288e4d0ebf5d6">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="e2a5a7afa2b2a7a5cfa397acb291">[email protected]</a> decrease the production of lactate detected in the medium. Interestingly, this result is consistent with previous results that demonstrated that lactate production decreased in pancreatic cells in the presence of gemcitabine alone.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Consequently, it seems that the metabolic impact of gemcitabine is comparable to the metabolic impact of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="15525058554550523854605b45663b">[email protected]</a> The same effect has been seen for TMZ and TMZ-AuNPs, suggesting that nanoconjugates entered into the cells.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0005.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Lactate concentration in the medium after 72 h of drug exposition (mmol·h<sup>–1</sup>·million·cells<sup>–1</sup>). Error bars indicate the errors of the biological triplicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">These results demonstrate that the glycolysis pathway in glioma cells is affected by the presence of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="73373230332336345e32063d2300">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="3671737b766673711b7743786645">[email protected]</a> in the culture medium (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Indeed, there is less lactate production in the culture medium of cells treated with these AuNP constructs.</div><figure id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0010.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Schematic Hypothesis of the Effects of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="7f383a323f2f3a38523e0a312f0c">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="e7a3a6a4a7b7a2a0caa692a9b794">[email protected]</a> on the Lactate Reduction, Metabolic, and Glycolysis Pathway in Glioma Cells</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The second part of our work was to explore the therapeutic effect of the two nanoconjugates. Adsorptive-mediated transport (AMT)<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> is a nonspecific process by which macromolecules are transported within membrane-bound vesicles between the apical and basolateral domains of polarized cells. This process is possible due to the abundance of polyanions surrounding the BBB endothelial cells that are able to interact electrostatically with circulating cationic molecules. The electrostatic interaction between the positively charged molecules and the negative charge of BBB cells has been used to favor GB targeting. We can make the hypothesis on the mechanism of the anticancer activity enhancement and the advantages of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="76223b2c5b31333b362633315b3703382605">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="4f1b0215620b0e0c0f1f0a08620e3a011f3c">[email protected]</a> by AMT (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>), which can be explained as follows: after the interaction of nanoparticles and U87 glial cells, TMZ-GEM was released in the cytoplasm as the TMZ-GEM-Au complex through migration in the PEG chains, blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex with evident variation in the driven force and electrolytic conditions. Consequently, the synergic effect of TMZ and GEM (and/or TMZ and DAC) as a complex under a different steric conformation improves the inhibition of nucleotide synthase and simultaneous reparation of anticancer activity.</div><figure id="sch5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0011.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Schematic Design of the Interaction of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="91c5dccbbcd5d0d2d1c1d4d6bcd0e4dfc1e2">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="61352c3b4c26242c213124264c20142f3112">[email protected]</a> with U87 Glia Cell through an Adsorption-Mediated Transport (AMT)<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For this reason, U87 cell lines were incubated in the presence of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="f4a0b9aed9b0b5b7b4a4b1b3d9b581baa487">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="f6a2bbacdbb1b3bbb6a6b3b1dbb783b8a685d8">[email protected]</a> TMZ treatment was assessed on the U87 cell line. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, the cell proliferation decreases by 12% after 72 h in the presence of temozolomide. This result is consistent with the previous results for other human glioma cell lines.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> It can be seen in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> that the nanoparticles in the presence of TMZ have a stronger effect than TMZ alone. It is particularly interesting to see that the combination of the two drugs (for <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="70243d2a5d343133302035375d31053e2003">[email protected]</a>) has a synergic effect. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B, the fold of change in cell numbers decreased strongly in the presence of both drugs on nanoparticles (63% for decitabine). This synergy has been seen previously in the case of DAC nanoconjugate in the presence of TMZ.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Both drugs induced DNA alkylation on different nucleosides with a consequent arrest of the cell cycle in the G2/M phase at 10 μM concentration. It can be seen that the effect of GEM and TMZ is stronger than the effect of DAC and TMZ.</div><figure id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0006.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Cell proliferation after 72 h incubation upon the indicated treatments. Live cells were counted using a hemocytometer (number of cells per mL/10<sup>6</sup>). (B) Fold of change in cell proliferation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Our results indicate that the TMZ hybrid nanoconjugates (<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="b1e5fceb9cf6f4fcf1e1f4f69cf0c4ffe1c2">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="acf8e1f681e8edefecfce9eb81edd9e2fcdf">[email protected]</a>) are more efficient than TMZ alone.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45238" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45238" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">This study shows the ability of hybrid gold nanovectors (<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="cc8b8981e19881968c9c898be18db9829cbf">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="cf8b8e8ce29b82958f9f8a88">[email protected]</a>) to amplify the synergistic effect between decitabine and gemcitabine with temozolomide to target human GBM. More specifically, we adopted an original synthetic protocol to obtain a hybrid nanovector in which the steric conformation of the drugs on pegylated gold nanoparticles was modulated to influence the damage in MGMT-expressing GBM cells. Our experimental data also indicate that the complementary effect of decitabine and gemcitabine with temozolomide induces a more significant impact on the glycolysis pathway in glioma cells in the culture medium. In a further study, we have described the experiments regarding the in vivo pharmacokinetics and pharmacodynamics of this nanovector, as well as its therapeutic potential in treating other solid tumors.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30131" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30131" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Materials and Methods</h3><div class="NLM_p last">All chemicals were reagent grade or higher and were used as received unless otherwise specified. Tetrachloroauric acid (HAuCl<sub>4</sub>·3H<sub>2</sub>O), sodium borohydride (NaBH<sub>4</sub>), dicarboxylic poly(ethylene glycol) (PEG)-600 (PEG), phosphate-buffered saline (PBS, 0.1 M, pH 7.0, 4.0, 9.0), temozolomide (TMZ) (≥98%), decitabine (DAC) (≥98%), and gemcitabine (GEM) (≥98%) were purchased from Sigma-Aldrich. Dulbecco’s modified Eagle’s medium (DMEM) and Chromogenic Endotoxin Quantitation kit were purchased from Thermo Fisher, France.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Synthesis of PEG-AuNPs</h3><div class="NLM_p last">Pegylated gold nanoparticles (PEG-AuNPs) were synthesized using a chemical protocol described previously.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Briefly, 20 mL of aqueous chloroauric acid (HAuCl<sub>4</sub>) solution (2.5 × 10<sup>–4</sup> M) was added to 0.25 mL of dicarboxylic PEG and mixed by magnetic stirring for 10 min at room temperature. To this solution, 6 mL of aqueous 0.01 M NaBH<sub>4</sub> was added at once. The PEG-AuNPs obtained were centrifuged twice at 5000 rpm for 10 min and dried under nitrogen.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Synthesis of Hybrid Drug Gold Nanoparticles (Hyb-D-AuNPs)</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Synthesis of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="bbeff6e1fbebfefc96facef5ebc8">[email protected]</a></h4><div class="NLM_p">The synthesis of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="adf9e0f7edfde8ea80ecd8e3fd">[email protected]</a> colloids is described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div><div class="NLM_p">Twenty milliliters of HAuCl<sub>4</sub> aqueous solution (2.5 × 10<sup>–4</sup> M) was added to TMZ (5 mL, 10 mM) and aged for 10 min. Then, 250 μL of dicarboxylic PEG was added and mixed by magnetic stirring for 10 min at room temperature. Finally, 1.5 mL of aqueous 0.01 M NaBH<sub>4</sub> was added at once. The formation of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="0551485f455540422844704b5576">[email protected]</a> was observed as an instantaneous color change of the solution from pale yellow to bright pink-violet after addition of the reducing agent.</div><div class="NLM_p">Products of each synthetic step were stored at 8 °C and characterized by UV–Vis spectroscopy, transmission electron microscopy, and Raman spectroscopy.</div><div class="NLM_p last">The “as-prepared” <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="4d1900170d1d080a600c38031d">[email protected]</a> solution was centrifuged at 9000 rpm twice for 10 min, and then the supernatant was discarded. The residue was redispersed in an equivalent amount of PBS (pH = 7). This was repeated twice to remove the excess of nonconjugated dicarboxylic PEG.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Synthesis of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="d295979f92829795ff93a79c82a1">[email protected]</a></h4><div class="NLM_p last">The synthesis of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="dd9a98909d8d989af09ca8938d">[email protected]</a> colloids was carried out in the same conditions as described above.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Synthesis of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="2e6a6f6d6e7e6b69036f5b607e5d">[email protected]</a></h4><div class="NLM_p last">The synthesis of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="7b3f3a383b2b3e3c563a0e352b">[email protected]</a> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) colloids was carried out in the same conditions as described previously with some modifications.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Briefly, 20 mL of aqueous HAuCl<sub>4</sub> solution (2.5 × 10<sup>–4</sup> M) was added to 250 μL of dicarboxylic PEG and then mixed by magnetic stirring for 10 min at room temperature. Then, 5 mL of DAC (6 mM in 0.05 mM of NaCl) was added to the solution under magnetic stirring for 3 h at room temperature. Finally, 1.2 mL of aqueous 0.01 M NaBH<sub>4</sub> was added at once until complete reduction. Colloids were purified by centrifugation and characterized as mentioned above.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Synthesis of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="83d7ced9aec7c2c0c3d3c6c4aec2f6cdd3f0">[email protected]</a></h4><div class="NLM_p last">TMZ solution (0.5 mL) (10 mM in 0.05 mM of NaCl) was added to 5 mL of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="1b5f5a585b4b5e5c365a6e554b">[email protected]</a> solution under magnetic stirring for 3 h at room temperature. The as-prepared colloids were purified by centrifugation and characterized as mentioned above.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Synthesis of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="94c0d9ceb9d3d1d9d4c4d1d3b9d5e1dac4e7">[email protected]</a></h4><div class="NLM_p last">TMZ solution (0.5 mL) (10 mM in 0.05 mM of NaCl) was added to 5 mL of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="bcfbf9f1fcecf9fb91fdc9f2ec">[email protected]</a> solution under magnetic stirring for 3 h at room temperature. The as-prepared colloids were purified by centrifugation and characterized as mentioned above.</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Stability of Hybrid Drug Gold Nanoparticles (Hyb-D-AuNPs) as a Function of pH</h4><div class="NLM_p last">The stability of nanoparticles was detected by UV–Vis spectroscopy. Hybrid drug gold nanoparticles (<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="aafee7f0eafaefed87ebdfe4fad9">[email protected]</a>, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="3a7e7b797a6a7f7d177b4f746a49">[email protected]</a>, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="9ecad3c4b3dadfdddecedbd9b3dfebd0ceed">[email protected]</a>, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="c0948d9aed87858d80908587ed81b58e90b3">[email protected]</a>) were dissolved in DMEM at a concentration of 1 mM for 48 h.</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Determination of Hyb-D-AuNP Concentration</h4><div class="NLM_p last">Hyb-D-AuNP concentration was determined by exploiting standard mathematical calculations in colloidal solution as described previously.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Briefly, the Lambert–Beer law (<i>A</i> = ε<i>Cl</i>) was used to determine the colloid concentration. In this equation, <i>A</i> is the maximum absorbance (corresponding to the surface plasmon resonance band at around 515–520 nm) of the UV–visible spectrum, ε is the molar extinction coefficient (equal to 3.07 × 10<sup>10</sup> M<sup>–1</sup> cm<sup>–1</sup>), <i>C</i> is the molar concentration of colloids, and <i>l</i> is the optical length of the cuvette (1 cm). The resulting <i>C</i> was multiplied by the dilution factor to obtain the concentration of colloids.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Physical and Chemical Characterization</h3><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> UV–Vis Measurements</h4><div class="NLM_p last">Absorption spectra were recorded using a Perkin Elmer Lambda UV–Vis 950 spectrophotometer in glass cuvettes with an optical path of 10 mm. The wavelength range was 200–900 nm.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Transmission Electron Microscopy (TEM)</h4><div class="NLM_p last">All microscopy analyses were realized as previously described.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Briefly, transmission electron microscopy (TEM) images were recorded using a JEOL JEM 1011 microscope operating (JEOL) at an accelerating voltage of 100 kV. TEM specimens were prepared after separating the surfactant from the metal particles by centrifugation. Typically, 1 mL of Hyb-D-AuNPs was centrifuged for 10 min at a speed of 9000 rpm. The upper part of the colorless solution was removed, and the solid portion was redispersed in 1 mL of water. Then, 2 μL of this redispersed particle suspension was placed on a carbon-coated copper grid manufactured by Smethurst High-Light Ltd. and marketed exclusively by Agar Scientific and dried at room temperature. Grids were imaged using a Philips EM420 electron microscope with an accelerating voltage of 120 kV to enhance the contrast of the electron-dense gold. Enough frames were collected to capture at least 400 particles per replicate. The nanoparticle diameter (<i>d</i>) was estimated using the formula <i>d</i> = <i>A</i>/π, where <i>A</i> is the cross-sectional area of a particle measured using Image J software.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Raman Spectroscopy</h4><div class="NLM_p last">The Raman experiments were performed on an Xplora spectrometer (Horiba Scientific-France). The Raman spectra were recorded using an excitation wavelength of 785 nm (diode laser) at room temperature. For measurements in solution, a macro-objective with a focal length of 40 mm (NA = 0.18) was used in backscattering configuration. The achieved spectral resolution is close to 2 cm<sup>–1</sup>.</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Dynamic Light Scattering (DLS)</h4><div class="NLM_p last">Aliquots of 0.2 mL of Hyb-D-AuNP suspension were diluted to 1.2 mL with Milli Q H<sub>2</sub>O. The hydrodynamic diameter (HD) and polydispersity index (PDI) were measured in polystyrene cuvettes at 25 °C after an equilibration time of 120 s using a Malvern Zetasizer Nano ZS equipped with a He–Ne laser (633 nm, fixed scattering angle of 173°) at room temperature.</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> ζ-Potential Measurements</h4><div class="NLM_p last">All measurements were carried out as described previously.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div></div><div id="sec4_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Temperature Elevation Measurements</h4><div class="NLM_p last">All measurements were carried out as described previously.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div></div><div id="sec4_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Drug Loading Efficiency</h4><div class="NLM_p last">The amount of the drugs (TMZ; DAC; GEM) incorporated into PEG-AuNPs was measured by UV–Vis absorption spectroscopy. Absorptions at 328, 254, and 258 nm were used to extrapolate TMZ and GEM or DAC concentrations based on a calibration curve (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00694/suppl_file/jm0c00694_si_001.pdf" class="ext-link">Figure S2</a> in the Supporting Information). The drug loading efficiency was calculated as follows (<a class="ref internalNav" href="#eq1" aria-label="eq 1">eq 1</a>):<span class="NLM_disp-formula" id="eq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_m001.gif" alt="" id="_i37" /></img><span class="labelSpan">(1)</span></span>where <i>C</i><sub>1</sub> is the initial drug content and <i>C</i><sub>2</sub> is the amount of free drugs (TMZ; DAC; GEM) in the filtrate after separation of the nanoparticles by ultrafiltration with an Ultrafree MC centrifugal filter units (30 000 NMWL, Millipore).</div></div><div id="sec4_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Drug Release from AuNPs</h4><div class="NLM_p last">Hyb-D-AuNPs, synthesized from the same batch, were divided equally in volume for each time point and placed in pH 4.0 citric acid or in pH 7.0 at a concentration of 1.3 × 10 <sup>12</sup> particles/mL in 1.0 mL PBS. All release studies were carried out at 37 °C. At each time point of 24, 48, 72, and 96 h, Hyb-D-AuNPs were centrifuged at 2000<i>g</i> for 20 min and the supernatant was collected. The concentration of the released drug (from collected supernatant) was quantified by UV–VIS spectra and compared to the concentration (equivalent to 100% drug release) of the pure drug in each buffer. The concentration of the drug released from AuNPs was expressed as a percentage of the total drug concentration present in the sample (<a class="ref internalNav" href="#eq2" aria-label="eq 2">eq 2</a>) and plotted as a function of time.<span class="NLM_disp-formula" id="eq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_m002.gif" alt="" id="_i39" /></img><span class="labelSpan">(2)</span></span></div></div><div id="sec4_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Endotoxin Content in Hyb-D-AuNPs</h4><div class="NLM_p last">To check the quality and endotoxin level, prior to biological testing, the Pierce LAL Chromogenic Endotoxin Quantitation kit was used in the presence of Hyb-D-AuNPs as described above.<a onclick="showRef(event, 'ref21 ref34'); return false;" href="javascript:void(0);" class="ref ref21 ref34">(21,34)</a> The results are reported in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> as average (<i>n</i><sub>test</sub> =3) ± standard deviation. Endotoxin contamination results were taken into account when defining the type of cytotoxic endpoint to be examined.</div></div><div id="sec4_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Cell Culture</h4><div class="NLM_p last">The human U87-MG cell lines (Sigma-Aldrich) were maintained in DMEM medium supplemented with 10% fetal bovine serum (FBS) heat-inactivated fetal bovine serum and in the presence of 50 U/mL of penicillin and 50 μg/mL of streptomycin. The cells were incubated at 37 °C with 5% CO<sub>2</sub>. The cultured cells were split every 2 days and maintained in an exponential growth phase.</div></div><div id="sec4_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Cell Culture with Hyb-D-AuNPs</h4><div class="NLM_p last">The cells were cultured in a 48-well plate. In each well, 4400 cells were kept overnight to make them adherent and to renew the medium. Three wells were seeded for each condition. Then, 600 μL of the prepared TMZ solution (diluted in DMEM) and pure DMEM medium (300 μL) were added at a concentration of 10 mM into three wells. Six hundred microliters of the prepared different AuNPs (PEG-AuNPs, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="adf9e0f7edfde8ea80ecd8e3fdde">[email protected]</a>, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="d490959794849193f995a19a84a7">[email protected]</a>, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="3f787a727f6f7a78127e4a716f4c">[email protected]</a>, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="94c0d9ceb9d0d5d7d4c4d1d3b9d5e1dac4e7">[email protected]</a>, or <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="4b1f0611660c0e060b1b0e0c660a3e051b38">[email protected]</a>, diluted in DMEM) and pure DMEM medium (300 μL) were added to different wells at a concentration of 10 mM. The cells were grown in these conditions for 72 h. Living cells were counted using trypan blue staining and a Malassez counting chamber after trypsinization, while supernatants were analyzed by NMR.</div></div><div id="sec4_4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> NMR Analysis of Exometabolome</h4><div class="NLM_p last">Supernatants from the culture were prepared as follows: 60 μL of a 10 mM trimethyl-silyl propionate (TMSP) with D<sub>2</sub>O solution was added to 540 μL supernatant samples. Solutions were mixed thoroughly, and 550 μL of the mixture was then transferred to 5 mm NMR tubes. NMR experiments were carried out using a Bruker 500 MHz NMR spectrometer equipped with a 5 mm PAQXI probe and a cooled SampleCase (RS232) autosampler, enabling high-throughput data acquisition for large collections of samples. The temperature was controlled at 298K throughout the experiments. Standard <sup>1</sup>H 1D NMR pulse sequence nuclear Overhauser effect spectroscopy (NOESY) with z-gradient (Bruker pulse program noesygppr1d) was applied on each sample to obtain the corresponding metabolic profiles. A total of 64 transient free induction decays (FID) were collected for each experiment with a spectral width of 12 ppm. The relaxation delay was set to 2 s. The 90° pulse length was automatically calibrated for each sample at around 10 μs. The NOESY mixing time was set to 10 ms. The total acquisition time for each sample was 2 min 25 s.</div></div><div id="sec4_4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Data Processing and Lactate Quantification</h4><div class="NLM_p last">All FIDs were multiplied by an exponential function corresponding to a 0.3 Hz line-broadening factor prior to Fourier transformation. <sup>1</sup>H NMR spectra were manually phased, baselined, and referenced to the TMSP signal (δ = 0 ppm) using Topspin software version 4.0.5 (Bruker GmbH, Rheinstetten, Germany). Concentrations of lactate were directly determined by calculation considering the signal integration of lactate signals (CH<sub>3</sub> signal at 1.33 ppm) compared to the one of TMSP. Normalization of lactate concentration was performed using the number of living cells.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00694" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26851" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26851" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00694?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00694</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Chemical structure differences of temozolomide (TMZ), gemcitabine, and decitabine (DAC); stability of Hyb-D-PEG-AuNPs in DMEM as a function of time; UV–Vis loading spectra of TMZ and DAC at increasing known concentrations; normalized UV–Vis absorption of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="8ecacfcdcedecbc9a3cffbc0defd">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="26726b7c0b626765667663610b6753687655">[email protected]</a>; Raman spectra <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="acf8e1f681e8edefecfce9eb81edd9e2fcdf">[email protected]</a> compared to free DAC as a control; drug release percentage of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="82d6cfd8afc5c7cfc2d2c7c5afc3f7ccd2f1">[email protected]</a> versus time in PBS at pH = 5.0 or 6.0 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00694/suppl_file/jm0c00694_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00694/suppl_file/jm0c00694_si_001.pdf">jm0c00694_si_001.pdf (387.2 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00694" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83021" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83021" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jolanda Spadavecchia</span> - <span class="hlFld-Affiliation affiliation">Laboratoire de Chimie, Structures
et Propriétés de Biomatériaux et d’Agents
Thérapeutiques, Université
Sorbonne Paris Nord, CNRS, NBD-CSPBAT, UMR 7244, Bobigny 93000, France</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6697-1174" title="Orcid link">http://orcid.org/0000-0001-6697-1174</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1c7673707d72787d326f6c7d787d6a797f7f74757d5c6972756a316c7d6e756f2d2f327a6e"><span class="__cf_email__" data-cfemail="1d7772717c73797c336e6d7c797c6b787e7e75747c5d6873746b306d7c6f746e2c2e337b6f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ferdaous Sahli</span> - <span class="hlFld-Affiliation affiliation">Laboratoire de Chimie, Structures
et Propriétés de Biomatériaux et d’Agents
Thérapeutiques, Université
Sorbonne Paris Nord, CNRS, NBD-CSPBAT, UMR 7244, Bobigny 93000, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Manon Courcelle</span> - <span class="hlFld-Affiliation affiliation">Laboratoire de Chimie, Structures
et Propriétés de Biomatériaux et d’Agents
Thérapeutiques, Université
Sorbonne Paris Nord, CNRS, NBD-CSPBAT, UMR 7244, Bobigny 93000, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tony Palama</span> - <span class="hlFld-Affiliation affiliation">Laboratoire de Chimie, Structures
et Propriétés de Biomatériaux et d’Agents
Thérapeutiques, Université
Sorbonne Paris Nord, CNRS, NBD-CSPBAT, UMR 7244, Bobigny 93000, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nadia Djaker</span> - <span class="hlFld-Affiliation affiliation">Laboratoire de Chimie, Structures
et Propriétés de Biomatériaux et d’Agents
Thérapeutiques, Université
Sorbonne Paris Nord, CNRS, NBD-CSPBAT, UMR 7244, Bobigny 93000, France</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7912-5436" title="Orcid link">http://orcid.org/0000-0001-7912-5436</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philippe Savarin</span> - <span class="hlFld-Affiliation affiliation">Laboratoire de Chimie, Structures
et Propriétés de Biomatériaux et d’Agents
Thérapeutiques, Université
Sorbonne Paris Nord, CNRS, NBD-CSPBAT, UMR 7244, Bobigny 93000, France</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Conceptualization: J.S.; methodology: J.S., T.P., and N.D.; validation: J.S. and P.S.; formal analysis: F.S. and M.C.; investigation: F.S., T.P., N.D., and M.C.; resources: J.S. and P.S.; data curation: J.S., N.D., T.P., and P.S.; writing—original draft preparation: J.S.; writing—review & editing: J.S. and P.S.; visualization: J.S.; supervision: J.S.; project administration: J.S.; and funding acquisition: J.S.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e1390-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24600" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24600" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors acknowledge the CNanoMat facility and the NMR-PF facility (University Paris 13 France).</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12054" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12054" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 61 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephen, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kievit, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Press, O. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span> <span> </span><span class="NLM_article-title">Temozolomide Nanoparticles for Targeted Glioblastoma Therapy</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">6674</span>– <span class="NLM_lpage">6682</span>, <span class="refDoi"> DOI: 10.1021/am5092165</span> </span><div class="citationLinks">[<a href="/doi/10.1021/am5092165" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFynsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=6674-6682&author=C.+Fangauthor=K.+Wangauthor=Z.+R.+Stephenauthor=Q.+Muauthor=F.+M.+Kievitauthor=D.+T.+Chiuauthor=O.+W.+Pressauthor=M.+Zhang&title=Temozolomide+Nanoparticles+for+Targeted+Glioblastoma+Therapy&doi=10.1021%2Fam5092165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Temozolomide Nanoparticles for Targeted Glioblastoma Therapy</span></div><div class="casAuthors">Fang, Chen; Wang, Kui; Stephen, Zachary R.; Mu, Qingxin; Kievit, Forrest M.; Chiu, Daniel T.; Press, Oliver W.; Zhang, Miqin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6674-6682</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glioblastoma (GBM) is a deadly and debilitating brain tumor with an abysmal prognosis.  The std. therapy for GBM is surgery followed by radiation and chemotherapy with Temozolomide (TMZ).  Treatment of GBMs remains a challenge, largely because of the fast degrdn. of TMZ, the inability to deliver an ED of TMZ to tumors, and a lack of target specificity that may cause systemic toxicity.  Here, we present a simple method for synthesizing a nanoparticle-based carrier that can protect TMZ from rapid degrdn. in physiol. solns. and can specifically deliver them to GBM cells through the mediation of a tumor-targeting peptide chlorotoxin (CTX).  Our nanoparticle, namely NP-TMZ-CTX, had a hydrodynamic size of <100 nm, exhibited sustained stability in cell culture media for up to 2 wk, and could accommodate stable drug loading.  TMZ bound to nanoparticles showed a much higher stability at physiol. pH, with a half-life 7-fold greater than that of free TMZ.  NP-TMZ-CTX was able to target GBM cells and achieved 2-6-fold higher uptake and a 50-90% redn. of IC50 72 h post-treatment as compared to nontargeted NP-TMZ.  NP-TMZ-CTX showed great promise in its ability to deliver a large therapeutic dose of TMZ to GBM cells and could serve as a template for targeted delivery of other therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp78ba64HyQybVg90H21EOLACvtfcHk0lhL7rhy02Sj8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFynsbs%253D&md5=5399bf35d5d14116d1bf24d3e968292c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fam5092165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fam5092165%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DStephen%26aufirst%3DZ.%2BR.%26aulast%3DMu%26aufirst%3DQ.%26aulast%3DKievit%26aufirst%3DF.%2BM.%26aulast%3DChiu%26aufirst%3DD.%2BT.%26aulast%3DPress%26aufirst%3DO.%2BW.%26aulast%3DZhang%26aufirst%3DM.%26atitle%3DTemozolomide%2520Nanoparticles%2520for%2520Targeted%2520Glioblastoma%2520Therapy%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2015%26volume%3D7%26spage%3D6674%26epage%3D6682%26doi%3D10.1021%2Fam5092165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kriel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Nedebock, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maarman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mbizana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojuka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumperman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loos, B.</span></span> <span> </span><span class="NLM_article-title">Coordinated Autophagy Modulation Overcomes Glioblastoma Chemoresistance through Disruption of Mitochondrial Bioenergetics</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">10348</span> <span class="refDoi"> DOI: 10.1038/s41598-018-28590-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1038%2Fs41598-018-28590-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=29985441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FmtVOhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&author=J.+Krielauthor=K.+M%C3%BCller-Nedebockauthor=G.+Maarmanauthor=S.+Mbizanaauthor=E.+Ojukaauthor=B.+Klumpermanauthor=B.+Loos&title=Coordinated+Autophagy+Modulation+Overcomes+Glioblastoma+Chemoresistance+through+Disruption+of+Mitochondrial+Bioenergetics&doi=10.1038%2Fs41598-018-28590-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Coordinated autophagy modulation overcomes glioblastoma chemoresistance through disruption of mitochondrial bioenergetics</span></div><div class="casAuthors">Kriel Jurgen; Loos Ben; Muller-Nedebock Kristian; Maarman Gerald; Ojuka Edward; Mbizana Siyasanga; Klumperman Bert</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10348</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Glioblastoma Multiforme (GBM) is known to be one of the most malignant and aggressive forms of brain cancer due to its resistance to chemotherapy.  Recently, GBM was found to not only utilise both oxidative phosphorylation (OXPHOS) and aerobic glycolysis, but also depend on the bulk protein degradation system known as macroautophagy to uphold proliferation.  Although autophagy modulators hold great potential as adjuvants to chemotherapy, the degree of upregulation or inhibition necessary to achieve cell death sensitisation remains unknown.  Therefore, this study aimed to determine the degree of autophagy modulation necessary to impair mitochondrial bioenergetics to the extent of promoting cell death onset.  It was shown that coordinated upregulation of autophagy followed by its inhibition prior to chemotherapy decreased electron transfer system (ETS) and oxidative phosphorylation (OXPHOS) capacity, impaired mitochondrial fission and fusion dynamics and enhanced apoptotic cell death onset in terms of cleaved caspase 3 and cleaved PARP expression.  Therefore, coordinated autophagy modulation may present a favourable avenue for improved chemotherapeutic intervention in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRqGvDjDP7DGxWfpMXQLRstfW6udTcc2eYRGfNRZpklJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FmtVOhtg%253D%253D&md5=83068c780137982d488c0144288cddca</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-28590-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-28590-9%26sid%3Dliteratum%253Aachs%26aulast%3DKriel%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller-Nedebock%26aufirst%3DK.%26aulast%3DMaarman%26aufirst%3DG.%26aulast%3DMbizana%26aufirst%3DS.%26aulast%3DOjuka%26aufirst%3DE.%26aulast%3DKlumperman%26aufirst%3DB.%26aulast%3DLoos%26aufirst%3DB.%26atitle%3DCoordinated%2520Autophagy%2520Modulation%2520Overcomes%2520Glioblastoma%2520Chemoresistance%2520through%2520Disruption%2520of%2520Mitochondrial%2520Bioenergetics%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26doi%3D10.1038%2Fs41598-018-28590-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chong, D. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toh, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sia, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yulyana, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinesh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tham, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, P. Y.</span></span> <span> </span><span class="NLM_article-title">Combined Treatment of Nimotuzumab and Rapamycin is Effective Against Temozolomide-Resistant Human Gliomas Regardless of the EGFR Mutation Status</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>, <span class="NLM_elocation-id">255</span> <span class="refDoi"> DOI: 10.1186/s12885-015-1191-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1186%2Fs12885-015-1191-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=25886314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A280%3ADC%252BC2MjkvFKrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&author=D.+Q.+Chongauthor=X.+Y.+Tohauthor=I.+A.+Hoauthor=K.+C.+Siaauthor=J.+P.+Newmanauthor=Y.+Yulyanaauthor=W.+H.+Ngauthor=S.+H.+Laiauthor=M.+M.+Hoauthor=N.+Dineshauthor=C.+K.+Thamauthor=P.+Y.+Lam&title=Combined+Treatment+of+Nimotuzumab+and+Rapamycin+is+Effective+Against+Temozolomide-Resistant+Human+Gliomas+Regardless+of+the+EGFR+Mutation+Status&doi=10.1186%2Fs12885-015-1191-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status</span></div><div class="casAuthors">Chong Dawn Q; Toh Xin Y; Ho Ivy A W; Sia Kian C; Newman Jennifer P; Yulyana Yulyana; Ho Mac M F; Tham Chee K; Lam Paula Y P; Ng Wai-Hoe; Lai Siang H; Dinesh Nivedh; Lam Paula Y P; Lam Paula Y P</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">255</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The treatment of glioblastoma multiforme (GBM) is an unmet clinical need.  The 5-year survival rate of patients with GBM is less than 3%.  Temozolomide (TMZ) remains the standard first-line treatment regimen for gliomas despite the fact that more than 90% of recurrent gliomas do not respond to TMZ after repeated exposure.  We have also independently shown that many of the Asian-derived glioma cell lines and primary cells derived from Singaporean high-grade glioma patients are indeed resistant to TMZ.  This issue highlights the need to develop new effective anti-cancer treatment strategies.  In a recent study, wild-type epidermal growth factor receptor (wtEGFR) has been shown to phosphorylate a truncated EGFR (known as EGFRvIII), leading to the phosphorylation of STAT proteins and progression in gliomagenesis.  Despite the fact that combination of EGFR targeting drugs and rapamycin has been used before, the effect of mono-treatment of Nimotuzumab, rapamycin and combination therapy in human glioma expressing different types of EGFR is not well-studied.  Herein, we evaluated the efficacy of dual blockage using monoclonal antibody against EGFR (Nimotuzumab) and an mTOR inhibitor (rapamycin) in Caucasian patient-derived human glioma cell lines, Asian patient-derived human glioma cell lines, primary glioma cells derived from the Mayo GBM xenografts, and primary short-term glioma culture derived from high-grade glioma patients.  METHODS:  The combination effect of Nimotuzumab and rapamycin was examined in a series of primary human glioma cell lines and glioma cell lines.  The cell viability was compared to TMZ treatment alone.  Endogenous expressions of EGFR in various GBM cells were determined by western blotting.  RESULTS:  The results showed that combination of Nimotuzumab with rapamycin significantly enhanced the therapeutic efficacy of human glioma cells compared to single treatment.  More importantly, many of the Asian patient-derived glioma cell lines and primary cells derived from Singaporean high-grade gliomas, which showed resistance to TMZ, were susceptible to the combined treatments.  CONCLUSIONS:  In conclusion, our results strongly suggest that combination usage of Nimotuzumab and rapamycin exert higher cytotoxic activities than TMZ.  Our data suggest that this combination may provide an alternative treatment for TMZ-resistant gliomas regardless of the EGFR status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ26obSlYBFLUQ0lWbKiCflfW6udTcc2eYHZNFhir7kwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjkvFKrtw%253D%253D&md5=36c13d655c30972a6568bdadb4a23066</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1186%2Fs12885-015-1191-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-015-1191-3%26sid%3Dliteratum%253Aachs%26aulast%3DChong%26aufirst%3DD.%2BQ.%26aulast%3DToh%26aufirst%3DX.%2BY.%26aulast%3DHo%26aufirst%3DI.%2BA.%26aulast%3DSia%26aufirst%3DK.%2BC.%26aulast%3DNewman%26aufirst%3DJ.%2BP.%26aulast%3DYulyana%26aufirst%3DY.%26aulast%3DNg%26aufirst%3DW.%2BH.%26aulast%3DLai%26aufirst%3DS.%2BH.%26aulast%3DHo%26aufirst%3DM.%2BM.%26aulast%3DDinesh%26aufirst%3DN.%26aulast%3DTham%26aufirst%3DC.%2BK.%26aulast%3DLam%26aufirst%3DP.%2BY.%26atitle%3DCombined%2520Treatment%2520of%2520Nimotuzumab%2520and%2520Rapamycin%2520is%2520Effective%2520Against%2520Temozolomide-Resistant%2520Human%2520Gliomas%2520Regardless%2520of%2520the%2520EGFR%2520Mutation%2520Status%26jtitle%3DBMC%2520Cancer%26date%3D2015%26volume%3D15%26doi%3D10.1186%2Fs12885-015-1191-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Italiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chitkara, D.</span></span> <span> </span><span class="NLM_article-title">New Strategies for Cancer Management: How can Temozolomide Carrier Modifications Improve its Delivery?</span>. <i>Ther. Delivery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">477</span>, <span class="refDoi"> DOI: 10.4155/tde-2017-0016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.4155%2Ftde-2017-0016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=28633588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVWmsLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=475-477&author=S.+Sharmaauthor=K.+Italiyaauthor=A.+Mittalauthor=D.+Chitkara&title=New+Strategies+for+Cancer+Management%3A+How+can+Temozolomide+Carrier+Modifications+Improve+its+Delivery%3F&doi=10.4155%2Ftde-2017-0016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">New strategies for cancer management: how can temozolomide carrier modifications improve its delivery?</span></div><div class="casAuthors">Sharma, Saurabh; Italiya, Kishan; Mittal, Anupama; Chitkara, Deepak</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Delivery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">475-477</span>CODEN:
                <span class="NLM_cas:coden">TDHEA7</span>;
        ISSN:<span class="NLM_cas:issn">2041-5990</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">New strategies for cancer management: how can temozolomide carrier modifications improve its delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcNC__N89Rn7Vg90H21EOLACvtfcHk0ljykSA9mnWmJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVWmsLnJ&md5=50999412524137232d641533a8f4b76a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.4155%2Ftde-2017-0016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ftde-2017-0016%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DItaliya%26aufirst%3DK.%26aulast%3DMittal%26aufirst%3DA.%26aulast%3DChitkara%26aufirst%3DD.%26atitle%3DNew%2520Strategies%2520for%2520Cancer%2520Management%253A%2520How%2520can%2520Temozolomide%2520Carrier%2520Modifications%2520Improve%2520its%2520Delivery%253F%26jtitle%3DTher.%2520Delivery%26date%3D2017%26volume%3D8%26spage%3D475%26epage%3D477%26doi%3D10.4155%2Ftde-2017-0016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalaydina, R.-V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajwa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qorri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decarlo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczuk, M. R.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in ″Smart″ Delivery Systems for Extended Drug Release in Cancer Therapy</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">4727</span>– <span class="NLM_lpage">4745</span>, <span class="refDoi"> DOI: 10.2147/IJN.S168053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.2147%2FIJN.S168053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=30154657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtleis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=4727-4745&author=R.-V.+Kalaydinaauthor=K.+Bajwaauthor=B.+Qorriauthor=A.+Decarloauthor=M.+R.+Szewczuk&title=Recent+Advances+in+%E2%80%B3Smart%E2%80%B3+Delivery+Systems+for+Extended+Drug+Release+in+Cancer+Therapy&doi=10.2147%2FIJN.S168053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in "smart" delivery systems for extended drug release in cancer therapy</span></div><div class="casAuthors">Kalaydina, Regina-Veronicka; Bajwa, Komal; Qorri, Bessi; Decarlo, Alexandria; Szewczuk, Myron R.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4727-4745</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Advances in nanomedicine have become indispensable for targeted drug delivery, early detection, and increasingly personalized approaches to cancer treatment.  Nanoparticlebased drug-delivery systems have overcome some of the limitations assocd. with traditional cancer-therapy administration, such as reduced drug soly., chemoresistance, systemic toxicity, narrow therapeutic indexes, and poor oral bioavailability.  Advances in the field of nanomedicine include "smart" drug delivery, or multiple levels of targeting, and extended-release drug-delivery systems that provide addnl. methods of overcoming these limitations.  More recently, the idea of combining smart drug delivery with extended-release has emerged in hopes of developing highly efficient nanoparticles with improved delivery, bioavailability, and safety profiles.  Although functionalized and extended-release drug-delivery systems have been studied extensively, there remain gaps in the literature concerning their application in cancer treatment.  We aim to provide an overview of smart and extended-release drug-delivery systems for the delivery of cancer therapies, as well as to introduce innovative advancements in nanoparticle design incorporating these principles.  With the growing need for increasingly personalized medicine in cancer treatment, smart extended-release nanoparticles have the potential to enhance chemotherapy delivery, patient adherence, and treatment outcomes in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQLHLr3X8jGrVg90H21EOLACvtfcHk0ljykSA9mnWmJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtleis7c%253D&md5=ac84a7f21fe78a239d9a4daca4883685</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2147%2FIJN.S168053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S168053%26sid%3Dliteratum%253Aachs%26aulast%3DKalaydina%26aufirst%3DR.-V.%26aulast%3DBajwa%26aufirst%3DK.%26aulast%3DQorri%26aufirst%3DB.%26aulast%3DDecarlo%26aufirst%3DA.%26aulast%3DSzewczuk%26aufirst%3DM.%2BR.%26atitle%3DRecent%2520Advances%2520in%2520%25E2%2580%25B3Smart%25E2%2580%25B3%2520Delivery%2520Systems%2520for%2520Extended%2520Drug%2520Release%2520in%2520Cancer%2520Therapy%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2018%26volume%3D13%26spage%3D4727%26epage%3D4745%26doi%3D10.2147%2FIJN.S168053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heyn, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteller, M.</span></span> <span> </span><span class="NLM_article-title">DNA Methylation Profiling in the Clinic: Applications and Challenges</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1038/nrg3270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1038%2Fnrg3270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=22945394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht12jsbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=679-692&author=H.+Heynauthor=M.+Esteller&title=DNA+Methylation+Profiling+in+the+Clinic%3A+Applications+and+Challenges&doi=10.1038%2Fnrg3270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">DNA methylation profiling in the clinic: applications and challenges</span></div><div class="casAuthors">Heyn, Holger; Esteller, Manel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">679-692</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Knowledge of epigenetic alterations in disease is rapidly increasing owing to the development of genome-wide techniques for their identification.  The ever-growing no. of genes that show epigenetic alterations in disease emphasizes the crucial role of these epigenetic alterations - particularly DNA methylation - for future diagnosis, prognosis and prediction of response to therapies.  This Review focuses on epigenetic profiling, which has started to be of clin. value in cancer and may in the future be extended to other diseases, such as neurol. and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGfpc3e1wCnrVg90H21EOLACvtfcHk0ljjidZn1po7dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht12jsbjK&md5=5fa838d2ef57f480240b06c663cdffb6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrg3270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg3270%26sid%3Dliteratum%253Aachs%26aulast%3DHeyn%26aufirst%3DH.%26aulast%3DEsteller%26aufirst%3DM.%26atitle%3DDNA%2520Methylation%2520Profiling%2520in%2520the%2520Clinic%253A%2520Applications%2520and%2520Challenges%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2012%26volume%3D13%26spage%3D679%26epage%3D692%26doi%3D10.1038%2Fnrg3270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lay, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. A.</span></span> <span> </span><span class="NLM_article-title">Targeting DNA Methylation for Epigenetic Therapy</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">536</span>– <span class="NLM_lpage">546</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2010.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.tips.2010.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=20846732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlensLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=536-546&author=X.+Yangauthor=F.+Layauthor=H.+Hanauthor=P.+A.+Jones&title=Targeting+DNA+Methylation+for+Epigenetic+Therapy&doi=10.1016%2Fj.tips.2010.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting DNA methylation for epigenetic therapy</span></div><div class="casAuthors">Yang, Xiaojing; Lay, Fides; Han, Han; Jones, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">536-546</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Patterns of DNA methylation are established during embryonic development and faithfully copied through somatic cell divisions.  Based on current understanding of DNA methylation and other interrelated epigenetic modifications, a comprehensive view of the epigenetic landscape' and cancer epigenome is evolving.  The cancer methylome is highly disrupted, making DNA methylation an excellent target for anticancer therapies.  During the last few decades, an increasing no. of drugs targeting DNA methylation have been developed to increase efficacy and stability and to decrease toxicity.  The earliest and the most successful epigenetic drug to date, 5-Azacytidine, is currently recommended as the first-line treatment of high-risk myelodysplastic syndromes (MDS).  Encouraging results from clin. trials have prompted further efforts to elucidate epigenetic alterations in cancer, and to subsequently develop new epigenetic therapies.  This review delineates the latest cancer epigenetic models, the recent discovery of hypomethylation agents as well as their application in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJKSZGI4LWvLVg90H21EOLACvtfcHk0ljjidZn1po7dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlensLfI&md5=362429dbc115e437aecc01aa12015ee7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2010.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2010.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLay%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DH.%26aulast%3DJones%26aufirst%3DP.%2BA.%26atitle%3DTargeting%2520DNA%2520Methylation%2520for%2520Epigenetic%2520Therapy%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2010%26volume%3D31%26spage%3D536%26epage%3D546%26doi%3D10.1016%2Fj.tips.2010.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moen, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godley, L. A.</span></span> <span> </span><span class="NLM_article-title">The Role of Gene Body Cytosine Modifications in MGMT Expression and Sensitivity to Temozolomide</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1334</span>– <span class="NLM_lpage">1344</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1158%2F1535-7163.MCT-13-0924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=24568970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFWjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1334-1344&author=E.+L.+Moenauthor=A.+L.+Starkauthor=W.+Zhangauthor=M.+E.+Dolanauthor=L.+A.+Godley&title=The+Role+of+Gene+Body+Cytosine+Modifications+in+MGMT+Expression+and+Sensitivity+to+Temozolomide&doi=10.1158%2F1535-7163.MCT-13-0924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Gene Body Cytosine Modifications in MGMT Expression and Sensitivity to Temozolomide</span></div><div class="casAuthors">Moen, Erika L.; Stark, Amy L.; Zhang, Wei; Dolan, M. Eileen; Godley, Lucy A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1334-1344</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) is known to play a role in sensitivity to temozolomide.  Promoter hypermethylation of MGMT is commonly used to predict low expression levels of MGMT in gliomas, despite obsd. discordance between promoter methylation and protein levels.  Here, we investigated the functional role of gene body cytosine modification in regulating levels of MGMT gene expression and sensitivity to temozolomide.  In 91 human glioblastoma samples, we obsd. significant variation in MGMT expression levels in patients with an unmethylated promoter, with higher levels of gene body cytosine modification correlating with higher gene expression levels.  Furthermore, inducing hypomethylation across the MGMT gene body with decitabine corresponded with decreased levels of MGMT gene expression in lymphoblastoid and glioblastoma cell lines, indicating an important functional role for gene body cytosine modifications in maintaining gene expression.  We reasoned that the decrease in MGMT expression induced by decitabine may render resistant glioblastoma cell lines more sensitive to temozolomide.  Consistent with this reasoning, we found that the MGMT-expressing glioblastoma cell lines exhibiting an unmethylated MGMT promoter that were pretreated with decitabine became significantly more sensitive to temozolomide.  Overall, our results suggest a functional role for gene body cytosine modification in regulating gene expression of MGMT and indicate that pretreating patients whose tumors have an unmethylated MGMT promoter with decitabine before temozolomide treatment may increase their response to therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcd2AnagQSDLVg90H21EOLACvtfcHk0ljjidZn1po7dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFWjtbw%253D&md5=d74b82afd114737c47f18212130e3e68</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0924%26sid%3Dliteratum%253Aachs%26aulast%3DMoen%26aufirst%3DE.%2BL.%26aulast%3DStark%26aufirst%3DA.%2BL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DDolan%26aufirst%3DM.%2BE.%26aulast%3DGodley%26aufirst%3DL.%2BA.%26atitle%3DThe%2520Role%2520of%2520Gene%2520Body%2520Cytosine%2520Modifications%2520in%2520MGMT%2520Expression%2520and%2520Sensitivity%2520to%2520Temozolomide%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1334%26epage%3D1344%26doi%3D10.1158%2F1535-7163.MCT-13-0924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toschi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finocchiaro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gioia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappuzzo, F.</span></span> <span> </span><span class="NLM_article-title">Role of Gemcitabine in Cancer Therapy</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1517/14796694.1.1.7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1517%2F14796694.1.1.7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=16555971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVyit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=7-17&author=L.+Toschiauthor=G.+Finocchiaroauthor=S.+Bartoliniauthor=V.+Gioiaauthor=F.+Cappuzzo&title=Role+of+Gemcitabine+in+Cancer+Therapy&doi=10.1517%2F14796694.1.1.7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Role of gemcitabine in cancer therapy</span></div><div class="casAuthors">Toschi, L.; Finocchiaro, G.; Bartolini, S.; Gioia, V.; Cappuzzo, F.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-17</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Gemcitabine, a pyrimidine nucleoside antimetabolite, is one of the most promising new cytotoxic agents.  The drug has shown activity in a variety of solid tumors, and has been approved for the treatment of non-small cell lung cancer, pancreatic, bladder, and breast cancer.  Recent data showed that gemcitabine is also active against ovarian cancer.  Gemcitabine has a good toxicity profile, with myelosuppression being the most common side effect, while non-hematol. events are relatively uncommon.  The low toxicity profile makes the drug a valid option for unfit and elderly patients.  Due to the synergistic activity with other chemotherapeutic compds., mainly cisplatinum, several trials have been conducted to evaluate the efficacy and tolerability of gemcitabine in combination with other cytotoxic agents.  Current clin. trials are evaluating the role of gemcitabine in combination with new targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowPU2VpcL_mLVg90H21EOLACvtfcHk0lj2oMH758TD5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVyit7c%253D&md5=d370f5b38970ce6d3ccf663151693651</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1517%2F14796694.1.1.7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14796694.1.1.7%26sid%3Dliteratum%253Aachs%26aulast%3DToschi%26aufirst%3DL.%26aulast%3DFinocchiaro%26aufirst%3DG.%26aulast%3DBartolini%26aufirst%3DS.%26aulast%3DGioia%26aufirst%3DV.%26aulast%3DCappuzzo%26aufirst%3DF.%26atitle%3DRole%2520of%2520Gemcitabine%2520in%2520Cancer%2520Therapy%26jtitle%3DFuture%2520Oncol.%26date%3D2005%26volume%3D1%26spage%3D7%26epage%3D17%26doi%3D10.1517%2F14796694.1.1.7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galmarini, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackey, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumontet, C.</span></span> <span> </span><span class="NLM_article-title">Nucleoside Analogues: Mechanisms of Drug Resistance and Reversal Strategies</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2402114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1038%2Fsj.leu.2402114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=11417472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkvVOit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2001&pages=875-890&author=C.+M.+Galmariniauthor=J.+R.+Mackeyauthor=C.+Dumontet&title=Nucleoside+Analogues%3A+Mechanisms+of+Drug+Resistance+and+Reversal+Strategies&doi=10.1038%2Fsj.leu.2402114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleoside analogues: Mechanisms of drug resistance and reversal strategies</span></div><div class="casAuthors">Galmarini, C. M.; Mackey, J. R.; Dumontet, C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">875-890</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review is given.  Nucleoside analogs (NA) are essential components of AML induction therapy (cytosine arabinoside), effective treatments of lymphoproliferative disorders (fludarabine, cladribine), and are also used in the treatment of some solid tumors (gemcitabine).  These important compds. share some general common characteristics, namely in terms of requiring transport by specific membrane transporters, metab., and interaction with intracellular targets.  However, these compds. differ in regard to the types of transporters that most efficiently transport a given compd., and their preferential interaction with certain targets which may explain why some compds. are more effective against rapidly proliferating tumors and others on neoplasia with a more protracted evolution.  In this review, the authors analyze the available data concerning mechanisms of action of and resistance to NA, with particular emphasis on recent advances in the characterization of nucleoside transporters and on the potential role of activating or inactivating enzymes in the induction of clin. resistance to these compds.  The authors performed an extensive search of published in vitro and clin. data in which the levels of expression of nucleoside-activating or inactivating enzymes were correlated with tumor response or patient outcome.  Strategies aiming to increase the intracellular concns. of active compds. are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl08mNYpow3bVg90H21EOLACvtfcHk0lj2oMH758TD5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkvVOit78%253D&md5=a34c882ac39abbe77062b6bacc753bc7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2402114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2402114%26sid%3Dliteratum%253Aachs%26aulast%3DGalmarini%26aufirst%3DC.%2BM.%26aulast%3DMackey%26aufirst%3DJ.%2BR.%26aulast%3DDumontet%26aufirst%3DC.%26atitle%3DNucleoside%2520Analogues%253A%2520Mechanisms%2520of%2520Drug%2520Resistance%2520and%2520Reversal%2520Strategies%26jtitle%3DLeukemia%26date%3D2001%26volume%3D15%26spage%3D875%26epage%3D890%26doi%3D10.1038%2Fsj.leu.2402114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamodu, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhopadhyay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-S.</span></span> <span> </span><span class="NLM_article-title">A Novel Multi-Target Small Molecule, LCC-09, Inhibits Stemness and Therapy-Resistant Phenotypes of Glioblastoma Cells by Increasing miR-34a and Deregulating the DRD4/Akt/mTOR Signaling Axis</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">1442</span> <span class="refDoi"> DOI: 10.3390/cancers11101442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.3390%2Fcancers11101442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BB3cXns1Glu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&author=Y.-T.+Wenauthor=A.+T.+Wuauthor=O.+A.+Bamoduauthor=L.+Weiauthor=C.-M.+Linauthor=Y.+Yenauthor=T.-Y.+Chaoauthor=D.+Mukhopadhyayauthor=M.+Hsiaoauthor=H.-S.+Huang&title=A+Novel+Multi-Target+Small+Molecule%2C+LCC-09%2C+Inhibits+Stemness+and+Therapy-Resistant+Phenotypes+of+Glioblastoma+Cells+by+Increasing+miR-34a+and+Deregulating+the+DRD4%2FAkt%2FmTOR+Signaling+Axis&doi=10.3390%2Fcancers11101442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A novel multi-target small molecule, LCC-09, inhibits stemness and therapy-resistant phenotypes of glioblastoma cells by increasing mir-34a and deregulating the DRD4/Akt/mTOR signaling axis</span></div><div class="casAuthors">Wen, Ya-Ting; Wu, Alexander T. H.; Bamodu, Oluwaseun Adebayo; Wei, Li; Lin, Chien-Min; Yen, Yun; Chao, Tsu-Yi; Mukhopadhyay, Debabrata; Hsiao, Michael; Huang, Hsu-Shan</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1442</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The management of glioblastomas (GBMs) is challenged by the development of therapeutic resistance and early disease recurrence, despite multi-modal therapy.  This may be attributed to the presence of glioma stem cells (GSCs) which are known to survive radio- and chemotherapy, by circumventing death signals and inducing cell re-population.  Recent findings suggest GSCs may be enriched by certain treatment modality.  These necessitate the development of novel therapeutics capable of targeting GBM cell plasticity and therapy-resistant GSCs.  Here, aided by computer-assisted structure characterization and target identification, we predicted that a novel 5-(2',4'-difluorophenyl)-salicylanilide deriv., LCC-09, could target dopamine receptors and oncogenic markers implicated in GBMs.  Bioinformatics data have indicated that dopamine receptor (DRD) 2, DRD4, CD133 and Nestin were elevated in GBM clin. samples and correlated to TMZ (Temozolomide) resistance and increased ALDH (Aldehyde dehydrogenase) activity (3.5-8.9%) as well as enhanced (2.1-2.4-fold) neurosphere formation efficiency in U87MG and D54MG GBM cell lines.  In addn., TMZ-resistant GSC phenotype was assocd. with up-regulated DRD4, Akt, mTOR, β-catenin, CDK6, NF-κB and Erk1/2 expression.  LCC-09 alone, or combined with TMZ, suppressed the tumorigenic and stemness traits of TMZ-resistant GBM cells while concomitantly down-regulating DRD4, Akt, mTOR, β-catenin, Erk1/2, NF-κB, and CDK6 expression.  Notably, LCC-09-mediated anti-GBM/GSC activities were assocd. with the re-expression of tumor suppressor miR-34a and reversal of TMZ-resistance, in vitro and in vivo.  Collectively, these data lay the foundation for further exploration of the clin. feasibility of administering LCC-09 as single-agent or combinatorial therapy for patients with TMZ-resistant GBMs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-_gXY9kO8sbVg90H21EOLACvtfcHk0lj2oMH758TD5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXns1Glu7Y%253D&md5=610b6356343f193586550bb091daf17a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.3390%2Fcancers11101442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11101442%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DY.-T.%26aulast%3DWu%26aufirst%3DA.%2BT.%26aulast%3DBamodu%26aufirst%3DO.%2BA.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DC.-M.%26aulast%3DYen%26aufirst%3DY.%26aulast%3DChao%26aufirst%3DT.-Y.%26aulast%3DMukhopadhyay%26aufirst%3DD.%26aulast%3DHsiao%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DH.-S.%26atitle%3DA%2520Novel%2520Multi-Target%2520Small%2520Molecule%252C%2520LCC-09%252C%2520Inhibits%2520Stemness%2520and%2520Therapy-Resistant%2520Phenotypes%2520of%2520Glioblastoma%2520Cells%2520by%2520Increasing%2520miR-34a%2520and%2520Deregulating%2520the%2520DRD4%252FAkt%252FmTOR%2520Signaling%2520Axis%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26doi%3D10.3390%2Fcancers11101442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wick, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermisson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortmann, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuker, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dichgans, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M.</span></span> <span> </span><span class="NLM_article-title">Neoadjuvant Gemcitabine/Treosulfan Chemotherapy for Newly Diagnosed Glioblastoma: A phase II study</span>. <i>J Neuro-Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">155</span>, <span class="refDoi"> DOI: 10.1023/A:1019641314661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1023%2FA%3A1019641314661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=12241108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A280%3ADC%252BD38vnvFKmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2002&pages=151-155&author=W.+Wickauthor=M.+Hermissonauthor=R.+D.+Kortmannauthor=W.+M.+Kukerauthor=F.+Duffnerauthor=J.+Dichgansauthor=M.+Bambergauthor=M.+Weller&title=Neoadjuvant+Gemcitabine%2FTreosulfan+Chemotherapy+for+Newly+Diagnosed+Glioblastoma%3A+A+phase+II+study&doi=10.1023%2FA%3A1019641314661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: a phase II study</span></div><div class="casAuthors">Wick Wolfgang; Hermisson Mirjam; Kortmann Rolf D; Kuker Wilhelm M; Duffner Frank; Dichgans Johannes; Bamberg Michael; Weller Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuro-oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-5</span>
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    </div><div class="casAbstract">The median survival for patients with glioblastoma is 12 months.  The authors evaluated whether preirradiation gemcitabine/treosulfan (GeT) chemotherapy followed by standard radiotherapy improved outcome in patients with glioblastoma.  Seventeen patients with newly diagnosed glioblastoma were enrolled in a prospective, unicenter trial of preirradiation GeT chemotherapy.  Chemotherapy included up to 4 cycles of intravenous gemcitabine (1000 mg/m2 body surface) and treosulfan (3500 mg/m2 body surface) on days 1 and 8 of 28 days treatment cycles.  Involved field radiotherapy (60 Gy in 30 fractions) was given after chemotherapy or earlier in the case of disease progression or drug intolerance.  There was no specific treatment-related neurotoxicity reported, but in 3 of 17 patients (18%) chemotherapy was stopped because of World Health Organization (WHO) IV hematological toxicity.  With GeT chemotherapy alone, there was a median progression-free survival of 12 weeks and a progression-free survival rate at 4 months of 29%.  In 16 of 17 patients who subsequently received a full course of radiotherapy, the median progression-free survival from the time of diagnosis was 8 months, and the progression-free survival rate at 12 months was 25% (4 of 16 patients).  The median overall survival was 12 months.  Neither age nor extent of the residual postoperative tumor predicted the duration of progression-free survival after chemotherapy alone or after chemotherapy followed by radiotherapy.  The combination of gemcitabine and treosulfan produced significant hematological toxicity in patients with newly diagnosed glioblastoma.  The schedule used in the present study did not confer any significant survival advantage compared with standard involved field radiotherapy alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4HSNmq-uSA5VVjGoY74BafW6udTcc2ebFueXRbgOzvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vnvFKmsA%253D%253D&md5=2b3ba5b0b10c3ff1f878275278033f0d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1023%2FA%3A1019641314661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1019641314661%26sid%3Dliteratum%253Aachs%26aulast%3DWick%26aufirst%3DW.%26aulast%3DHermisson%26aufirst%3DM.%26aulast%3DKortmann%26aufirst%3DR.%2BD.%26aulast%3DKuker%26aufirst%3DW.%2BM.%26aulast%3DDuffner%26aufirst%3DF.%26aulast%3DDichgans%26aufirst%3DJ.%26aulast%3DBamberg%26aufirst%3DM.%26aulast%3DWeller%26aufirst%3DM.%26atitle%3DNeoadjuvant%2520Gemcitabine%252FTreosulfan%2520Chemotherapy%2520for%2520Newly%2520Diagnosed%2520Glioblastoma%253A%2520A%2520phase%2520II%2520study%26jtitle%3DJ%2520Neuro-Oncol.%26date%3D2002%26volume%3D59%26spage%3D151%26epage%3D155%26doi%3D10.1023%2FA%3A1019641314661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Metro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirri, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidiri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carosi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maschio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannarelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pompili, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cognetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carapella, C. M.</span></span> <span> </span><span class="NLM_article-title">Phase II study of Fixed Dose Rate Gemcitabine as Radiosensitizer for Newly Diagnosed Glioblastoma Multiforme</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">397</span>, <span class="refDoi"> DOI: 10.1007/s00280-009-1155-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1007%2Fs00280-009-1155-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=19847425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKnsL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2010&pages=391-397&author=G.+Metroauthor=A.+Fabiauthor=M.+A.+Mirriauthor=A.+Vidiriauthor=A.+Paceauthor=M.+Carosiauthor=M.+Russilloauthor=M.+Maschioauthor=D.+Giannarelliauthor=D.+Pellegriniauthor=A.+Pompiliauthor=F.+Cognettiauthor=C.+M.+Carapella&title=Phase+II+study+of+Fixed+Dose+Rate+Gemcitabine+as+Radiosensitizer+for+Newly+Diagnosed+Glioblastoma+Multiforme&doi=10.1007%2Fs00280-009-1155-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme</span></div><div class="casAuthors">Metro, Giulio; Fabi, Alessandra; Mirri, Maria A.; Vidiri, Antonello; Pace, Andrea; Carosi, Mariantonia; Russillo, Michelangelo; Maschio, Marta; Giannarelli, Diana; Pellegrini, Domenica; Pompili, Alfredo; Cognetti, Francesco; Carapella, Carmine M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">391-397</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: In order to evaluate the activity of gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme (GBM), a prospective single-center phase II study was conducted.  Methods: Eligible patients were required to have histol. proven GBM with evaluable and/or measurable disease after surgery.  They were treated by std. cranial irradn. plus concomitant fixed dose rate gemcitabine given i.v. at 175 mg/m2 weekly for 6 wk.  After chemo-radiotherapy, irresp. of tumor response, patients went on to receive oral temozolomide at 150-200 mg/m2 for 5 days every 28 days.  Results: Twenty-three patients were enrolled.  Median age was 57 years (range 43-72) and median Karnofsky performance status was 90 (range 70-100).  Seventeen patients had received subtotal resection of the tumor, while six patients had biopsied-only tumors.  Four patients responded to treatment (17.5%) with addnl. 14 (61%) experiencing stable disease for an overall disease control rate of 78.5%.  Median progression-free and overall survival were 6.8 and 10.1 mo, resp.  The concomitant radiotherapy-gemcitabine combination was well tolerated and severe adverse events were rare, consisting of grade 3 neutropenia and hypertransaminasemia in two cases each.  Twenty patients were assessable for methylguanine methyltransferase (MGMT) promoter methylation, 11 of which were found methylated.  In the methylated and unmethylated cohorts, disease control was obtained in 10/11 patients (91%) and 7/9 patients (77.5%), resp.  Conclusions: Concomitant radiotherapy-gemcitabine is active and well tolerated in newly diagnosed glioblastoma multiforme.  Activity is obsd. both in tumors with methylated and unmethylated MGMT promoter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLBVlyyD7y2rVg90H21EOLACvtfcHk0lhkA5iQWkb04w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKnsL%252FM&md5=02e69cafcf490d3f86102e9c75b5e7ca</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs00280-009-1155-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-009-1155-x%26sid%3Dliteratum%253Aachs%26aulast%3DMetro%26aufirst%3DG.%26aulast%3DFabi%26aufirst%3DA.%26aulast%3DMirri%26aufirst%3DM.%2BA.%26aulast%3DVidiri%26aufirst%3DA.%26aulast%3DPace%26aufirst%3DA.%26aulast%3DCarosi%26aufirst%3DM.%26aulast%3DRussillo%26aufirst%3DM.%26aulast%3DMaschio%26aufirst%3DM.%26aulast%3DGiannarelli%26aufirst%3DD.%26aulast%3DPellegrini%26aufirst%3DD.%26aulast%3DPompili%26aufirst%3DA.%26aulast%3DCognetti%26aufirst%3DF.%26aulast%3DCarapella%26aufirst%3DC.%2BM.%26atitle%3DPhase%2520II%2520study%2520of%2520Fixed%2520Dose%2520Rate%2520Gemcitabine%2520as%2520Radiosensitizer%2520for%2520Newly%2520Diagnosed%2520Glioblastoma%2520Multiforme%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2010%26volume%3D65%26spage%3D391%26epage%3D397%26doi%3D10.1007%2Fs00280-009-1155-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sela, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zach, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpas, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeiri, Y.</span></span> <span> </span><span class="NLM_article-title">Spontaneous Penetration of Gold Nanoparticles Through the Blood Brain Barrier (BBB)</span>. <i>J. Nanobiotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">71</span> <span class="refDoi"> DOI: 10.1186/s12951-015-0133-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1186%2Fs12951-015-0133-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=26489846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVKisLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&author=H.+Selaauthor=H.+Cohenauthor=P.+Eliaauthor=R.+Zachauthor=Z.+Karpasauthor=Y.+Zeiri&title=Spontaneous+Penetration+of+Gold+Nanoparticles+Through+the+Blood+Brain+Barrier+%28BBB%29&doi=10.1186%2Fs12951-015-0133-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Spontaneous penetration of gold nanoparticles through the blood brain barrier (BBB)</span></div><div class="casAuthors">Sela, Hagit; Cohen, Hagit; Elia, Paz; Zach, Raya; Karpas, Zeev; Zeiri, Yehuda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nanobiotechnology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">71/1-71/9</span>CODEN:
                <span class="NLM_cas:coden">JNOAAO</span>;
        ISSN:<span class="NLM_cas:issn">1477-3155</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The blood brain barrier (BBB) controls the brain microenvironment and limits penetration of the central nervous system (CNS) by chems., thus creating an obstacle to many medical imaging and treatment procedures.  Research efforts to identify viable routes of BBB penetration have focused on structures such as micelles, polymeric nanoparticles and liposomes as drug carriers, however, many of them failed to provide unequivocal proof of BBB penetration.  Here we proved that gold nanoparticles (AuNPs) penetrate the BBB in rats to reach brain regions.  Results: Injection of AuNPs to the abdominal cavity of rats resulted in levels of gold found in blood, urine, brain regions and body organs.  After perfusion the concn. of gold in brain regions diminished dramatically indicating that most of the gold was in venous blood and not in the brain tissues.  Injection of Na, K or Ca ion channel blockers reduced BBB penetration by half.  A biol. half-life of 12.9 ± 4.9 h was found for the gold nanoparticles.  Possible mechanisms for the transport of AuNPs through the BBB are discussed.  Conclusions: BBB penetration by AuNPs is spontaneous without the application of an external field.  A major amt. of gold resides in blood vessels therefore perfusion required.  Ion channel blockers can be used to control the transport of AuNPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEsfstst-18rVg90H21EOLACvtfcHk0lhkA5iQWkb04w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVKisLvM&md5=428b6a328780c79096e3de766c320d8a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1186%2Fs12951-015-0133-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12951-015-0133-1%26sid%3Dliteratum%253Aachs%26aulast%3DSela%26aufirst%3DH.%26aulast%3DCohen%26aufirst%3DH.%26aulast%3DElia%26aufirst%3DP.%26aulast%3DZach%26aufirst%3DR.%26aulast%3DKarpas%26aufirst%3DZ.%26aulast%3DZeiri%26aufirst%3DY.%26atitle%3DSpontaneous%2520Penetration%2520of%2520Gold%2520Nanoparticles%2520Through%2520the%2520Blood%2520Brain%2520Barrier%2520%2528BBB%2529%26jtitle%3DJ.%2520Nanobiotechnol.%26date%3D2015%26volume%3D13%26doi%3D10.1186%2Fs12951-015-0133-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khongkow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boonrungsiman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruktanonchai, U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namdee, K.</span></span> <span> </span><span class="NLM_article-title">Surface Modification of Gold Nanoparticles with Neuron-Targeted Exosome for Enhanced Blood–Brain Barrier Penetration</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">8278</span> <span class="refDoi"> DOI: 10.1038/s41598-019-44569-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1038%2Fs41598-019-44569-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=31164665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A280%3ADC%252BB3M3jtlejsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&author=M.+Khongkowauthor=T.+Yataauthor=S.+Boonrungsimanauthor=U.+R.+Ruktanonchaiauthor=D.+Grahamauthor=K.+Namdee&title=Surface+Modification+of+Gold+Nanoparticles+with+Neuron-Targeted+Exosome+for+Enhanced+Blood%E2%80%93Brain+Barrier+Penetration&doi=10.1038%2Fs41598-019-44569-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Surface modification of gold nanoparticles with neuron-targeted exosome for enhanced blood-brain barrier penetration</span></div><div class="casAuthors">Khongkow Mattaka; Yata Teerapong; Boonrungsiman Suwimon; Ruktanonchai Uracha Rungsardthong; Namdee Katawut; Graham Duncan</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8278</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Gold nanoparticles (AuNPs) have been extensively used as nanomaterials for theranostic applications due to their multifunctional characteristics in therapeutics, imaging, and surface modification.  In this study, the unique functionalities of exosome-derived membranes were combined with synthetic AuNPs for targeted delivery to brain cells.  Here, we report the surface modification of AuNPs with brain-targeted exosomes derived from genetically engineered mammalian cells by using the mechanical method or extrusion to create these novel nanomaterials.  The unique targeting properties of the AuNPs after fabrication with the brain-targeted exosomes was demonstrated by their binding to brain cells under laminar flow conditions as well as their enhanced transport across the blood brain barrier.  In a further demonstration of their ability to target brain cells, in vivo bioluminescence imaging revealed that targeted-exosome coated AuNPs accumulated in the mouse brain after intravenous injection.  The surface modification of synthetic AuNPs with the brain-targeted exosome demonstrated in this work represents a highly novel and effective strategy to provide efficient brain targeting and shows promise for the future in using modified AuNPs to penetrate the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQtNvhc13OavjMsgLhIoICsfW6udTcc2ebSKQRQbcUGnbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3jtlejsA%253D%253D&md5=4ad5c15c9811b0b3c2bf50c977c50c80</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-44569-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-44569-6%26sid%3Dliteratum%253Aachs%26aulast%3DKhongkow%26aufirst%3DM.%26aulast%3DYata%26aufirst%3DT.%26aulast%3DBoonrungsiman%26aufirst%3DS.%26aulast%3DRuktanonchai%26aufirst%3DU.%2BR.%26aulast%3DGraham%26aufirst%3DD.%26aulast%3DNamdee%26aufirst%3DK.%26atitle%3DSurface%2520Modification%2520of%2520Gold%2520Nanoparticles%2520with%2520Neuron-Targeted%2520Exosome%2520for%2520Enhanced%2520Blood%25E2%2580%2593Brain%2520Barrier%2520Penetration%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26doi%3D10.1038%2Fs41598-019-44569-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span> <span> </span><span class="NLM_article-title">Nanocarriers as a Powerful Vehicle to Overcome Blood-brain Barrier in Treating Neurodegenerative Diseases: Focus on Recent Advances</span>. <i>Asian J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1016/j.ajps.2018.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.ajps.2018.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=32104476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A280%3ADC%252BB387mslWquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=480-496&author=X.+Niuauthor=J.+Chenauthor=J.+Gao&title=Nanocarriers+as+a+Powerful+Vehicle+to+Overcome+Blood-brain+Barrier+in+Treating+Neurodegenerative+Diseases%3A+Focus+on+Recent+Advances&doi=10.1016%2Fj.ajps.2018.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: Focus on recent advances</span></div><div class="casAuthors">Niu Xiaoqian; Chen Jiejian; Gao Jianqing; Chen Jiejian</div><div class="citationInfo"><span class="NLM_cas:title">Asian journal of pharmaceutical sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">480-496</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington disease and amyotrophic lateral sclerosis throw a heavy burden on families and society.  Related scientific researches make tardy progress.  One reason is that the known pathogeny is just the tip of the iceberg.  Another reason is that various physiological barriers, especially blood-brain barrier (BBB), hamper effective therapeutic substances from reaching site of action.  Drugs in clinical treatment of neurodegenerative diseases are basically administered orally.  And generally speaking, the brain targeting efficiency is pretty low.  Nano-delivery technology brings hope for neurodegenerative diseases.  The use of nanocarriers encapsulating molecules such as peptides and genomic medicine may enhance drug transport through the BBB in neurodegenerative disease and target relevant regions in the brain for regenerative processes.  In this review, we discuss BBB composition and applications of nanocarriers -liposomes, nanoparticles, nanomicelles and new emerging exosomes in neurodegenerative diseases.  Furthermore, the disadvantages and the potential neurotoxicity of nanocarriers according pharmacokinetics theory are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTCdgsCrkmMWK_SFaaT9INfW6udTcc2ebSKQRQbcUGnbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387mslWquw%253D%253D&md5=384cf8723cf814d8af867906f1f428b9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ajps.2018.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajps.2018.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DNiu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DJ.%26atitle%3DNanocarriers%2520as%2520a%2520Powerful%2520Vehicle%2520to%2520Overcome%2520Blood-brain%2520Barrier%2520in%2520Treating%2520Neurodegenerative%2520Diseases%253A%2520Focus%2520on%2520Recent%2520Advances%26jtitle%3DAsian%2520J.%2520Pharm.%2520Sci.%26date%3D2019%26volume%3D14%26spage%3D480%26epage%3D496%26doi%3D10.1016%2Fj.ajps.2018.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masserini, M.</span></span> <span> </span><span class="NLM_article-title">Nanoparticles for Brain Drug Delivery</span>. <i>ISRN Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2013</i></span>, <span class="NLM_elocation-id">238428</span> <span class="refDoi"> DOI: 10.1155/2013/238428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1155%2F2013%2F238428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=25937958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A280%3ADC%252BC2Mfgt1Oltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2013&publication_year=2013&author=M.+Masserini&title=Nanoparticles+for+Brain+Drug+Delivery&doi=10.1155%2F2013%2F238428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticles for brain drug delivery</span></div><div class="casAuthors">Masserini Massimo</div><div class="citationInfo"><span class="NLM_cas:title">ISRN biochemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2013</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">238428</span>
        ISSN:<span class="NLM_cas:issn">2090-7729</span>.
    </div><div class="casAbstract">The central nervous system, one of the most delicate microenvironments of the body, is protected by the blood-brain barrier (BBB) regulating its homeostasis.  BBB is a highly complex structure that tightly regulates the movement of ions of a limited number of small molecules and of an even more restricted number of macromolecules from the blood to the brain, protecting it from injuries and diseases.  However, the BBB also significantly precludes the delivery of drugs to the brain, thus, preventing the therapy of a number of neurological disorders.  As a consequence, several strategies are currently being sought after to enhance the delivery of drugs across the BBB.  Within this review, the recently born strategy of brain drug delivery based on the use of nanoparticles, multifunctional drug delivery systems with size in the order of one-billionth of meters, is described.  The review also includes a brief description of the structural and physiological features of the barrier and of the most utilized nanoparticles for medical use.  Finally, the potential neurotoxicity of nanoparticles is discussed, and future technological approaches are described.  The strong efforts to allow the translation from preclinical to concrete clinical applications are worth the economic investments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSyIOcdVvZ2uuqrn-c4Of3KfW6udTcc2ebSKQRQbcUGnbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mfgt1Oltg%253D%253D&md5=223c94a82dd4754dc5f5adf3f9246e35</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1155%2F2013%2F238428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2013%252F238428%26sid%3Dliteratum%253Aachs%26aulast%3DMasserini%26aufirst%3DM.%26atitle%3DNanoparticles%2520for%2520Brain%2520Drug%2520Delivery%26jtitle%3DISRN%2520Biochem.%26date%3D2013%26volume%3D2013%26doi%3D10.1155%2F2013%2F238428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span> <span> </span><span class="NLM_article-title">Current Strategies for Brain Drug Delivery</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1481</span>– <span class="NLM_lpage">1493</span>, <span class="refDoi"> DOI: 10.7150/thno.21254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.7150%2Fthno.21254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=29556336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFKqtrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1481-1493&author=X.+Dong&title=Current+Strategies+for+Brain+Drug+Delivery&doi=10.7150%2Fthno.21254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Current strategies for brain drug delivery</span></div><div class="casAuthors">Dong, Xiaowei</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1481-1493</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">The blood-brain barrier (BBB) has been a great hurdle for brain drug delivery.  The BBB in healthy brain is a diffusion barrier essential for protecting normal brain function by impeding most compds. from transiting from the blood to the brain; only small mols. can cross the BBB.  Under certain pathol. conditions of diseases such as stroke, diabetes, seizures, multiple sclerosis, Parkinson's disease and Alzheimer disease, the BBB is disrupted.  The objective of this review is to provide a broad overview on current strategies for brain drug delivery and related subjects from the past five years.  It is hoped that this review could inspire readers to discover possible approaches to deliver drugs into the brain.  After an initial overview of the BBB structure and function in both healthy and pathol. conditions, this review re-visits, according to recent publications, some questions that are controversial, such as whether nanoparticles by themselves could cross the BBB and whether drugs are specifically transferred to the brain by actively targeted nanoparticles.  Current non-nanoparticle strategies are also reviewed, such as delivery of drugs through the permeable BBB under pathol. conditions and using non-invasive techniques to enhance brain drug uptake.  Finally, one particular area that is often neglected in brain drug delivery is the influence of aging on the BBB, which is captured in this review based on the limited studies in the literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnXjLFpM3RsLVg90H21EOLACvtfcHk0lh6ZycMbEMVGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFKqtrzF&md5=2afa4d9ae415cbece75305614787920a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.7150%2Fthno.21254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.21254%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DX.%26atitle%3DCurrent%2520Strategies%2520for%2520Brain%2520Drug%2520Delivery%26jtitle%3DTheranostics%26date%3D2018%26volume%3D8%26spage%3D1481%26epage%3D1493%26doi%3D10.7150%2Fthno.21254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moustaoui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Movia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupont, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouchemal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djaker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savarin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prina-Mello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Chapelle, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span> <span> </span><span class="NLM_article-title">Tunable Design of Gold(III)–Doxorubicin Complex–PEGylated Nanocarrier. The Golden Doxorubicin for Oncological Applications</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">19946</span>– <span class="NLM_lpage">19957</span>, <span class="refDoi"> DOI: 10.1021/acsami.6b07250</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.6b07250" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOktbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=19946-19957&author=H.+Moustaouiauthor=D.+Moviaauthor=N.+Dupontauthor=N.+Bouchemalauthor=S.+Casaleauthor=N.+Djakerauthor=P.+Savarinauthor=A.+Prina-Melloauthor=M.+L.+de+la+Chapelleauthor=J.+Spadavecchia&title=Tunable+Design+of+Gold%28III%29%E2%80%93Doxorubicin+Complex%E2%80%93PEGylated+Nanocarrier.+The+Golden+Doxorubicin+for+Oncological+Applications&doi=10.1021%2Facsami.6b07250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Tunable Design of Gold(III)-Doxorubicin Complex-PEGylated Nanocarrier. The Golden Doxorubicin for Oncological Applications</span></div><div class="casAuthors">Moustaoui, Hanane; Movia, Dania; Dupont, Nathalie; Bouchemal, Nadia; Casale, Sandra; Djaker, Nadia; Savarin, Philippe; Prina-Mello, Adriele; de la Chapelle, Marc Lamy; Spadavecchia, Jolanda</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">19946-19957</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To date, the translation of Au (III) complexes into chemotherapeutic agents has been hindered by their low stability under physiol. conditions, a crucial parameter in drug development.  In this study, we report an innovative four-step synthesis of a stable Au (III)-doxorubicin (DOX) complex, acting as a key constitutive component of doxorubicin-loaded PEG-coated nanoparticles (DOX IN-PEG-AuNPs).  For therapeutic purposes, such AuNPs were then functionalized with the anti-Kv11.1 polyclonal antibody (pAb), which specifically recognizes the hERG1 channel that is overexpressed on the membrane of human pancreatic cancer cells.  The nature of the interactions between DOX and Au (III) ions was probed by various anal. techniques (Raman spectroscopy, UV-vis, and 1H NMR), which enabled studying the Au (III)-DOX interactions during AuNPs formation.  The theor. characterization of the vibrational bands and the electronic transitions of the Au (III)-DOX complex calcd. through computational studies showed significant qual. agreement with the exptl. observations on AuNPs samples.  Stability in physiol. conditions and efficient drug loading (up to 85 wt./wt. %) were achieved, while drug release was strongly dependent on the structure of DOX IN-PEG-AuNPs and on the pH.  Furthermore, the interactions among DOX, PEG, and Au (III) ions in DOX IN-PEG-AuNPs differed significantly from those found in polymer-modified AuNPs loaded with DOX by covalent linkage, referred to as DOX ON-PEG-AuNPs.  In vitro expts. indeed demonstrated that such differences strongly influenced the therapeutic potential of AuNPs in pancreatic cancer treatment, with a significant increase of the DOX therapeutic index when complexed to Au (III) ions.  Collectively, our study demonstrated that Au (III)-DOX complexes as building blocks of PEGylated AuNPs constitutes a promising approach to transform promising Au (III) complexes into real chemotherapeutic drugs for the treatment of pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJCPhW_fRD9LVg90H21EOLACvtfcHk0ljS0T9sNFdzdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOktbrP&md5=60f89be35b3ab4710ca5ae7d5c0505b4</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facsami.6b07250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.6b07250%26sid%3Dliteratum%253Aachs%26aulast%3DMoustaoui%26aufirst%3DH.%26aulast%3DMovia%26aufirst%3DD.%26aulast%3DDupont%26aufirst%3DN.%26aulast%3DBouchemal%26aufirst%3DN.%26aulast%3DCasale%26aufirst%3DS.%26aulast%3DDjaker%26aufirst%3DN.%26aulast%3DSavarin%26aufirst%3DP.%26aulast%3DPrina-Mello%26aufirst%3DA.%26aulast%3Dde%2Bla%2BChapelle%26aufirst%3DM.%2BL.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26atitle%3DTunable%2520Design%2520of%2520Gold%2528III%2529%25E2%2580%2593Doxorubicin%2520Complex%25E2%2580%2593PEGylated%2520Nanocarrier.%2520The%2520Golden%2520Doxorubicin%2520for%2520Oncological%2520Applications%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2016%26volume%3D8%26spage%3D19946%26epage%3D19957%26doi%3D10.1021%2Facsami.6b07250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marguerit, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moustaoui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddada, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djaker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Chapelle, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span> <span> </span><span class="NLM_article-title">Taxanes Hybrid Nanovectors: From Design to Physico-Chemical Evaluation of Docetaxel and Paclitaxel Gold (III)-PEGylated Complex Nanocarriers</span>. <i>Part. Part. Syst. Charact.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>35</i></span>, <span class="NLM_elocation-id">1700299</span> <span class="refDoi"> DOI: 10.1002/ppsc.201700299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1002%2Fppsc.201700299" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2018&author=G.+Margueritauthor=H.+Moustaouiauthor=M.+B.+Haddadaauthor=N.+Djakerauthor=M.+L.+de+la+Chapelleauthor=J.+Spadavecchia&title=Taxanes+Hybrid+Nanovectors%3A+From+Design+to+Physico-Chemical+Evaluation+of+Docetaxel+and+Paclitaxel+Gold+%28III%29-PEGylated+Complex+Nanocarriers&doi=10.1002%2Fppsc.201700299"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fppsc.201700299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fppsc.201700299%26sid%3Dliteratum%253Aachs%26aulast%3DMarguerit%26aufirst%3DG.%26aulast%3DMoustaoui%26aufirst%3DH.%26aulast%3DHaddada%26aufirst%3DM.%2BB.%26aulast%3DDjaker%26aufirst%3DN.%26aulast%3Dde%2Bla%2BChapelle%26aufirst%3DM.%2BL.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26atitle%3DTaxanes%2520Hybrid%2520Nanovectors%253A%2520From%2520Design%2520to%2520Physico-Chemical%2520Evaluation%2520of%2520Docetaxel%2520and%2520Paclitaxel%2520Gold%2520%2528III%2529-PEGylated%2520Complex%2520Nanocarriers%26jtitle%3DPart.%2520Part.%2520Syst.%2520Charact.%26date%3D2018%26volume%3D35%26doi%3D10.1002%2Fppsc.201700299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djaker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span> <span> </span><span class="NLM_article-title">HIV-1 Tat Peptide-Gemcitabine Gold (III)-PEGylated Complex—Nanoflowers: A Sleek Thermosensitive Hybrid Nanocarrier as Prospective Anticancer</span>. <i>Part. Part. Syst. Charact.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>35</i></span>, <span class="NLM_elocation-id">1800082</span> <span class="refDoi"> DOI: 10.1002/ppsc.201800082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1002%2Fppsc.201800082" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2018&author=H.+Liuauthor=P.+Jiangauthor=Z.+Liauthor=X.+Liauthor=N.+Djakerauthor=J.+Spadavecchia&title=HIV-1+Tat+Peptide-Gemcitabine+Gold+%28III%29-PEGylated+Complex%E2%80%94Nanoflowers%3A+A+Sleek+Thermosensitive+Hybrid+Nanocarrier+as+Prospective+Anticancer&doi=10.1002%2Fppsc.201800082"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fppsc.201800082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fppsc.201800082%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DDjaker%26aufirst%3DN.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26atitle%3DHIV-1%2520Tat%2520Peptide-Gemcitabine%2520Gold%2520%2528III%2529-PEGylated%2520Complex%25E2%2580%2594Nanoflowers%253A%2520A%2520Sleek%2520Thermosensitive%2520Hybrid%2520Nanocarrier%2520as%2520Prospective%2520Anticancer%26jtitle%3DPart.%2520Part.%2520Syst.%2520Charact.%26date%3D2018%26volume%3D35%26doi%3D10.1002%2Fppsc.201800082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furlani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arib, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djaker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Chapelle, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span> <span> </span><span class="NLM_article-title">Lactose-Modified Chitosan Gold(III)-PEGylated Complex-Bioconjugates: From Synthesis to Interaction with Targeted Galectin-1 Protein</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3352</span>– <span class="NLM_lpage">3361</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.8b00520</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.8b00520" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslWhtbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=3352-3361&author=Q.+Liuauthor=P.+Saccoauthor=E.+Marsichauthor=F.+Furlaniauthor=C.+Aribauthor=N.+Djakerauthor=M.+L.+de+la+Chapelleauthor=I.+Donatiauthor=J.+Spadavecchia&title=Lactose-Modified+Chitosan+Gold%28III%29-PEGylated+Complex-Bioconjugates%3A+From+Synthesis+to+Interaction+with+Targeted+Galectin-1+Protein&doi=10.1021%2Facs.bioconjchem.8b00520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Lactose-Modified Chitosan Gold(III)-PEGylated Complex-Bioconjugates: From Synthesis to Interaction with Targeted Galectin-1 Protein</span></div><div class="casAuthors">Liu, Qiqian; Sacco, Pasquale; Marsich, Eleonora; Furlani, Franco; Arib, Celia; Djaker, Nadia; Lamy de la Chapelle, Marc; Donati, Ivan; Spadavecchia, Jolanda</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3352-3361</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Galectins (Gal) are a family of glycan-binding proteins characterized by their affinity for β-galactosides.  Galectin-1 (Gal-1), a dimeric lectin with two galactoside-binding sites, regulates cancer progression and immune responses.  Coordination chem. has been engaged to develop versatile multivalent neoglycoconjugates for binding Gal-1.  In this study we report a fast and original method to synthesize hybrid gold nanoparticles in which a hydrochloride lactose-modified chitosan, named CTL, is mixed with dicarboxylic acid-terminated polyethylene glycol (PEG), leading to shell-like hybrid polymer-sugar-metal nanoparticles (CTL-PEG-AuNPs).  The aim of this paper is to preliminarily study the interaction of the CTL-PEG-AuNPs with a target protein, namely, Gal-1, under specific conditions.  The mol. interaction has been measured by Transmission Electron Microscopy (TEM), UV-vis, and Raman Spectroscopy on a large range of Gal-1 concns. (from 0 to 10-12 M).  We obsd. that the interaction was strongly dependent on the Gal-1 concn. at the surface of the gold nanoparticles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot1xqZPgmVWrVg90H21EOLACvtfcHk0ljS0T9sNFdzdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslWhtbbE&md5=13342fd42f17bd06aa40cb1926bba3b6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.8b00520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.8b00520%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSacco%26aufirst%3DP.%26aulast%3DMarsich%26aufirst%3DE.%26aulast%3DFurlani%26aufirst%3DF.%26aulast%3DArib%26aufirst%3DC.%26aulast%3DDjaker%26aufirst%3DN.%26aulast%3Dde%2Bla%2BChapelle%26aufirst%3DM.%2BL.%26aulast%3DDonati%26aufirst%3DI.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26atitle%3DLactose-Modified%2520Chitosan%2520Gold%2528III%2529-PEGylated%2520Complex-Bioconjugates%253A%2520From%2520Synthesis%2520to%2520Interaction%2520with%2520Targeted%2520Galectin-1%2520Protein%26jtitle%3DBioconjugate%2520Chem.%26date%3D2018%26volume%3D29%26spage%3D3352%26epage%3D3361%26doi%3D10.1021%2Facs.bioconjchem.8b00520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aouidat, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djaker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span> <span> </span><span class="NLM_article-title">Galectin-1 Protein Modified Gold (III)-PEGylated Complex-Nanoparticles: Proof of Concept of Alternative Probe in Colorimetric Glucose Detection</span>. <i>Colloids Surf., B</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>185</i></span>, <span class="NLM_elocation-id">110588</span> <span class="refDoi"> DOI: 10.1016/j.colsurfb.2019.110588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.colsurfb.2019.110588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=31654887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVaksb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=2020&author=Q.+Liuauthor=F.+Aouidatauthor=P.+Saccoauthor=E.+Marsichauthor=N.+Djakerauthor=J.+Spadavecchia&title=Galectin-1+Protein+Modified+Gold+%28III%29-PEGylated+Complex-Nanoparticles%3A+Proof+of+Concept+of+Alternative+Probe+in+Colorimetric+Glucose+Detection&doi=10.1016%2Fj.colsurfb.2019.110588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Galectin-1 protein modified gold (III)-PEGylated complex-nanoparticles: Proof of concept of alternative probe in colorimetric glucose detection</span></div><div class="casAuthors">Liu, Qiqian; Aouidat, Fatima; Sacco, Pasquale; Marsich, Eleonora; Djaker, Nadia; Spadavecchia, Jolanda</div><div class="citationInfo"><span class="NLM_cas:title">Colloids and Surfaces, B: Biointerfaces</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">110588</span>CODEN:
                <span class="NLM_cas:coden">CSBBEQ</span>;
        ISSN:<span class="NLM_cas:issn">0927-7765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Galectins (Gal) are a family of dimeric lectins, composed by two galactoside-binding sites implicated in the regulation of cancer progression and immune responses.  In this study, we report for the first time the synthesis and the phys.-chem. characterization of galectin-1-complex-gold COOH-terminated polyethlenglicole (PEG)-coated NPs (Gal-1 IN PEG-AuNPs) and their ability to recognize glucose in an aq. soln. with a concn. varying from 10 mM to 100 pM.  The chem. protocol consistsof three steps: (i) complexation between galectin-1Gal-1 and tetrachloroauric acid (HAuCl4) to form gold-protein grains; (ii) staking process of COOH-terminated polyethlenglicole mols. (PEG) onto Gal-1-Au complex and (iii) redn. of hybrid metal ions to obtain a colloidal stable soln.  During the complexation, the spectral signatures related to the Gal-1 orientation on the gold surface have been found to change due to its protonation state.  The effective glucose monitoring was detected by UV-vis, Raman spectroscopy and Transmission Electron Microscopy (TEM).  Overall, we obsd. that the interaction is strongly dependent on the Gal-1 conformation at the surface of gold nanoparticles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfZxFB8Q_wT7Vg90H21EOLACvtfcHk0lhw9Y6oXQRuiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVaksb7N&md5=13097338f46a34beaef1ae58ae831aac</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.colsurfb.2019.110588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.colsurfb.2019.110588%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DAouidat%26aufirst%3DF.%26aulast%3DSacco%26aufirst%3DP.%26aulast%3DMarsich%26aufirst%3DE.%26aulast%3DDjaker%26aufirst%3DN.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26atitle%3DGalectin-1%2520Protein%2520Modified%2520Gold%2520%2528III%2529-PEGylated%2520Complex-Nanoparticles%253A%2520Proof%2520of%2520Concept%2520of%2520Alternative%2520Probe%2520in%2520Colorimetric%2520Glucose%2520Detection%26jtitle%3DColloids%2520Surf.%252C%2520B%26date%3D2020%26volume%3D185%26doi%3D10.1016%2Fj.colsurfb.2019.110588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apchain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiche, I.</span></span> <span> </span><span class="NLM_article-title">One-Step Synthesis of Collagen Hybrid Gold Nanoparticles and Formation on Egyptian-Like Gold-Plated Archaeological Ivory</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8363</span>– <span class="NLM_lpage">8366</span>, <span class="refDoi"> DOI: 10.1002/anie.201403567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1002%2Fanie.201403567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVGqt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=8363-8366&author=J.+Spadavecchiaauthor=E.+Apchainauthor=M.+Albericauthor=E.+Fontanauthor=I.+Reiche&title=One-Step+Synthesis+of+Collagen+Hybrid+Gold+Nanoparticles+and+Formation+on+Egyptian-Like+Gold-Plated+Archaeological+Ivory&doi=10.1002%2Fanie.201403567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">One-Step Synthesis of Collagen Hybrid Gold Nanoparticles and Formation on Egyptian-like Gold-Plated Archaeological Ivory</span></div><div class="casAuthors">Spadavecchia, Jolanda; Apchain, Emilande; Alberic, Marie; Fontan, Elisabeth; Reiche, Ina</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">8363-8366</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A one-step method is reported to synthesize hybrid gold nanoparticles (AuNPs) by redn. of HAuCl4 in acetic soln. in the presence of collagen (Col), dicarboxylic acid-terminated polyethylene glycol (PEG), and cetyltetrammonium bromide (CTAB) mixed with hydoxyapatite (HAP) as surfactants.  Such formation process of AuNPs was shown to be responsible for purple stains naturally formed on Egyptianizing archaeol. gilded ivories from 8th BC Syria.  The understanding of this formation mechanism, which most likely involves a step with hybrid AuNPs, allows the establishing of an authenticity marker of ancient gold-plated ivories.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCwyUOqhVvwLVg90H21EOLACvtfcHk0lhw9Y6oXQRuiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVGqt7zP&md5=082173d94738668b123e2e22ead2a215</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fanie.201403567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201403567%26sid%3Dliteratum%253Aachs%26aulast%3DSpadavecchia%26aufirst%3DJ.%26aulast%3DApchain%26aufirst%3DE.%26aulast%3DAlberic%26aufirst%3DM.%26aulast%3DFontan%26aufirst%3DE.%26aulast%3DReiche%26aufirst%3DI.%26atitle%3DOne-Step%2520Synthesis%2520of%2520Collagen%2520Hybrid%2520Gold%2520Nanoparticles%2520and%2520Formation%2520on%2520Egyptian-Like%2520Gold-Plated%2520Archaeological%2520Ivory%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D8363%26epage%3D8366%26doi%3D10.1002%2Fanie.201403567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aouidat, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boumati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tielens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doan, B.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Gold-Gadolinium-Core-Shell Nanoparticles as Contrast Agent: a Smart Way to Future Nanomaterials for Nanomedicine Applications</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">9309</span>– <span class="NLM_lpage">9324</span>, <span class="refDoi"> DOI: 10.2147/IJN.S224805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.2147%2FIJN.S224805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=31819433" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=9309-9324&author=F.+Aouidatauthor=S.+Boumatiauthor=M.+Khanauthor=F.+Tielensauthor=B.-T.+Doanauthor=J.+Spadavecchia&title=Design+and+Synthesis+of+Gold-Gadolinium-Core-Shell+Nanoparticles+as+Contrast+Agent%3A+a+Smart+Way+to+Future+Nanomaterials+for+Nanomedicine+Applications&doi=10.2147%2FIJN.S224805"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2147%2FIJN.S224805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S224805%26sid%3Dliteratum%253Aachs%26aulast%3DAouidat%26aufirst%3DF.%26aulast%3DBoumati%26aufirst%3DS.%26aulast%3DKhan%26aufirst%3DM.%26aulast%3DTielens%26aufirst%3DF.%26aulast%3DDoan%26aufirst%3DB.-T.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Gold-Gadolinium-Core-Shell%2520Nanoparticles%2520as%2520Contrast%2520Agent%253A%2520a%2520Smart%2520Way%2520to%2520Future%2520Nanomaterials%2520for%2520Nanomedicine%2520Applications%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2019%26volume%3D14%26spage%3D9309%26epage%3D9324%26doi%3D10.2147%2FIJN.S224805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morel, A.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bialecki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moustaoui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de La Chapelle, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span> <span> </span><span class="NLM_article-title">Green Extraction of Endemic Plants to Synthesize Gold Nanoparticles for Theranostic Applications</span>. <i>Front. Lab. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">171</span>, <span class="refDoi"> DOI: 10.1016/j.flm.2017.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.flm.2017.10.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=158-171&author=A.-L.+Morelauthor=S.+Giraudauthor=A.+Bialeckiauthor=H.+Moustaouiauthor=M.+L.+de+La+Chapelleauthor=J.+Spadavecchia&title=Green+Extraction+of+Endemic+Plants+to+Synthesize+Gold+Nanoparticles+for+Theranostic+Applications&doi=10.1016%2Fj.flm.2017.10.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.flm.2017.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.flm.2017.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DMorel%26aufirst%3DA.-L.%26aulast%3DGiraud%26aufirst%3DS.%26aulast%3DBialecki%26aufirst%3DA.%26aulast%3DMoustaoui%26aufirst%3DH.%26aulast%3Dde%2BLa%2BChapelle%26aufirst%3DM.%2BL.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26atitle%3DGreen%2520Extraction%2520of%2520Endemic%2520Plants%2520to%2520Synthesize%2520Gold%2520Nanoparticles%2520for%2520Theranostic%2520Applications%26jtitle%3DFront.%2520Lab.%2520Med.%26date%3D2017%26volume%3D1%26spage%3D158%26epage%3D171%26doi%3D10.1016%2Fj.flm.2017.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noble, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goa, K. L.</span></span> <span> </span><span class="NLM_article-title">Gemcitabine. A Review of its Pharmacology and Clinical Potential in Non-Small Cell Lung Cancer and Pancreatic Cancer</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">447</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.2165/00003495-199754030-00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.2165%2F00003495-199754030-00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=9279506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADyaK2sXlvFelt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1997&pages=447-472&author=S.+Nobleauthor=K.+L.+Goa&title=Gemcitabine.+A+Review+of+its+Pharmacology+and+Clinical+Potential+in+Non-Small+Cell+Lung+Cancer+and+Pancreatic+Cancer&doi=10.2165%2F00003495-199754030-00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Gemcitabine. A review of its pharmacology and clinical potential in non-small-cell lung cancer and pancreatic cancer</span></div><div class="casAuthors">Noble, Stuart; Goa, Karen L.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">447-472</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">A review with 119 refs. Gemcitabine is a deoxycytidine analog which was originally investigated for its antiviral effects but has since been developed as an anticancer therapy.  Gemcitabine monotherapy produced an objective tumor response in 18-26% of patients with advanced non-small-cell lung cancer (NSCLC) and appears to have efficacy similar to that of cisplatin plus etoposide.  Objective response rates ranging 26-54% were recorded when gemcitabine was combined with cisplatin, and 1-yr survival duration after such treatment ranged 35-61%.  Improvements in a range of NSCLC disease symptoms and/or in general performance status occurred in many patients who received gemcitabine, with or without cisplatin, in 3 clin. trials.  Gemcitabine appears to be cost effective compared with best supportive care for NSCLC.  In addn., direct costs assocd. with administration of gemcitabine monotherapy may be lower than those for some other NSCLC chemotherapy options.  The combination of gemcitabine plus cisplatin was assocd. with a lower cost-per-tumor response than cisplatin plus etoposide or cisplatin plus vinorelbine, according to a retrospective cost-effectiveness anal.  In a single comparative study in patients with advanced pancreatic cancer, gemcitabine was more effective than fluorouracil with respect to survival duration and general clin. status.  It also showed modest antitumor and palliative efficacy in patients refractory to fluorouracil.  Gemcitabine appears to be well tolerated, although further comparisons with other chemotherapy regimens are required.  The data indicate that gemcitabine monotherapy is better tolerated than cisplatin plus etoposide in patients with NSCLC.  Data from noncomparative studies suggest that the combination of gemcitabine and cisplatin has an acceptable tolerability profile.  In a single trial in patients with pancreatic cancer, fluorouracil was better tolerated than gemcitabine; however, gemcitabine was generally well tolerated overall in this study.  Thus, gemcitabine (with or without cisplatin) may prove attractive to patients with advanced NSCLC, given their limited life expectancy and the toxicity assocd. with many other chemotherapy regimens.  Gemcitabine is a valuable new chemotherapy option for patients with advanced pancreatic cancer, a disease considered incurable at present.  Its apparent survival and palliative benefits over fluorouracil require confirmation, but are encouraging, as the need to improve both the duration and quality of survival in these patients is well recognized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5SrlK09kwnrVg90H21EOLACvtfcHk0lg51ugWzRCvTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlvFelt7c%253D&md5=2479ca53d998ad70275a54db2b212169</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2165%2F00003495-199754030-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-199754030-00009%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DS.%26aulast%3DGoa%26aufirst%3DK.%2BL.%26atitle%3DGemcitabine.%2520A%2520Review%2520of%2520its%2520Pharmacology%2520and%2520Clinical%2520Potential%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520and%2520Pancreatic%2520Cancer%26jtitle%3DDrugs%26date%3D1997%26volume%3D54%26spage%3D447%26epage%3D472%26doi%3D10.2165%2F00003495-199754030-00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oluwasanmi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Shakarchi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldebasi, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsini, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albusair, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haxton, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, A. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoskins, C.</span></span> <span> </span><span class="NLM_article-title">Diels Alder-Mediated Release of Gemcitabine from Hybrid Nanoparticles for Enhanced Pancreatic Cancer Therapy</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>266</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2017.09.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.jconrel.2017.09.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=28943195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslOisLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=266&publication_year=2017&pages=355-364&author=A.+Oluwasanmiauthor=W.+Al-Shakarchiauthor=A.+Manzurauthor=M.+H.+Aldebasiauthor=R.+S.+Elsiniauthor=M.+K.+Albusairauthor=K.+J.+Haxtonauthor=A.+D.+M.+Curtisauthor=C.+Hoskins&title=Diels+Alder-Mediated+Release+of+Gemcitabine+from+Hybrid+Nanoparticles+for+Enhanced+Pancreatic+Cancer+Therapy&doi=10.1016%2Fj.jconrel.2017.09.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy</span></div><div class="casAuthors">Oluwasanmi, Adeolu; Al-Shakarchi, Wejdan; Manzur, Ayesha; Aldebasi, Mohammed H.; Elsini, Rayan S.; Albusair, Malek K.; Haxton, Katherine J.; Curtis, Anthony D. M.; Hoskins, Clare</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">266</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">355-364</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hybrid nanoparticles (HNPs) have shown huge potential as drug delivery vehicles for pancreatic cancer.  Currently, the first line treatment, gemcitabine, is only effective in 23.8% of patients.  To improve this, a thermally activated system was developed by introducing a linker between HNPs and gemcitabine.  Whereby, heat generation resulting from laser irradn. of the HNPs promoted linker breakdown resulting in prodrug liberation.  In vitro evaluation in pancreatic adenocarcinoma cells, showed the prodrug was 4.3 times less cytotoxic than gemcitabine, but exhibited 11-fold improvement in cellular uptake.  Heat activation of the formulation led to a 56% rise in cytotoxicity causing it to outperform gemcitabine by 26%.  In vivo the formulation outperformed free gemcitabine with a 62% redn. in tumor wt. in pancreatic xenografts.  This HNP formulation is the first of its kind and has displayed superior anti-cancer activity as compared to the current first line drug gemcitabine after heat mediated controlled release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOfoaRwMMJebVg90H21EOLACvtfcHk0lg51ugWzRCvTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslOisLzN&md5=01a80b5617e3120c9ced4ab6d0df2152</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2017.09.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2017.09.027%26sid%3Dliteratum%253Aachs%26aulast%3DOluwasanmi%26aufirst%3DA.%26aulast%3DAl-Shakarchi%26aufirst%3DW.%26aulast%3DManzur%26aufirst%3DA.%26aulast%3DAldebasi%26aufirst%3DM.%2BH.%26aulast%3DElsini%26aufirst%3DR.%2BS.%26aulast%3DAlbusair%26aufirst%3DM.%2BK.%26aulast%3DHaxton%26aufirst%3DK.%2BJ.%26aulast%3DCurtis%26aufirst%3DA.%2BD.%2BM.%26aulast%3DHoskins%26aufirst%3DC.%26atitle%3DDiels%2520Alder-Mediated%2520Release%2520of%2520Gemcitabine%2520from%2520Hybrid%2520Nanoparticles%2520for%2520Enhanced%2520Pancreatic%2520Cancer%2520Therapy%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2017%26volume%3D266%26spage%3D355%26epage%3D364%26doi%3D10.1016%2Fj.jconrel.2017.09.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karahoca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momparler, R. L.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic and Pharmacodynamic Analysis of 5-Aza-2′-Deoxycytidine (Decitabine) in the Design of its Dose-Schedule for Cancer Therapy</span>. <i>Clin. Epigenet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">3</span> <span class="refDoi"> DOI: 10.1186/1868-7083-5-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1186%2F1868-7083-5-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=23369223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslCisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&author=M.+Karahocaauthor=R.+L.+Momparler&title=Pharmacokinetic+and+Pharmacodynamic+Analysis+of+5-Aza-2%E2%80%B2-Deoxycytidine+%28Decitabine%29+in+the+Design+of+its+Dose-Schedule+for+Cancer+Therapy&doi=10.1186%2F1868-7083-5-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy</span></div><div class="casAuthors">Karahoca, Metin; Momparler, Richard L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Epigenetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3</span>CODEN:
                <span class="NLM_cas:coden">CELPCI</span>;
        ISSN:<span class="NLM_cas:issn">1868-7083</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  5-Aza-2'-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under investigation for treating acute myeloid leukemia (AML) and other malignancies.  5-AZA-CdR can reactivate tumor suppressor genes silenced by aberrant DNA methylation, a frequent event in all types of cancer.  Because this epigenetic change is reversible, it is a good target for 5-AZA-CdR therapy.  We have reviewed the preclin. data of 5-AZA-CdR to analyze the concns. and exposure times required to eradicate cancer stem cells.  We analyzed the dose-schedules used in animal models that show potent antineoplastic activity of 5-AZA-CdR.  We attempted to correlate the preclin. data with the responses obtained in clin. trials of 5-AZA-CdR in patients with cancer.  The pharmacokinetics and drug distribution of 5-AZA-CdR are key parameters because adequate therapeutic drug levels are required to eliminate cancer stem cells in all anat. compartments.  The plasma half-life of 5-AZA-CdR in humans is approx. 20 min due to the high levels in the liver of cytidine deaminase, the enzyme that inactivates this analog.  This provides a rationale to use an inhibitor of cytidine deaminase in combination with 5-AZA-CdR.  Low-dose 5-AZA-CdR is effective for MDS and AML and can induce complete remissions (CR).  However, maintenance of CR with low-dose 5-AZA-CdR is difficult.  Based on analyses of preclin. and clin. data, low-dose 5-AZA-CdR has the potential to be an effective form of therapy in some patients with cancer.  For patients who do not respond to low-dose therapy we recommend dose-intensive treatment with 5-AZA-CdR.  Patients who are candidates for intensive dose 5-AZA-CdR should have a good bone marrow status so as to permit adequate recovery from myelosuppression, the major toxicity of 5-AZA-CdR.  Solid tumors are also interesting targets for therapy with 5-AZA-CdR.  Both low-dose and intensive therapy with 5-AZA-CdR can reduce the proliferative potential of tumor stem cells in animal models.  We propose novel dose schedules of 5-AZA-CdR for investigation in patients with cancer.  The full chemotherapeutic potential of 5-AZA-CdR to treat cancer merits further clin. investigation and can only be realized when its optimal dose-schedule is detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVWSDOAcgpjrVg90H21EOLACvtfcHk0lg51ugWzRCvTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslCisbk%253D&md5=8fcc05a772220b95101dd85d9894b674</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1186%2F1868-7083-5-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1868-7083-5-3%26sid%3Dliteratum%253Aachs%26aulast%3DKarahoca%26aufirst%3DM.%26aulast%3DMomparler%26aufirst%3DR.%2BL.%26atitle%3DPharmacokinetic%2520and%2520Pharmacodynamic%2520Analysis%2520of%25205-Aza-2%25E2%2580%25B2-Deoxycytidine%2520%2528Decitabine%2529%2520in%2520the%2520Design%2520of%2520its%2520Dose-Schedule%2520for%2520Cancer%2520Therapy%26jtitle%3DClin.%2520Epigenet.%26date%3D2013%26volume%3D5%26doi%3D10.1186%2F1868-7083-5-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cashen, A. F.</span></span> <span> </span><span class="NLM_article-title">Decitabine in the Treatment of Acute Myeloid Leukemia in Elderly Patients</span>. <i>Cancer Manage. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.2147/CMAR.S40600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.2147%2FCMAR.S40600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=24520204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptVKhtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=53-61&author=P.+Malikauthor=A.+F.+Cashen&title=Decitabine+in+the+Treatment+of+Acute+Myeloid+Leukemia+in+Elderly+Patients&doi=10.2147%2FCMAR.S40600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Decitabine in the treatment of acute myeloid leukemia in elderly patients</span></div><div class="casAuthors">Malik, Priya; Cashen, Amanda F.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Management and Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53-61, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">CMRACP</span>;
        ISSN:<span class="NLM_cas:issn">1179-1322</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  The majority of patients with acute myeloid leukemia (AML) are elderly and have a poor prognosis despite induction therapy.  Decitabine, a DNA-hypomethylating agent that induces differentiation and apoptosis of leukemic cells, is a well-tolerated alternative to aggressive chemotherapy.  It is currently FDA-approved for myelodysplastic syndrome, including patients with 20%-30% bone marrow blasts.  Recent clin. attention has focused on evaluating decitabine as frontline therapy for untreated high-risk elderly AML patients.  A large randomized international phase III study comparing decitabine to supportive care and cytarabine in elderly AML patients demonstrated significantly improved complete remission rates, but the survival difference did not reach significance.  Due to this, decitabine did not achieve FDA approval for AML, but continues to be used off-label.  Current research is focused on further defining subgroups of elderly AML patients who may derive greater benefit from decitabine therapy and combining it with other low-intensity active agents for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqDbuBrriRdbVg90H21EOLACvtfcHk0lg51ugWzRCvTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptVKhtrw%253D&md5=ab9f4fa47c153e35aed543237ebf67a6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2147%2FCMAR.S40600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCMAR.S40600%26sid%3Dliteratum%253Aachs%26aulast%3DMalik%26aufirst%3DP.%26aulast%3DCashen%26aufirst%3DA.%2BF.%26atitle%3DDecitabine%2520in%2520the%2520Treatment%2520of%2520Acute%2520Myeloid%2520Leukemia%2520in%2520Elderly%2520Patients%26jtitle%3DCancer%2520Manage.%2520Res.%26date%3D2014%26volume%3D6%26spage%3D53%26epage%3D61%26doi%3D10.2147%2FCMAR.S40600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irudayaraj, J.</span></span> <span> </span><span class="NLM_article-title">Decitabine Nanoconjugate Sensitizes Human Glioblastoma Cells to Temozolomide</span>. <i>Mol. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1279</span>– <span class="NLM_lpage">1288</span>, <span class="refDoi"> DOI: 10.1021/mp500815b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp500815b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFyntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=1279-1288&author=Y.+Cuiauthor=A.+Nazauthor=D.+H.+Thompsonauthor=J.+Irudayaraj&title=Decitabine+Nanoconjugate+Sensitizes+Human+Glioblastoma+Cells+to+Temozolomide&doi=10.1021%2Fmp500815b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Decitabine Nanoconjugate Sensitizes Human Glioblastoma Cells to Temozolomide</span></div><div class="casAuthors">Cui, Yi; Naz, Asia; Thompson, David H.; Irudayaraj, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1279-1288</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this study, we developed and characterized a delivery system for the epigenetic demethylating drug, decitabine, to sensitize temozolomide-resistant human glioblastoma multiforme (GBM) cells to alkylating chemotherapy.  A poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG) based nanoconjugate was fabricated to encapsulate decitabine and achieved a better therapeutic response in GBM cells than that with the free drug.  After synthesis, the highly efficient uptake process and intracellular dynamics of this nanoconjugate were monitored by single-mol. fluorescence tools.  Our expts. demonstrated that, under an acidic pH due to active glycolysis in cancer cells, the PLGA-PEG nanovector could release the conjugated decitabine at a faster rate, after which the hydrolyzed lactic acid and glycolic acid would further acidify the intracellular microenvironment, thus providing pos. feedback to increase the effective drug concn. and realize growth inhibition.  In temozolomide-resistant GBM cells, decitabine can potentiate the cytotoxic DNA alkylation by counteracting cytosine methylation and reactivating tumor suppressor genes, such as p53 and p21.  Owing to the excellent internalization and endolysosomal escape enabled by the PLGA-PEG backbone, the encapsulated decitabine exhibited a better anti-GBM potential than that of free drug mols.  Hence, the synthesized nanoconjugate and temozolomide could act in synergy to deliver a more potent and long-term antiproliferative effect against malignant GBM cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrruZPTyejx8LVg90H21EOLACvtfcHk0li4OERO1rwhlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFyntbs%253D&md5=15876d49f21053c48c0996cc8ce63d1d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fmp500815b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp500815b%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DY.%26aulast%3DNaz%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DD.%2BH.%26aulast%3DIrudayaraj%26aufirst%3DJ.%26atitle%3DDecitabine%2520Nanoconjugate%2520Sensitizes%2520Human%2520Glioblastoma%2520Cells%2520to%2520Temozolomide%26jtitle%3DMol.%2520Pharm.%26date%3D2015%26volume%3D12%26spage%3D1279%26epage%3D1288%26doi%3D10.1021%2Fmp500815b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raucher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragojevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J.</span></span> <span> </span><span class="NLM_article-title">Macromolecular Drug Carriers for Targeted Glioblastoma Therapy: Preclinical Studies, Challenges, and Future Perspectives</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">624</span> <span class="refDoi"> DOI: 10.3389/fonc.2018.00624</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.3389%2Ffonc.2018.00624" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=30619758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A280%3ADC%252BB3cnptVyjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&author=D.+Raucherauthor=S.+Dragojevicauthor=J.+Ryu&title=Macromolecular+Drug+Carriers+for+Targeted+Glioblastoma+Therapy%3A+Preclinical+Studies%2C+Challenges%2C+and+Future+Perspectives&doi=10.3389%2Ffonc.2018.00624"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Macromolecular Drug Carriers for Targeted Glioblastoma Therapy: Preclinical Studies, Challenges, and Future Perspectives</span></div><div class="casAuthors">Raucher Drazen; Dragojevic Sonja; Ryu Jungsu</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">624</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Glioblastoma, the most common, aggressive brain tumor, ranks among the least curable cancers-owing to its strong tendency for intracranial dissemination, high proliferation potential, and inherent tumor resistance to radiation and chemotherapy.  Current glioblastoma treatment strategies are further hampered by a critical challenge: adverse, non-specific treatment effects in normal tissue combined with the inability of drugs to penetrate the blood brain barrier and reach the tumor microenvironment.  Thus, the creation of effective therapies for glioblastoma requires development of targeted drug-delivery systems that increase accumulation of the drug in the tumor tissue while minimizing systemic toxicity in healthy tissues.  As demonstrated in various preclinical glioblastoma models, macromolecular drug carriers have the potential to improve delivery of small molecule drugs, therapeutic peptides, proteins, and genes to brain tumors.  Currently used macromolecular drug delivery systems, such as liposomes and polymers, passively target solid tumors, including glioblastoma, by capitalizing on abnormalities of the tumor vasculature, its lack of lymphatic drainage, and the enhanced permeation and retention (EPR) effect.  In addition to passive targeting, active targeting approaches include the incorporation of various ligands on the surface of macromolecules that bind to cell surface receptors expressed on specific cancer cells.  Active targeting approaches also utilize stimulus responsive macromolecules which further improve tumor accumulation by triggering changes in the physical properties of the macromolecular carrier.  The stimulus can be an intrinsic property of the tumor tissue, such as low pH, or extrinsic, such as local application of ultrasound or heat.  This review article explores current preclinical studies and future perspectives of targeted drug delivery to glioblastoma by macromolecular carrier systems, including polymeric micelles, nanoparticles, and biopolymers.  We highlight key aspects of the design of diverse macromolecular drug delivery systems through a review of their preclinical applications in various glioblastoma animal models.  We also review the principles and advantages of passive and active targeting based on various macromolecular carriers.  Additionally, we discuss the potential disadvantages that may prevent clinical application of these carriers in targeting glioblastoma, as well as approaches to overcoming these obstacles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDRk0Zhzo17OdfST00W0BcfW6udTcc2ealD59emJIL57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnptVyjsA%253D%253D&md5=8b128439e8d157fdabd8d91713a991a4</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2018.00624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2018.00624%26sid%3Dliteratum%253Aachs%26aulast%3DRaucher%26aufirst%3DD.%26aulast%3DDragojevic%26aufirst%3DS.%26aulast%3DRyu%26aufirst%3DJ.%26atitle%3DMacromolecular%2520Drug%2520Carriers%2520for%2520Targeted%2520Glioblastoma%2520Therapy%253A%2520Preclinical%2520Studies%252C%2520Challenges%252C%2520and%2520Future%2520Perspectives%26jtitle%3DFront.%2520Oncol.%26date%3D2018%26volume%3D8%26doi%3D10.3389%2Ffonc.2018.00624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, T.</span></span> <span> </span><span class="NLM_article-title">Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists</span>. <i>World Neurosurg.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">e468</span>– <span class="NLM_lpage">e477</span>, <span class="refDoi"> DOI: 10.1016/j.wneu.2019.04.180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.wneu.2019.04.180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=31048057" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2019&pages=e468-e477&author=Z.+Liuauthor=X.+Jiangauthor=L.+Gaoauthor=X.+Liuauthor=J.+Liauthor=X.+Huangauthor=T.+Zeng&title=Synergistic+Suppression+of+Glioblastoma+Cell+Growth+by+Combined+Application+of+Temozolomide+and+Dopamine+D2+Receptor+Antagonists&doi=10.1016%2Fj.wneu.2019.04.180"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.wneu.2019.04.180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.wneu.2019.04.180%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DZeng%26aufirst%3DT.%26atitle%3DSynergistic%2520Suppression%2520of%2520Glioblastoma%2520Cell%2520Growth%2520by%2520Combined%2520Application%2520of%2520Temozolomide%2520and%2520Dopamine%2520D2%2520Receptor%2520Antagonists%26jtitle%3DWorld%2520Neurosurg.%26date%3D2019%26volume%3D128%26spage%3De468%26epage%3De477%26doi%3D10.1016%2Fj.wneu.2019.04.180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Movia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moustaoui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prina-Mello, A.</span></span> <span> </span><span class="NLM_article-title">Targeted Polyethylene Glycol Gold Nanoparticles for the Treatment of Pancreatic Cancer: From Synthesis to Proof-Of-Concept in Vitro Studies</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">822</span>, <span class="refDoi"> DOI: 10.2147/IJN.S97476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.2147%2FIJN.S97476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=27013874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFChtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=791-822&author=J.+Spadavecchiaauthor=D.+Moviaauthor=C.+Mooreauthor=C.+M.+Maguireauthor=H.+Moustaouiauthor=S.+Casaleauthor=Y.+Volkovauthor=A.+Prina-Mello&title=Targeted+Polyethylene+Glycol+Gold+Nanoparticles+for+the+Treatment+of+Pancreatic+Cancer%3A+From+Synthesis+to+Proof-Of-Concept+in+Vitro+Studies&doi=10.2147%2FIJN.S97476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted polyethylene glycol gold nanoparticles for the treatment of pancreatic cancer: from synthesis to proof-of-concept in vitro studies</span></div><div class="casAuthors">Spadavecchia, Jolanda; Movia, Dania; Moore, Caroline; Maguire, Ciaran Manus; Moustaoui, Hanane; Casale, Sandra; Volkov, Yuri; Prina-Mello, Adriele</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">791-822</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">The main objective of this study was to optimize and characterize a drug delivery carrier for doxorubicin, intended to be i.v. administered, capable of improving the therapeutic index of the chemotherapeutic agent itself, and aimed at the treatment of pancreatic cancer.  In light of this goal, we report a robust one-step method for the synthesis of dicarboxylic acid-terminated polyethylene glycol (PEG)-gold nanoparticles (AuNPs) and doxorubicin-loaded PEG-AuNPs, and their further antibody targeting (anti-Kv11.1 polyclonal antibody [pAb]).  In in vitro proof-of-concept studies, we evaluated the influence of the nanocarrier and of the active targeting functionality on the anti-tumor efficacy of doxorubicin, with respect to its half-maximal effective concn. (EC50) and drug-triggered changes in the cell cycle.  Our results demonstrated that the therapeutic efficacy of doxorubicin was pos. influenced not only by the active targeting exploited through anti-Kv11.1-pAb but also by the drug coupling with a nanometer-sized delivery system, which indeed resulted in a 30-fold decrease of doxorubicin EC50, cell cycle blockage, and drug localization in the cell nuclei.  The cell internalization pathway was strongly influenced by the active targeting of the Kv11.1 subunit of the human Ether-a-go-go related gene 1 (hERG1) channel aberrantly expressed on the membrane of pancreatic cancer cells.  Targeted PEG-AuNPs were translocated into the lysosomes and were assocd. to an increased lysosomal function in PANC-1 cells.  Addnl., doxorubicin release into an aq. environment was almost negligible after 7 days, suggesting that drug release from PEG-AuNPs was triggered by enzymic activity.  Although preliminary, data gathered from this study have considerable potential in the application of safe-by-design nano-enabled drug-delivery systems (ie, nanomedicines) for the treatment of pancreatic cancer, a disease with a poor prognosis and one of the main current burdens of today's health care bill of industrialized countries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZU_bX9-GcsbVg90H21EOLACvtfcHk0lhhy0zKVJQJEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFChtL4%253D&md5=154e1f94dfa7b905213bd34e96c6a482</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2147%2FIJN.S97476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S97476%26sid%3Dliteratum%253Aachs%26aulast%3DSpadavecchia%26aufirst%3DJ.%26aulast%3DMovia%26aufirst%3DD.%26aulast%3DMoore%26aufirst%3DC.%26aulast%3DMaguire%26aufirst%3DC.%2BM.%26aulast%3DMoustaoui%26aufirst%3DH.%26aulast%3DCasale%26aufirst%3DS.%26aulast%3DVolkov%26aufirst%3DY.%26aulast%3DPrina-Mello%26aufirst%3DA.%26atitle%3DTargeted%2520Polyethylene%2520Glycol%2520Gold%2520Nanoparticles%2520for%2520the%2520Treatment%2520of%2520Pancreatic%2520Cancer%253A%2520From%2520Synthesis%2520to%2520Proof-Of-Concept%2520in%2520Vitro%2520Studies%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2016%26volume%3D11%26spage%3D791%26epage%3D822%26doi%3D10.2147%2FIJN.S97476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monteil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moustaoui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picardi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aouidat, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djaker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De La Chapelle, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecouvey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span> <span> </span><span class="NLM_article-title">Polyphosphonate Ligands: From Synthesis to Design of Hybrid PEGylated Nanoparticles Toward Phototherapy Studies</span>. <i>J. Colloid Interface Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>513</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1016/j.jcis.2017.10.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.jcis.2017.10.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=29153714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWmt7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=513&publication_year=2018&pages=205-213&author=M.+Monteilauthor=H.+Moustaouiauthor=G.+Picardiauthor=F.+Aouidatauthor=N.+Djakerauthor=M.+L.+De+La+Chapelleauthor=M.+Lecouveyauthor=J.+Spadavecchia&title=Polyphosphonate+Ligands%3A+From+Synthesis+to+Design+of+Hybrid+PEGylated+Nanoparticles+Toward+Phototherapy+Studies&doi=10.1016%2Fj.jcis.2017.10.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Polyphosphonate ligands: From synthesis to design of hybrid PEGylated nanoparticles toward phototherapy studies</span></div><div class="casAuthors">Monteil, Maelle; Moustaoui, Hanane; Picardi, Gennaro; Aouidat, Fatima; Djaker, Nadia; de La Chapelle, Marc Lamy; Lecouvey, Marc; Spadavecchia, Jolanda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Colloid and Interface Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">513</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205-213</span>CODEN:
                <span class="NLM_cas:coden">JCISA5</span>;
        ISSN:<span class="NLM_cas:issn">0021-9797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The use of phosphonate ligands to modify the nanoparticle (NPs) surface has attracted a strong interest in the last years for the design of highly functional hybrid materials.  The authors applied a methodol. to synthesize bisphosphonates having functionalized PEG side chains with a specific length in order to design a novel class of hybrid nanomaterials composed by tetraphosphonate-complex-gold COOH-terminated PEG-coated NPs (Bis-PO-PEG-AuNPs).  The synthetic approach consist in three steps: (1) Complexation between new phosphonate ligands (Bis PO) and tetrachloroauric acid (HAuCl4) to form gold clusters; (2) adsorption of COOH-terminated PEG mols. (PEG) onto Bis PO-Au complex; (3) redn. of metal ions in that vicinity, growth of gold particles and colloidal stabilization.  The obtained snow-shape-like hybrid nanoparticles, have been characterized by ultra-violet/visible, Raman spectroscopies, and electron microscopy imaging, involving their optical properties and photothermal activity in pancreatic adenocarcinoma cancer cells (PDAC).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ53zUcesuCrVg90H21EOLACvtfcHk0lhhy0zKVJQJEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWmt7vN&md5=316bc832c5f534ef65ac56c857b37bd8</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.jcis.2017.10.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcis.2017.10.055%26sid%3Dliteratum%253Aachs%26aulast%3DMonteil%26aufirst%3DM.%26aulast%3DMoustaoui%26aufirst%3DH.%26aulast%3DPicardi%26aufirst%3DG.%26aulast%3DAouidat%26aufirst%3DF.%26aulast%3DDjaker%26aufirst%3DN.%26aulast%3DDe%2BLa%2BChapelle%26aufirst%3DM.%2BL.%26aulast%3DLecouvey%26aufirst%3DM.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26atitle%3DPolyphosphonate%2520Ligands%253A%2520From%2520Synthesis%2520to%2520Design%2520of%2520Hybrid%2520PEGylated%2520Nanoparticles%2520Toward%2520Phototherapy%2520Studies%26jtitle%3DJ.%2520Colloid%2520Interface%2520Sci.%26date%3D2018%26volume%3D513%26spage%3D205%26epage%3D213%26doi%3D10.1016%2Fj.jcis.2017.10.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landoulsi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradier, C.-M.</span></span> <span> </span><span class="NLM_article-title">Tuning the Shape and Size of Hybrid Gold Nanoparticles by Porphyrins using Seed-Mediated Synthesis</span>. <i>Chem. Phys. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>609</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">141</span>, <span class="refDoi"> DOI: 10.1016/j.cplett.2014.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.cplett.2014.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1aktrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=609&publication_year=2014&pages=134-141&author=J.+Spadavecchiaauthor=S.+Casaleauthor=J.+Landoulsiauthor=C.-M.+Pradier&title=Tuning+the+Shape+and+Size+of+Hybrid+Gold+Nanoparticles+by+Porphyrins+using+Seed-Mediated+Synthesis&doi=10.1016%2Fj.cplett.2014.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Tuning the shape and size of hybrid gold nanoparticles by porphyrins using seed-mediated synthesis</span></div><div class="casAuthors">Spadavecchia, Jolanda; Casale, Sandra; Landoulsi, Jessem; Pradier, Claire-Marie</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Physics Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">609</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">134-141</span>CODEN:
                <span class="NLM_cas:coden">CHPLBC</span>;
        ISSN:<span class="NLM_cas:issn">0009-2614</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The authors report the synthesis of hybrid gold nanostructures by seed/growth approach, using porphyrin mols. (protoporphyrin IX) in addn. to cetyltetraammonium bromide (CTAB) as surfactants and/or shape-modulating agents.  The combination of CTAB and porphyrin yields stable complexes that act as co-directing agents and favor the anisotropic growth of gold nanostructures.  The authors' results revealed the ability of porphyrins to tune the shape and size of gold nanostructures, giving a variety of hybrid nano-objects, including bones, thorns, polyhedral and stars.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE_tvNmLmz-rVg90H21EOLACvtfcHk0lhhy0zKVJQJEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1aktrvI&md5=d81164dd6c783b38ede5e9d1b9359c49</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.cplett.2014.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cplett.2014.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DSpadavecchia%26aufirst%3DJ.%26aulast%3DCasale%26aufirst%3DS.%26aulast%3DLandoulsi%26aufirst%3DJ.%26aulast%3DPradier%26aufirst%3DC.-M.%26atitle%3DTuning%2520the%2520Shape%2520and%2520Size%2520of%2520Hybrid%2520Gold%2520Nanoparticles%2520by%2520Porphyrins%2520using%2520Seed-Mediated%2520Synthesis%26jtitle%3DChem.%2520Phys.%2520Lett.%26date%3D2014%26volume%3D609%26spage%3D134%26epage%3D141%26doi%3D10.1016%2Fj.cplett.2014.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Politi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Stefano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longobardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giardina, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Methivier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradier, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span> <span> </span><span class="NLM_article-title">The Amphiphilic Hydrophobin Vmh2 Plays a Key Role in One Step Synthesis of Hybrid Protein-Gold Nanoparticles</span>. <i>Colloids Surf., B</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.colsurfb.2015.09.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.colsurfb.2015.09.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=26402419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFGhsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2015&pages=214-221&author=J.+Politiauthor=L.+De+Stefanoauthor=S.+Longobardiauthor=P.+Giardinaauthor=I.+Reaauthor=C.+Methivierauthor=C.+M.+Pradierauthor=S.+Casaleauthor=J.+Spadavecchia&title=The+Amphiphilic+Hydrophobin+Vmh2+Plays+a+Key+Role+in+One+Step+Synthesis+of+Hybrid+Protein-Gold+Nanoparticles&doi=10.1016%2Fj.colsurfb.2015.09.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The amphiphilic hydrophobin Vmh2 plays a key role in one step synthesis of hybrid protein-gold nanoparticles</span></div><div class="casAuthors">Politi, Jane; De Stefano, Luca; Longobardi, Sara; Giardina, Paola; Rea, Ilaria; Methivier, Christophe; Pradier, Claire-Marie; Casale, Sandra; Spadavecchia, Jolanda</div><div class="citationInfo"><span class="NLM_cas:title">Colloids and Surfaces, B: Biointerfaces</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">214-221</span>CODEN:
                <span class="NLM_cas:coden">CSBBEQ</span>;
        ISSN:<span class="NLM_cas:issn">0927-7765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We report a simple and original method to synthesize gold nanoparticles in which a fungal protein, the hydrophobin Vmh2 from Pleurotus ostreatus and dicarboxylic acid-terminated polyethylene-glycol (PEG) has been used as addnl. components in a one step process, leading to hybrid protein-metal nanoparticles (NPs).  The nanoparticles have been characterized by ultra-violet/visible, IR and X-ray photoelectron spectroscopies, dynamic light scattering and also by electron microscopy imaging.  The results of these anal. techniques highlight nanometric sized, stable, hybrid complexes of about 12 nm, with outer surface rich in functional chem. groups.  Interaction with protein and antibodies has also been exploited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2D1lPW0mz1LVg90H21EOLACvtfcHk0lgidseKqlIBWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFGhsLvP&md5=fb7d6d01dbaab289617f116b38cc81e6</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.colsurfb.2015.09.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.colsurfb.2015.09.021%26sid%3Dliteratum%253Aachs%26aulast%3DPoliti%26aufirst%3DJ.%26aulast%3DDe%2BStefano%26aufirst%3DL.%26aulast%3DLongobardi%26aufirst%3DS.%26aulast%3DGiardina%26aufirst%3DP.%26aulast%3DRea%26aufirst%3DI.%26aulast%3DMethivier%26aufirst%3DC.%26aulast%3DPradier%26aufirst%3DC.%2BM.%26aulast%3DCasale%26aufirst%3DS.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26atitle%3DThe%2520Amphiphilic%2520Hydrophobin%2520Vmh2%2520Plays%2520a%2520Key%2520Role%2520in%2520One%2520Step%2520Synthesis%2520of%2520Hybrid%2520Protein-Gold%2520Nanoparticles%26jtitle%3DColloids%2520Surf.%252C%2520B%26date%3D2015%26volume%3D136%26spage%3D214%26epage%3D221%26doi%3D10.1016%2Fj.colsurfb.2015.09.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephen, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kievit, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Press, O. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span> <span> </span><span class="NLM_article-title">Temozolomide Nanoparticles for Targeted Glioblastoma Therapy</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">6674</span>– <span class="NLM_lpage">6682</span>, <span class="refDoi"> DOI: 10.1021/am5092165</span> </span><div class="citationLinks">[<a href="/doi/10.1021/am5092165" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFynsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=6674-6682&author=C.+Fangauthor=K.+Wangauthor=Z.+R.+Stephenauthor=Q.+Muauthor=F.+M.+Kievitauthor=D.+T.+Chiuauthor=O.+W.+Pressauthor=M.+Zhang&title=Temozolomide+Nanoparticles+for+Targeted+Glioblastoma+Therapy&doi=10.1021%2Fam5092165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Temozolomide Nanoparticles for Targeted Glioblastoma Therapy</span></div><div class="casAuthors">Fang, Chen; Wang, Kui; Stephen, Zachary R.; Mu, Qingxin; Kievit, Forrest M.; Chiu, Daniel T.; Press, Oliver W.; Zhang, Miqin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6674-6682</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glioblastoma (GBM) is a deadly and debilitating brain tumor with an abysmal prognosis.  The std. therapy for GBM is surgery followed by radiation and chemotherapy with Temozolomide (TMZ).  Treatment of GBMs remains a challenge, largely because of the fast degrdn. of TMZ, the inability to deliver an ED of TMZ to tumors, and a lack of target specificity that may cause systemic toxicity.  Here, we present a simple method for synthesizing a nanoparticle-based carrier that can protect TMZ from rapid degrdn. in physiol. solns. and can specifically deliver them to GBM cells through the mediation of a tumor-targeting peptide chlorotoxin (CTX).  Our nanoparticle, namely NP-TMZ-CTX, had a hydrodynamic size of <100 nm, exhibited sustained stability in cell culture media for up to 2 wk, and could accommodate stable drug loading.  TMZ bound to nanoparticles showed a much higher stability at physiol. pH, with a half-life 7-fold greater than that of free TMZ.  NP-TMZ-CTX was able to target GBM cells and achieved 2-6-fold higher uptake and a 50-90% redn. of IC50 72 h post-treatment as compared to nontargeted NP-TMZ.  NP-TMZ-CTX showed great promise in its ability to deliver a large therapeutic dose of TMZ to GBM cells and could serve as a template for targeted delivery of other therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp78ba64HyQybVg90H21EOLACvtfcHk0lgidseKqlIBWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFynsbs%253D&md5=5399bf35d5d14116d1bf24d3e968292c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fam5092165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fam5092165%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DStephen%26aufirst%3DZ.%2BR.%26aulast%3DMu%26aufirst%3DQ.%26aulast%3DKievit%26aufirst%3DF.%2BM.%26aulast%3DChiu%26aufirst%3DD.%2BT.%26aulast%3DPress%26aufirst%3DO.%2BW.%26aulast%3DZhang%26aufirst%3DM.%26atitle%3DTemozolomide%2520Nanoparticles%2520for%2520Targeted%2520Glioblastoma%2520Therapy%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2015%26volume%3D7%26spage%3D6674%26epage%3D6682%26doi%3D10.1021%2Fam5092165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marguerit, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moustaoui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddada, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djaker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Chapelle, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span> <span> </span><span class="NLM_article-title">Taxanes Hybrid Nanovectors: From Design to Physico-Chemical Evaluation of Docetaxel and Paclitaxel Gold (III)-PEGylated Complex Nanocarriers</span>. <i>Part. Part. Syst. Charact.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>35</i></span>, <span class="NLM_elocation-id">1700299</span> <span class="refDoi"> DOI: 10.1002/ppsc.201700299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1002%2Fppsc.201700299" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2018&author=G.+Margueritauthor=H.+Moustaouiauthor=M.+B.+Haddadaauthor=N.+Djakerauthor=M.+L.+de+la+Chapelleauthor=J.+Spadavecchia&title=Taxanes+Hybrid+Nanovectors%3A+From+Design+to+Physico-Chemical+Evaluation+of+Docetaxel+and+Paclitaxel+Gold+%28III%29-PEGylated+Complex+Nanocarriers&doi=10.1002%2Fppsc.201700299"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fppsc.201700299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fppsc.201700299%26sid%3Dliteratum%253Aachs%26aulast%3DMarguerit%26aufirst%3DG.%26aulast%3DMoustaoui%26aufirst%3DH.%26aulast%3DHaddada%26aufirst%3DM.%2BB.%26aulast%3DDjaker%26aufirst%3DN.%26aulast%3Dde%2Bla%2BChapelle%26aufirst%3DM.%2BL.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26atitle%3DTaxanes%2520Hybrid%2520Nanovectors%253A%2520From%2520Design%2520to%2520Physico-Chemical%2520Evaluation%2520of%2520Docetaxel%2520and%2520Paclitaxel%2520Gold%2520%2528III%2529-PEGylated%2520Complex%2520Nanocarriers%26jtitle%3DPart.%2520Part.%2520Syst.%2520Charact.%26date%3D2018%26volume%3D35%26doi%3D10.1002%2Fppsc.201700299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, S.</span></span> <span> </span><span class="NLM_article-title">Quantum Chemical Calculations and Analysis of FTIR, FT–Raman and UV–Vis Spectra of Temozolomide Molecule</span>. <i>J. Mol. Struct.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1099</i></span>,  <span class="NLM_fpage">453</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1016/j.molstruc.2015.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.molstruc.2015.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOmtbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1099&publication_year=2015&pages=453-462&author=S.+A.+Bhatauthor=S.+Ahmad&title=Quantum+Chemical+Calculations+and+Analysis+of+FTIR%2C+FT%E2%80%93Raman+and+UV%E2%80%93Vis+Spectra+of+Temozolomide+Molecule&doi=10.1016%2Fj.molstruc.2015.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Quantum chemical calculations and analysis of FTIR, FT-Raman and UV-Vis spectra of temozolomide molecule</span></div><div class="casAuthors">Bhat, Sheeraz Ahmad; Ahmad, Shabbir</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Structure</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1099</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">453-462</span>CODEN:
                <span class="NLM_cas:coden">JMOSB4</span>;
        ISSN:<span class="NLM_cas:issn">0022-2860</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A combined exptl. and theor. study of the structure, vibrational and electronic spectra of temozolomide mol., which is largely used in the treatment of brain tumors, is presented.  FTIR (4000-400 cm-1) and FT-Raman spectra (4000-50 cm-1) were recorded and analyzed using anharmonic frequency calcns. using VPT2, VSCF and CC-VSCF levels of theory within B3LYP/6-311++G(d,p) framework.  Anharmonic methods give accurate frequencies of fundamental modes, overtones as well as Fermi resonances and account for coupling of different modes.  The anharmonic frequencies calcd. using VPT2 and CC-VSCF methods show better agreement with the exptl. data.  Harmonic frequencies including solvent effects are also computed using IEF-PCM model.  The magnitudes of coupling between pair of modes were calcd. using coupling integral based on 2MR-QFF approxn.  Intermol. interactions are discussed for three possible dimers of temozolomide.  UV-visible spectrum, examd. in ethanol solvent, is compared with the calcd. spectrum at TD-DFT/6-311++G(d,p) level of theory.  The electronic properties, such as excitation energy, frontier MO energies and the assignments of the absorption bands are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqhw40XOjx-bVg90H21EOLACvtfcHk0lgidseKqlIBWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOmtbzN&md5=234b6195fd2b19c8bb50c554011c0443</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.molstruc.2015.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molstruc.2015.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DS.%2BA.%26aulast%3DAhmad%26aufirst%3DS.%26atitle%3DQuantum%2520Chemical%2520Calculations%2520and%2520Analysis%2520of%2520FTIR%252C%2520FT%25E2%2580%2593Raman%2520and%2520UV%25E2%2580%2593Vis%2520Spectra%2520of%2520Temozolomide%2520Molecule%26jtitle%3DJ.%2520Mol.%2520Struct.%26date%3D2015%26volume%3D1099%26spage%3D453%26epage%3D462%26doi%3D10.1016%2Fj.molstruc.2015.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayne, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Englander, S. W.</span></span> <span> </span><span class="NLM_article-title">Primary Structure Effects on Peptide Group Hydrogen Exchange</span>. <i>Proteins</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1002/prot.340170110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1002%2Fprot.340170110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=8234246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADyaK2cXitl2nu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1993&pages=75-86&author=Y.+Baiauthor=J.+S.+Milneauthor=L.+Mayneauthor=S.+W.+Englander&title=Primary+Structure+Effects+on+Peptide+Group+Hydrogen+Exchange&doi=10.1002%2Fprot.340170110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Primary structure effects on peptide group hydrogen exchange</span></div><div class="casAuthors">Bai, Yawen; Milne, John S.; Mayne, Leland; Englander, S. Walter</div><div class="citationInfo"><span class="NLM_cas:title">Proteins:  Structure, Function, and Genetics</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-86</span>CODEN:
                <span class="NLM_cas:coden">PSFGEY</span>;
        ISSN:<span class="NLM_cas:issn">0887-3585</span>.
    </div><div class="casAbstract">The rate of exchange of peptide group NH hydrogens with the hydrogens of aq. solvent is sensitive to neighboring side chains.  To evaluate the effects of protein side chains, all 20 naturally occurring amino acids were studied using dipeptide models.  Both inductive and steric blocking effects are apparent.  The additivity of nearest-neighbor blocking and inductive effects was tested in oligo and polypeptides and, surprisingly, confirmed.  Ref. rates for alanine-contg. peptides were detd. and effects of temp. considered.  These results provide the information necessary to evaluate measured protein NH to ND exchange rates by comparing them with rates to be expected for the same amino acid sequence is unstructured oligo- and polypeptides.  The application of this approach to protein studies is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp_wWU7X49a7Vg90H21EOLACvtfcHk0lgoQBGPp9qmZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitl2nu74%253D&md5=2611cbff4c86fafe936447fb007d1768</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fprot.340170110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.340170110%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DY.%26aulast%3DMilne%26aufirst%3DJ.%2BS.%26aulast%3DMayne%26aufirst%3DL.%26aulast%3DEnglander%26aufirst%3DS.%2BW.%26atitle%3DPrimary%2520Structure%2520Effects%2520on%2520Peptide%2520Group%2520Hydrogen%2520Exchange%26jtitle%3DProteins%26date%3D1993%26volume%3D17%26spage%3D75%26epage%3D86%26doi%3D10.1002%2Fprot.340170110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gharib, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalaf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afroz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feliu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parak, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, I.</span></span> <span> </span><span class="NLM_article-title">Sustainable Synthesis and Improved Colloidal Stability of Pop Corn-Shaped Gold Nanoparticles</span>. <i>ACS Sustainable Chem. Eng.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">9834</span>– <span class="NLM_lpage">9841</span>, <span class="refDoi"> DOI: 10.1021/acssuschemeng.9b00295</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acssuschemeng.9b00295" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVKmt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=9834-9841&author=M.+Gharibauthor=M.+Khalafauthor=S.+Afrozauthor=N.+Feliuauthor=W.+J.+Parakauthor=I.+Chakraborty&title=Sustainable+Synthesis+and+Improved+Colloidal+Stability+of+Pop+Corn-Shaped+Gold+Nanoparticles&doi=10.1021%2Facssuschemeng.9b00295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Sustainable Synthesis and Improved Colloidal Stability of Popcorn-Shaped Gold Nanoparticles</span></div><div class="casAuthors">Gharib, Mustafa; Khalaf, Mahmoud; Afroz, Sharmin; Feliu, Neus; Parak, Wolfgang J.; Chakraborty, Indranath</div><div class="citationInfo"><span class="NLM_cas:title">ACS Sustainable Chemistry & Engineering</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">9834-9841</span>CODEN:
                <span class="NLM_cas:coden">ASCECG</span>;
        ISSN:<span class="NLM_cas:issn">2168-0485</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anisotropic popcorn-shaped gold nanoparticles (GNPCs) were synthesized through a sustainable route.  Proteins were used as ligands, and among several proteins, bovine serum albumin (BSA) produced high-quality GNPCs.  The method is scalable to produce liters of NPs (with almost mM elemental Au concn.) in a single batch.  Structural changes of proteins due to GNPC formation were studied in detail using CD and fluorescence spectroscopy.  The secondary structure of proteins was lost in the growth step, which facilitates the formation of GNPCs.  Among other similar sized gold nanoparticles, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="33747d637073716072">[email protected]</a> was found to have high colloidal stability and biocompatibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYPG9G5AU1YLVg90H21EOLACvtfcHk0lgoQBGPp9qmZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVKmt7Y%253D&md5=bf90ef100fea009c5e6842551a99aedf</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facssuschemeng.9b00295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facssuschemeng.9b00295%26sid%3Dliteratum%253Aachs%26aulast%3DGharib%26aufirst%3DM.%26aulast%3DKhalaf%26aufirst%3DM.%26aulast%3DAfroz%26aufirst%3DS.%26aulast%3DFeliu%26aufirst%3DN.%26aulast%3DParak%26aufirst%3DW.%2BJ.%26aulast%3DChakraborty%26aufirst%3DI.%26atitle%3DSustainable%2520Synthesis%2520and%2520Improved%2520Colloidal%2520Stability%2520of%2520Pop%2520Corn-Shaped%2520Gold%2520Nanoparticles%26jtitle%3DACS%2520Sustainable%2520Chem.%2520Eng.%26date%3D2019%26volume%3D7%26spage%3D9834%26epage%3D9841%26doi%3D10.1021%2Facssuschemeng.9b00295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klekotko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brach, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olesiak-Banska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samoc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matczyszyn, K.</span></span> <span> </span><span class="NLM_article-title">Pop Corn-Shaped Gold Nanoparticles: Plant Extract-Mediated Synthesis, Characterization and Multiphoton-Excited Luminescence Properties</span>. <i>Mater. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>229</i></span>,  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1016/j.matchemphys.2019.02.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.matchemphys.2019.02.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktFemtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=229&publication_year=2019&pages=56-60&author=M.+Klekotkoauthor=K.+Brachauthor=J.+Olesiak-Banskaauthor=M.+Samocauthor=K.+Matczyszyn&title=Pop+Corn-Shaped+Gold+Nanoparticles%3A+Plant+Extract-Mediated+Synthesis%2C+Characterization+and+Multiphoton-Excited+Luminescence+Properties&doi=10.1016%2Fj.matchemphys.2019.02.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Popcorn-shaped gold nanoparticles: Plant extract-mediated synthesis, characterization and multiphoton-excited luminescence properties</span></div><div class="casAuthors">Klekotko, Magdalena; Brach, Katarzyna; Olesiak-Banska, Joanna; Samoc, Marek; Matczyszyn, Katarzyna</div><div class="citationInfo"><span class="NLM_cas:title">Materials Chemistry and Physics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">229</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">56-60</span>CODEN:
                <span class="NLM_cas:coden">MCHPDR</span>;
        ISSN:<span class="NLM_cas:issn">0254-0584</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We describe the application of Cistus incanus ext. as a source of reducing, structure-directing and stabilizing agents in the fabrication of gold nanoparticles (GNPs) from tetrachloroauric acid soln.  The synthesis resulted in the formation of nanostructures with highly extended surface area, resembling the shape of popcorn.  Various ratios of plant ext. vol. to chloroauric acid vol. were investigated in order to obtain nanoparticles with desired shapes having the narrowest size distribution.  The synthesized nanoparticles were characterized using UV-Vis absorption spectroscopy, transmission electron microscopy (TEM) and at. force microscopy (AFM).  Multiphoton-excited luminescence (MPL) properties of plant ext. synthesized popcorn-shaped gold nanoparticles were examd. in comparison with gold nanostars synthesized chem.  The obtained results suggest that the GNPs synthesized using cistus ext. may be useful imaging agents for multiphoton microscopy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0KNmNhaHoGLVg90H21EOLACvtfcHk0lgoQBGPp9qmZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktFemtrs%253D&md5=41e91325a5b2684c18b6d3437c475261</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.matchemphys.2019.02.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.matchemphys.2019.02.066%26sid%3Dliteratum%253Aachs%26aulast%3DKlekotko%26aufirst%3DM.%26aulast%3DBrach%26aufirst%3DK.%26aulast%3DOlesiak-Banska%26aufirst%3DJ.%26aulast%3DSamoc%26aufirst%3DM.%26aulast%3DMatczyszyn%26aufirst%3DK.%26atitle%3DPop%2520Corn-Shaped%2520Gold%2520Nanoparticles%253A%2520Plant%2520Extract-Mediated%2520Synthesis%252C%2520Characterization%2520and%2520Multiphoton-Excited%2520Luminescence%2520Properties%26jtitle%3DMater.%2520Chem.%2520Phys.%26date%3D2019%26volume%3D229%26spage%3D56%26epage%3D60%26doi%3D10.1016%2Fj.matchemphys.2019.02.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moustaoui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djeddi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diallo, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Chapelle, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djaker, N.</span></span> <span> </span><span class="NLM_article-title">Shape and Size Effect on Photothermal Heat Elevation of Gold Nanoparticles: Absorption Coefficient Experimental Measurement of Spherical and Urchin-Shaped Gold Nanoparticles</span>. <i>J. Phys. Chem. C</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">17548</span>– <span class="NLM_lpage">17554</span>, <span class="refDoi"> DOI: 10.1021/acs.jpcc.9b03122</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jpcc.9b03122" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Oqs7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2019&pages=17548-17554&author=H.+Moustaouiauthor=J.+Saberauthor=I.+Djeddiauthor=Q.+Liuauthor=A.+T.+Dialloauthor=J.+Spadavecchiaauthor=M.+L.+de+la+Chapelleauthor=N.+Djaker&title=Shape+and+Size+Effect+on+Photothermal+Heat+Elevation+of+Gold+Nanoparticles%3A+Absorption+Coefficient+Experimental+Measurement+of+Spherical+and+Urchin-Shaped+Gold+Nanoparticles&doi=10.1021%2Facs.jpcc.9b03122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Shape and Size Effect on Photothermal Heat Elevation of Gold Nanoparticles: Absorption Coefficient Experimental Measurement of Spherical and Urchin-Shaped Gold Nanoparticles</span></div><div class="casAuthors">Moustaoui, Hanane; Saber, Justine; Djeddi, Ines; Liu, Qiqian; Diallo, Amadou Thierno; Spadavecchia, Jolanda; Lamy de la Chapelle, Marc; Djaker, Nadia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry C</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">17548-17554</span>CODEN:
                <span class="NLM_cas:coden">JPCCCK</span>;
        ISSN:<span class="NLM_cas:issn">1932-7447</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Gold nanoparticles (GNP) are very suitable agents for thermal destruction of cancer cells because of their photothermal heating ability.  Photothermal properties of different sizes and shapes of GNPs were studied regarding different parameters such as GNP concn., laser excitation intensity, and exposure time.  By using the heat transfer theory, the temp. elevation in the GNP solns. was converted in temp. elevation at the GNP surface.  This allows the authors to det. the absorption cross section (σabs) of two different sizes of spherical gold nanoparticles (GNS), which were compared with the theor. calcns. based on the Mie theory, and both results were in a good agreement. σabs was detd. also for gold nanourchins with different sizes (50, 80, and 90 nm) with high precision.  Finally, the temp. elevation speeds were exptl. measured for all GNPs, and they are proportional to the GNP surface area as demonstrated in the classical diffusive heat transport theory.  The proposed approaches can be used to monitor the local heat generation around the GNP and pave the way to the optimization of the photothermal properties of GNPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNxIAcBo9-GLVg90H21EOLACvtfcHk0lgoQBGPp9qmZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Oqs7vM&md5=d94a6228c86f63d42e567202c7d92006</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jpcc.9b03122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jpcc.9b03122%26sid%3Dliteratum%253Aachs%26aulast%3DMoustaoui%26aufirst%3DH.%26aulast%3DSaber%26aufirst%3DJ.%26aulast%3DDjeddi%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DDiallo%26aufirst%3DA.%2BT.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26aulast%3Dde%2Bla%2BChapelle%26aufirst%3DM.%2BL.%26aulast%3DDjaker%26aufirst%3DN.%26atitle%3DShape%2520and%2520Size%2520Effect%2520on%2520Photothermal%2520Heat%2520Elevation%2520of%2520Gold%2520Nanoparticles%253A%2520Absorption%2520Coefficient%2520Experimental%2520Measurement%2520of%2520Spherical%2520and%2520Urchin-Shaped%2520Gold%2520Nanoparticles%26jtitle%3DJ.%2520Phys.%2520Chem.%2520C%26date%3D2019%26volume%3D123%26spage%3D17548%26epage%3D17554%26doi%3D10.1021%2Facs.jpcc.9b03122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clemente, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigliotti, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capucchio, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biasibetti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annovazzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cangemi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muntoni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miglio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dianzani, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battaglia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dianzani, C.</span></span> <span> </span><span class="NLM_article-title">Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>, <span class="NLM_elocation-id">255</span> <span class="refDoi"> DOI: 10.3390/ijms19020255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.3390%2Fijms19020255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wjs7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&author=N.+Clementeauthor=B.+Ferraraauthor=C.+L.+Gigliottiauthor=E.+Boggioauthor=M.+T.+Capucchioauthor=E.+Biasibettiauthor=D.+Schifferauthor=M.+Mellaiauthor=L.+Annovazziauthor=L.+Cangemiauthor=E.+Muntoniauthor=G.+Miglioauthor=U.+Dianzaniauthor=L.+Battagliaauthor=C.+Dianzani&title=Solid+Lipid+Nanoparticles+Carrying+Temozolomide+for+Melanoma+Treatment.+Preliminary+In+Vitro+and+In+Vivo+Studies&doi=10.3390%2Fijms19020255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Solid lipid nanoparticles carrying temozolomide for melanoma treatment. Preliminary in vitro and in vivo studies</span></div><div class="casAuthors">Clemente, Nausicaa; Ferrara, Benedetta; Gigliotti, Casimiro Luca; Boggio, Elena; Capucchio, Maria Teresa; Biasibetti, Elena; Schiffer, Davide; Mellai, Marta; Annovazzi, Laura; Cangemi, Luigi; Muntoni, Elisabetta; Miglio, Gianluca; Dianzani, Umberto; Battaglia, Luigi; Dianzani, Chiara</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">255/1-255/19</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Aim: To develop an innovative delivery system for temozolomide (TMZ) in solid lipid nanoparticles (SLN), which has been preliminarily investigated for the treatment of melanoma.  Materials and Methods: SLN-TMZ was obtained through fatty acid coacervation.  Its pharmacol. effects were assessed and compared with free TMZ in in vitro and in vivo models of melanoma and glioblastoma.  Results: Compared to the std. free TMZ, SLN-TMZ exerted larger effects, when cell proliferation of melanoma cells, and neoangiogeneis were evaluated.  SLN-TMZ also inhibited growth and vascularization of B16-F10 melanoma in C57/BL6 mice, without apparent toxic effects.  Conclusion: SLN could be a promising strategy for the delivery of TMZ, allowing an increased stability of the drug and thereby its employment in the treatment of aggressive malignacies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN14iGHbohd7Vg90H21EOLACvtfcHk0lg5v_kvwB9EIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wjs7jN&md5=050fa5e31342682fed8333a7c0edd5ea</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.3390%2Fijms19020255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19020255%26sid%3Dliteratum%253Aachs%26aulast%3DClemente%26aufirst%3DN.%26aulast%3DFerrara%26aufirst%3DB.%26aulast%3DGigliotti%26aufirst%3DC.%2BL.%26aulast%3DBoggio%26aufirst%3DE.%26aulast%3DCapucchio%26aufirst%3DM.%2BT.%26aulast%3DBiasibetti%26aufirst%3DE.%26aulast%3DSchiffer%26aufirst%3DD.%26aulast%3DMellai%26aufirst%3DM.%26aulast%3DAnnovazzi%26aufirst%3DL.%26aulast%3DCangemi%26aufirst%3DL.%26aulast%3DMuntoni%26aufirst%3DE.%26aulast%3DMiglio%26aufirst%3DG.%26aulast%3DDianzani%26aufirst%3DU.%26aulast%3DBattaglia%26aufirst%3DL.%26aulast%3DDianzani%26aufirst%3DC.%26atitle%3DSolid%2520Lipid%2520Nanoparticles%2520Carrying%2520Temozolomide%2520for%2520Melanoma%2520Treatment.%2520Preliminary%2520In%2520Vitro%2520and%2520In%2520Vivo%2520Studies%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26doi%3D10.3390%2Fijms19020255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emrick, T.</span></span> <span> </span><span class="NLM_article-title">Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma</span>. <i>Mol. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">5263</span>– <span class="NLM_lpage">5276</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.8b00766</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.8b00766" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFSiurbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=5263-5276&author=S.+M.+Wardauthor=M.+Skinnerauthor=B.+Sahaauthor=T.+Emrick&title=Polymer-Temozolomide+Conjugates+as+Therapeutics+for+Treating+Glioblastoma&doi=10.1021%2Facs.molpharmaceut.8b00766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma</span></div><div class="casAuthors">Ward, Sarah M.; Skinner, Matthew; Saha, Banishree; Emrick, Todd</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5263-5276</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of polymer-drug conjugates based on 2-methacryloyloxyethyl phosphorylcholine (MPC) was prepd. with the glioblastoma drug Temozolomide (TMZ) as pendent groups.  Random and block copolymers were synthesized by reversible addn.-fragmentation chain-transfer (RAFT) polymn. using a TMZ-contg. methacrylate monomer.  The soln. properties of the polyMPC-TMZ copolymers were investigated by dynamic light scattering and transmission electron microscopy, revealing well-defined nanostructures from the block copolymers.  Conjugation of TMZ to polyMPC enhanced drug stability, with decompn. half-life values ranging from 2- to 19-fold that of free TMZ.  The cytotoxicity of polyMPC-TMZ was evaluated in both chemosensitive (U87MG) and chemoresistant (T98G) glioblastoma cell lines.  Furthermore, the polyMPC-TMZ platform was expanded considerably by the prepn. of redox-sensitive polyMPC-TMZ copolymers utilizing disulfides as the polymer-to-drug linker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5xGQTVBKpHrVg90H21EOLACvtfcHk0lg5v_kvwB9EIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFSiurbI&md5=02586adbb935033043345e533fd5a16c</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.8b00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.8b00766%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DS.%2BM.%26aulast%3DSkinner%26aufirst%3DM.%26aulast%3DSaha%26aufirst%3DB.%26aulast%3DEmrick%26aufirst%3DT.%26atitle%3DPolymer-Temozolomide%2520Conjugates%2520as%2520Therapeutics%2520for%2520Treating%2520Glioblastoma%26jtitle%3DMol.%2520Pharm.%26date%3D2018%26volume%3D15%26spage%3D5263%26epage%3D5276%26doi%3D10.1021%2Facs.molpharmaceut.8b00766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ananta, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulmurugan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massoud, T. F.</span></span> <span> </span><span class="NLM_article-title">Temozolomide-loaded PLGA Nanoparticles to Treat Glioblastoma Cells: A Biophysical and Cell Culture Evaluation</span>. <i>Neurol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1080/01616412.2015.1133025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1080%2F01616412.2015.1133025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=26905383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A280%3ADC%252BC28jjslSjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2016&pages=51-59&author=J.+S.+Anantaauthor=R.+Paulmuruganauthor=T.+F.+Massoud&title=Temozolomide-loaded+PLGA+Nanoparticles+to+Treat+Glioblastoma+Cells%3A+A+Biophysical+and+Cell+Culture+Evaluation&doi=10.1080%2F01616412.2015.1133025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Temozolomide-loaded PLGA nanoparticles to treat glioblastoma cells: a biophysical and cell culture evaluation</span></div><div class="casAuthors">Ananta Jeyarama S; Massoud Tarik F; Paulmurugan Ramasamy</div><div class="citationInfo"><span class="NLM_cas:title">Neurological research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  Current chemotherapies for brain glioblastoma do not achieve sufficient drug concentrations within tumors.  Polymeric nanoparticles have useful physicochemical properties that make them promising as nanoparticle platforms for glioblastoma drug delivery.  Poly[lactic-co-glycolic acid] (PLGA) nanoparticles encapsulating temozolomide (TMZ) could improve localized delivery and sustained drug release to glioblastomas.  METHODS:  We investigated three different procedures to encapsulate TMZ within PLGA nanoparticles.  We studied the biophysical features of optimized nanocarriers, including their size, shape, surface properties, and release characteristics of TMZ.  We evaluated the antiproliferative and cytotoxic effects of TMZ-loaded PLGA nanoparticles on U87 MG glioblastoma cells.  RESULTS:  A single emulsion technique using a TMZ saturated aqueous phase produced nanoparticles ≤200 nm in size allowing a maximal drug loading of 4.4% w/w of polymer.  There was a bi-phasic drug release pattern, with 80% of TMZ released within the first 6 h.  Nanoparticles accumulated in the cytoplasm after effective endocytosis.  There was no significant difference in cytotoxic effect of TMZ encapsulated within PLGA nanoparticles and free TMZ.  CONCLUSIONS:  PLGA nanoparticles are not suitable as carriers of TMZ for glioblastoma drug delivery on account of the overall high IC50 values of glioblastoma cells to TMZ and poor loading and encapsulation efficiencies.  Further biotechnological developments aimed at improving the loading of TMZ in PLGA nanoparticles or co-delivery of small molecule sensitizers to improve the response of human glioblastoma cells to TMZ are required for this approach to be considered and optimized for future clinical translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmgm9nomqNH3ELvajU9pjPfW6udTcc2eZdQ_ym-zY1Wrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jjslSjsA%253D%253D&md5=709de28142b312948221afa6d9694d31</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1080%2F01616412.2015.1133025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F01616412.2015.1133025%26sid%3Dliteratum%253Aachs%26aulast%3DAnanta%26aufirst%3DJ.%2BS.%26aulast%3DPaulmurugan%26aufirst%3DR.%26aulast%3DMassoud%26aufirst%3DT.%2BF.%26atitle%3DTemozolomide-loaded%2520PLGA%2520Nanoparticles%2520to%2520Treat%2520Glioblastoma%2520Cells%253A%2520A%2520Biophysical%2520and%2520Cell%2520Culture%2520Evaluation%26jtitle%3DNeurol.%2520Res.%26date%3D2016%26volume%3D38%26spage%3D51%26epage%3D59%26doi%3D10.1080%2F01616412.2015.1133025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portilla-Arias, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konda, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wawrowsky, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ljubimova, J. Y.</span></span> <span> </span><span class="NLM_article-title">Temozolomide Delivery to Tumor Cells by A Multifunctional Nano Vehicle Based on Poly(beta-<span class="smallcaps smallerCapital">l</span>-malic acid)</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2317</span>– <span class="NLM_lpage">2329</span>, <span class="refDoi"> DOI: 10.1007/s11095-010-0091-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1007%2Fs11095-010-0091-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=20387095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKntrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2010&pages=2317-2329&author=R.+Patilauthor=J.+Portilla-Ariasauthor=H.+Dingauthor=S.+Inoueauthor=B.+Kondaauthor=J.+Huauthor=K.+A.+Wawrowskyauthor=P.+K.+Shinauthor=K.+L.+Blackauthor=E.+Hollerauthor=J.+Y.+Ljubimova&title=Temozolomide+Delivery+to+Tumor+Cells+by+A+Multifunctional+Nano+Vehicle+Based+on+Poly%28beta-l-malic+acid%29&doi=10.1007%2Fs11095-010-0091-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Temozolomide Delivery to Tumor Cells by a Multifunctional Nano Vehicle Based on Poly(β-L-malic acid)</span></div><div class="casAuthors">Patil, Rameshwar; Portilla-Arias, Jose; Ding, Hui; Inoue, Satoshi; Konda, Bindu; Hu, Jinwei; Wawrowsky, Kolja A.; Shin, Paul K.; Black, Keith L.; Holler, Eggehard; Ljubimova, Julia Y.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2317-2329</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Temozolomide (TMZ) is a pro-drug releasing a DNA alkylating agent that is the most effective drug to treat glial tumors when combined with radiation.  TMZ is toxic, and therapeutic dosages are limited by severe side effects.  Targeted delivery is thus needed to improve efficiency and reduce non-tumor tissue toxicity.  Methods: Multifunctional targetable nanoconjugates of TMZ hydrazide were synthesized using poly(β-L-malic acid) platform, which contained a targeting monoclonal antibody to transferrin receptor (TfR), trileucine (LLL), for pH-dependent endosomal membrane disruption, and PEG for protection.  Results: The water-sol. TMZ nanoconjugates had hydrodynamic diams. in the range of 6.5 to 14.8 nm and ζ potentials in the range of -6.3 to -17.7 mV.  Fifty percent degrdn. in human plasma was obsd. in 40 h at 37°C.  TMZ conjugated with polymer had a half-life of 5-7 h, compared with 1.8 h for free TMZ.  The strongest redn. of human brain and breast cancer cell viability was obtained by versions of TMZ nanoconjugates contg. LLL and anti-TfR antibody.  TMZ-resistant cancer cell lines were sensitive to TMZ nanoconjugate treatment.  Conclusions: TMZ-polymer nanoconjugates entered the tumor cells by receptor-mediated endocytosis, effectively reduced cancer cell viability, and can potentially be used for targeted tumor treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9l3dXRdn_47Vg90H21EOLACvtfcHk0liGc6O7hLgDRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKntrY%253D&md5=13d07834b0e25f339beab8e7a2b7749a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1007%2Fs11095-010-0091-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-010-0091-0%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DR.%26aulast%3DPortilla-Arias%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DInoue%26aufirst%3DS.%26aulast%3DKonda%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DWawrowsky%26aufirst%3DK.%2BA.%26aulast%3DShin%26aufirst%3DP.%2BK.%26aulast%3DBlack%26aufirst%3DK.%2BL.%26aulast%3DHoller%26aufirst%3DE.%26aulast%3DLjubimova%26aufirst%3DJ.%2BY.%26atitle%3DTemozolomide%2520Delivery%2520to%2520Tumor%2520Cells%2520by%2520A%2520Multifunctional%2520Nano%2520Vehicle%2520Based%2520on%2520Poly%2528beta-l-malic%2520acid%2529%26jtitle%3DPharm.%2520Res.%26date%3D2010%26volume%3D27%26spage%3D2317%26epage%3D2329%26doi%3D10.1007%2Fs11095-010-0091-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rekechenetskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ljubimova, J. Y.</span></span> <span> </span><span class="NLM_article-title">Nanomedicine Therapeutic Approaches to Overcome Cancer Drug Resistance</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1866</span>– <span class="NLM_lpage">1879</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2013.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.addr.2013.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=24120656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs12ktr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=1866-1879&author=J.+L.+Markmanauthor=A.+Rekechenetskiyauthor=E.+Hollerauthor=J.+Y.+Ljubimova&title=Nanomedicine+Therapeutic+Approaches+to+Overcome+Cancer+Drug+Resistance&doi=10.1016%2Fj.addr.2013.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Nanomedicine therapeutic approaches to overcome cancer drug resistance</span></div><div class="casAuthors">Markman, Janet L.; Rekechenetskiy, Arthur; Holler, Eggehard; Ljubimova, Julia Y.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">13-14</span>),
    <span class="NLM_cas:pages">1866-1879</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Nanomedicine is an emerging form of therapy that focuses on alternative drug delivery and improvement of the treatment efficacy while reducing detrimental side effects to normal tissues.  Cancer drug resistance is a complicated process that involves multiple mechanisms.  Here we discuss the major forms of drug resistance and the new possibilities that nanomedicines offer to overcome these treatment obstacles.  Novel nanomedicines that have a high ability for flexible, fast drug design and prodn. based on tumor genetic profiles can be created making drug selection for personal patient treatment much more intensive and effective.  This review aims to demonstrate the advantage of the young medical science field, nanomedicine, for overcoming cancer drug resistance.  With the advanced design and alternative mechanisms of drug delivery known for different nanodrugs including liposomes, polymer conjugates, micelles, dendrimers, carbon-based, and metallic nanoparticles, overcoming various forms of multi-drug resistance looks promising and opens new horizons for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt538MrygldrVg90H21EOLACvtfcHk0liGc6O7hLgDRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs12ktr%252FM&md5=33cfbc666ad0d655232bf8d8f373a4e0</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2013.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2013.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DMarkman%26aufirst%3DJ.%2BL.%26aulast%3DRekechenetskiy%26aufirst%3DA.%26aulast%3DHoller%26aufirst%3DE.%26aulast%3DLjubimova%26aufirst%3DJ.%2BY.%26atitle%3DNanomedicine%2520Therapeutic%2520Approaches%2520to%2520Overcome%2520Cancer%2520Drug%2520Resistance%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2013%26volume%3D65%26spage%3D1866%26epage%3D1879%26doi%3D10.1016%2Fj.addr.2013.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Jong, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borm, P. J. A.</span></span> <span> </span><span class="NLM_article-title">Drug Delivery and Nanoparticles:Applications and Hazards</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.2147/IJN.S596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.2147%2FIJN.S596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=18686775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Wjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=133-149&author=W.+H.+De%0AJongauthor=P.+J.+A.+Borm&title=Drug+Delivery+and+Nanoparticles%3AApplications+and+Hazards&doi=10.2147%2FIJN.S596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Drug delivery and nanoparticles: applications and hazards</span></div><div class="casAuthors">De Jong, Wim H.; Borm, Paul J. A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-149</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1176-9114</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  The use of nanotechnol. in medicine and more specifically drug delivery is set to spread rapidly.  Currently many substances are under investigation for drug delivery and more specifically for cancer therapy.  Interestingly pharmaceutical sciences are using nanoparticles to reduce toxicity and side effects of drugs and up to recently did not realize that carrier systems themselves may impose risks to the patient.  The kind of hazards that are introduced by using nanoparticles for drug delivery are beyond that posed by conventional hazards imposed by chems. in classical delivery matrixes.  For nanoparticles the knowledge on particle toxicity as obtained in inhalation toxicity shows the way how to investigate the potential hazards of nanoparticles.  The toxicol. of particulate matter differs from toxicol. of substances as the composing chem.(s) may or may not be sol. in biol. matrixes, thus influencing greatly the potential exposure of various internal organs.  This may vary from a rather high local exposure in the lungs and a low or neglectable exposure for other organ systems after inhalation.  However, absorbed species may also influence the potential toxicity of the inhaled particles.  For nanoparticles the situation is different as their size opens the potential for crossing the various biol. barriers within the body.  From a pos. viewpoint, esp. the potential to cross the blood brain barrier may open new ways for drug delivery into the brain.  In addn., the nanosize also allows for access into the cell and various cellular compartments including the nucleus.  A multitude of substances are currently under investigation for the prepn. of nanoparticles for drug delivery, varying from biol. substances like albumin, gelatine and phospholipids for liposomes, and more substances of a chem. nature like various polymers and solid metal contg. nanoparticles.  It is obvious that the potential interaction with tissues and cells, and the potential toxicity, greatly depends on the actual compn. of the nanoparticle formulation.  This paper provides an overview on some of the currently used systems for drug delivery.  Besides the potential beneficial use also attention is drawn to the questions how we should proceed with the safety evaluation of the nanoparticle formulations for drug delivery.  For such testing the lessons learned from particle toxicity as applied in inhalation toxicol. may be of use.  Although for pharmaceutical use the current requirements seem to be adequate to detect most of the adverse effects of nanoparticle formulations, it can not be expected that all aspects of nanoparticle toxicol. will be detected.  So, probably addnl. more specific testing would be needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2ffgu7g8Mh7Vg90H21EOLACvtfcHk0liGc6O7hLgDRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Wjt7w%253D&md5=db515c60ea3c5b6596b8802e82594c34</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.2147%2FIJN.S596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S596%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BJong%26aufirst%3DW.%2BH.%26aulast%3DBorm%26aufirst%3DP.%2BJ.%2BA.%26atitle%3DDrug%2520Delivery%2520and%2520Nanoparticles%253AApplications%2520and%2520Hazards%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2008%26volume%3D3%26spage%3D133%26epage%3D149%26doi%3D10.2147%2FIJN.S596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span> <span> </span><span class="NLM_article-title">pH-Sensitive Polymeric Micelles Triggered Drug Release for Extracellular and Intracellular Drug Targeting Delivery</span>. <i>Asian J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1016/j.ajps.2013.07.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.ajps.2013.07.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=159-167&author=Y.+Liuauthor=W.+Wangauthor=J.+Yangauthor=C.+Zhouauthor=J.+Sun&title=pH-Sensitive+Polymeric+Micelles+Triggered+Drug+Release+for+Extracellular+and+Intracellular+Drug+Targeting+Delivery&doi=10.1016%2Fj.ajps.2013.07.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.ajps.2013.07.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajps.2013.07.021%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26atitle%3DpH-Sensitive%2520Polymeric%2520Micelles%2520Triggered%2520Drug%2520Release%2520for%2520Extracellular%2520and%2520Intracellular%2520Drug%2520Targeting%2520Delivery%26jtitle%3DAsian%2520J.%2520Pharm.%2520Sci.%26date%3D2013%26volume%3D8%26spage%3D159%26epage%3D167%26doi%3D10.1016%2Fj.ajps.2013.07.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daniele, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zappelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trincavelli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minutolo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, C.</span></span> <span> </span><span class="NLM_article-title">Lactate Dehydrogenase-A Inhibition Induces Human Glioblastoma Multiforme Stem Cell Differentiation and Death</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">15556</span> <span class="refDoi"> DOI: 10.1038/srep15556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1038%2Fsrep15556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=26494310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslans7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&author=S.+Danieleauthor=C.+Giacomelliauthor=E.+Zappelliauthor=C.+Granchiauthor=M.+L.+Trincavelliauthor=F.+Minutoloauthor=C.+Martini&title=Lactate+Dehydrogenase-A+Inhibition+Induces+Human+Glioblastoma+Multiforme+Stem+Cell+Differentiation+and+Death&doi=10.1038%2Fsrep15556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Lactate dehydrogenase-A inhibition induces human glioblastoma multiforme stem cell differentiation and death</span></div><div class="casAuthors">Daniele, Simona; Giacomelli, Chiara; Zappelli, Elisa; Granchi, Carlotta; Trincavelli, Maria Letizia; Minutolo, Filippo; Martini, Claudia</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15556</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Therapies that target the signal transduction and metabolic pathways of cancer stem cells (CSCs) are innovative strategies to effectively reduce the recurrence and significantly improve the outcome of glioblastoma multiforme (GBM).  CSCs exhibit an increased rate of glycolysis, thus rendering them intrinsically more sensitive to prospective therapeutic strategies based on the inhibition of the glycolytic pathway.  The enzyme lactate dehydrogenase-A (LDH-A), which catalyzes the interconversion of pyruvate and lactate, is up-regulated in human cancers, including GBM.  Although several papers have explored the benefits of targeting cancer metab. in GBM, the effects of direct LDH-A inhibition in glial tumors have not yet been investigated, particularly in the stem cell subpopulation.  Here, two representative LDH-A inhibitors (NHI-1 and NHI-2) were studied in GBM-derived CSCs and compared to differentiated tumor cells.  LDH-A inhibition was particularly effective in CSCs isolated from different GBM cell lines, where the two compds. blocked CSC formation and elicited long-lasting effects by triggering both apoptosis and cellular differentiation.  These data demonstrate that GBM, particularly the stem cell subpopulation, is sensitive to glycolytic inhibition and shed light on the therapeutic potential of LDH-A inhibitors in this tumor type.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeQln7yDbAH7Vg90H21EOLACvtfcHk0lhT5xSEKWZasw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslans7jO&md5=ee9925b21e5f1418f2ce668c5796d6db</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fsrep15556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep15556%26sid%3Dliteratum%253Aachs%26aulast%3DDaniele%26aufirst%3DS.%26aulast%3DGiacomelli%26aufirst%3DC.%26aulast%3DZappelli%26aufirst%3DE.%26aulast%3DGranchi%26aufirst%3DC.%26aulast%3DTrincavelli%26aufirst%3DM.%2BL.%26aulast%3DMinutolo%26aufirst%3DF.%26aulast%3DMartini%26aufirst%3DC.%26atitle%3DLactate%2520Dehydrogenase-A%2520Inhibition%2520Induces%2520Human%2520Glioblastoma%2520Multiforme%2520Stem%2520Cell%2520Differentiation%2520and%2520Death%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26doi%3D10.1038%2Fsrep15556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohd Omar, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soong, R.</span></span> <span> </span><span class="NLM_article-title">The Warburg Effect and Drug Resistance</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">970</span>– <span class="NLM_lpage">979</span>, <span class="refDoi"> DOI: 10.1111/bph.13422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1111%2Fbph.13422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=26750865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC28Xis1GjtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=970-979&author=B.+Bhattacharyaauthor=M.+F.+Mohd+Omarauthor=R.+Soong&title=The+Warburg+Effect+and+Drug+Resistance&doi=10.1111%2Fbph.13422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The Warburg effect and drug resistance</span></div><div class="casAuthors">Bhattacharya, Bhaskar; Mohd. Omar, Mohd Feroz; Soong, Richie</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">970-979</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The Warburg effect describes the increased utilization of glycolysis rather than oxidative phosphorylation by tumor cells for their energy requirements under physiol. oxygen conditions.  This effect has been the basis for much speculation on the survival advantage of tumor cells, tumorigenesis and the microenvironment of tumors.  More recently, studies have begun to reveal how the Warburg effect could influence drug efficacy and how our understanding of tumor energetics could be exploited to improve drug development.  In particular, evidence is emerging demonstrating how better modeling of the tumor metabolic microenvironment could lead to a better prediction of drug efficacy and the identification of new combination strategies.  This review will provide details of the current understanding of the complex interplay between glucose metab. and pharmacol. and discuss opportunities for utilizing the Warburg effect in future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMWLsbfrBry7Vg90H21EOLACvtfcHk0lhT5xSEKWZasw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xis1GjtrY%253D&md5=d7141e6ce6fd1ef30136a1f6ff944c1b</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1111%2Fbph.13422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13422%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharya%26aufirst%3DB.%26aulast%3DMohd%2BOmar%26aufirst%3DM.%2BF.%26aulast%3DSoong%26aufirst%3DR.%26atitle%3DThe%2520Warburg%2520Effect%2520and%2520Drug%2520Resistance%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D173%26spage%3D970%26epage%3D979%26doi%3D10.1111%2Fbph.13422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.</span></span> <span> </span><span class="NLM_article-title">Targeting Cellular Metabolism to Improve Cancer Therapeutics</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e532</span> <span class="refDoi"> DOI: 10.1038/cddis.2013.60</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1038%2Fcddis.2013.60" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=23470539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVyku7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&author=Y.+Zhaoauthor=E.+B.+Butlerauthor=M.+Tan&title=Targeting+Cellular+Metabolism+to+Improve+Cancer+Therapeutics&doi=10.1038%2Fcddis.2013.60"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cellular metabolism to improve cancer therapeutics</span></div><div class="casAuthors">Zhao, Y.; Butler, E. B.; Tan, M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">March</span>),
    <span class="NLM_cas:pages">e532</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The metabolic properties of cancer cells diverge significantly from those of normal cells.  Energy prodn. in cancer cells is abnormally dependent on aerobic glycolysis.  In addn. to the dependency on glycolysis, cancer cells have other atypical metabolic characteristics such as increased fatty acid synthesis and increased rates of glutamine metab.  Emerging evidence shows that many features characteristic to cancer cells, such as dysregulated Warburg-like glucose metab., fatty acid synthesis and glutaminolysis are linked to therapeutic resistance in cancer treatment.  Therefore, targeting cellular metab. may improve the response to cancer therapeutics and the combination of chemotherapeutic drugs with cellular metab. inhibitors may represent a promising strategy to overcome drug resistance in cancer therapy.  Recently, several review articles have summarized the anticancer targets in the metabolic pathways and metabolic inhibitor-induced cell death pathways, however, the dysregulated metab. in therapeutic resistance, which is a highly clin. relevant area in cancer metab. research, has not been specifically addressed.  From this unique angle, this review article will discuss the relationship between dysregulated cellular metab. and cancer drug resistance and how targeting of metabolic enzymes, such as glucose transporters, hexokinase, pyruvate kinase M2, lactate dehydrogenase A, pyruvate dehydrogenase kinase, fatty acid synthase and glutaminase can enhance the efficacy of common therapeutic agents or overcome resistance to chemotherapy or radiotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMC5ekN6_UhbVg90H21EOLACvtfcHk0lhT5xSEKWZasw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVyku7%252FJ&md5=fef8a7abec0d228e32fd03cfb85f3ca6</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2013.60&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2013.60%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DButler%26aufirst%3DE.%2BB.%26aulast%3DTan%26aufirst%3DM.%26atitle%3DTargeting%2520Cellular%2520Metabolism%2520to%2520Improve%2520Cancer%2520Therapeutics%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2013%26volume%3D4%26doi%3D10.1038%2Fcddis.2013.60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galluzzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kepp, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Heiden, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">Metabolic Targets for Cancer Therapy</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">829</span>– <span class="NLM_lpage">846</span>, <span class="refDoi"> DOI: 10.1038/nrd4145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1038%2Fnrd4145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=24113830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2nsr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=829-846&author=L.+Galluzziauthor=O.+Keppauthor=M.+G.+Vander+Heidenauthor=G.+Kroemer&title=Metabolic+Targets+for+Cancer+Therapy&doi=10.1038%2Fnrd4145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic targets for cancer therapy</span></div><div class="casAuthors">Galluzzi, Lorenzo; Kepp, Oliver; Vander Heiden, Matthew G.; Kroemer, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">829-846</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Malignant cells exhibit metabolic changes, when compared to their normal counterparts, owing to both genetic and epigenetic alterations.  Although such a metabolic rewiring has recently been indicated as yet another general hallmark of cancer, accumulating evidence suggests that the metabolic alterations of each neoplasm represent a mol. signature that intimately accompanies and allows for different facets of malignant transformation.  During the past decade, targeting cancer metab. has emerged as a promising strategy for the development of selective antineoplastic agents.  Here, we discuss the intimate relationship between metab. and malignancy, focusing on strategies through which this central aspect of tumor biol. might be turned into cancer's Achilles heel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWJB7NELP1nLVg90H21EOLACvtfcHk0ljB2FeZFDL54Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2nsr3M&md5=1c7d31d1d4494cfabe08604fbd44ffe0</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnrd4145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4145%26sid%3Dliteratum%253Aachs%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DKepp%26aufirst%3DO.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DMetabolic%2520Targets%2520for%2520Cancer%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D829%26epage%3D846%26doi%3D10.1038%2Fnrd4145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shingu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span> <span> </span><span class="NLM_article-title">Metabolic Alterations in Highly Tumorigenic Glioblastoma Cells: Preference for Hypoxia and High Dependency on Glycolysis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">32843</span>– <span class="NLM_lpage">32853</span>, <span class="refDoi"> DOI: 10.1074/jbc.M111.260935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1074%2Fjbc.M111.260935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=21795717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCisr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=32843-32853&author=Y.+Zhouauthor=Y.+Zhouauthor=T.+Shinguauthor=L.+Fengauthor=Z.+Chenauthor=M.+Ogasawaraauthor=M.+J.+Keatingauthor=S.+Kondoauthor=P.+Huang&title=Metabolic+Alterations+in+Highly+Tumorigenic+Glioblastoma+Cells%3A+Preference+for+Hypoxia+and+High+Dependency+on+Glycolysis&doi=10.1074%2Fjbc.M111.260935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis</span></div><div class="casAuthors">Zhou, Yunfei; Zhou, Yan; Shingu, Takashi; Feng, Li; Chen, Zhao; Ogasawara, Marcia; Keating, Michael J.; Kondo, Seiji; Huang, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">32843-32853, S32743/1-S32743/4</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Recent studies suggest that a small subpopulation of malignant cells with stem-like properties is resistant to chemotherapy and may be responsible for the existence of residual cancer after treatment.  We have isolated highly tumorigenic cancer cells with 100-fold increase in tumor initiating capacity from the tumor xenografts of human glioblastoma U87 cells in mice.  These cells exhibit stem-like properties and show unique energy metabolic characteristics including low mitochondrial respiration, increased glycolysis for ATP generation, and preference for hypoxia to maintain their stemness and tumor forming capacity.  Mechanistically, mitochondrial depression in the highly tumorigenic cells occurs mainly at complex II of the electron transport chain with a down-regulation of the succinate dehydrogenase subunit B, leading to deregulation of hypoxia-inducible factors.  Under hypoxia, the stem-like cancer cells are resistant to conventional anticancer agents but are sensitive to glycolytic inhibition.  Furthermore, combination of glycolytic inhibition with std. therapeutic agents is effective in killing the tumor-initiating cells in vitro and inhibits tumor formation in vivo.  Our study suggests that stem-like cancer cells prefer a low oxygen microenvironment and actively utilize the glycolytic pathway for ATP generation.  Inhibition of glycolysis may be an effective strategy to eradicate residual cancer stem cells that are otherwise resistant to chemotherapeutic agents in their hypoxic niches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowyx7mytI3hrVg90H21EOLACvtfcHk0ljB2FeZFDL54Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCisr7M&md5=c50be3969643e7e19aa239154db8c096</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.260935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.260935%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DShingu%26aufirst%3DT.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DOgasawara%26aufirst%3DM.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DKondo%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DP.%26atitle%3DMetabolic%2520Alterations%2520in%2520Highly%2520Tumorigenic%2520Glioblastoma%2520Cells%253A%2520Preference%2520for%2520Hypoxia%2520and%2520High%2520Dependency%2520on%2520Glycolysis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D32843%26epage%3D32853%26doi%3D10.1074%2Fjbc.M111.260935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minafra, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcino, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravatà, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaglio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanomi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amore, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cammarata, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Militello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoca, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baglio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbate, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacoviello, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelista, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilardi, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondì, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forte, G. I.</span></span> <span> </span><span class="NLM_article-title">Radiosensitizing Effect of Curcumin-Loaded Lipid Nanoparticles in Breast Cancer Cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">11134</span> <span class="refDoi"> DOI: 10.1038/s41598-019-47553-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1038%2Fs41598-019-47553-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=31366901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A280%3ADC%252BB3MvjsVejug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&author=L.+Minafraauthor=N.+Porcinoauthor=V.+Bravat%C3%A0author=D.+Gaglioauthor=M.+Bonanomiauthor=E.+Amoreauthor=F.+P.+Cammarataauthor=G.+Russoauthor=C.+Militelloauthor=G.+Savocaauthor=M.+Baglioauthor=B.+Abbateauthor=G.+Iacovielloauthor=G.+Evangelistaauthor=M.+C.+Gilardiauthor=M.+L.+Bond%C3%ACauthor=G.+I.+Forte&title=Radiosensitizing+Effect+of+Curcumin-Loaded+Lipid+Nanoparticles+in+Breast+Cancer+Cells&doi=10.1038%2Fs41598-019-47553-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Radiosensitizing effect of curcumin-loaded lipid nanoparticles in breast cancer cells</span></div><div class="casAuthors">Minafra Luigi; Porcino Nunziatina; Bravata Valentina; Gaglio Daniela; Cammarata Francesco Paolo; Russo Giorgio; Militello Carmelo; Savoca Gaetano; Baglio Margherita; Gilardi Maria Carla; Forte Giusi Irma; Gaglio Daniela; Bonanomi Marcella; Amore Erika; Bondi Maria Luisa; Abbate Boris; Iacoviello Giuseppina; Evangelista Giovanna; Gilardi Maria Carla</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11134</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In breast cancer (BC) care, radiotherapy is considered an efficient treatment, prescribed both for controlling localized tumors or as a therapeutic option in case of inoperable, incompletely resected or recurrent tumors.  However, approximately 90% of BC-related deaths are due to the metastatic tumor progression.  Then, it is strongly desirable to improve tumor radiosensitivity using molecules with synergistic action.  The main aim of this study is to develop curcumin-loaded solid nanoparticles (Cur-SLN) in order to increase curcumin bioavailability and to evaluate their radiosensitizing ability in comparison to free curcumin (free-Cur), by using an in vitro approach on BC cell lines.  In addition, transcriptomic and metabolomic profiles, induced by Cur-SLN treatments, highlighted networks involved in this radiosensitization ability.  The non tumorigenic MCF10A and the tumorigenic MCF7 and MDA-MB-231 BC cell lines were used.  Curcumin-loaded solid nanoparticles were prepared using ethanolic precipitation and the loading capacity was evaluated by UV spectrophotometer analysis.  Cell survival after treatments was evaluated by clonogenic assay.  Dose-response curves were generated testing three concentrations of free-Cur and Cur-SLN in combination with increasing doses of IR (2-9 Gy).  IC50 value and Dose Modifying Factor (DMF) was measured to quantify the sensitivity to curcumin and to combined treatments.  A multi-"omic" approach was used to explain the Cur-SLN radiosensitizer effect by microarray and metobolomic analysis.  We have shown the efficacy of the Cur-SLN formulation as radiosensitizer on three BC cell lines.  The DMFs values, calculated at the isoeffect of SF = 50%, showed that the Luminal A MCF7 resulted sensitive to the combined treatments using increasing concentration of vehicled curcumin Cur-SLN (DMF: 1,78 with 10 μM Cur-SLN.) Instead, triple negative MDA-MB-231 cells were more sensitive to free-Cur, although these cells also receive a radiosensitization effect by combination with Cur-SLN (DMF: 1.38 with 10 μM Cur-SLN).  The Cur-SLN radiosensitizing function, evaluated by transcriptomic and metabolomic approach, revealed anti-oxidant and anti-tumor effects.  Curcumin loaded- SLN can be suggested in future preclinical and clinical studies to test its concomitant use during radiotherapy treatments with the double implications of being a radiosensitizing molecule against cancer cells, with a protective role against IR side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwPdPrOAUoaXy-c-E1v-fmfW6udTcc2ea-5MGMe-CvBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvjsVejug%253D%253D&md5=28edf721ecffd8220c6cdef2fbba1ae7</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-47553-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-47553-2%26sid%3Dliteratum%253Aachs%26aulast%3DMinafra%26aufirst%3DL.%26aulast%3DPorcino%26aufirst%3DN.%26aulast%3DBravat%25C3%25A0%26aufirst%3DV.%26aulast%3DGaglio%26aufirst%3DD.%26aulast%3DBonanomi%26aufirst%3DM.%26aulast%3DAmore%26aufirst%3DE.%26aulast%3DCammarata%26aufirst%3DF.%2BP.%26aulast%3DRusso%26aufirst%3DG.%26aulast%3DMilitello%26aufirst%3DC.%26aulast%3DSavoca%26aufirst%3DG.%26aulast%3DBaglio%26aufirst%3DM.%26aulast%3DAbbate%26aufirst%3DB.%26aulast%3DIacoviello%26aufirst%3DG.%26aulast%3DEvangelista%26aufirst%3DG.%26aulast%3DGilardi%26aufirst%3DM.%2BC.%26aulast%3DBond%25C3%25AC%26aufirst%3DM.%2BL.%26aulast%3DForte%26aufirst%3DG.%2BI.%26atitle%3DRadiosensitizing%2520Effect%2520of%2520Curcumin-Loaded%2520Lipid%2520Nanoparticles%2520in%2520Breast%2520Cancer%2520Cells%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26doi%3D10.1038%2Fs41598-019-47553-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liberti, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locasale, J. W.</span></span> <span> </span><span class="NLM_article-title">The Warburg Effect: How Does it Benefit Cancer Cells?</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1016/j.tibs.2015.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.tibs.2015.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=26778478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGrtrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=211-218&author=M.+V.+Libertiauthor=J.+W.+Locasale&title=The+Warburg+Effect%3A+How+Does+it+Benefit+Cancer+Cells%3F&doi=10.1016%2Fj.tibs.2015.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The Warburg Effect: How Does it Benefit Cancer Cells?</span></div><div class="casAuthors">Liberti, Maria V.; Locasale, Jason W.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">211-218</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cancer cells rewire their metab. to promote growth, survival, proliferation, and long-term maintenance.  The common feature of this altered metab. is the increased glucose uptake and fermn. of glucose to lactate.  This phenomenon is obsd. even in the presence of completely functioning mitochondria and, together, is known as the 'Warburg Effect'.  The Warburg Effect has been documented for over 90 years and extensively studied over the past 10 years, with thousands of papers reporting to have established either its causes or its functions.  Despite this intense interest, the function of the Warburg Effect remains unclear.  Here, we analyze several proposed explanations for the function of Warburg Effect, emphasize their rationale, and discuss their controversies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql0YNvFw6E-7Vg90H21EOLACvtfcHk0ljB2FeZFDL54Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGrtrvJ&md5=c693279b35f3942e9a10f130d375e6e2</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2015.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2015.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DLiberti%26aufirst%3DM.%2BV.%26aulast%3DLocasale%26aufirst%3DJ.%2BW.%26atitle%3DThe%2520Warburg%2520Effect%253A%2520How%2520Does%2520it%2520Benefit%2520Cancer%2520Cells%253F%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2016%26volume%3D41%26spage%3D211%26epage%3D218%26doi%3D10.1016%2Fj.tibs.2015.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gebregiworgis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhinderwala, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaika, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, R.</span></span> <span> </span><span class="NLM_article-title">Insights into Gemcitabine Resistance and the Potential for Therapeutic Monitoring</span>. <i>Metabolomics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">156</span> <span class="refDoi"> DOI: 10.1007/s11306-018-1452-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1007%2Fs11306-018-1452-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=30830412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A280%3ADC%252BB3cbgtVOrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&author=T.+Gebregiworgisauthor=F.+Bhinderwalaauthor=V.+Purohitauthor=N.+V.+Chaikaauthor=P.+K.+Singhauthor=R.+Powers&title=Insights+into+Gemcitabine+Resistance+and+the+Potential+for+Therapeutic+Monitoring&doi=10.1007%2Fs11306-018-1452-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into gemcitabine resistance and the potential for therapeutic monitoring</span></div><div class="casAuthors">Gebregiworgis Teklab; Bhinderwala Fatema; Powers Robert; Bhinderwala Fatema; Powers Robert; Purohit Vinee; Chaika Nina V; Singh Pankaj K; Singh Pankaj K; Singh Pankaj K; Singh Pankaj K</div><div class="citationInfo"><span class="NLM_cas:title">Metabolomics : Official journal of the Metabolomic Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">156</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Gemcitabine is an important component of pancreatic cancer clinical management.  Unfortunately, acquired gemcitabine resistance is widespread and there are limitations to predicting and monitoring therapeutic outcomes.  OBJECTIVE:  To investigate the potential of metabolomics to differentiate pancreatic cancer cells that develops resistance or respond to gemcitabine treatment.  RESULTS:  We applied 1D (1)H and 2D (1)H-(13)C HSQC NMR methods to profile the metabolic signature of pancreatic cancer cells. (13)C6-glucose labeling identified 30 key metabolites uniquely altered between wild-type and gemcitabine-resistant cells upon gemcitabine treatment.  Gemcitabine resistance was observed to reprogram glucose metabolism and to enhance the pyrimidine synthesis pathway.  Myo-inositol, taurine, glycerophosphocholine and creatinine phosphate exhibited a "binary switch" in response to gemcitabine treatment and acquired resistance.  CONCLUSION:  Metabolic differences between naive and resistant pancreatic cancer cells and, accordingly, their unique responses to gemcitabine treatment were revealed, which may be useful in the clinical setting for monitoring a patient's therapeutic response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRc-0Sx9gELaEPI-fCgwosgfW6udTcc2eYKwFt52d7UObntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbgtVOrsQ%253D%253D&md5=2d3318923654247500ab50a15a003e45</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1007%2Fs11306-018-1452-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11306-018-1452-7%26sid%3Dliteratum%253Aachs%26aulast%3DGebregiworgis%26aufirst%3DT.%26aulast%3DBhinderwala%26aufirst%3DF.%26aulast%3DPurohit%26aufirst%3DV.%26aulast%3DChaika%26aufirst%3DN.%2BV.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DPowers%26aufirst%3DR.%26atitle%3DInsights%2520into%2520Gemcitabine%2520Resistance%2520and%2520the%2520Potential%2520for%2520Therapeutic%2520Monitoring%26jtitle%3DMetabolomics%26date%3D2018%26volume%3D14%26doi%3D10.1007%2Fs11306-018-1452-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mendes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pais, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitorino, C.</span></span> <span> </span><span class="NLM_article-title">Targeted Theranostic Nanoparticles for Brain Tumor Treatment</span>. <i>Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">181</span> <span class="refDoi"> DOI: 10.3390/pharmaceutics10040181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.3390%2Fpharmaceutics10040181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFWktbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&author=M.+Mendesauthor=J.+J.+Sousaauthor=A.+Paisauthor=C.+Vitorino&title=Targeted+Theranostic+Nanoparticles+for+Brain+Tumor+Treatment&doi=10.3390%2Fpharmaceutics10040181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted theranostic nanoparticles for brain tumor treatment</span></div><div class="casAuthors">Mendes, Maria; Sousa, Joao Jose; Pais, Alberto; Vitorino, Carla</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">181</span>CODEN:
                <span class="NLM_cas:coden">PHARK5</span>;
        ISSN:<span class="NLM_cas:issn">1999-4923</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The poor prognosis and rapid recurrence of glioblastoma (GB) are assocd. to its fast-growing process and invasive nature, which make difficult the complete removal of the cancer infiltrated tissues.  Addnl., GB heterogeneity within and between patients demands a patient-focused method of treatment.  Thus, the implementation of nanotechnol. is an attractive approach considering all anat. issues of GB, since it will potentially improve brain drug distribution, due to the interaction between the blood-brain barrier and nanoparticles (NPs).  In recent years, theranostic techniques have also been proposed and regarded as promising.  NPs are advantageous for this application, due to their resp. size, easy surface modification and versatility to integrate multiple functional components in one system.  The design of nanoparticles focused on therapeutic and diagnostic applications has increased exponentially for the treatment of cancer.  This dual approach helps to understand the location of the tumor tissue, the biodistribution of nanoparticles, the progress and efficacy of the treatment, and is highly useful for personalized medicine-based therapeutic interventions.  To improve theranostic approaches, different active strategies can be used to modulate the surface of the nanotheranostic particle, including surface markers, proteins, drugs or genes, and take advantage of the characteristics of the microenvironment using stimuli responsive triggers.  This review focuses on the different strategies to improve the GB treatment, describing some cell surface mark.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqORBKqPBo3G7Vg90H21EOLACvtfcHk0liqchzmE-IJVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFWktbbM&md5=e5021e6677458d42bc7c7370bb4a88be</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.3390%2Fpharmaceutics10040181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fpharmaceutics10040181%26sid%3Dliteratum%253Aachs%26aulast%3DMendes%26aufirst%3DM.%26aulast%3DSousa%26aufirst%3DJ.%2BJ.%26aulast%3DPais%26aufirst%3DA.%26aulast%3DVitorino%26aufirst%3DC.%26atitle%3DTargeted%2520Theranostic%2520Nanoparticles%2520for%2520Brain%2520Tumor%2520Treatment%26jtitle%3DPharmaceutics%26date%3D2018%26volume%3D10%26doi%3D10.3390%2Fpharmaceutics10040181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J. S.</span></span> <span> </span><span class="NLM_article-title">Mechanism of Temozolomide-Induced Antitumour Effects on Glioma Cells</span>. <i>J. Int. Med. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1177/0300060513501753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1177%2F0300060513501753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=24326954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Omt77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=164-172&author=W.+Shenauthor=J.+A.+Huauthor=J.+S.+Zheng&title=Mechanism+of+Temozolomide-Induced+Antitumour+Effects+on+Glioma+Cells&doi=10.1177%2F0300060513501753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of temozolomide-induced antitumour effects on glioma cells</span></div><div class="casAuthors">Shen, Wei; Hu, Jun-An; Zheng, Jie-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of International Medical Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">164-172, 9</span>CODEN:
                <span class="NLM_cas:coden">JIMRBV</span>;
        ISSN:<span class="NLM_cas:issn">0300-0605</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Objective: To investigate the mechanisms of action of the tumoricidal effects of temozolomide against the human glioma cell line U251 in vitro, and to provide preclin. proof-of-concept studies of the effects of temozolomide-contg. regimens.  Methods: U251 cells were exposed to 100 μmol/l temozolomide.  Morphol. alterations were monitored by light microscopy.  Cell viability was measured using the 3 -(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.  Cell cycle anal. and the rate of apoptosis were detd. using flow cytometry and the no. of acidic vesicular organelles stained with acridine orange were analyzed by fluorescence microscopy.  The scratch recovery test was used to measure cell migration.  Results: U251 cells that were treated with temozolomide displayed morphol. alterations indicative of a rounder shape and impaired cellular adhesion to the cell culture plate compared with control U251 cells.  Temozolomide reduced cell viability as measured by the MTTassay, caused cell cycle arrest in the gap 2/mitosis phase, inhibited cell migration and promoted autophagy in U251 cells.  Conclusion: Temozolomide induced autophagic, but not apoptotic processes, in U251 cells and thus reduced their viability and migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1pUre_1WsB7Vg90H21EOLACvtfcHk0liqchzmE-IJVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Omt77P&md5=dcbb5da90767a03ff645c2f5c3eb710b</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1177%2F0300060513501753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0300060513501753%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DJ.%2BA.%26aulast%3DZheng%26aufirst%3DJ.%2BS.%26atitle%3DMechanism%2520of%2520Temozolomide-Induced%2520Antitumour%2520Effects%2520on%2520Glioma%2520Cells%26jtitle%3DJ.%2520Int.%2520Med.%2520Res.%26date%3D2014%26volume%3D42%26spage%3D164%26epage%3D172%26doi%3D10.1177%2F0300060513501753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 6 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Carole Barbey, Nadia Bouchemal, Pascal Retailleau, Nathalie Dupont, <span class="NLM_string-name hlFld-ContribAuthor">Jolanda Spadavecchia</span>. </span><span class="cited-content_cbyCitation_article-title">Idarubicin–Gold Complex: From Crystal Growth to Gold Nanoparticles. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2021,</strong> <em>6 </em>
                                    (2)
                                     , 1235-1245. <a href="https://doi.org/10.1021/acsomega.0c04501" title="DOI URL">https://doi.org/10.1021/acsomega.0c04501</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c04501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c04501%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DIdarubicin%2525E2%252580%252593Gold%252BComplex%25253A%252BFrom%252BCrystal%252BGrowth%252Bto%252BGold%252BNanoparticles%26aulast%3DBarbey%26aufirst%3DCarole%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D14092020%26date%3D29102020%26date%3D04012021%26volume%3D6%26issue%3D2%26spage%3D1235%26epage%3D1245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Célia  Arib</span>, <span class="hlFld-ContribAuthor ">Jolanda  Spadavecchia</span>, <span class="hlFld-ContribAuthor ">Marc Lamy  de la Chapelle</span>. </span><span class="cited-content_cbyCitation_article-title">Enzyme mediated synthesis of hybrid polyedric gold nanoparticles. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-021-81751-1" title="DOI URL">https://doi.org/10.1038/s41598-021-81751-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-021-81751-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-021-81751-1%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DEnzyme%252Bmediated%252Bsynthesis%252Bof%252Bhybrid%252Bpolyedric%252Bgold%252Bnanoparticles%26aulast%3DArib%26aufirst%3DC%25C3%25A9lia%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">P. Soma  Yasaswi</span>, <span class="hlFld-ContribAuthor ">Karishma  Shetty</span>, <span class="hlFld-ContribAuthor ">Khushwant S.  Yadav</span>. </span><span class="cited-content_cbyCitation_article-title">Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Controlled Release</span><span> <strong>2021,</strong> <em>336 </em>, 549-571. <a href="https://doi.org/10.1016/j.jconrel.2021.07.003" title="DOI URL">https://doi.org/10.1016/j.jconrel.2021.07.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jconrel.2021.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jconrel.2021.07.003%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Controlled%2520Release%26atitle%3DTemozolomide%252Bnano%252Benabled%252Bmedicine%25253A%252Bpromises%252Bmade%252Bby%252Bthe%252Bnanocarriers%252Bin%252Bglioblastoma%252Btherapy%26aulast%3DYasaswi%26aufirst%3DP.%2BSoma%26date%3D2021%26volume%3D336%26spage%3D549%26epage%3D571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kang  Xu</span>, <span class="hlFld-ContribAuthor ">Long  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuqi  Gu</span>, <span class="hlFld-ContribAuthor ">Huasha  Yang</span>, <span class="hlFld-ContribAuthor ">Baixiang  Du</span>, <span class="hlFld-ContribAuthor ">Hongmei  Liu</span>, <span class="hlFld-ContribAuthor ">Yuling  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Increased the TMZ concentration in brain by poly(2-ethyl-2-oxazoline) conjugated temozolomide prodrug micelles for glioblastoma treatment. </span><span class="cited-content_cbyCitation_journal-name">European Polymer Journal</span><span> <strong>2021,</strong> <em>145 </em>, 110232. <a href="https://doi.org/10.1016/j.eurpolymj.2020.110232" title="DOI URL">https://doi.org/10.1016/j.eurpolymj.2020.110232</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.eurpolymj.2020.110232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.eurpolymj.2020.110232%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Polymer%2520Journal%26atitle%3DIncreased%252Bthe%252BTMZ%252Bconcentration%252Bin%252Bbrain%252Bby%252Bpoly%2525282-ethyl-2-oxazoline%252529%252Bconjugated%252Btemozolomide%252Bprodrug%252Bmicelles%252Bfor%252Bglioblastoma%252Btreatment%26aulast%3DXu%26aufirst%3DKang%26date%3D2021%26volume%3D145%26spage%3D110232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Memona  Khan</span>, <span class="hlFld-ContribAuthor ">Sarah  Boumati</span>, <span class="hlFld-ContribAuthor ">Celia  Arib</span>, <span class="hlFld-ContribAuthor ">Amadou  Thierno Diallo</span>, <span class="hlFld-ContribAuthor ">Nadia  Djaker</span>, <span class="hlFld-ContribAuthor ">Bich-thuy  Doan</span>, <span class="hlFld-ContribAuthor ">Jolanda  Spadavecchia</span>. </span><span class="cited-content_cbyCitation_article-title">Doxorubicin (DOX) Gadolinium–Gold-Complex: A New Way to Tune Hybrid Nanorods as Theranostic Agent. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Nanomedicine</span><span> <strong>2021,</strong> <em>Volume 16 </em>, 2219-2236. <a href="https://doi.org/10.2147/IJN.S295809" title="DOI URL">https://doi.org/10.2147/IJN.S295809</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2147/IJN.S295809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2147%2FIJN.S295809%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Nanomedicine%26atitle%3DDoxorubicin%252B%252528DOX%252529%252BGadolinium%2525E2%252580%252593Gold-Complex%25253A%252BA%252BNew%252BWay%252Bto%252BTune%252BHybrid%252BNanorods%252Bas%252BTheranostic%252BAgent%26aulast%3DKhan%26aufirst%3DMemona%26date%3D2021%26date%3D2021%26volume%3DVolume%252016%26spage%3D2219%26epage%3D2236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">June  Baik</span>, <span class="hlFld-ContribAuthor ">Martin  Felices</span>, <span class="hlFld-ContribAuthor ">Ashley  Yingst</span>, <span class="hlFld-ContribAuthor ">Charles P.  Theuer</span>, <span class="hlFld-ContribAuthor ">Michael R.  Verneris</span>, <span class="hlFld-ContribAuthor ">Jeffrey S.  Miller</span>, <span class="hlFld-ContribAuthor ">Rita  Perlingeiro</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic effect of TRC105 and decitabine combination in AML xenografts. </span><span class="cited-content_cbyCitation_journal-name">Heliyon</span><span> <strong>2020,</strong> <em>6 </em>
                                    (10)
                                     , e05242. <a href="https://doi.org/10.1016/j.heliyon.2020.e05242" title="DOI URL">https://doi.org/10.1016/j.heliyon.2020.e05242</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.heliyon.2020.e05242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.heliyon.2020.e05242%26sid%3Dliteratum%253Aachs%26jtitle%3DHeliyon%26atitle%3DTherapeutic%252Beffect%252Bof%252BTRC105%252Band%252Bdecitabine%252Bcombination%252Bin%252BAML%252Bxenografts%26aulast%3DBaik%26aufirst%3DJune%26date%3D2020%26volume%3D6%26issue%3D10%26spage%3De05242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="c89c859288988d8fe589bd8698bb">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="e9ada8aaa9b9acaec4a89ca7b99a">[email protected]</a> via Chelation Process (Please Note that the Drawings Are Not to Scale)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Procedure of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="02564f582f45474f425247452f43774c5271">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="84d0c9dea9c0c5c7c4d4c1c3a9c5f1cad4f7">[email protected]</a> by Electrostatic Adsorption (Please Note that the Drawings Are Not to Scale)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0009.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Schematic Hypothesis of the Chelation Process and the Electrostatic Interaction between the Polymer (PEG Diacid)-Gold Salt and Drugs (TMZ, GEM, DAC)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0001.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Normalized UV–Vis absorption of PEG-AuNPs (red line) and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="96c2dbccd6c6d3d1bbd7e3d8c6e5">[email protected]</a> (black line). (B) TEM images of PEG-AuNPs (panel 1) and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="085c455248">[email protected]</a> PEG-AuNPs (panel 2); 1′, 2′: histogram size distribution. (C) Raman spectra <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="d1859c8b91819496fc90a49f81">[email protected]</a> products (black line) compared to free PEG-AuNPs as control (red line). Experimental conditions: λ<sub>exc</sub> = 785 nm; laser power 20 mW; accumulation time 180 s.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Normalized UV–Vis absorption of PEG-AuNPs (red line), <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="682f2d2528382d2f45291d26381b">[email protected]</a> (blue line), and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="e5b1a8bfc8a2a0a8a5b5a0a2c8a490abb596">[email protected]</a> (green line). (B) TEM images (scale bars: 50 and 20 nm) of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="ffb8bab2bfafbab8d2be8ab1af8c">[email protected]</a> (panels 1, 1′) and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="e4b0a9bec9a3a1a9a4b4a1a3c9a591aab497">[email protected]</a> (panels 2, 2′). (C) <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="682f253228382d2f45291d26381b">[email protected]</a> (blue line) and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="1a4e5740375d5f575a4a5f5d375b6f544a69">[email protected]</a> (green line) products compared to free PEG-AuNPs as control (red line) Raman spectra. Experimental conditions: λ<sub>exc</sub> = 785 nm; laser power 20 mW; accumulation time 180 s.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Measurements of temperature elevation (Δ<i>T</i>) during 15 min in 1 mL nanoparticle solutions: <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="782c3522553f3d3538283d3f55390d36280b">[email protected]</a>, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="2470697e09606567647461630965516a7457">[email protected]</a>, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="c490899e84948183e985b18a94b7">[email protected]</a>, and PEG-AuNPs (A). Δ<i>T</i> measured in the same experimental conditions (1 mL) of GEM, DAC, and TMZ solutions without nanoparticles (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Drug release percentage (%) of Hyb-D-AuNPs in PBS (37 °C) at pH = 4.0 (blue line) or at pH = 7.0 (red line).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0005.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Lactate concentration in the medium after 72 h of drug exposition (mmol·h<sup>–1</sup>·million·cells<sup>–1</sup>). Error bars indicate the errors of the biological triplicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0010.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Schematic Hypothesis of the Effects of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="b2f5f7fff2e2f7f59ff3c7fce2c1">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="c286838182928785ef83b78c92b1">[email protected]</a> on the Lactate Reduction, Metabolic, and Glycolysis Pathway in Glioma Cells</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0011.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Schematic Design of the Interaction of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="84d0c9dea9c0c5c7c4d4c1c3a9c5f1cad4f7">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="5f0b120572181a121f0f1a18721e2a110f2c">[email protected]</a> with U87 Glia Cell through an Adsorption-Mediated Transport (AMT)<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/medium/jm0c00694_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0006.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Cell proliferation after 72 h incubation upon the indicated treatments. Live cells were counted using a hemocytometer (number of cells per mL/10<sup>6</sup>). (B) Fold of change in cell proliferation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-13/acs.jmedchem.0c00694/20200701/images/large/jm0c00694_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00694&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75701" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75701" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 61 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephen, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kievit, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Press, O. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span> <span> </span><span class="NLM_article-title">Temozolomide Nanoparticles for Targeted Glioblastoma Therapy</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">6674</span>– <span class="NLM_lpage">6682</span>, <span class="refDoi"> DOI: 10.1021/am5092165</span> </span><div class="citationLinks">[<a href="/doi/10.1021/am5092165" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFynsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=6674-6682&author=C.+Fangauthor=K.+Wangauthor=Z.+R.+Stephenauthor=Q.+Muauthor=F.+M.+Kievitauthor=D.+T.+Chiuauthor=O.+W.+Pressauthor=M.+Zhang&title=Temozolomide+Nanoparticles+for+Targeted+Glioblastoma+Therapy&doi=10.1021%2Fam5092165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Temozolomide Nanoparticles for Targeted Glioblastoma Therapy</span></div><div class="casAuthors">Fang, Chen; Wang, Kui; Stephen, Zachary R.; Mu, Qingxin; Kievit, Forrest M.; Chiu, Daniel T.; Press, Oliver W.; Zhang, Miqin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6674-6682</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glioblastoma (GBM) is a deadly and debilitating brain tumor with an abysmal prognosis.  The std. therapy for GBM is surgery followed by radiation and chemotherapy with Temozolomide (TMZ).  Treatment of GBMs remains a challenge, largely because of the fast degrdn. of TMZ, the inability to deliver an ED of TMZ to tumors, and a lack of target specificity that may cause systemic toxicity.  Here, we present a simple method for synthesizing a nanoparticle-based carrier that can protect TMZ from rapid degrdn. in physiol. solns. and can specifically deliver them to GBM cells through the mediation of a tumor-targeting peptide chlorotoxin (CTX).  Our nanoparticle, namely NP-TMZ-CTX, had a hydrodynamic size of <100 nm, exhibited sustained stability in cell culture media for up to 2 wk, and could accommodate stable drug loading.  TMZ bound to nanoparticles showed a much higher stability at physiol. pH, with a half-life 7-fold greater than that of free TMZ.  NP-TMZ-CTX was able to target GBM cells and achieved 2-6-fold higher uptake and a 50-90% redn. of IC50 72 h post-treatment as compared to nontargeted NP-TMZ.  NP-TMZ-CTX showed great promise in its ability to deliver a large therapeutic dose of TMZ to GBM cells and could serve as a template for targeted delivery of other therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp78ba64HyQybVg90H21EOLACvtfcHk0lhqoOm6WCv3dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFynsbs%253D&md5=5399bf35d5d14116d1bf24d3e968292c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fam5092165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fam5092165%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DStephen%26aufirst%3DZ.%2BR.%26aulast%3DMu%26aufirst%3DQ.%26aulast%3DKievit%26aufirst%3DF.%2BM.%26aulast%3DChiu%26aufirst%3DD.%2BT.%26aulast%3DPress%26aufirst%3DO.%2BW.%26aulast%3DZhang%26aufirst%3DM.%26atitle%3DTemozolomide%2520Nanoparticles%2520for%2520Targeted%2520Glioblastoma%2520Therapy%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2015%26volume%3D7%26spage%3D6674%26epage%3D6682%26doi%3D10.1021%2Fam5092165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kriel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Nedebock, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maarman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mbizana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojuka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumperman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loos, B.</span></span> <span> </span><span class="NLM_article-title">Coordinated Autophagy Modulation Overcomes Glioblastoma Chemoresistance through Disruption of Mitochondrial Bioenergetics</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">10348</span> <span class="refDoi"> DOI: 10.1038/s41598-018-28590-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1038%2Fs41598-018-28590-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=29985441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FmtVOhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&author=J.+Krielauthor=K.+M%C3%BCller-Nedebockauthor=G.+Maarmanauthor=S.+Mbizanaauthor=E.+Ojukaauthor=B.+Klumpermanauthor=B.+Loos&title=Coordinated+Autophagy+Modulation+Overcomes+Glioblastoma+Chemoresistance+through+Disruption+of+Mitochondrial+Bioenergetics&doi=10.1038%2Fs41598-018-28590-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Coordinated autophagy modulation overcomes glioblastoma chemoresistance through disruption of mitochondrial bioenergetics</span></div><div class="casAuthors">Kriel Jurgen; Loos Ben; Muller-Nedebock Kristian; Maarman Gerald; Ojuka Edward; Mbizana Siyasanga; Klumperman Bert</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10348</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Glioblastoma Multiforme (GBM) is known to be one of the most malignant and aggressive forms of brain cancer due to its resistance to chemotherapy.  Recently, GBM was found to not only utilise both oxidative phosphorylation (OXPHOS) and aerobic glycolysis, but also depend on the bulk protein degradation system known as macroautophagy to uphold proliferation.  Although autophagy modulators hold great potential as adjuvants to chemotherapy, the degree of upregulation or inhibition necessary to achieve cell death sensitisation remains unknown.  Therefore, this study aimed to determine the degree of autophagy modulation necessary to impair mitochondrial bioenergetics to the extent of promoting cell death onset.  It was shown that coordinated upregulation of autophagy followed by its inhibition prior to chemotherapy decreased electron transfer system (ETS) and oxidative phosphorylation (OXPHOS) capacity, impaired mitochondrial fission and fusion dynamics and enhanced apoptotic cell death onset in terms of cleaved caspase 3 and cleaved PARP expression.  Therefore, coordinated autophagy modulation may present a favourable avenue for improved chemotherapeutic intervention in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRqGvDjDP7DGxWfpMXQLRstfW6udTcc2ea0yDjTWRqCjrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FmtVOhtg%253D%253D&md5=83068c780137982d488c0144288cddca</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-28590-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-28590-9%26sid%3Dliteratum%253Aachs%26aulast%3DKriel%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller-Nedebock%26aufirst%3DK.%26aulast%3DMaarman%26aufirst%3DG.%26aulast%3DMbizana%26aufirst%3DS.%26aulast%3DOjuka%26aufirst%3DE.%26aulast%3DKlumperman%26aufirst%3DB.%26aulast%3DLoos%26aufirst%3DB.%26atitle%3DCoordinated%2520Autophagy%2520Modulation%2520Overcomes%2520Glioblastoma%2520Chemoresistance%2520through%2520Disruption%2520of%2520Mitochondrial%2520Bioenergetics%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26doi%3D10.1038%2Fs41598-018-28590-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chong, D. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toh, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sia, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yulyana, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinesh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tham, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, P. Y.</span></span> <span> </span><span class="NLM_article-title">Combined Treatment of Nimotuzumab and Rapamycin is Effective Against Temozolomide-Resistant Human Gliomas Regardless of the EGFR Mutation Status</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>, <span class="NLM_elocation-id">255</span> <span class="refDoi"> DOI: 10.1186/s12885-015-1191-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1186%2Fs12885-015-1191-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=25886314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A280%3ADC%252BC2MjkvFKrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&author=D.+Q.+Chongauthor=X.+Y.+Tohauthor=I.+A.+Hoauthor=K.+C.+Siaauthor=J.+P.+Newmanauthor=Y.+Yulyanaauthor=W.+H.+Ngauthor=S.+H.+Laiauthor=M.+M.+Hoauthor=N.+Dineshauthor=C.+K.+Thamauthor=P.+Y.+Lam&title=Combined+Treatment+of+Nimotuzumab+and+Rapamycin+is+Effective+Against+Temozolomide-Resistant+Human+Gliomas+Regardless+of+the+EGFR+Mutation+Status&doi=10.1186%2Fs12885-015-1191-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status</span></div><div class="casAuthors">Chong Dawn Q; Toh Xin Y; Ho Ivy A W; Sia Kian C; Newman Jennifer P; Yulyana Yulyana; Ho Mac M F; Tham Chee K; Lam Paula Y P; Ng Wai-Hoe; Lai Siang H; Dinesh Nivedh; Lam Paula Y P; Lam Paula Y P</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">255</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The treatment of glioblastoma multiforme (GBM) is an unmet clinical need.  The 5-year survival rate of patients with GBM is less than 3%.  Temozolomide (TMZ) remains the standard first-line treatment regimen for gliomas despite the fact that more than 90% of recurrent gliomas do not respond to TMZ after repeated exposure.  We have also independently shown that many of the Asian-derived glioma cell lines and primary cells derived from Singaporean high-grade glioma patients are indeed resistant to TMZ.  This issue highlights the need to develop new effective anti-cancer treatment strategies.  In a recent study, wild-type epidermal growth factor receptor (wtEGFR) has been shown to phosphorylate a truncated EGFR (known as EGFRvIII), leading to the phosphorylation of STAT proteins and progression in gliomagenesis.  Despite the fact that combination of EGFR targeting drugs and rapamycin has been used before, the effect of mono-treatment of Nimotuzumab, rapamycin and combination therapy in human glioma expressing different types of EGFR is not well-studied.  Herein, we evaluated the efficacy of dual blockage using monoclonal antibody against EGFR (Nimotuzumab) and an mTOR inhibitor (rapamycin) in Caucasian patient-derived human glioma cell lines, Asian patient-derived human glioma cell lines, primary glioma cells derived from the Mayo GBM xenografts, and primary short-term glioma culture derived from high-grade glioma patients.  METHODS:  The combination effect of Nimotuzumab and rapamycin was examined in a series of primary human glioma cell lines and glioma cell lines.  The cell viability was compared to TMZ treatment alone.  Endogenous expressions of EGFR in various GBM cells were determined by western blotting.  RESULTS:  The results showed that combination of Nimotuzumab with rapamycin significantly enhanced the therapeutic efficacy of human glioma cells compared to single treatment.  More importantly, many of the Asian patient-derived glioma cell lines and primary cells derived from Singaporean high-grade gliomas, which showed resistance to TMZ, were susceptible to the combined treatments.  CONCLUSIONS:  In conclusion, our results strongly suggest that combination usage of Nimotuzumab and rapamycin exert higher cytotoxic activities than TMZ.  Our data suggest that this combination may provide an alternative treatment for TMZ-resistant gliomas regardless of the EGFR status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ26obSlYBFLUQ0lWbKiCflfW6udTcc2eZ12sqG6USDlrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjkvFKrtw%253D%253D&md5=36c13d655c30972a6568bdadb4a23066</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1186%2Fs12885-015-1191-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-015-1191-3%26sid%3Dliteratum%253Aachs%26aulast%3DChong%26aufirst%3DD.%2BQ.%26aulast%3DToh%26aufirst%3DX.%2BY.%26aulast%3DHo%26aufirst%3DI.%2BA.%26aulast%3DSia%26aufirst%3DK.%2BC.%26aulast%3DNewman%26aufirst%3DJ.%2BP.%26aulast%3DYulyana%26aufirst%3DY.%26aulast%3DNg%26aufirst%3DW.%2BH.%26aulast%3DLai%26aufirst%3DS.%2BH.%26aulast%3DHo%26aufirst%3DM.%2BM.%26aulast%3DDinesh%26aufirst%3DN.%26aulast%3DTham%26aufirst%3DC.%2BK.%26aulast%3DLam%26aufirst%3DP.%2BY.%26atitle%3DCombined%2520Treatment%2520of%2520Nimotuzumab%2520and%2520Rapamycin%2520is%2520Effective%2520Against%2520Temozolomide-Resistant%2520Human%2520Gliomas%2520Regardless%2520of%2520the%2520EGFR%2520Mutation%2520Status%26jtitle%3DBMC%2520Cancer%26date%3D2015%26volume%3D15%26doi%3D10.1186%2Fs12885-015-1191-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Italiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chitkara, D.</span></span> <span> </span><span class="NLM_article-title">New Strategies for Cancer Management: How can Temozolomide Carrier Modifications Improve its Delivery?</span>. <i>Ther. Delivery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">477</span>, <span class="refDoi"> DOI: 10.4155/tde-2017-0016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.4155%2Ftde-2017-0016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=28633588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVWmsLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=475-477&author=S.+Sharmaauthor=K.+Italiyaauthor=A.+Mittalauthor=D.+Chitkara&title=New+Strategies+for+Cancer+Management%3A+How+can+Temozolomide+Carrier+Modifications+Improve+its+Delivery%3F&doi=10.4155%2Ftde-2017-0016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">New strategies for cancer management: how can temozolomide carrier modifications improve its delivery?</span></div><div class="casAuthors">Sharma, Saurabh; Italiya, Kishan; Mittal, Anupama; Chitkara, Deepak</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Delivery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">475-477</span>CODEN:
                <span class="NLM_cas:coden">TDHEA7</span>;
        ISSN:<span class="NLM_cas:issn">2041-5990</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">New strategies for cancer management: how can temozolomide carrier modifications improve its delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcNC__N89Rn7Vg90H21EOLACvtfcHk0lgdbg1BMV0NFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVWmsLnJ&md5=50999412524137232d641533a8f4b76a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.4155%2Ftde-2017-0016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ftde-2017-0016%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DItaliya%26aufirst%3DK.%26aulast%3DMittal%26aufirst%3DA.%26aulast%3DChitkara%26aufirst%3DD.%26atitle%3DNew%2520Strategies%2520for%2520Cancer%2520Management%253A%2520How%2520can%2520Temozolomide%2520Carrier%2520Modifications%2520Improve%2520its%2520Delivery%253F%26jtitle%3DTher.%2520Delivery%26date%3D2017%26volume%3D8%26spage%3D475%26epage%3D477%26doi%3D10.4155%2Ftde-2017-0016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalaydina, R.-V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajwa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qorri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decarlo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczuk, M. R.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in ″Smart″ Delivery Systems for Extended Drug Release in Cancer Therapy</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">4727</span>– <span class="NLM_lpage">4745</span>, <span class="refDoi"> DOI: 10.2147/IJN.S168053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.2147%2FIJN.S168053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=30154657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtleis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=4727-4745&author=R.-V.+Kalaydinaauthor=K.+Bajwaauthor=B.+Qorriauthor=A.+Decarloauthor=M.+R.+Szewczuk&title=Recent+Advances+in+%E2%80%B3Smart%E2%80%B3+Delivery+Systems+for+Extended+Drug+Release+in+Cancer+Therapy&doi=10.2147%2FIJN.S168053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in "smart" delivery systems for extended drug release in cancer therapy</span></div><div class="casAuthors">Kalaydina, Regina-Veronicka; Bajwa, Komal; Qorri, Bessi; Decarlo, Alexandria; Szewczuk, Myron R.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4727-4745</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Advances in nanomedicine have become indispensable for targeted drug delivery, early detection, and increasingly personalized approaches to cancer treatment.  Nanoparticlebased drug-delivery systems have overcome some of the limitations assocd. with traditional cancer-therapy administration, such as reduced drug soly., chemoresistance, systemic toxicity, narrow therapeutic indexes, and poor oral bioavailability.  Advances in the field of nanomedicine include "smart" drug delivery, or multiple levels of targeting, and extended-release drug-delivery systems that provide addnl. methods of overcoming these limitations.  More recently, the idea of combining smart drug delivery with extended-release has emerged in hopes of developing highly efficient nanoparticles with improved delivery, bioavailability, and safety profiles.  Although functionalized and extended-release drug-delivery systems have been studied extensively, there remain gaps in the literature concerning their application in cancer treatment.  We aim to provide an overview of smart and extended-release drug-delivery systems for the delivery of cancer therapies, as well as to introduce innovative advancements in nanoparticle design incorporating these principles.  With the growing need for increasingly personalized medicine in cancer treatment, smart extended-release nanoparticles have the potential to enhance chemotherapy delivery, patient adherence, and treatment outcomes in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQLHLr3X8jGrVg90H21EOLACvtfcHk0lgdbg1BMV0NFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtleis7c%253D&md5=ac84a7f21fe78a239d9a4daca4883685</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2147%2FIJN.S168053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S168053%26sid%3Dliteratum%253Aachs%26aulast%3DKalaydina%26aufirst%3DR.-V.%26aulast%3DBajwa%26aufirst%3DK.%26aulast%3DQorri%26aufirst%3DB.%26aulast%3DDecarlo%26aufirst%3DA.%26aulast%3DSzewczuk%26aufirst%3DM.%2BR.%26atitle%3DRecent%2520Advances%2520in%2520%25E2%2580%25B3Smart%25E2%2580%25B3%2520Delivery%2520Systems%2520for%2520Extended%2520Drug%2520Release%2520in%2520Cancer%2520Therapy%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2018%26volume%3D13%26spage%3D4727%26epage%3D4745%26doi%3D10.2147%2FIJN.S168053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heyn, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteller, M.</span></span> <span> </span><span class="NLM_article-title">DNA Methylation Profiling in the Clinic: Applications and Challenges</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">679</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1038/nrg3270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1038%2Fnrg3270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=22945394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht12jsbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=679-692&author=H.+Heynauthor=M.+Esteller&title=DNA+Methylation+Profiling+in+the+Clinic%3A+Applications+and+Challenges&doi=10.1038%2Fnrg3270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">DNA methylation profiling in the clinic: applications and challenges</span></div><div class="casAuthors">Heyn, Holger; Esteller, Manel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">679-692</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Knowledge of epigenetic alterations in disease is rapidly increasing owing to the development of genome-wide techniques for their identification.  The ever-growing no. of genes that show epigenetic alterations in disease emphasizes the crucial role of these epigenetic alterations - particularly DNA methylation - for future diagnosis, prognosis and prediction of response to therapies.  This Review focuses on epigenetic profiling, which has started to be of clin. value in cancer and may in the future be extended to other diseases, such as neurol. and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGfpc3e1wCnrVg90H21EOLACvtfcHk0liBoM_sh_x3Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht12jsbjK&md5=5fa838d2ef57f480240b06c663cdffb6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrg3270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg3270%26sid%3Dliteratum%253Aachs%26aulast%3DHeyn%26aufirst%3DH.%26aulast%3DEsteller%26aufirst%3DM.%26atitle%3DDNA%2520Methylation%2520Profiling%2520in%2520the%2520Clinic%253A%2520Applications%2520and%2520Challenges%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2012%26volume%3D13%26spage%3D679%26epage%3D692%26doi%3D10.1038%2Fnrg3270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lay, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. A.</span></span> <span> </span><span class="NLM_article-title">Targeting DNA Methylation for Epigenetic Therapy</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">536</span>– <span class="NLM_lpage">546</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2010.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.tips.2010.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=20846732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlensLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=536-546&author=X.+Yangauthor=F.+Layauthor=H.+Hanauthor=P.+A.+Jones&title=Targeting+DNA+Methylation+for+Epigenetic+Therapy&doi=10.1016%2Fj.tips.2010.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting DNA methylation for epigenetic therapy</span></div><div class="casAuthors">Yang, Xiaojing; Lay, Fides; Han, Han; Jones, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">536-546</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Patterns of DNA methylation are established during embryonic development and faithfully copied through somatic cell divisions.  Based on current understanding of DNA methylation and other interrelated epigenetic modifications, a comprehensive view of the epigenetic landscape' and cancer epigenome is evolving.  The cancer methylome is highly disrupted, making DNA methylation an excellent target for anticancer therapies.  During the last few decades, an increasing no. of drugs targeting DNA methylation have been developed to increase efficacy and stability and to decrease toxicity.  The earliest and the most successful epigenetic drug to date, 5-Azacytidine, is currently recommended as the first-line treatment of high-risk myelodysplastic syndromes (MDS).  Encouraging results from clin. trials have prompted further efforts to elucidate epigenetic alterations in cancer, and to subsequently develop new epigenetic therapies.  This review delineates the latest cancer epigenetic models, the recent discovery of hypomethylation agents as well as their application in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJKSZGI4LWvLVg90H21EOLACvtfcHk0liBoM_sh_x3Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlensLfI&md5=362429dbc115e437aecc01aa12015ee7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2010.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2010.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLay%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DH.%26aulast%3DJones%26aufirst%3DP.%2BA.%26atitle%3DTargeting%2520DNA%2520Methylation%2520for%2520Epigenetic%2520Therapy%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2010%26volume%3D31%26spage%3D536%26epage%3D546%26doi%3D10.1016%2Fj.tips.2010.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moen, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godley, L. A.</span></span> <span> </span><span class="NLM_article-title">The Role of Gene Body Cytosine Modifications in MGMT Expression and Sensitivity to Temozolomide</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1334</span>– <span class="NLM_lpage">1344</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1158%2F1535-7163.MCT-13-0924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=24568970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFWjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1334-1344&author=E.+L.+Moenauthor=A.+L.+Starkauthor=W.+Zhangauthor=M.+E.+Dolanauthor=L.+A.+Godley&title=The+Role+of+Gene+Body+Cytosine+Modifications+in+MGMT+Expression+and+Sensitivity+to+Temozolomide&doi=10.1158%2F1535-7163.MCT-13-0924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Gene Body Cytosine Modifications in MGMT Expression and Sensitivity to Temozolomide</span></div><div class="casAuthors">Moen, Erika L.; Stark, Amy L.; Zhang, Wei; Dolan, M. Eileen; Godley, Lucy A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1334-1344</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) is known to play a role in sensitivity to temozolomide.  Promoter hypermethylation of MGMT is commonly used to predict low expression levels of MGMT in gliomas, despite obsd. discordance between promoter methylation and protein levels.  Here, we investigated the functional role of gene body cytosine modification in regulating levels of MGMT gene expression and sensitivity to temozolomide.  In 91 human glioblastoma samples, we obsd. significant variation in MGMT expression levels in patients with an unmethylated promoter, with higher levels of gene body cytosine modification correlating with higher gene expression levels.  Furthermore, inducing hypomethylation across the MGMT gene body with decitabine corresponded with decreased levels of MGMT gene expression in lymphoblastoid and glioblastoma cell lines, indicating an important functional role for gene body cytosine modifications in maintaining gene expression.  We reasoned that the decrease in MGMT expression induced by decitabine may render resistant glioblastoma cell lines more sensitive to temozolomide.  Consistent with this reasoning, we found that the MGMT-expressing glioblastoma cell lines exhibiting an unmethylated MGMT promoter that were pretreated with decitabine became significantly more sensitive to temozolomide.  Overall, our results suggest a functional role for gene body cytosine modification in regulating gene expression of MGMT and indicate that pretreating patients whose tumors have an unmethylated MGMT promoter with decitabine before temozolomide treatment may increase their response to therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcd2AnagQSDLVg90H21EOLACvtfcHk0liBoM_sh_x3Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFWjtbw%253D&md5=d74b82afd114737c47f18212130e3e68</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0924%26sid%3Dliteratum%253Aachs%26aulast%3DMoen%26aufirst%3DE.%2BL.%26aulast%3DStark%26aufirst%3DA.%2BL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DDolan%26aufirst%3DM.%2BE.%26aulast%3DGodley%26aufirst%3DL.%2BA.%26atitle%3DThe%2520Role%2520of%2520Gene%2520Body%2520Cytosine%2520Modifications%2520in%2520MGMT%2520Expression%2520and%2520Sensitivity%2520to%2520Temozolomide%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1334%26epage%3D1344%26doi%3D10.1158%2F1535-7163.MCT-13-0924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toschi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finocchiaro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gioia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappuzzo, F.</span></span> <span> </span><span class="NLM_article-title">Role of Gemcitabine in Cancer Therapy</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1517/14796694.1.1.7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1517%2F14796694.1.1.7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=16555971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVyit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=7-17&author=L.+Toschiauthor=G.+Finocchiaroauthor=S.+Bartoliniauthor=V.+Gioiaauthor=F.+Cappuzzo&title=Role+of+Gemcitabine+in+Cancer+Therapy&doi=10.1517%2F14796694.1.1.7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Role of gemcitabine in cancer therapy</span></div><div class="casAuthors">Toschi, L.; Finocchiaro, G.; Bartolini, S.; Gioia, V.; Cappuzzo, F.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-17</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Gemcitabine, a pyrimidine nucleoside antimetabolite, is one of the most promising new cytotoxic agents.  The drug has shown activity in a variety of solid tumors, and has been approved for the treatment of non-small cell lung cancer, pancreatic, bladder, and breast cancer.  Recent data showed that gemcitabine is also active against ovarian cancer.  Gemcitabine has a good toxicity profile, with myelosuppression being the most common side effect, while non-hematol. events are relatively uncommon.  The low toxicity profile makes the drug a valid option for unfit and elderly patients.  Due to the synergistic activity with other chemotherapeutic compds., mainly cisplatinum, several trials have been conducted to evaluate the efficacy and tolerability of gemcitabine in combination with other cytotoxic agents.  Current clin. trials are evaluating the role of gemcitabine in combination with new targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowPU2VpcL_mLVg90H21EOLACvtfcHk0lj-86WHyvUp3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVyit7c%253D&md5=d370f5b38970ce6d3ccf663151693651</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1517%2F14796694.1.1.7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14796694.1.1.7%26sid%3Dliteratum%253Aachs%26aulast%3DToschi%26aufirst%3DL.%26aulast%3DFinocchiaro%26aufirst%3DG.%26aulast%3DBartolini%26aufirst%3DS.%26aulast%3DGioia%26aufirst%3DV.%26aulast%3DCappuzzo%26aufirst%3DF.%26atitle%3DRole%2520of%2520Gemcitabine%2520in%2520Cancer%2520Therapy%26jtitle%3DFuture%2520Oncol.%26date%3D2005%26volume%3D1%26spage%3D7%26epage%3D17%26doi%3D10.1517%2F14796694.1.1.7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galmarini, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackey, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumontet, C.</span></span> <span> </span><span class="NLM_article-title">Nucleoside Analogues: Mechanisms of Drug Resistance and Reversal Strategies</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2402114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1038%2Fsj.leu.2402114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=11417472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkvVOit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2001&pages=875-890&author=C.+M.+Galmariniauthor=J.+R.+Mackeyauthor=C.+Dumontet&title=Nucleoside+Analogues%3A+Mechanisms+of+Drug+Resistance+and+Reversal+Strategies&doi=10.1038%2Fsj.leu.2402114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleoside analogues: Mechanisms of drug resistance and reversal strategies</span></div><div class="casAuthors">Galmarini, C. M.; Mackey, J. R.; Dumontet, C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">875-890</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review is given.  Nucleoside analogs (NA) are essential components of AML induction therapy (cytosine arabinoside), effective treatments of lymphoproliferative disorders (fludarabine, cladribine), and are also used in the treatment of some solid tumors (gemcitabine).  These important compds. share some general common characteristics, namely in terms of requiring transport by specific membrane transporters, metab., and interaction with intracellular targets.  However, these compds. differ in regard to the types of transporters that most efficiently transport a given compd., and their preferential interaction with certain targets which may explain why some compds. are more effective against rapidly proliferating tumors and others on neoplasia with a more protracted evolution.  In this review, the authors analyze the available data concerning mechanisms of action of and resistance to NA, with particular emphasis on recent advances in the characterization of nucleoside transporters and on the potential role of activating or inactivating enzymes in the induction of clin. resistance to these compds.  The authors performed an extensive search of published in vitro and clin. data in which the levels of expression of nucleoside-activating or inactivating enzymes were correlated with tumor response or patient outcome.  Strategies aiming to increase the intracellular concns. of active compds. are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl08mNYpow3bVg90H21EOLACvtfcHk0lj-86WHyvUp3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkvVOit78%253D&md5=a34c882ac39abbe77062b6bacc753bc7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2402114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2402114%26sid%3Dliteratum%253Aachs%26aulast%3DGalmarini%26aufirst%3DC.%2BM.%26aulast%3DMackey%26aufirst%3DJ.%2BR.%26aulast%3DDumontet%26aufirst%3DC.%26atitle%3DNucleoside%2520Analogues%253A%2520Mechanisms%2520of%2520Drug%2520Resistance%2520and%2520Reversal%2520Strategies%26jtitle%3DLeukemia%26date%3D2001%26volume%3D15%26spage%3D875%26epage%3D890%26doi%3D10.1038%2Fsj.leu.2402114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamodu, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhopadhyay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-S.</span></span> <span> </span><span class="NLM_article-title">A Novel Multi-Target Small Molecule, LCC-09, Inhibits Stemness and Therapy-Resistant Phenotypes of Glioblastoma Cells by Increasing miR-34a and Deregulating the DRD4/Akt/mTOR Signaling Axis</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">1442</span> <span class="refDoi"> DOI: 10.3390/cancers11101442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.3390%2Fcancers11101442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BB3cXns1Glu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&author=Y.-T.+Wenauthor=A.+T.+Wuauthor=O.+A.+Bamoduauthor=L.+Weiauthor=C.-M.+Linauthor=Y.+Yenauthor=T.-Y.+Chaoauthor=D.+Mukhopadhyayauthor=M.+Hsiaoauthor=H.-S.+Huang&title=A+Novel+Multi-Target+Small+Molecule%2C+LCC-09%2C+Inhibits+Stemness+and+Therapy-Resistant+Phenotypes+of+Glioblastoma+Cells+by+Increasing+miR-34a+and+Deregulating+the+DRD4%2FAkt%2FmTOR+Signaling+Axis&doi=10.3390%2Fcancers11101442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A novel multi-target small molecule, LCC-09, inhibits stemness and therapy-resistant phenotypes of glioblastoma cells by increasing mir-34a and deregulating the DRD4/Akt/mTOR signaling axis</span></div><div class="casAuthors">Wen, Ya-Ting; Wu, Alexander T. H.; Bamodu, Oluwaseun Adebayo; Wei, Li; Lin, Chien-Min; Yen, Yun; Chao, Tsu-Yi; Mukhopadhyay, Debabrata; Hsiao, Michael; Huang, Hsu-Shan</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1442</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The management of glioblastomas (GBMs) is challenged by the development of therapeutic resistance and early disease recurrence, despite multi-modal therapy.  This may be attributed to the presence of glioma stem cells (GSCs) which are known to survive radio- and chemotherapy, by circumventing death signals and inducing cell re-population.  Recent findings suggest GSCs may be enriched by certain treatment modality.  These necessitate the development of novel therapeutics capable of targeting GBM cell plasticity and therapy-resistant GSCs.  Here, aided by computer-assisted structure characterization and target identification, we predicted that a novel 5-(2',4'-difluorophenyl)-salicylanilide deriv., LCC-09, could target dopamine receptors and oncogenic markers implicated in GBMs.  Bioinformatics data have indicated that dopamine receptor (DRD) 2, DRD4, CD133 and Nestin were elevated in GBM clin. samples and correlated to TMZ (Temozolomide) resistance and increased ALDH (Aldehyde dehydrogenase) activity (3.5-8.9%) as well as enhanced (2.1-2.4-fold) neurosphere formation efficiency in U87MG and D54MG GBM cell lines.  In addn., TMZ-resistant GSC phenotype was assocd. with up-regulated DRD4, Akt, mTOR, β-catenin, CDK6, NF-κB and Erk1/2 expression.  LCC-09 alone, or combined with TMZ, suppressed the tumorigenic and stemness traits of TMZ-resistant GBM cells while concomitantly down-regulating DRD4, Akt, mTOR, β-catenin, Erk1/2, NF-κB, and CDK6 expression.  Notably, LCC-09-mediated anti-GBM/GSC activities were assocd. with the re-expression of tumor suppressor miR-34a and reversal of TMZ-resistance, in vitro and in vivo.  Collectively, these data lay the foundation for further exploration of the clin. feasibility of administering LCC-09 as single-agent or combinatorial therapy for patients with TMZ-resistant GBMs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-_gXY9kO8sbVg90H21EOLACvtfcHk0lj-86WHyvUp3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXns1Glu7Y%253D&md5=610b6356343f193586550bb091daf17a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.3390%2Fcancers11101442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11101442%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DY.-T.%26aulast%3DWu%26aufirst%3DA.%2BT.%26aulast%3DBamodu%26aufirst%3DO.%2BA.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DC.-M.%26aulast%3DYen%26aufirst%3DY.%26aulast%3DChao%26aufirst%3DT.-Y.%26aulast%3DMukhopadhyay%26aufirst%3DD.%26aulast%3DHsiao%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DH.-S.%26atitle%3DA%2520Novel%2520Multi-Target%2520Small%2520Molecule%252C%2520LCC-09%252C%2520Inhibits%2520Stemness%2520and%2520Therapy-Resistant%2520Phenotypes%2520of%2520Glioblastoma%2520Cells%2520by%2520Increasing%2520miR-34a%2520and%2520Deregulating%2520the%2520DRD4%252FAkt%252FmTOR%2520Signaling%2520Axis%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26doi%3D10.3390%2Fcancers11101442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wick, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermisson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortmann, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuker, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dichgans, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M.</span></span> <span> </span><span class="NLM_article-title">Neoadjuvant Gemcitabine/Treosulfan Chemotherapy for Newly Diagnosed Glioblastoma: A phase II study</span>. <i>J Neuro-Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">155</span>, <span class="refDoi"> DOI: 10.1023/A:1019641314661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1023%2FA%3A1019641314661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=12241108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A280%3ADC%252BD38vnvFKmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2002&pages=151-155&author=W.+Wickauthor=M.+Hermissonauthor=R.+D.+Kortmannauthor=W.+M.+Kukerauthor=F.+Duffnerauthor=J.+Dichgansauthor=M.+Bambergauthor=M.+Weller&title=Neoadjuvant+Gemcitabine%2FTreosulfan+Chemotherapy+for+Newly+Diagnosed+Glioblastoma%3A+A+phase+II+study&doi=10.1023%2FA%3A1019641314661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: a phase II study</span></div><div class="casAuthors">Wick Wolfgang; Hermisson Mirjam; Kortmann Rolf D; Kuker Wilhelm M; Duffner Frank; Dichgans Johannes; Bamberg Michael; Weller Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuro-oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-5</span>
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    </div><div class="casAbstract">The median survival for patients with glioblastoma is 12 months.  The authors evaluated whether preirradiation gemcitabine/treosulfan (GeT) chemotherapy followed by standard radiotherapy improved outcome in patients with glioblastoma.  Seventeen patients with newly diagnosed glioblastoma were enrolled in a prospective, unicenter trial of preirradiation GeT chemotherapy.  Chemotherapy included up to 4 cycles of intravenous gemcitabine (1000 mg/m2 body surface) and treosulfan (3500 mg/m2 body surface) on days 1 and 8 of 28 days treatment cycles.  Involved field radiotherapy (60 Gy in 30 fractions) was given after chemotherapy or earlier in the case of disease progression or drug intolerance.  There was no specific treatment-related neurotoxicity reported, but in 3 of 17 patients (18%) chemotherapy was stopped because of World Health Organization (WHO) IV hematological toxicity.  With GeT chemotherapy alone, there was a median progression-free survival of 12 weeks and a progression-free survival rate at 4 months of 29%.  In 16 of 17 patients who subsequently received a full course of radiotherapy, the median progression-free survival from the time of diagnosis was 8 months, and the progression-free survival rate at 12 months was 25% (4 of 16 patients).  The median overall survival was 12 months.  Neither age nor extent of the residual postoperative tumor predicted the duration of progression-free survival after chemotherapy alone or after chemotherapy followed by radiotherapy.  The combination of gemcitabine and treosulfan produced significant hematological toxicity in patients with newly diagnosed glioblastoma.  The schedule used in the present study did not confer any significant survival advantage compared with standard involved field radiotherapy alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4HSNmq-uSA5VVjGoY74BafW6udTcc2ebn4ATlANz75rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vnvFKmsA%253D%253D&md5=2b3ba5b0b10c3ff1f878275278033f0d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1023%2FA%3A1019641314661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1019641314661%26sid%3Dliteratum%253Aachs%26aulast%3DWick%26aufirst%3DW.%26aulast%3DHermisson%26aufirst%3DM.%26aulast%3DKortmann%26aufirst%3DR.%2BD.%26aulast%3DKuker%26aufirst%3DW.%2BM.%26aulast%3DDuffner%26aufirst%3DF.%26aulast%3DDichgans%26aufirst%3DJ.%26aulast%3DBamberg%26aufirst%3DM.%26aulast%3DWeller%26aufirst%3DM.%26atitle%3DNeoadjuvant%2520Gemcitabine%252FTreosulfan%2520Chemotherapy%2520for%2520Newly%2520Diagnosed%2520Glioblastoma%253A%2520A%2520phase%2520II%2520study%26jtitle%3DJ%2520Neuro-Oncol.%26date%3D2002%26volume%3D59%26spage%3D151%26epage%3D155%26doi%3D10.1023%2FA%3A1019641314661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Metro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirri, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidiri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carosi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maschio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannarelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pompili, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cognetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carapella, C. M.</span></span> <span> </span><span class="NLM_article-title">Phase II study of Fixed Dose Rate Gemcitabine as Radiosensitizer for Newly Diagnosed Glioblastoma Multiforme</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">397</span>, <span class="refDoi"> DOI: 10.1007/s00280-009-1155-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1007%2Fs00280-009-1155-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=19847425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKnsL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2010&pages=391-397&author=G.+Metroauthor=A.+Fabiauthor=M.+A.+Mirriauthor=A.+Vidiriauthor=A.+Paceauthor=M.+Carosiauthor=M.+Russilloauthor=M.+Maschioauthor=D.+Giannarelliauthor=D.+Pellegriniauthor=A.+Pompiliauthor=F.+Cognettiauthor=C.+M.+Carapella&title=Phase+II+study+of+Fixed+Dose+Rate+Gemcitabine+as+Radiosensitizer+for+Newly+Diagnosed+Glioblastoma+Multiforme&doi=10.1007%2Fs00280-009-1155-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme</span></div><div class="casAuthors">Metro, Giulio; Fabi, Alessandra; Mirri, Maria A.; Vidiri, Antonello; Pace, Andrea; Carosi, Mariantonia; Russillo, Michelangelo; Maschio, Marta; Giannarelli, Diana; Pellegrini, Domenica; Pompili, Alfredo; Cognetti, Francesco; Carapella, Carmine M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">391-397</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: In order to evaluate the activity of gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme (GBM), a prospective single-center phase II study was conducted.  Methods: Eligible patients were required to have histol. proven GBM with evaluable and/or measurable disease after surgery.  They were treated by std. cranial irradn. plus concomitant fixed dose rate gemcitabine given i.v. at 175 mg/m2 weekly for 6 wk.  After chemo-radiotherapy, irresp. of tumor response, patients went on to receive oral temozolomide at 150-200 mg/m2 for 5 days every 28 days.  Results: Twenty-three patients were enrolled.  Median age was 57 years (range 43-72) and median Karnofsky performance status was 90 (range 70-100).  Seventeen patients had received subtotal resection of the tumor, while six patients had biopsied-only tumors.  Four patients responded to treatment (17.5%) with addnl. 14 (61%) experiencing stable disease for an overall disease control rate of 78.5%.  Median progression-free and overall survival were 6.8 and 10.1 mo, resp.  The concomitant radiotherapy-gemcitabine combination was well tolerated and severe adverse events were rare, consisting of grade 3 neutropenia and hypertransaminasemia in two cases each.  Twenty patients were assessable for methylguanine methyltransferase (MGMT) promoter methylation, 11 of which were found methylated.  In the methylated and unmethylated cohorts, disease control was obtained in 10/11 patients (91%) and 7/9 patients (77.5%), resp.  Conclusions: Concomitant radiotherapy-gemcitabine is active and well tolerated in newly diagnosed glioblastoma multiforme.  Activity is obsd. both in tumors with methylated and unmethylated MGMT promoter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLBVlyyD7y2rVg90H21EOLACvtfcHk0liI1wEq-fGR9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKnsL%252FM&md5=02e69cafcf490d3f86102e9c75b5e7ca</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs00280-009-1155-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-009-1155-x%26sid%3Dliteratum%253Aachs%26aulast%3DMetro%26aufirst%3DG.%26aulast%3DFabi%26aufirst%3DA.%26aulast%3DMirri%26aufirst%3DM.%2BA.%26aulast%3DVidiri%26aufirst%3DA.%26aulast%3DPace%26aufirst%3DA.%26aulast%3DCarosi%26aufirst%3DM.%26aulast%3DRussillo%26aufirst%3DM.%26aulast%3DMaschio%26aufirst%3DM.%26aulast%3DGiannarelli%26aufirst%3DD.%26aulast%3DPellegrini%26aufirst%3DD.%26aulast%3DPompili%26aufirst%3DA.%26aulast%3DCognetti%26aufirst%3DF.%26aulast%3DCarapella%26aufirst%3DC.%2BM.%26atitle%3DPhase%2520II%2520study%2520of%2520Fixed%2520Dose%2520Rate%2520Gemcitabine%2520as%2520Radiosensitizer%2520for%2520Newly%2520Diagnosed%2520Glioblastoma%2520Multiforme%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2010%26volume%3D65%26spage%3D391%26epage%3D397%26doi%3D10.1007%2Fs00280-009-1155-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sela, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zach, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpas, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeiri, Y.</span></span> <span> </span><span class="NLM_article-title">Spontaneous Penetration of Gold Nanoparticles Through the Blood Brain Barrier (BBB)</span>. <i>J. Nanobiotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">71</span> <span class="refDoi"> DOI: 10.1186/s12951-015-0133-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1186%2Fs12951-015-0133-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=26489846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVKisLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&author=H.+Selaauthor=H.+Cohenauthor=P.+Eliaauthor=R.+Zachauthor=Z.+Karpasauthor=Y.+Zeiri&title=Spontaneous+Penetration+of+Gold+Nanoparticles+Through+the+Blood+Brain+Barrier+%28BBB%29&doi=10.1186%2Fs12951-015-0133-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Spontaneous penetration of gold nanoparticles through the blood brain barrier (BBB)</span></div><div class="casAuthors">Sela, Hagit; Cohen, Hagit; Elia, Paz; Zach, Raya; Karpas, Zeev; Zeiri, Yehuda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nanobiotechnology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">71/1-71/9</span>CODEN:
                <span class="NLM_cas:coden">JNOAAO</span>;
        ISSN:<span class="NLM_cas:issn">1477-3155</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The blood brain barrier (BBB) controls the brain microenvironment and limits penetration of the central nervous system (CNS) by chems., thus creating an obstacle to many medical imaging and treatment procedures.  Research efforts to identify viable routes of BBB penetration have focused on structures such as micelles, polymeric nanoparticles and liposomes as drug carriers, however, many of them failed to provide unequivocal proof of BBB penetration.  Here we proved that gold nanoparticles (AuNPs) penetrate the BBB in rats to reach brain regions.  Results: Injection of AuNPs to the abdominal cavity of rats resulted in levels of gold found in blood, urine, brain regions and body organs.  After perfusion the concn. of gold in brain regions diminished dramatically indicating that most of the gold was in venous blood and not in the brain tissues.  Injection of Na, K or Ca ion channel blockers reduced BBB penetration by half.  A biol. half-life of 12.9 ± 4.9 h was found for the gold nanoparticles.  Possible mechanisms for the transport of AuNPs through the BBB are discussed.  Conclusions: BBB penetration by AuNPs is spontaneous without the application of an external field.  A major amt. of gold resides in blood vessels therefore perfusion required.  Ion channel blockers can be used to control the transport of AuNPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEsfstst-18rVg90H21EOLACvtfcHk0liI1wEq-fGR9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVKisLvM&md5=428b6a328780c79096e3de766c320d8a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1186%2Fs12951-015-0133-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12951-015-0133-1%26sid%3Dliteratum%253Aachs%26aulast%3DSela%26aufirst%3DH.%26aulast%3DCohen%26aufirst%3DH.%26aulast%3DElia%26aufirst%3DP.%26aulast%3DZach%26aufirst%3DR.%26aulast%3DKarpas%26aufirst%3DZ.%26aulast%3DZeiri%26aufirst%3DY.%26atitle%3DSpontaneous%2520Penetration%2520of%2520Gold%2520Nanoparticles%2520Through%2520the%2520Blood%2520Brain%2520Barrier%2520%2528BBB%2529%26jtitle%3DJ.%2520Nanobiotechnol.%26date%3D2015%26volume%3D13%26doi%3D10.1186%2Fs12951-015-0133-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khongkow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boonrungsiman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruktanonchai, U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namdee, K.</span></span> <span> </span><span class="NLM_article-title">Surface Modification of Gold Nanoparticles with Neuron-Targeted Exosome for Enhanced Blood–Brain Barrier Penetration</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">8278</span> <span class="refDoi"> DOI: 10.1038/s41598-019-44569-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1038%2Fs41598-019-44569-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=31164665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A280%3ADC%252BB3M3jtlejsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&author=M.+Khongkowauthor=T.+Yataauthor=S.+Boonrungsimanauthor=U.+R.+Ruktanonchaiauthor=D.+Grahamauthor=K.+Namdee&title=Surface+Modification+of+Gold+Nanoparticles+with+Neuron-Targeted+Exosome+for+Enhanced+Blood%E2%80%93Brain+Barrier+Penetration&doi=10.1038%2Fs41598-019-44569-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Surface modification of gold nanoparticles with neuron-targeted exosome for enhanced blood-brain barrier penetration</span></div><div class="casAuthors">Khongkow Mattaka; Yata Teerapong; Boonrungsiman Suwimon; Ruktanonchai Uracha Rungsardthong; Namdee Katawut; Graham Duncan</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8278</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Gold nanoparticles (AuNPs) have been extensively used as nanomaterials for theranostic applications due to their multifunctional characteristics in therapeutics, imaging, and surface modification.  In this study, the unique functionalities of exosome-derived membranes were combined with synthetic AuNPs for targeted delivery to brain cells.  Here, we report the surface modification of AuNPs with brain-targeted exosomes derived from genetically engineered mammalian cells by using the mechanical method or extrusion to create these novel nanomaterials.  The unique targeting properties of the AuNPs after fabrication with the brain-targeted exosomes was demonstrated by their binding to brain cells under laminar flow conditions as well as their enhanced transport across the blood brain barrier.  In a further demonstration of their ability to target brain cells, in vivo bioluminescence imaging revealed that targeted-exosome coated AuNPs accumulated in the mouse brain after intravenous injection.  The surface modification of synthetic AuNPs with the brain-targeted exosome demonstrated in this work represents a highly novel and effective strategy to provide efficient brain targeting and shows promise for the future in using modified AuNPs to penetrate the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQtNvhc13OavjMsgLhIoICsfW6udTcc2eaJ8iU6LbZFurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3jtlejsA%253D%253D&md5=4ad5c15c9811b0b3c2bf50c977c50c80</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-44569-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-44569-6%26sid%3Dliteratum%253Aachs%26aulast%3DKhongkow%26aufirst%3DM.%26aulast%3DYata%26aufirst%3DT.%26aulast%3DBoonrungsiman%26aufirst%3DS.%26aulast%3DRuktanonchai%26aufirst%3DU.%2BR.%26aulast%3DGraham%26aufirst%3DD.%26aulast%3DNamdee%26aufirst%3DK.%26atitle%3DSurface%2520Modification%2520of%2520Gold%2520Nanoparticles%2520with%2520Neuron-Targeted%2520Exosome%2520for%2520Enhanced%2520Blood%25E2%2580%2593Brain%2520Barrier%2520Penetration%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26doi%3D10.1038%2Fs41598-019-44569-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span> <span> </span><span class="NLM_article-title">Nanocarriers as a Powerful Vehicle to Overcome Blood-brain Barrier in Treating Neurodegenerative Diseases: Focus on Recent Advances</span>. <i>Asian J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1016/j.ajps.2018.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.ajps.2018.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=32104476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A280%3ADC%252BB387mslWquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=480-496&author=X.+Niuauthor=J.+Chenauthor=J.+Gao&title=Nanocarriers+as+a+Powerful+Vehicle+to+Overcome+Blood-brain+Barrier+in+Treating+Neurodegenerative+Diseases%3A+Focus+on+Recent+Advances&doi=10.1016%2Fj.ajps.2018.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: Focus on recent advances</span></div><div class="casAuthors">Niu Xiaoqian; Chen Jiejian; Gao Jianqing; Chen Jiejian</div><div class="citationInfo"><span class="NLM_cas:title">Asian journal of pharmaceutical sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">480-496</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington disease and amyotrophic lateral sclerosis throw a heavy burden on families and society.  Related scientific researches make tardy progress.  One reason is that the known pathogeny is just the tip of the iceberg.  Another reason is that various physiological barriers, especially blood-brain barrier (BBB), hamper effective therapeutic substances from reaching site of action.  Drugs in clinical treatment of neurodegenerative diseases are basically administered orally.  And generally speaking, the brain targeting efficiency is pretty low.  Nano-delivery technology brings hope for neurodegenerative diseases.  The use of nanocarriers encapsulating molecules such as peptides and genomic medicine may enhance drug transport through the BBB in neurodegenerative disease and target relevant regions in the brain for regenerative processes.  In this review, we discuss BBB composition and applications of nanocarriers -liposomes, nanoparticles, nanomicelles and new emerging exosomes in neurodegenerative diseases.  Furthermore, the disadvantages and the potential neurotoxicity of nanocarriers according pharmacokinetics theory are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTCdgsCrkmMWK_SFaaT9INfW6udTcc2eaJ8iU6LbZFurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387mslWquw%253D%253D&md5=384cf8723cf814d8af867906f1f428b9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ajps.2018.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajps.2018.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DNiu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DJ.%26atitle%3DNanocarriers%2520as%2520a%2520Powerful%2520Vehicle%2520to%2520Overcome%2520Blood-brain%2520Barrier%2520in%2520Treating%2520Neurodegenerative%2520Diseases%253A%2520Focus%2520on%2520Recent%2520Advances%26jtitle%3DAsian%2520J.%2520Pharm.%2520Sci.%26date%3D2019%26volume%3D14%26spage%3D480%26epage%3D496%26doi%3D10.1016%2Fj.ajps.2018.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masserini, M.</span></span> <span> </span><span class="NLM_article-title">Nanoparticles for Brain Drug Delivery</span>. <i>ISRN Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2013</i></span>, <span class="NLM_elocation-id">238428</span> <span class="refDoi"> DOI: 10.1155/2013/238428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1155%2F2013%2F238428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=25937958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A280%3ADC%252BC2Mfgt1Oltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2013&publication_year=2013&author=M.+Masserini&title=Nanoparticles+for+Brain+Drug+Delivery&doi=10.1155%2F2013%2F238428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticles for brain drug delivery</span></div><div class="casAuthors">Masserini Massimo</div><div class="citationInfo"><span class="NLM_cas:title">ISRN biochemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2013</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">238428</span>
        ISSN:<span class="NLM_cas:issn">2090-7729</span>.
    </div><div class="casAbstract">The central nervous system, one of the most delicate microenvironments of the body, is protected by the blood-brain barrier (BBB) regulating its homeostasis.  BBB is a highly complex structure that tightly regulates the movement of ions of a limited number of small molecules and of an even more restricted number of macromolecules from the blood to the brain, protecting it from injuries and diseases.  However, the BBB also significantly precludes the delivery of drugs to the brain, thus, preventing the therapy of a number of neurological disorders.  As a consequence, several strategies are currently being sought after to enhance the delivery of drugs across the BBB.  Within this review, the recently born strategy of brain drug delivery based on the use of nanoparticles, multifunctional drug delivery systems with size in the order of one-billionth of meters, is described.  The review also includes a brief description of the structural and physiological features of the barrier and of the most utilized nanoparticles for medical use.  Finally, the potential neurotoxicity of nanoparticles is discussed, and future technological approaches are described.  The strong efforts to allow the translation from preclinical to concrete clinical applications are worth the economic investments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSyIOcdVvZ2uuqrn-c4Of3KfW6udTcc2eaJ8iU6LbZFurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mfgt1Oltg%253D%253D&md5=223c94a82dd4754dc5f5adf3f9246e35</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1155%2F2013%2F238428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2013%252F238428%26sid%3Dliteratum%253Aachs%26aulast%3DMasserini%26aufirst%3DM.%26atitle%3DNanoparticles%2520for%2520Brain%2520Drug%2520Delivery%26jtitle%3DISRN%2520Biochem.%26date%3D2013%26volume%3D2013%26doi%3D10.1155%2F2013%2F238428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span> <span> </span><span class="NLM_article-title">Current Strategies for Brain Drug Delivery</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1481</span>– <span class="NLM_lpage">1493</span>, <span class="refDoi"> DOI: 10.7150/thno.21254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.7150%2Fthno.21254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=29556336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFKqtrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1481-1493&author=X.+Dong&title=Current+Strategies+for+Brain+Drug+Delivery&doi=10.7150%2Fthno.21254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Current strategies for brain drug delivery</span></div><div class="casAuthors">Dong, Xiaowei</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1481-1493</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">The blood-brain barrier (BBB) has been a great hurdle for brain drug delivery.  The BBB in healthy brain is a diffusion barrier essential for protecting normal brain function by impeding most compds. from transiting from the blood to the brain; only small mols. can cross the BBB.  Under certain pathol. conditions of diseases such as stroke, diabetes, seizures, multiple sclerosis, Parkinson's disease and Alzheimer disease, the BBB is disrupted.  The objective of this review is to provide a broad overview on current strategies for brain drug delivery and related subjects from the past five years.  It is hoped that this review could inspire readers to discover possible approaches to deliver drugs into the brain.  After an initial overview of the BBB structure and function in both healthy and pathol. conditions, this review re-visits, according to recent publications, some questions that are controversial, such as whether nanoparticles by themselves could cross the BBB and whether drugs are specifically transferred to the brain by actively targeted nanoparticles.  Current non-nanoparticle strategies are also reviewed, such as delivery of drugs through the permeable BBB under pathol. conditions and using non-invasive techniques to enhance brain drug uptake.  Finally, one particular area that is often neglected in brain drug delivery is the influence of aging on the BBB, which is captured in this review based on the limited studies in the literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnXjLFpM3RsLVg90H21EOLACvtfcHk0lgdpd3PHzN40g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFKqtrzF&md5=2afa4d9ae415cbece75305614787920a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.7150%2Fthno.21254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.21254%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DX.%26atitle%3DCurrent%2520Strategies%2520for%2520Brain%2520Drug%2520Delivery%26jtitle%3DTheranostics%26date%3D2018%26volume%3D8%26spage%3D1481%26epage%3D1493%26doi%3D10.7150%2Fthno.21254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moustaoui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Movia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupont, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouchemal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djaker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savarin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prina-Mello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Chapelle, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span> <span> </span><span class="NLM_article-title">Tunable Design of Gold(III)–Doxorubicin Complex–PEGylated Nanocarrier. The Golden Doxorubicin for Oncological Applications</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">19946</span>– <span class="NLM_lpage">19957</span>, <span class="refDoi"> DOI: 10.1021/acsami.6b07250</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.6b07250" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOktbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=19946-19957&author=H.+Moustaouiauthor=D.+Moviaauthor=N.+Dupontauthor=N.+Bouchemalauthor=S.+Casaleauthor=N.+Djakerauthor=P.+Savarinauthor=A.+Prina-Melloauthor=M.+L.+de+la+Chapelleauthor=J.+Spadavecchia&title=Tunable+Design+of+Gold%28III%29%E2%80%93Doxorubicin+Complex%E2%80%93PEGylated+Nanocarrier.+The+Golden+Doxorubicin+for+Oncological+Applications&doi=10.1021%2Facsami.6b07250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Tunable Design of Gold(III)-Doxorubicin Complex-PEGylated Nanocarrier. The Golden Doxorubicin for Oncological Applications</span></div><div class="casAuthors">Moustaoui, Hanane; Movia, Dania; Dupont, Nathalie; Bouchemal, Nadia; Casale, Sandra; Djaker, Nadia; Savarin, Philippe; Prina-Mello, Adriele; de la Chapelle, Marc Lamy; Spadavecchia, Jolanda</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">19946-19957</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To date, the translation of Au (III) complexes into chemotherapeutic agents has been hindered by their low stability under physiol. conditions, a crucial parameter in drug development.  In this study, we report an innovative four-step synthesis of a stable Au (III)-doxorubicin (DOX) complex, acting as a key constitutive component of doxorubicin-loaded PEG-coated nanoparticles (DOX IN-PEG-AuNPs).  For therapeutic purposes, such AuNPs were then functionalized with the anti-Kv11.1 polyclonal antibody (pAb), which specifically recognizes the hERG1 channel that is overexpressed on the membrane of human pancreatic cancer cells.  The nature of the interactions between DOX and Au (III) ions was probed by various anal. techniques (Raman spectroscopy, UV-vis, and 1H NMR), which enabled studying the Au (III)-DOX interactions during AuNPs formation.  The theor. characterization of the vibrational bands and the electronic transitions of the Au (III)-DOX complex calcd. through computational studies showed significant qual. agreement with the exptl. observations on AuNPs samples.  Stability in physiol. conditions and efficient drug loading (up to 85 wt./wt. %) were achieved, while drug release was strongly dependent on the structure of DOX IN-PEG-AuNPs and on the pH.  Furthermore, the interactions among DOX, PEG, and Au (III) ions in DOX IN-PEG-AuNPs differed significantly from those found in polymer-modified AuNPs loaded with DOX by covalent linkage, referred to as DOX ON-PEG-AuNPs.  In vitro expts. indeed demonstrated that such differences strongly influenced the therapeutic potential of AuNPs in pancreatic cancer treatment, with a significant increase of the DOX therapeutic index when complexed to Au (III) ions.  Collectively, our study demonstrated that Au (III)-DOX complexes as building blocks of PEGylated AuNPs constitutes a promising approach to transform promising Au (III) complexes into real chemotherapeutic drugs for the treatment of pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJCPhW_fRD9LVg90H21EOLACvtfcHk0lgdpd3PHzN40g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOktbrP&md5=60f89be35b3ab4710ca5ae7d5c0505b4</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facsami.6b07250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.6b07250%26sid%3Dliteratum%253Aachs%26aulast%3DMoustaoui%26aufirst%3DH.%26aulast%3DMovia%26aufirst%3DD.%26aulast%3DDupont%26aufirst%3DN.%26aulast%3DBouchemal%26aufirst%3DN.%26aulast%3DCasale%26aufirst%3DS.%26aulast%3DDjaker%26aufirst%3DN.%26aulast%3DSavarin%26aufirst%3DP.%26aulast%3DPrina-Mello%26aufirst%3DA.%26aulast%3Dde%2Bla%2BChapelle%26aufirst%3DM.%2BL.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26atitle%3DTunable%2520Design%2520of%2520Gold%2528III%2529%25E2%2580%2593Doxorubicin%2520Complex%25E2%2580%2593PEGylated%2520Nanocarrier.%2520The%2520Golden%2520Doxorubicin%2520for%2520Oncological%2520Applications%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2016%26volume%3D8%26spage%3D19946%26epage%3D19957%26doi%3D10.1021%2Facsami.6b07250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marguerit, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moustaoui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddada, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djaker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Chapelle, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span> <span> </span><span class="NLM_article-title">Taxanes Hybrid Nanovectors: From Design to Physico-Chemical Evaluation of Docetaxel and Paclitaxel Gold (III)-PEGylated Complex Nanocarriers</span>. <i>Part. Part. Syst. Charact.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>35</i></span>, <span class="NLM_elocation-id">1700299</span> <span class="refDoi"> DOI: 10.1002/ppsc.201700299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1002%2Fppsc.201700299" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2018&author=G.+Margueritauthor=H.+Moustaouiauthor=M.+B.+Haddadaauthor=N.+Djakerauthor=M.+L.+de+la+Chapelleauthor=J.+Spadavecchia&title=Taxanes+Hybrid+Nanovectors%3A+From+Design+to+Physico-Chemical+Evaluation+of+Docetaxel+and+Paclitaxel+Gold+%28III%29-PEGylated+Complex+Nanocarriers&doi=10.1002%2Fppsc.201700299"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fppsc.201700299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fppsc.201700299%26sid%3Dliteratum%253Aachs%26aulast%3DMarguerit%26aufirst%3DG.%26aulast%3DMoustaoui%26aufirst%3DH.%26aulast%3DHaddada%26aufirst%3DM.%2BB.%26aulast%3DDjaker%26aufirst%3DN.%26aulast%3Dde%2Bla%2BChapelle%26aufirst%3DM.%2BL.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26atitle%3DTaxanes%2520Hybrid%2520Nanovectors%253A%2520From%2520Design%2520to%2520Physico-Chemical%2520Evaluation%2520of%2520Docetaxel%2520and%2520Paclitaxel%2520Gold%2520%2528III%2529-PEGylated%2520Complex%2520Nanocarriers%26jtitle%3DPart.%2520Part.%2520Syst.%2520Charact.%26date%3D2018%26volume%3D35%26doi%3D10.1002%2Fppsc.201700299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djaker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span> <span> </span><span class="NLM_article-title">HIV-1 Tat Peptide-Gemcitabine Gold (III)-PEGylated Complex—Nanoflowers: A Sleek Thermosensitive Hybrid Nanocarrier as Prospective Anticancer</span>. <i>Part. Part. Syst. Charact.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>35</i></span>, <span class="NLM_elocation-id">1800082</span> <span class="refDoi"> DOI: 10.1002/ppsc.201800082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1002%2Fppsc.201800082" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2018&author=H.+Liuauthor=P.+Jiangauthor=Z.+Liauthor=X.+Liauthor=N.+Djakerauthor=J.+Spadavecchia&title=HIV-1+Tat+Peptide-Gemcitabine+Gold+%28III%29-PEGylated+Complex%E2%80%94Nanoflowers%3A+A+Sleek+Thermosensitive+Hybrid+Nanocarrier+as+Prospective+Anticancer&doi=10.1002%2Fppsc.201800082"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fppsc.201800082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fppsc.201800082%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DDjaker%26aufirst%3DN.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26atitle%3DHIV-1%2520Tat%2520Peptide-Gemcitabine%2520Gold%2520%2528III%2529-PEGylated%2520Complex%25E2%2580%2594Nanoflowers%253A%2520A%2520Sleek%2520Thermosensitive%2520Hybrid%2520Nanocarrier%2520as%2520Prospective%2520Anticancer%26jtitle%3DPart.%2520Part.%2520Syst.%2520Charact.%26date%3D2018%26volume%3D35%26doi%3D10.1002%2Fppsc.201800082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furlani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arib, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djaker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Chapelle, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span> <span> </span><span class="NLM_article-title">Lactose-Modified Chitosan Gold(III)-PEGylated Complex-Bioconjugates: From Synthesis to Interaction with Targeted Galectin-1 Protein</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3352</span>– <span class="NLM_lpage">3361</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.8b00520</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.8b00520" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslWhtbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=3352-3361&author=Q.+Liuauthor=P.+Saccoauthor=E.+Marsichauthor=F.+Furlaniauthor=C.+Aribauthor=N.+Djakerauthor=M.+L.+de+la+Chapelleauthor=I.+Donatiauthor=J.+Spadavecchia&title=Lactose-Modified+Chitosan+Gold%28III%29-PEGylated+Complex-Bioconjugates%3A+From+Synthesis+to+Interaction+with+Targeted+Galectin-1+Protein&doi=10.1021%2Facs.bioconjchem.8b00520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Lactose-Modified Chitosan Gold(III)-PEGylated Complex-Bioconjugates: From Synthesis to Interaction with Targeted Galectin-1 Protein</span></div><div class="casAuthors">Liu, Qiqian; Sacco, Pasquale; Marsich, Eleonora; Furlani, Franco; Arib, Celia; Djaker, Nadia; Lamy de la Chapelle, Marc; Donati, Ivan; Spadavecchia, Jolanda</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3352-3361</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Galectins (Gal) are a family of glycan-binding proteins characterized by their affinity for β-galactosides.  Galectin-1 (Gal-1), a dimeric lectin with two galactoside-binding sites, regulates cancer progression and immune responses.  Coordination chem. has been engaged to develop versatile multivalent neoglycoconjugates for binding Gal-1.  In this study we report a fast and original method to synthesize hybrid gold nanoparticles in which a hydrochloride lactose-modified chitosan, named CTL, is mixed with dicarboxylic acid-terminated polyethylene glycol (PEG), leading to shell-like hybrid polymer-sugar-metal nanoparticles (CTL-PEG-AuNPs).  The aim of this paper is to preliminarily study the interaction of the CTL-PEG-AuNPs with a target protein, namely, Gal-1, under specific conditions.  The mol. interaction has been measured by Transmission Electron Microscopy (TEM), UV-vis, and Raman Spectroscopy on a large range of Gal-1 concns. (from 0 to 10-12 M).  We obsd. that the interaction was strongly dependent on the Gal-1 concn. at the surface of the gold nanoparticles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot1xqZPgmVWrVg90H21EOLACvtfcHk0lgkQFeveVXRIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslWhtbbE&md5=13342fd42f17bd06aa40cb1926bba3b6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.8b00520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.8b00520%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSacco%26aufirst%3DP.%26aulast%3DMarsich%26aufirst%3DE.%26aulast%3DFurlani%26aufirst%3DF.%26aulast%3DArib%26aufirst%3DC.%26aulast%3DDjaker%26aufirst%3DN.%26aulast%3Dde%2Bla%2BChapelle%26aufirst%3DM.%2BL.%26aulast%3DDonati%26aufirst%3DI.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26atitle%3DLactose-Modified%2520Chitosan%2520Gold%2528III%2529-PEGylated%2520Complex-Bioconjugates%253A%2520From%2520Synthesis%2520to%2520Interaction%2520with%2520Targeted%2520Galectin-1%2520Protein%26jtitle%3DBioconjugate%2520Chem.%26date%3D2018%26volume%3D29%26spage%3D3352%26epage%3D3361%26doi%3D10.1021%2Facs.bioconjchem.8b00520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aouidat, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djaker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span> <span> </span><span class="NLM_article-title">Galectin-1 Protein Modified Gold (III)-PEGylated Complex-Nanoparticles: Proof of Concept of Alternative Probe in Colorimetric Glucose Detection</span>. <i>Colloids Surf., B</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>185</i></span>, <span class="NLM_elocation-id">110588</span> <span class="refDoi"> DOI: 10.1016/j.colsurfb.2019.110588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.colsurfb.2019.110588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=31654887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVaksb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=2020&author=Q.+Liuauthor=F.+Aouidatauthor=P.+Saccoauthor=E.+Marsichauthor=N.+Djakerauthor=J.+Spadavecchia&title=Galectin-1+Protein+Modified+Gold+%28III%29-PEGylated+Complex-Nanoparticles%3A+Proof+of+Concept+of+Alternative+Probe+in+Colorimetric+Glucose+Detection&doi=10.1016%2Fj.colsurfb.2019.110588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Galectin-1 protein modified gold (III)-PEGylated complex-nanoparticles: Proof of concept of alternative probe in colorimetric glucose detection</span></div><div class="casAuthors">Liu, Qiqian; Aouidat, Fatima; Sacco, Pasquale; Marsich, Eleonora; Djaker, Nadia; Spadavecchia, Jolanda</div><div class="citationInfo"><span class="NLM_cas:title">Colloids and Surfaces, B: Biointerfaces</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">110588</span>CODEN:
                <span class="NLM_cas:coden">CSBBEQ</span>;
        ISSN:<span class="NLM_cas:issn">0927-7765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Galectins (Gal) are a family of dimeric lectins, composed by two galactoside-binding sites implicated in the regulation of cancer progression and immune responses.  In this study, we report for the first time the synthesis and the phys.-chem. characterization of galectin-1-complex-gold COOH-terminated polyethlenglicole (PEG)-coated NPs (Gal-1 IN PEG-AuNPs) and their ability to recognize glucose in an aq. soln. with a concn. varying from 10 mM to 100 pM.  The chem. protocol consistsof three steps: (i) complexation between galectin-1Gal-1 and tetrachloroauric acid (HAuCl4) to form gold-protein grains; (ii) staking process of COOH-terminated polyethlenglicole mols. (PEG) onto Gal-1-Au complex and (iii) redn. of hybrid metal ions to obtain a colloidal stable soln.  During the complexation, the spectral signatures related to the Gal-1 orientation on the gold surface have been found to change due to its protonation state.  The effective glucose monitoring was detected by UV-vis, Raman spectroscopy and Transmission Electron Microscopy (TEM).  Overall, we obsd. that the interaction is strongly dependent on the Gal-1 conformation at the surface of gold nanoparticles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfZxFB8Q_wT7Vg90H21EOLACvtfcHk0lgkQFeveVXRIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVaksb7N&md5=13097338f46a34beaef1ae58ae831aac</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.colsurfb.2019.110588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.colsurfb.2019.110588%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DAouidat%26aufirst%3DF.%26aulast%3DSacco%26aufirst%3DP.%26aulast%3DMarsich%26aufirst%3DE.%26aulast%3DDjaker%26aufirst%3DN.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26atitle%3DGalectin-1%2520Protein%2520Modified%2520Gold%2520%2528III%2529-PEGylated%2520Complex-Nanoparticles%253A%2520Proof%2520of%2520Concept%2520of%2520Alternative%2520Probe%2520in%2520Colorimetric%2520Glucose%2520Detection%26jtitle%3DColloids%2520Surf.%252C%2520B%26date%3D2020%26volume%3D185%26doi%3D10.1016%2Fj.colsurfb.2019.110588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apchain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiche, I.</span></span> <span> </span><span class="NLM_article-title">One-Step Synthesis of Collagen Hybrid Gold Nanoparticles and Formation on Egyptian-Like Gold-Plated Archaeological Ivory</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8363</span>– <span class="NLM_lpage">8366</span>, <span class="refDoi"> DOI: 10.1002/anie.201403567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1002%2Fanie.201403567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVGqt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=8363-8366&author=J.+Spadavecchiaauthor=E.+Apchainauthor=M.+Albericauthor=E.+Fontanauthor=I.+Reiche&title=One-Step+Synthesis+of+Collagen+Hybrid+Gold+Nanoparticles+and+Formation+on+Egyptian-Like+Gold-Plated+Archaeological+Ivory&doi=10.1002%2Fanie.201403567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">One-Step Synthesis of Collagen Hybrid Gold Nanoparticles and Formation on Egyptian-like Gold-Plated Archaeological Ivory</span></div><div class="casAuthors">Spadavecchia, Jolanda; Apchain, Emilande; Alberic, Marie; Fontan, Elisabeth; Reiche, Ina</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">8363-8366</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A one-step method is reported to synthesize hybrid gold nanoparticles (AuNPs) by redn. of HAuCl4 in acetic soln. in the presence of collagen (Col), dicarboxylic acid-terminated polyethylene glycol (PEG), and cetyltetrammonium bromide (CTAB) mixed with hydoxyapatite (HAP) as surfactants.  Such formation process of AuNPs was shown to be responsible for purple stains naturally formed on Egyptianizing archaeol. gilded ivories from 8th BC Syria.  The understanding of this formation mechanism, which most likely involves a step with hybrid AuNPs, allows the establishing of an authenticity marker of ancient gold-plated ivories.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCwyUOqhVvwLVg90H21EOLACvtfcHk0lgkQFeveVXRIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVGqt7zP&md5=082173d94738668b123e2e22ead2a215</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fanie.201403567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201403567%26sid%3Dliteratum%253Aachs%26aulast%3DSpadavecchia%26aufirst%3DJ.%26aulast%3DApchain%26aufirst%3DE.%26aulast%3DAlberic%26aufirst%3DM.%26aulast%3DFontan%26aufirst%3DE.%26aulast%3DReiche%26aufirst%3DI.%26atitle%3DOne-Step%2520Synthesis%2520of%2520Collagen%2520Hybrid%2520Gold%2520Nanoparticles%2520and%2520Formation%2520on%2520Egyptian-Like%2520Gold-Plated%2520Archaeological%2520Ivory%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D8363%26epage%3D8366%26doi%3D10.1002%2Fanie.201403567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aouidat, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boumati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tielens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doan, B.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Gold-Gadolinium-Core-Shell Nanoparticles as Contrast Agent: a Smart Way to Future Nanomaterials for Nanomedicine Applications</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">9309</span>– <span class="NLM_lpage">9324</span>, <span class="refDoi"> DOI: 10.2147/IJN.S224805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.2147%2FIJN.S224805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=31819433" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=9309-9324&author=F.+Aouidatauthor=S.+Boumatiauthor=M.+Khanauthor=F.+Tielensauthor=B.-T.+Doanauthor=J.+Spadavecchia&title=Design+and+Synthesis+of+Gold-Gadolinium-Core-Shell+Nanoparticles+as+Contrast+Agent%3A+a+Smart+Way+to+Future+Nanomaterials+for+Nanomedicine+Applications&doi=10.2147%2FIJN.S224805"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2147%2FIJN.S224805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S224805%26sid%3Dliteratum%253Aachs%26aulast%3DAouidat%26aufirst%3DF.%26aulast%3DBoumati%26aufirst%3DS.%26aulast%3DKhan%26aufirst%3DM.%26aulast%3DTielens%26aufirst%3DF.%26aulast%3DDoan%26aufirst%3DB.-T.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Gold-Gadolinium-Core-Shell%2520Nanoparticles%2520as%2520Contrast%2520Agent%253A%2520a%2520Smart%2520Way%2520to%2520Future%2520Nanomaterials%2520for%2520Nanomedicine%2520Applications%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2019%26volume%3D14%26spage%3D9309%26epage%3D9324%26doi%3D10.2147%2FIJN.S224805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morel, A.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bialecki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moustaoui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de La Chapelle, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span> <span> </span><span class="NLM_article-title">Green Extraction of Endemic Plants to Synthesize Gold Nanoparticles for Theranostic Applications</span>. <i>Front. Lab. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">171</span>, <span class="refDoi"> DOI: 10.1016/j.flm.2017.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.flm.2017.10.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=158-171&author=A.-L.+Morelauthor=S.+Giraudauthor=A.+Bialeckiauthor=H.+Moustaouiauthor=M.+L.+de+La+Chapelleauthor=J.+Spadavecchia&title=Green+Extraction+of+Endemic+Plants+to+Synthesize+Gold+Nanoparticles+for+Theranostic+Applications&doi=10.1016%2Fj.flm.2017.10.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.flm.2017.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.flm.2017.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DMorel%26aufirst%3DA.-L.%26aulast%3DGiraud%26aufirst%3DS.%26aulast%3DBialecki%26aufirst%3DA.%26aulast%3DMoustaoui%26aufirst%3DH.%26aulast%3Dde%2BLa%2BChapelle%26aufirst%3DM.%2BL.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26atitle%3DGreen%2520Extraction%2520of%2520Endemic%2520Plants%2520to%2520Synthesize%2520Gold%2520Nanoparticles%2520for%2520Theranostic%2520Applications%26jtitle%3DFront.%2520Lab.%2520Med.%26date%3D2017%26volume%3D1%26spage%3D158%26epage%3D171%26doi%3D10.1016%2Fj.flm.2017.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noble, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goa, K. L.</span></span> <span> </span><span class="NLM_article-title">Gemcitabine. A Review of its Pharmacology and Clinical Potential in Non-Small Cell Lung Cancer and Pancreatic Cancer</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">447</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.2165/00003495-199754030-00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.2165%2F00003495-199754030-00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=9279506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADyaK2sXlvFelt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1997&pages=447-472&author=S.+Nobleauthor=K.+L.+Goa&title=Gemcitabine.+A+Review+of+its+Pharmacology+and+Clinical+Potential+in+Non-Small+Cell+Lung+Cancer+and+Pancreatic+Cancer&doi=10.2165%2F00003495-199754030-00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Gemcitabine. A review of its pharmacology and clinical potential in non-small-cell lung cancer and pancreatic cancer</span></div><div class="casAuthors">Noble, Stuart; Goa, Karen L.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">447-472</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">A review with 119 refs. Gemcitabine is a deoxycytidine analog which was originally investigated for its antiviral effects but has since been developed as an anticancer therapy.  Gemcitabine monotherapy produced an objective tumor response in 18-26% of patients with advanced non-small-cell lung cancer (NSCLC) and appears to have efficacy similar to that of cisplatin plus etoposide.  Objective response rates ranging 26-54% were recorded when gemcitabine was combined with cisplatin, and 1-yr survival duration after such treatment ranged 35-61%.  Improvements in a range of NSCLC disease symptoms and/or in general performance status occurred in many patients who received gemcitabine, with or without cisplatin, in 3 clin. trials.  Gemcitabine appears to be cost effective compared with best supportive care for NSCLC.  In addn., direct costs assocd. with administration of gemcitabine monotherapy may be lower than those for some other NSCLC chemotherapy options.  The combination of gemcitabine plus cisplatin was assocd. with a lower cost-per-tumor response than cisplatin plus etoposide or cisplatin plus vinorelbine, according to a retrospective cost-effectiveness anal.  In a single comparative study in patients with advanced pancreatic cancer, gemcitabine was more effective than fluorouracil with respect to survival duration and general clin. status.  It also showed modest antitumor and palliative efficacy in patients refractory to fluorouracil.  Gemcitabine appears to be well tolerated, although further comparisons with other chemotherapy regimens are required.  The data indicate that gemcitabine monotherapy is better tolerated than cisplatin plus etoposide in patients with NSCLC.  Data from noncomparative studies suggest that the combination of gemcitabine and cisplatin has an acceptable tolerability profile.  In a single trial in patients with pancreatic cancer, fluorouracil was better tolerated than gemcitabine; however, gemcitabine was generally well tolerated overall in this study.  Thus, gemcitabine (with or without cisplatin) may prove attractive to patients with advanced NSCLC, given their limited life expectancy and the toxicity assocd. with many other chemotherapy regimens.  Gemcitabine is a valuable new chemotherapy option for patients with advanced pancreatic cancer, a disease considered incurable at present.  Its apparent survival and palliative benefits over fluorouracil require confirmation, but are encouraging, as the need to improve both the duration and quality of survival in these patients is well recognized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5SrlK09kwnrVg90H21EOLACvtfcHk0ljh9qjISLu6Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlvFelt7c%253D&md5=2479ca53d998ad70275a54db2b212169</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2165%2F00003495-199754030-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-199754030-00009%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DS.%26aulast%3DGoa%26aufirst%3DK.%2BL.%26atitle%3DGemcitabine.%2520A%2520Review%2520of%2520its%2520Pharmacology%2520and%2520Clinical%2520Potential%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520and%2520Pancreatic%2520Cancer%26jtitle%3DDrugs%26date%3D1997%26volume%3D54%26spage%3D447%26epage%3D472%26doi%3D10.2165%2F00003495-199754030-00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oluwasanmi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Shakarchi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldebasi, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsini, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albusair, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haxton, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, A. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoskins, C.</span></span> <span> </span><span class="NLM_article-title">Diels Alder-Mediated Release of Gemcitabine from Hybrid Nanoparticles for Enhanced Pancreatic Cancer Therapy</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>266</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2017.09.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.jconrel.2017.09.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=28943195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslOisLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=266&publication_year=2017&pages=355-364&author=A.+Oluwasanmiauthor=W.+Al-Shakarchiauthor=A.+Manzurauthor=M.+H.+Aldebasiauthor=R.+S.+Elsiniauthor=M.+K.+Albusairauthor=K.+J.+Haxtonauthor=A.+D.+M.+Curtisauthor=C.+Hoskins&title=Diels+Alder-Mediated+Release+of+Gemcitabine+from+Hybrid+Nanoparticles+for+Enhanced+Pancreatic+Cancer+Therapy&doi=10.1016%2Fj.jconrel.2017.09.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy</span></div><div class="casAuthors">Oluwasanmi, Adeolu; Al-Shakarchi, Wejdan; Manzur, Ayesha; Aldebasi, Mohammed H.; Elsini, Rayan S.; Albusair, Malek K.; Haxton, Katherine J.; Curtis, Anthony D. M.; Hoskins, Clare</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">266</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">355-364</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hybrid nanoparticles (HNPs) have shown huge potential as drug delivery vehicles for pancreatic cancer.  Currently, the first line treatment, gemcitabine, is only effective in 23.8% of patients.  To improve this, a thermally activated system was developed by introducing a linker between HNPs and gemcitabine.  Whereby, heat generation resulting from laser irradn. of the HNPs promoted linker breakdown resulting in prodrug liberation.  In vitro evaluation in pancreatic adenocarcinoma cells, showed the prodrug was 4.3 times less cytotoxic than gemcitabine, but exhibited 11-fold improvement in cellular uptake.  Heat activation of the formulation led to a 56% rise in cytotoxicity causing it to outperform gemcitabine by 26%.  In vivo the formulation outperformed free gemcitabine with a 62% redn. in tumor wt. in pancreatic xenografts.  This HNP formulation is the first of its kind and has displayed superior anti-cancer activity as compared to the current first line drug gemcitabine after heat mediated controlled release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOfoaRwMMJebVg90H21EOLACvtfcHk0ljh9qjISLu6Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslOisLzN&md5=01a80b5617e3120c9ced4ab6d0df2152</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2017.09.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2017.09.027%26sid%3Dliteratum%253Aachs%26aulast%3DOluwasanmi%26aufirst%3DA.%26aulast%3DAl-Shakarchi%26aufirst%3DW.%26aulast%3DManzur%26aufirst%3DA.%26aulast%3DAldebasi%26aufirst%3DM.%2BH.%26aulast%3DElsini%26aufirst%3DR.%2BS.%26aulast%3DAlbusair%26aufirst%3DM.%2BK.%26aulast%3DHaxton%26aufirst%3DK.%2BJ.%26aulast%3DCurtis%26aufirst%3DA.%2BD.%2BM.%26aulast%3DHoskins%26aufirst%3DC.%26atitle%3DDiels%2520Alder-Mediated%2520Release%2520of%2520Gemcitabine%2520from%2520Hybrid%2520Nanoparticles%2520for%2520Enhanced%2520Pancreatic%2520Cancer%2520Therapy%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2017%26volume%3D266%26spage%3D355%26epage%3D364%26doi%3D10.1016%2Fj.jconrel.2017.09.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karahoca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momparler, R. L.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic and Pharmacodynamic Analysis of 5-Aza-2′-Deoxycytidine (Decitabine) in the Design of its Dose-Schedule for Cancer Therapy</span>. <i>Clin. Epigenet.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">3</span> <span class="refDoi"> DOI: 10.1186/1868-7083-5-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1186%2F1868-7083-5-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=23369223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslCisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&author=M.+Karahocaauthor=R.+L.+Momparler&title=Pharmacokinetic+and+Pharmacodynamic+Analysis+of+5-Aza-2%E2%80%B2-Deoxycytidine+%28Decitabine%29+in+the+Design+of+its+Dose-Schedule+for+Cancer+Therapy&doi=10.1186%2F1868-7083-5-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy</span></div><div class="casAuthors">Karahoca, Metin; Momparler, Richard L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Epigenetics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3</span>CODEN:
                <span class="NLM_cas:coden">CELPCI</span>;
        ISSN:<span class="NLM_cas:issn">1868-7083</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  5-Aza-2'-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under investigation for treating acute myeloid leukemia (AML) and other malignancies.  5-AZA-CdR can reactivate tumor suppressor genes silenced by aberrant DNA methylation, a frequent event in all types of cancer.  Because this epigenetic change is reversible, it is a good target for 5-AZA-CdR therapy.  We have reviewed the preclin. data of 5-AZA-CdR to analyze the concns. and exposure times required to eradicate cancer stem cells.  We analyzed the dose-schedules used in animal models that show potent antineoplastic activity of 5-AZA-CdR.  We attempted to correlate the preclin. data with the responses obtained in clin. trials of 5-AZA-CdR in patients with cancer.  The pharmacokinetics and drug distribution of 5-AZA-CdR are key parameters because adequate therapeutic drug levels are required to eliminate cancer stem cells in all anat. compartments.  The plasma half-life of 5-AZA-CdR in humans is approx. 20 min due to the high levels in the liver of cytidine deaminase, the enzyme that inactivates this analog.  This provides a rationale to use an inhibitor of cytidine deaminase in combination with 5-AZA-CdR.  Low-dose 5-AZA-CdR is effective for MDS and AML and can induce complete remissions (CR).  However, maintenance of CR with low-dose 5-AZA-CdR is difficult.  Based on analyses of preclin. and clin. data, low-dose 5-AZA-CdR has the potential to be an effective form of therapy in some patients with cancer.  For patients who do not respond to low-dose therapy we recommend dose-intensive treatment with 5-AZA-CdR.  Patients who are candidates for intensive dose 5-AZA-CdR should have a good bone marrow status so as to permit adequate recovery from myelosuppression, the major toxicity of 5-AZA-CdR.  Solid tumors are also interesting targets for therapy with 5-AZA-CdR.  Both low-dose and intensive therapy with 5-AZA-CdR can reduce the proliferative potential of tumor stem cells in animal models.  We propose novel dose schedules of 5-AZA-CdR for investigation in patients with cancer.  The full chemotherapeutic potential of 5-AZA-CdR to treat cancer merits further clin. investigation and can only be realized when its optimal dose-schedule is detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVWSDOAcgpjrVg90H21EOLACvtfcHk0ljh9qjISLu6Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslCisbk%253D&md5=8fcc05a772220b95101dd85d9894b674</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1186%2F1868-7083-5-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1868-7083-5-3%26sid%3Dliteratum%253Aachs%26aulast%3DKarahoca%26aufirst%3DM.%26aulast%3DMomparler%26aufirst%3DR.%2BL.%26atitle%3DPharmacokinetic%2520and%2520Pharmacodynamic%2520Analysis%2520of%25205-Aza-2%25E2%2580%25B2-Deoxycytidine%2520%2528Decitabine%2529%2520in%2520the%2520Design%2520of%2520its%2520Dose-Schedule%2520for%2520Cancer%2520Therapy%26jtitle%3DClin.%2520Epigenet.%26date%3D2013%26volume%3D5%26doi%3D10.1186%2F1868-7083-5-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cashen, A. F.</span></span> <span> </span><span class="NLM_article-title">Decitabine in the Treatment of Acute Myeloid Leukemia in Elderly Patients</span>. <i>Cancer Manage. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.2147/CMAR.S40600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.2147%2FCMAR.S40600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=24520204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptVKhtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=53-61&author=P.+Malikauthor=A.+F.+Cashen&title=Decitabine+in+the+Treatment+of+Acute+Myeloid+Leukemia+in+Elderly+Patients&doi=10.2147%2FCMAR.S40600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Decitabine in the treatment of acute myeloid leukemia in elderly patients</span></div><div class="casAuthors">Malik, Priya; Cashen, Amanda F.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Management and Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53-61, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">CMRACP</span>;
        ISSN:<span class="NLM_cas:issn">1179-1322</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  The majority of patients with acute myeloid leukemia (AML) are elderly and have a poor prognosis despite induction therapy.  Decitabine, a DNA-hypomethylating agent that induces differentiation and apoptosis of leukemic cells, is a well-tolerated alternative to aggressive chemotherapy.  It is currently FDA-approved for myelodysplastic syndrome, including patients with 20%-30% bone marrow blasts.  Recent clin. attention has focused on evaluating decitabine as frontline therapy for untreated high-risk elderly AML patients.  A large randomized international phase III study comparing decitabine to supportive care and cytarabine in elderly AML patients demonstrated significantly improved complete remission rates, but the survival difference did not reach significance.  Due to this, decitabine did not achieve FDA approval for AML, but continues to be used off-label.  Current research is focused on further defining subgroups of elderly AML patients who may derive greater benefit from decitabine therapy and combining it with other low-intensity active agents for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqDbuBrriRdbVg90H21EOLACvtfcHk0liw-ebd1XBjPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptVKhtrw%253D&md5=ab9f4fa47c153e35aed543237ebf67a6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2147%2FCMAR.S40600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCMAR.S40600%26sid%3Dliteratum%253Aachs%26aulast%3DMalik%26aufirst%3DP.%26aulast%3DCashen%26aufirst%3DA.%2BF.%26atitle%3DDecitabine%2520in%2520the%2520Treatment%2520of%2520Acute%2520Myeloid%2520Leukemia%2520in%2520Elderly%2520Patients%26jtitle%3DCancer%2520Manage.%2520Res.%26date%3D2014%26volume%3D6%26spage%3D53%26epage%3D61%26doi%3D10.2147%2FCMAR.S40600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irudayaraj, J.</span></span> <span> </span><span class="NLM_article-title">Decitabine Nanoconjugate Sensitizes Human Glioblastoma Cells to Temozolomide</span>. <i>Mol. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1279</span>– <span class="NLM_lpage">1288</span>, <span class="refDoi"> DOI: 10.1021/mp500815b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp500815b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFyntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=1279-1288&author=Y.+Cuiauthor=A.+Nazauthor=D.+H.+Thompsonauthor=J.+Irudayaraj&title=Decitabine+Nanoconjugate+Sensitizes+Human+Glioblastoma+Cells+to+Temozolomide&doi=10.1021%2Fmp500815b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Decitabine Nanoconjugate Sensitizes Human Glioblastoma Cells to Temozolomide</span></div><div class="casAuthors">Cui, Yi; Naz, Asia; Thompson, David H.; Irudayaraj, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1279-1288</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this study, we developed and characterized a delivery system for the epigenetic demethylating drug, decitabine, to sensitize temozolomide-resistant human glioblastoma multiforme (GBM) cells to alkylating chemotherapy.  A poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG) based nanoconjugate was fabricated to encapsulate decitabine and achieved a better therapeutic response in GBM cells than that with the free drug.  After synthesis, the highly efficient uptake process and intracellular dynamics of this nanoconjugate were monitored by single-mol. fluorescence tools.  Our expts. demonstrated that, under an acidic pH due to active glycolysis in cancer cells, the PLGA-PEG nanovector could release the conjugated decitabine at a faster rate, after which the hydrolyzed lactic acid and glycolic acid would further acidify the intracellular microenvironment, thus providing pos. feedback to increase the effective drug concn. and realize growth inhibition.  In temozolomide-resistant GBM cells, decitabine can potentiate the cytotoxic DNA alkylation by counteracting cytosine methylation and reactivating tumor suppressor genes, such as p53 and p21.  Owing to the excellent internalization and endolysosomal escape enabled by the PLGA-PEG backbone, the encapsulated decitabine exhibited a better anti-GBM potential than that of free drug mols.  Hence, the synthesized nanoconjugate and temozolomide could act in synergy to deliver a more potent and long-term antiproliferative effect against malignant GBM cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrruZPTyejx8LVg90H21EOLACvtfcHk0liw-ebd1XBjPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFyntbs%253D&md5=15876d49f21053c48c0996cc8ce63d1d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fmp500815b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp500815b%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DY.%26aulast%3DNaz%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DD.%2BH.%26aulast%3DIrudayaraj%26aufirst%3DJ.%26atitle%3DDecitabine%2520Nanoconjugate%2520Sensitizes%2520Human%2520Glioblastoma%2520Cells%2520to%2520Temozolomide%26jtitle%3DMol.%2520Pharm.%26date%3D2015%26volume%3D12%26spage%3D1279%26epage%3D1288%26doi%3D10.1021%2Fmp500815b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raucher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragojevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J.</span></span> <span> </span><span class="NLM_article-title">Macromolecular Drug Carriers for Targeted Glioblastoma Therapy: Preclinical Studies, Challenges, and Future Perspectives</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">624</span> <span class="refDoi"> DOI: 10.3389/fonc.2018.00624</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.3389%2Ffonc.2018.00624" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=30619758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A280%3ADC%252BB3cnptVyjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&author=D.+Raucherauthor=S.+Dragojevicauthor=J.+Ryu&title=Macromolecular+Drug+Carriers+for+Targeted+Glioblastoma+Therapy%3A+Preclinical+Studies%2C+Challenges%2C+and+Future+Perspectives&doi=10.3389%2Ffonc.2018.00624"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Macromolecular Drug Carriers for Targeted Glioblastoma Therapy: Preclinical Studies, Challenges, and Future Perspectives</span></div><div class="casAuthors">Raucher Drazen; Dragojevic Sonja; Ryu Jungsu</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">624</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Glioblastoma, the most common, aggressive brain tumor, ranks among the least curable cancers-owing to its strong tendency for intracranial dissemination, high proliferation potential, and inherent tumor resistance to radiation and chemotherapy.  Current glioblastoma treatment strategies are further hampered by a critical challenge: adverse, non-specific treatment effects in normal tissue combined with the inability of drugs to penetrate the blood brain barrier and reach the tumor microenvironment.  Thus, the creation of effective therapies for glioblastoma requires development of targeted drug-delivery systems that increase accumulation of the drug in the tumor tissue while minimizing systemic toxicity in healthy tissues.  As demonstrated in various preclinical glioblastoma models, macromolecular drug carriers have the potential to improve delivery of small molecule drugs, therapeutic peptides, proteins, and genes to brain tumors.  Currently used macromolecular drug delivery systems, such as liposomes and polymers, passively target solid tumors, including glioblastoma, by capitalizing on abnormalities of the tumor vasculature, its lack of lymphatic drainage, and the enhanced permeation and retention (EPR) effect.  In addition to passive targeting, active targeting approaches include the incorporation of various ligands on the surface of macromolecules that bind to cell surface receptors expressed on specific cancer cells.  Active targeting approaches also utilize stimulus responsive macromolecules which further improve tumor accumulation by triggering changes in the physical properties of the macromolecular carrier.  The stimulus can be an intrinsic property of the tumor tissue, such as low pH, or extrinsic, such as local application of ultrasound or heat.  This review article explores current preclinical studies and future perspectives of targeted drug delivery to glioblastoma by macromolecular carrier systems, including polymeric micelles, nanoparticles, and biopolymers.  We highlight key aspects of the design of diverse macromolecular drug delivery systems through a review of their preclinical applications in various glioblastoma animal models.  We also review the principles and advantages of passive and active targeting based on various macromolecular carriers.  Additionally, we discuss the potential disadvantages that may prevent clinical application of these carriers in targeting glioblastoma, as well as approaches to overcoming these obstacles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDRk0Zhzo17OdfST00W0BcfW6udTcc2eaoboXzxgE5jbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnptVyjsA%253D%253D&md5=8b128439e8d157fdabd8d91713a991a4</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2018.00624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2018.00624%26sid%3Dliteratum%253Aachs%26aulast%3DRaucher%26aufirst%3DD.%26aulast%3DDragojevic%26aufirst%3DS.%26aulast%3DRyu%26aufirst%3DJ.%26atitle%3DMacromolecular%2520Drug%2520Carriers%2520for%2520Targeted%2520Glioblastoma%2520Therapy%253A%2520Preclinical%2520Studies%252C%2520Challenges%252C%2520and%2520Future%2520Perspectives%26jtitle%3DFront.%2520Oncol.%26date%3D2018%26volume%3D8%26doi%3D10.3389%2Ffonc.2018.00624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, T.</span></span> <span> </span><span class="NLM_article-title">Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists</span>. <i>World Neurosurg.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">e468</span>– <span class="NLM_lpage">e477</span>, <span class="refDoi"> DOI: 10.1016/j.wneu.2019.04.180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.wneu.2019.04.180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=31048057" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2019&pages=e468-e477&author=Z.+Liuauthor=X.+Jiangauthor=L.+Gaoauthor=X.+Liuauthor=J.+Liauthor=X.+Huangauthor=T.+Zeng&title=Synergistic+Suppression+of+Glioblastoma+Cell+Growth+by+Combined+Application+of+Temozolomide+and+Dopamine+D2+Receptor+Antagonists&doi=10.1016%2Fj.wneu.2019.04.180"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.wneu.2019.04.180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.wneu.2019.04.180%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DZeng%26aufirst%3DT.%26atitle%3DSynergistic%2520Suppression%2520of%2520Glioblastoma%2520Cell%2520Growth%2520by%2520Combined%2520Application%2520of%2520Temozolomide%2520and%2520Dopamine%2520D2%2520Receptor%2520Antagonists%26jtitle%3DWorld%2520Neurosurg.%26date%3D2019%26volume%3D128%26spage%3De468%26epage%3De477%26doi%3D10.1016%2Fj.wneu.2019.04.180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Movia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moustaoui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prina-Mello, A.</span></span> <span> </span><span class="NLM_article-title">Targeted Polyethylene Glycol Gold Nanoparticles for the Treatment of Pancreatic Cancer: From Synthesis to Proof-Of-Concept in Vitro Studies</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">822</span>, <span class="refDoi"> DOI: 10.2147/IJN.S97476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.2147%2FIJN.S97476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=27013874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFChtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=791-822&author=J.+Spadavecchiaauthor=D.+Moviaauthor=C.+Mooreauthor=C.+M.+Maguireauthor=H.+Moustaouiauthor=S.+Casaleauthor=Y.+Volkovauthor=A.+Prina-Mello&title=Targeted+Polyethylene+Glycol+Gold+Nanoparticles+for+the+Treatment+of+Pancreatic+Cancer%3A+From+Synthesis+to+Proof-Of-Concept+in+Vitro+Studies&doi=10.2147%2FIJN.S97476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted polyethylene glycol gold nanoparticles for the treatment of pancreatic cancer: from synthesis to proof-of-concept in vitro studies</span></div><div class="casAuthors">Spadavecchia, Jolanda; Movia, Dania; Moore, Caroline; Maguire, Ciaran Manus; Moustaoui, Hanane; Casale, Sandra; Volkov, Yuri; Prina-Mello, Adriele</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">791-822</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">The main objective of this study was to optimize and characterize a drug delivery carrier for doxorubicin, intended to be i.v. administered, capable of improving the therapeutic index of the chemotherapeutic agent itself, and aimed at the treatment of pancreatic cancer.  In light of this goal, we report a robust one-step method for the synthesis of dicarboxylic acid-terminated polyethylene glycol (PEG)-gold nanoparticles (AuNPs) and doxorubicin-loaded PEG-AuNPs, and their further antibody targeting (anti-Kv11.1 polyclonal antibody [pAb]).  In in vitro proof-of-concept studies, we evaluated the influence of the nanocarrier and of the active targeting functionality on the anti-tumor efficacy of doxorubicin, with respect to its half-maximal effective concn. (EC50) and drug-triggered changes in the cell cycle.  Our results demonstrated that the therapeutic efficacy of doxorubicin was pos. influenced not only by the active targeting exploited through anti-Kv11.1-pAb but also by the drug coupling with a nanometer-sized delivery system, which indeed resulted in a 30-fold decrease of doxorubicin EC50, cell cycle blockage, and drug localization in the cell nuclei.  The cell internalization pathway was strongly influenced by the active targeting of the Kv11.1 subunit of the human Ether-a-go-go related gene 1 (hERG1) channel aberrantly expressed on the membrane of pancreatic cancer cells.  Targeted PEG-AuNPs were translocated into the lysosomes and were assocd. to an increased lysosomal function in PANC-1 cells.  Addnl., doxorubicin release into an aq. environment was almost negligible after 7 days, suggesting that drug release from PEG-AuNPs was triggered by enzymic activity.  Although preliminary, data gathered from this study have considerable potential in the application of safe-by-design nano-enabled drug-delivery systems (ie, nanomedicines) for the treatment of pancreatic cancer, a disease with a poor prognosis and one of the main current burdens of today's health care bill of industrialized countries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZU_bX9-GcsbVg90H21EOLACvtfcHk0liEYsQuibaDgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFChtL4%253D&md5=154e1f94dfa7b905213bd34e96c6a482</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2147%2FIJN.S97476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S97476%26sid%3Dliteratum%253Aachs%26aulast%3DSpadavecchia%26aufirst%3DJ.%26aulast%3DMovia%26aufirst%3DD.%26aulast%3DMoore%26aufirst%3DC.%26aulast%3DMaguire%26aufirst%3DC.%2BM.%26aulast%3DMoustaoui%26aufirst%3DH.%26aulast%3DCasale%26aufirst%3DS.%26aulast%3DVolkov%26aufirst%3DY.%26aulast%3DPrina-Mello%26aufirst%3DA.%26atitle%3DTargeted%2520Polyethylene%2520Glycol%2520Gold%2520Nanoparticles%2520for%2520the%2520Treatment%2520of%2520Pancreatic%2520Cancer%253A%2520From%2520Synthesis%2520to%2520Proof-Of-Concept%2520in%2520Vitro%2520Studies%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2016%26volume%3D11%26spage%3D791%26epage%3D822%26doi%3D10.2147%2FIJN.S97476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monteil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moustaoui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picardi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aouidat, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djaker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De La Chapelle, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecouvey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span> <span> </span><span class="NLM_article-title">Polyphosphonate Ligands: From Synthesis to Design of Hybrid PEGylated Nanoparticles Toward Phototherapy Studies</span>. <i>J. Colloid Interface Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>513</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1016/j.jcis.2017.10.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.jcis.2017.10.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=29153714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWmt7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=513&publication_year=2018&pages=205-213&author=M.+Monteilauthor=H.+Moustaouiauthor=G.+Picardiauthor=F.+Aouidatauthor=N.+Djakerauthor=M.+L.+De+La+Chapelleauthor=M.+Lecouveyauthor=J.+Spadavecchia&title=Polyphosphonate+Ligands%3A+From+Synthesis+to+Design+of+Hybrid+PEGylated+Nanoparticles+Toward+Phototherapy+Studies&doi=10.1016%2Fj.jcis.2017.10.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Polyphosphonate ligands: From synthesis to design of hybrid PEGylated nanoparticles toward phototherapy studies</span></div><div class="casAuthors">Monteil, Maelle; Moustaoui, Hanane; Picardi, Gennaro; Aouidat, Fatima; Djaker, Nadia; de La Chapelle, Marc Lamy; Lecouvey, Marc; Spadavecchia, Jolanda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Colloid and Interface Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">513</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">205-213</span>CODEN:
                <span class="NLM_cas:coden">JCISA5</span>;
        ISSN:<span class="NLM_cas:issn">0021-9797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The use of phosphonate ligands to modify the nanoparticle (NPs) surface has attracted a strong interest in the last years for the design of highly functional hybrid materials.  The authors applied a methodol. to synthesize bisphosphonates having functionalized PEG side chains with a specific length in order to design a novel class of hybrid nanomaterials composed by tetraphosphonate-complex-gold COOH-terminated PEG-coated NPs (Bis-PO-PEG-AuNPs).  The synthetic approach consist in three steps: (1) Complexation between new phosphonate ligands (Bis PO) and tetrachloroauric acid (HAuCl4) to form gold clusters; (2) adsorption of COOH-terminated PEG mols. (PEG) onto Bis PO-Au complex; (3) redn. of metal ions in that vicinity, growth of gold particles and colloidal stabilization.  The obtained snow-shape-like hybrid nanoparticles, have been characterized by ultra-violet/visible, Raman spectroscopies, and electron microscopy imaging, involving their optical properties and photothermal activity in pancreatic adenocarcinoma cancer cells (PDAC).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ53zUcesuCrVg90H21EOLACvtfcHk0liEYsQuibaDgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWmt7vN&md5=316bc832c5f534ef65ac56c857b37bd8</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.jcis.2017.10.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcis.2017.10.055%26sid%3Dliteratum%253Aachs%26aulast%3DMonteil%26aufirst%3DM.%26aulast%3DMoustaoui%26aufirst%3DH.%26aulast%3DPicardi%26aufirst%3DG.%26aulast%3DAouidat%26aufirst%3DF.%26aulast%3DDjaker%26aufirst%3DN.%26aulast%3DDe%2BLa%2BChapelle%26aufirst%3DM.%2BL.%26aulast%3DLecouvey%26aufirst%3DM.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26atitle%3DPolyphosphonate%2520Ligands%253A%2520From%2520Synthesis%2520to%2520Design%2520of%2520Hybrid%2520PEGylated%2520Nanoparticles%2520Toward%2520Phototherapy%2520Studies%26jtitle%3DJ.%2520Colloid%2520Interface%2520Sci.%26date%3D2018%26volume%3D513%26spage%3D205%26epage%3D213%26doi%3D10.1016%2Fj.jcis.2017.10.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landoulsi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradier, C.-M.</span></span> <span> </span><span class="NLM_article-title">Tuning the Shape and Size of Hybrid Gold Nanoparticles by Porphyrins using Seed-Mediated Synthesis</span>. <i>Chem. Phys. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>609</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">141</span>, <span class="refDoi"> DOI: 10.1016/j.cplett.2014.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.cplett.2014.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1aktrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=609&publication_year=2014&pages=134-141&author=J.+Spadavecchiaauthor=S.+Casaleauthor=J.+Landoulsiauthor=C.-M.+Pradier&title=Tuning+the+Shape+and+Size+of+Hybrid+Gold+Nanoparticles+by+Porphyrins+using+Seed-Mediated+Synthesis&doi=10.1016%2Fj.cplett.2014.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Tuning the shape and size of hybrid gold nanoparticles by porphyrins using seed-mediated synthesis</span></div><div class="casAuthors">Spadavecchia, Jolanda; Casale, Sandra; Landoulsi, Jessem; Pradier, Claire-Marie</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Physics Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">609</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">134-141</span>CODEN:
                <span class="NLM_cas:coden">CHPLBC</span>;
        ISSN:<span class="NLM_cas:issn">0009-2614</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The authors report the synthesis of hybrid gold nanostructures by seed/growth approach, using porphyrin mols. (protoporphyrin IX) in addn. to cetyltetraammonium bromide (CTAB) as surfactants and/or shape-modulating agents.  The combination of CTAB and porphyrin yields stable complexes that act as co-directing agents and favor the anisotropic growth of gold nanostructures.  The authors' results revealed the ability of porphyrins to tune the shape and size of gold nanostructures, giving a variety of hybrid nano-objects, including bones, thorns, polyhedral and stars.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE_tvNmLmz-rVg90H21EOLACvtfcHk0liEYsQuibaDgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1aktrvI&md5=d81164dd6c783b38ede5e9d1b9359c49</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.cplett.2014.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cplett.2014.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DSpadavecchia%26aufirst%3DJ.%26aulast%3DCasale%26aufirst%3DS.%26aulast%3DLandoulsi%26aufirst%3DJ.%26aulast%3DPradier%26aufirst%3DC.-M.%26atitle%3DTuning%2520the%2520Shape%2520and%2520Size%2520of%2520Hybrid%2520Gold%2520Nanoparticles%2520by%2520Porphyrins%2520using%2520Seed-Mediated%2520Synthesis%26jtitle%3DChem.%2520Phys.%2520Lett.%26date%3D2014%26volume%3D609%26spage%3D134%26epage%3D141%26doi%3D10.1016%2Fj.cplett.2014.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Politi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Stefano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longobardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giardina, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Methivier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradier, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span> <span> </span><span class="NLM_article-title">The Amphiphilic Hydrophobin Vmh2 Plays a Key Role in One Step Synthesis of Hybrid Protein-Gold Nanoparticles</span>. <i>Colloids Surf., B</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.colsurfb.2015.09.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.colsurfb.2015.09.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=26402419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFGhsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2015&pages=214-221&author=J.+Politiauthor=L.+De+Stefanoauthor=S.+Longobardiauthor=P.+Giardinaauthor=I.+Reaauthor=C.+Methivierauthor=C.+M.+Pradierauthor=S.+Casaleauthor=J.+Spadavecchia&title=The+Amphiphilic+Hydrophobin+Vmh2+Plays+a+Key+Role+in+One+Step+Synthesis+of+Hybrid+Protein-Gold+Nanoparticles&doi=10.1016%2Fj.colsurfb.2015.09.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The amphiphilic hydrophobin Vmh2 plays a key role in one step synthesis of hybrid protein-gold nanoparticles</span></div><div class="casAuthors">Politi, Jane; De Stefano, Luca; Longobardi, Sara; Giardina, Paola; Rea, Ilaria; Methivier, Christophe; Pradier, Claire-Marie; Casale, Sandra; Spadavecchia, Jolanda</div><div class="citationInfo"><span class="NLM_cas:title">Colloids and Surfaces, B: Biointerfaces</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">214-221</span>CODEN:
                <span class="NLM_cas:coden">CSBBEQ</span>;
        ISSN:<span class="NLM_cas:issn">0927-7765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We report a simple and original method to synthesize gold nanoparticles in which a fungal protein, the hydrophobin Vmh2 from Pleurotus ostreatus and dicarboxylic acid-terminated polyethylene-glycol (PEG) has been used as addnl. components in a one step process, leading to hybrid protein-metal nanoparticles (NPs).  The nanoparticles have been characterized by ultra-violet/visible, IR and X-ray photoelectron spectroscopies, dynamic light scattering and also by electron microscopy imaging.  The results of these anal. techniques highlight nanometric sized, stable, hybrid complexes of about 12 nm, with outer surface rich in functional chem. groups.  Interaction with protein and antibodies has also been exploited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2D1lPW0mz1LVg90H21EOLACvtfcHk0liqXRIy5b0o4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFGhsLvP&md5=fb7d6d01dbaab289617f116b38cc81e6</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.colsurfb.2015.09.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.colsurfb.2015.09.021%26sid%3Dliteratum%253Aachs%26aulast%3DPoliti%26aufirst%3DJ.%26aulast%3DDe%2BStefano%26aufirst%3DL.%26aulast%3DLongobardi%26aufirst%3DS.%26aulast%3DGiardina%26aufirst%3DP.%26aulast%3DRea%26aufirst%3DI.%26aulast%3DMethivier%26aufirst%3DC.%26aulast%3DPradier%26aufirst%3DC.%2BM.%26aulast%3DCasale%26aufirst%3DS.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26atitle%3DThe%2520Amphiphilic%2520Hydrophobin%2520Vmh2%2520Plays%2520a%2520Key%2520Role%2520in%2520One%2520Step%2520Synthesis%2520of%2520Hybrid%2520Protein-Gold%2520Nanoparticles%26jtitle%3DColloids%2520Surf.%252C%2520B%26date%3D2015%26volume%3D136%26spage%3D214%26epage%3D221%26doi%3D10.1016%2Fj.colsurfb.2015.09.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephen, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kievit, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Press, O. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span> <span> </span><span class="NLM_article-title">Temozolomide Nanoparticles for Targeted Glioblastoma Therapy</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">6674</span>– <span class="NLM_lpage">6682</span>, <span class="refDoi"> DOI: 10.1021/am5092165</span> </span><div class="citationLinks">[<a href="/doi/10.1021/am5092165" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFynsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=6674-6682&author=C.+Fangauthor=K.+Wangauthor=Z.+R.+Stephenauthor=Q.+Muauthor=F.+M.+Kievitauthor=D.+T.+Chiuauthor=O.+W.+Pressauthor=M.+Zhang&title=Temozolomide+Nanoparticles+for+Targeted+Glioblastoma+Therapy&doi=10.1021%2Fam5092165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Temozolomide Nanoparticles for Targeted Glioblastoma Therapy</span></div><div class="casAuthors">Fang, Chen; Wang, Kui; Stephen, Zachary R.; Mu, Qingxin; Kievit, Forrest M.; Chiu, Daniel T.; Press, Oliver W.; Zhang, Miqin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6674-6682</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glioblastoma (GBM) is a deadly and debilitating brain tumor with an abysmal prognosis.  The std. therapy for GBM is surgery followed by radiation and chemotherapy with Temozolomide (TMZ).  Treatment of GBMs remains a challenge, largely because of the fast degrdn. of TMZ, the inability to deliver an ED of TMZ to tumors, and a lack of target specificity that may cause systemic toxicity.  Here, we present a simple method for synthesizing a nanoparticle-based carrier that can protect TMZ from rapid degrdn. in physiol. solns. and can specifically deliver them to GBM cells through the mediation of a tumor-targeting peptide chlorotoxin (CTX).  Our nanoparticle, namely NP-TMZ-CTX, had a hydrodynamic size of <100 nm, exhibited sustained stability in cell culture media for up to 2 wk, and could accommodate stable drug loading.  TMZ bound to nanoparticles showed a much higher stability at physiol. pH, with a half-life 7-fold greater than that of free TMZ.  NP-TMZ-CTX was able to target GBM cells and achieved 2-6-fold higher uptake and a 50-90% redn. of IC50 72 h post-treatment as compared to nontargeted NP-TMZ.  NP-TMZ-CTX showed great promise in its ability to deliver a large therapeutic dose of TMZ to GBM cells and could serve as a template for targeted delivery of other therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp78ba64HyQybVg90H21EOLACvtfcHk0liqXRIy5b0o4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFynsbs%253D&md5=5399bf35d5d14116d1bf24d3e968292c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fam5092165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fam5092165%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DStephen%26aufirst%3DZ.%2BR.%26aulast%3DMu%26aufirst%3DQ.%26aulast%3DKievit%26aufirst%3DF.%2BM.%26aulast%3DChiu%26aufirst%3DD.%2BT.%26aulast%3DPress%26aufirst%3DO.%2BW.%26aulast%3DZhang%26aufirst%3DM.%26atitle%3DTemozolomide%2520Nanoparticles%2520for%2520Targeted%2520Glioblastoma%2520Therapy%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2015%26volume%3D7%26spage%3D6674%26epage%3D6682%26doi%3D10.1021%2Fam5092165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marguerit, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moustaoui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddada, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djaker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Chapelle, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span> <span> </span><span class="NLM_article-title">Taxanes Hybrid Nanovectors: From Design to Physico-Chemical Evaluation of Docetaxel and Paclitaxel Gold (III)-PEGylated Complex Nanocarriers</span>. <i>Part. Part. Syst. Charact.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>35</i></span>, <span class="NLM_elocation-id">1700299</span> <span class="refDoi"> DOI: 10.1002/ppsc.201700299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1002%2Fppsc.201700299" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2018&author=G.+Margueritauthor=H.+Moustaouiauthor=M.+B.+Haddadaauthor=N.+Djakerauthor=M.+L.+de+la+Chapelleauthor=J.+Spadavecchia&title=Taxanes+Hybrid+Nanovectors%3A+From+Design+to+Physico-Chemical+Evaluation+of+Docetaxel+and+Paclitaxel+Gold+%28III%29-PEGylated+Complex+Nanocarriers&doi=10.1002%2Fppsc.201700299"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fppsc.201700299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fppsc.201700299%26sid%3Dliteratum%253Aachs%26aulast%3DMarguerit%26aufirst%3DG.%26aulast%3DMoustaoui%26aufirst%3DH.%26aulast%3DHaddada%26aufirst%3DM.%2BB.%26aulast%3DDjaker%26aufirst%3DN.%26aulast%3Dde%2Bla%2BChapelle%26aufirst%3DM.%2BL.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26atitle%3DTaxanes%2520Hybrid%2520Nanovectors%253A%2520From%2520Design%2520to%2520Physico-Chemical%2520Evaluation%2520of%2520Docetaxel%2520and%2520Paclitaxel%2520Gold%2520%2528III%2529-PEGylated%2520Complex%2520Nanocarriers%26jtitle%3DPart.%2520Part.%2520Syst.%2520Charact.%26date%3D2018%26volume%3D35%26doi%3D10.1002%2Fppsc.201700299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, S.</span></span> <span> </span><span class="NLM_article-title">Quantum Chemical Calculations and Analysis of FTIR, FT–Raman and UV–Vis Spectra of Temozolomide Molecule</span>. <i>J. Mol. Struct.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1099</i></span>,  <span class="NLM_fpage">453</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1016/j.molstruc.2015.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.molstruc.2015.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOmtbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1099&publication_year=2015&pages=453-462&author=S.+A.+Bhatauthor=S.+Ahmad&title=Quantum+Chemical+Calculations+and+Analysis+of+FTIR%2C+FT%E2%80%93Raman+and+UV%E2%80%93Vis+Spectra+of+Temozolomide+Molecule&doi=10.1016%2Fj.molstruc.2015.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Quantum chemical calculations and analysis of FTIR, FT-Raman and UV-Vis spectra of temozolomide molecule</span></div><div class="casAuthors">Bhat, Sheeraz Ahmad; Ahmad, Shabbir</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Structure</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1099</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">453-462</span>CODEN:
                <span class="NLM_cas:coden">JMOSB4</span>;
        ISSN:<span class="NLM_cas:issn">0022-2860</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A combined exptl. and theor. study of the structure, vibrational and electronic spectra of temozolomide mol., which is largely used in the treatment of brain tumors, is presented.  FTIR (4000-400 cm-1) and FT-Raman spectra (4000-50 cm-1) were recorded and analyzed using anharmonic frequency calcns. using VPT2, VSCF and CC-VSCF levels of theory within B3LYP/6-311++G(d,p) framework.  Anharmonic methods give accurate frequencies of fundamental modes, overtones as well as Fermi resonances and account for coupling of different modes.  The anharmonic frequencies calcd. using VPT2 and CC-VSCF methods show better agreement with the exptl. data.  Harmonic frequencies including solvent effects are also computed using IEF-PCM model.  The magnitudes of coupling between pair of modes were calcd. using coupling integral based on 2MR-QFF approxn.  Intermol. interactions are discussed for three possible dimers of temozolomide.  UV-visible spectrum, examd. in ethanol solvent, is compared with the calcd. spectrum at TD-DFT/6-311++G(d,p) level of theory.  The electronic properties, such as excitation energy, frontier MO energies and the assignments of the absorption bands are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqhw40XOjx-bVg90H21EOLACvtfcHk0liqXRIy5b0o4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOmtbzN&md5=234b6195fd2b19c8bb50c554011c0443</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.molstruc.2015.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molstruc.2015.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DS.%2BA.%26aulast%3DAhmad%26aufirst%3DS.%26atitle%3DQuantum%2520Chemical%2520Calculations%2520and%2520Analysis%2520of%2520FTIR%252C%2520FT%25E2%2580%2593Raman%2520and%2520UV%25E2%2580%2593Vis%2520Spectra%2520of%2520Temozolomide%2520Molecule%26jtitle%3DJ.%2520Mol.%2520Struct.%26date%3D2015%26volume%3D1099%26spage%3D453%26epage%3D462%26doi%3D10.1016%2Fj.molstruc.2015.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayne, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Englander, S. W.</span></span> <span> </span><span class="NLM_article-title">Primary Structure Effects on Peptide Group Hydrogen Exchange</span>. <i>Proteins</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1002/prot.340170110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1002%2Fprot.340170110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=8234246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADyaK2cXitl2nu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1993&pages=75-86&author=Y.+Baiauthor=J.+S.+Milneauthor=L.+Mayneauthor=S.+W.+Englander&title=Primary+Structure+Effects+on+Peptide+Group+Hydrogen+Exchange&doi=10.1002%2Fprot.340170110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Primary structure effects on peptide group hydrogen exchange</span></div><div class="casAuthors">Bai, Yawen; Milne, John S.; Mayne, Leland; Englander, S. Walter</div><div class="citationInfo"><span class="NLM_cas:title">Proteins:  Structure, Function, and Genetics</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-86</span>CODEN:
                <span class="NLM_cas:coden">PSFGEY</span>;
        ISSN:<span class="NLM_cas:issn">0887-3585</span>.
    </div><div class="casAbstract">The rate of exchange of peptide group NH hydrogens with the hydrogens of aq. solvent is sensitive to neighboring side chains.  To evaluate the effects of protein side chains, all 20 naturally occurring amino acids were studied using dipeptide models.  Both inductive and steric blocking effects are apparent.  The additivity of nearest-neighbor blocking and inductive effects was tested in oligo and polypeptides and, surprisingly, confirmed.  Ref. rates for alanine-contg. peptides were detd. and effects of temp. considered.  These results provide the information necessary to evaluate measured protein NH to ND exchange rates by comparing them with rates to be expected for the same amino acid sequence is unstructured oligo- and polypeptides.  The application of this approach to protein studies is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp_wWU7X49a7Vg90H21EOLACvtfcHk0ljQARkeM9jkoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitl2nu74%253D&md5=2611cbff4c86fafe936447fb007d1768</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fprot.340170110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.340170110%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DY.%26aulast%3DMilne%26aufirst%3DJ.%2BS.%26aulast%3DMayne%26aufirst%3DL.%26aulast%3DEnglander%26aufirst%3DS.%2BW.%26atitle%3DPrimary%2520Structure%2520Effects%2520on%2520Peptide%2520Group%2520Hydrogen%2520Exchange%26jtitle%3DProteins%26date%3D1993%26volume%3D17%26spage%3D75%26epage%3D86%26doi%3D10.1002%2Fprot.340170110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gharib, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalaf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afroz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feliu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parak, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, I.</span></span> <span> </span><span class="NLM_article-title">Sustainable Synthesis and Improved Colloidal Stability of Pop Corn-Shaped Gold Nanoparticles</span>. <i>ACS Sustainable Chem. Eng.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">9834</span>– <span class="NLM_lpage">9841</span>, <span class="refDoi"> DOI: 10.1021/acssuschemeng.9b00295</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acssuschemeng.9b00295" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVKmt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=9834-9841&author=M.+Gharibauthor=M.+Khalafauthor=S.+Afrozauthor=N.+Feliuauthor=W.+J.+Parakauthor=I.+Chakraborty&title=Sustainable+Synthesis+and+Improved+Colloidal+Stability+of+Pop+Corn-Shaped+Gold+Nanoparticles&doi=10.1021%2Facssuschemeng.9b00295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Sustainable Synthesis and Improved Colloidal Stability of Popcorn-Shaped Gold Nanoparticles</span></div><div class="casAuthors">Gharib, Mustafa; Khalaf, Mahmoud; Afroz, Sharmin; Feliu, Neus; Parak, Wolfgang J.; Chakraborty, Indranath</div><div class="citationInfo"><span class="NLM_cas:title">ACS Sustainable Chemistry & Engineering</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">9834-9841</span>CODEN:
                <span class="NLM_cas:coden">ASCECG</span>;
        ISSN:<span class="NLM_cas:issn">2168-0485</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anisotropic popcorn-shaped gold nanoparticles (GNPCs) were synthesized through a sustainable route.  Proteins were used as ligands, and among several proteins, bovine serum albumin (BSA) produced high-quality GNPCs.  The method is scalable to produce liters of NPs (with almost mM elemental Au concn.) in a single batch.  Structural changes of proteins due to GNPC formation were studied in detail using CD and fluorescence spectroscopy.  The secondary structure of proteins was lost in the growth step, which facilitates the formation of GNPCs.  Among other similar sized gold nanoparticles, <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="97d0d9c7d4d7d5c4d6">[email protected]</a> was found to have high colloidal stability and biocompatibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYPG9G5AU1YLVg90H21EOLACvtfcHk0ljQARkeM9jkoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVKmt7Y%253D&md5=bf90ef100fea009c5e6842551a99aedf</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facssuschemeng.9b00295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facssuschemeng.9b00295%26sid%3Dliteratum%253Aachs%26aulast%3DGharib%26aufirst%3DM.%26aulast%3DKhalaf%26aufirst%3DM.%26aulast%3DAfroz%26aufirst%3DS.%26aulast%3DFeliu%26aufirst%3DN.%26aulast%3DParak%26aufirst%3DW.%2BJ.%26aulast%3DChakraborty%26aufirst%3DI.%26atitle%3DSustainable%2520Synthesis%2520and%2520Improved%2520Colloidal%2520Stability%2520of%2520Pop%2520Corn-Shaped%2520Gold%2520Nanoparticles%26jtitle%3DACS%2520Sustainable%2520Chem.%2520Eng.%26date%3D2019%26volume%3D7%26spage%3D9834%26epage%3D9841%26doi%3D10.1021%2Facssuschemeng.9b00295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klekotko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brach, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olesiak-Banska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samoc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matczyszyn, K.</span></span> <span> </span><span class="NLM_article-title">Pop Corn-Shaped Gold Nanoparticles: Plant Extract-Mediated Synthesis, Characterization and Multiphoton-Excited Luminescence Properties</span>. <i>Mater. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>229</i></span>,  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1016/j.matchemphys.2019.02.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.matchemphys.2019.02.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktFemtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=229&publication_year=2019&pages=56-60&author=M.+Klekotkoauthor=K.+Brachauthor=J.+Olesiak-Banskaauthor=M.+Samocauthor=K.+Matczyszyn&title=Pop+Corn-Shaped+Gold+Nanoparticles%3A+Plant+Extract-Mediated+Synthesis%2C+Characterization+and+Multiphoton-Excited+Luminescence+Properties&doi=10.1016%2Fj.matchemphys.2019.02.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Popcorn-shaped gold nanoparticles: Plant extract-mediated synthesis, characterization and multiphoton-excited luminescence properties</span></div><div class="casAuthors">Klekotko, Magdalena; Brach, Katarzyna; Olesiak-Banska, Joanna; Samoc, Marek; Matczyszyn, Katarzyna</div><div class="citationInfo"><span class="NLM_cas:title">Materials Chemistry and Physics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">229</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">56-60</span>CODEN:
                <span class="NLM_cas:coden">MCHPDR</span>;
        ISSN:<span class="NLM_cas:issn">0254-0584</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We describe the application of Cistus incanus ext. as a source of reducing, structure-directing and stabilizing agents in the fabrication of gold nanoparticles (GNPs) from tetrachloroauric acid soln.  The synthesis resulted in the formation of nanostructures with highly extended surface area, resembling the shape of popcorn.  Various ratios of plant ext. vol. to chloroauric acid vol. were investigated in order to obtain nanoparticles with desired shapes having the narrowest size distribution.  The synthesized nanoparticles were characterized using UV-Vis absorption spectroscopy, transmission electron microscopy (TEM) and at. force microscopy (AFM).  Multiphoton-excited luminescence (MPL) properties of plant ext. synthesized popcorn-shaped gold nanoparticles were examd. in comparison with gold nanostars synthesized chem.  The obtained results suggest that the GNPs synthesized using cistus ext. may be useful imaging agents for multiphoton microscopy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0KNmNhaHoGLVg90H21EOLACvtfcHk0ljQARkeM9jkoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktFemtrs%253D&md5=41e91325a5b2684c18b6d3437c475261</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.matchemphys.2019.02.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.matchemphys.2019.02.066%26sid%3Dliteratum%253Aachs%26aulast%3DKlekotko%26aufirst%3DM.%26aulast%3DBrach%26aufirst%3DK.%26aulast%3DOlesiak-Banska%26aufirst%3DJ.%26aulast%3DSamoc%26aufirst%3DM.%26aulast%3DMatczyszyn%26aufirst%3DK.%26atitle%3DPop%2520Corn-Shaped%2520Gold%2520Nanoparticles%253A%2520Plant%2520Extract-Mediated%2520Synthesis%252C%2520Characterization%2520and%2520Multiphoton-Excited%2520Luminescence%2520Properties%26jtitle%3DMater.%2520Chem.%2520Phys.%26date%3D2019%26volume%3D229%26spage%3D56%26epage%3D60%26doi%3D10.1016%2Fj.matchemphys.2019.02.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moustaoui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djeddi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diallo, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spadavecchia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Chapelle, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djaker, N.</span></span> <span> </span><span class="NLM_article-title">Shape and Size Effect on Photothermal Heat Elevation of Gold Nanoparticles: Absorption Coefficient Experimental Measurement of Spherical and Urchin-Shaped Gold Nanoparticles</span>. <i>J. Phys. Chem. C</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">17548</span>– <span class="NLM_lpage">17554</span>, <span class="refDoi"> DOI: 10.1021/acs.jpcc.9b03122</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jpcc.9b03122" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Oqs7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2019&pages=17548-17554&author=H.+Moustaouiauthor=J.+Saberauthor=I.+Djeddiauthor=Q.+Liuauthor=A.+T.+Dialloauthor=J.+Spadavecchiaauthor=M.+L.+de+la+Chapelleauthor=N.+Djaker&title=Shape+and+Size+Effect+on+Photothermal+Heat+Elevation+of+Gold+Nanoparticles%3A+Absorption+Coefficient+Experimental+Measurement+of+Spherical+and+Urchin-Shaped+Gold+Nanoparticles&doi=10.1021%2Facs.jpcc.9b03122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Shape and Size Effect on Photothermal Heat Elevation of Gold Nanoparticles: Absorption Coefficient Experimental Measurement of Spherical and Urchin-Shaped Gold Nanoparticles</span></div><div class="casAuthors">Moustaoui, Hanane; Saber, Justine; Djeddi, Ines; Liu, Qiqian; Diallo, Amadou Thierno; Spadavecchia, Jolanda; Lamy de la Chapelle, Marc; Djaker, Nadia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry C</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">17548-17554</span>CODEN:
                <span class="NLM_cas:coden">JPCCCK</span>;
        ISSN:<span class="NLM_cas:issn">1932-7447</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Gold nanoparticles (GNP) are very suitable agents for thermal destruction of cancer cells because of their photothermal heating ability.  Photothermal properties of different sizes and shapes of GNPs were studied regarding different parameters such as GNP concn., laser excitation intensity, and exposure time.  By using the heat transfer theory, the temp. elevation in the GNP solns. was converted in temp. elevation at the GNP surface.  This allows the authors to det. the absorption cross section (σabs) of two different sizes of spherical gold nanoparticles (GNS), which were compared with the theor. calcns. based on the Mie theory, and both results were in a good agreement. σabs was detd. also for gold nanourchins with different sizes (50, 80, and 90 nm) with high precision.  Finally, the temp. elevation speeds were exptl. measured for all GNPs, and they are proportional to the GNP surface area as demonstrated in the classical diffusive heat transport theory.  The proposed approaches can be used to monitor the local heat generation around the GNP and pave the way to the optimization of the photothermal properties of GNPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNxIAcBo9-GLVg90H21EOLACvtfcHk0lipnj6RRgwo8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Oqs7vM&md5=d94a6228c86f63d42e567202c7d92006</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jpcc.9b03122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jpcc.9b03122%26sid%3Dliteratum%253Aachs%26aulast%3DMoustaoui%26aufirst%3DH.%26aulast%3DSaber%26aufirst%3DJ.%26aulast%3DDjeddi%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DDiallo%26aufirst%3DA.%2BT.%26aulast%3DSpadavecchia%26aufirst%3DJ.%26aulast%3Dde%2Bla%2BChapelle%26aufirst%3DM.%2BL.%26aulast%3DDjaker%26aufirst%3DN.%26atitle%3DShape%2520and%2520Size%2520Effect%2520on%2520Photothermal%2520Heat%2520Elevation%2520of%2520Gold%2520Nanoparticles%253A%2520Absorption%2520Coefficient%2520Experimental%2520Measurement%2520of%2520Spherical%2520and%2520Urchin-Shaped%2520Gold%2520Nanoparticles%26jtitle%3DJ.%2520Phys.%2520Chem.%2520C%26date%3D2019%26volume%3D123%26spage%3D17548%26epage%3D17554%26doi%3D10.1021%2Facs.jpcc.9b03122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clemente, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gigliotti, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capucchio, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biasibetti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiffer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annovazzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cangemi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muntoni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miglio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dianzani, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battaglia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dianzani, C.</span></span> <span> </span><span class="NLM_article-title">Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>, <span class="NLM_elocation-id">255</span> <span class="refDoi"> DOI: 10.3390/ijms19020255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.3390%2Fijms19020255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wjs7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&author=N.+Clementeauthor=B.+Ferraraauthor=C.+L.+Gigliottiauthor=E.+Boggioauthor=M.+T.+Capucchioauthor=E.+Biasibettiauthor=D.+Schifferauthor=M.+Mellaiauthor=L.+Annovazziauthor=L.+Cangemiauthor=E.+Muntoniauthor=G.+Miglioauthor=U.+Dianzaniauthor=L.+Battagliaauthor=C.+Dianzani&title=Solid+Lipid+Nanoparticles+Carrying+Temozolomide+for+Melanoma+Treatment.+Preliminary+In+Vitro+and+In+Vivo+Studies&doi=10.3390%2Fijms19020255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Solid lipid nanoparticles carrying temozolomide for melanoma treatment. Preliminary in vitro and in vivo studies</span></div><div class="casAuthors">Clemente, Nausicaa; Ferrara, Benedetta; Gigliotti, Casimiro Luca; Boggio, Elena; Capucchio, Maria Teresa; Biasibetti, Elena; Schiffer, Davide; Mellai, Marta; Annovazzi, Laura; Cangemi, Luigi; Muntoni, Elisabetta; Miglio, Gianluca; Dianzani, Umberto; Battaglia, Luigi; Dianzani, Chiara</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">255/1-255/19</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Aim: To develop an innovative delivery system for temozolomide (TMZ) in solid lipid nanoparticles (SLN), which has been preliminarily investigated for the treatment of melanoma.  Materials and Methods: SLN-TMZ was obtained through fatty acid coacervation.  Its pharmacol. effects were assessed and compared with free TMZ in in vitro and in vivo models of melanoma and glioblastoma.  Results: Compared to the std. free TMZ, SLN-TMZ exerted larger effects, when cell proliferation of melanoma cells, and neoangiogeneis were evaluated.  SLN-TMZ also inhibited growth and vascularization of B16-F10 melanoma in C57/BL6 mice, without apparent toxic effects.  Conclusion: SLN could be a promising strategy for the delivery of TMZ, allowing an increased stability of the drug and thereby its employment in the treatment of aggressive malignacies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN14iGHbohd7Vg90H21EOLACvtfcHk0lipnj6RRgwo8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wjs7jN&md5=050fa5e31342682fed8333a7c0edd5ea</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.3390%2Fijms19020255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19020255%26sid%3Dliteratum%253Aachs%26aulast%3DClemente%26aufirst%3DN.%26aulast%3DFerrara%26aufirst%3DB.%26aulast%3DGigliotti%26aufirst%3DC.%2BL.%26aulast%3DBoggio%26aufirst%3DE.%26aulast%3DCapucchio%26aufirst%3DM.%2BT.%26aulast%3DBiasibetti%26aufirst%3DE.%26aulast%3DSchiffer%26aufirst%3DD.%26aulast%3DMellai%26aufirst%3DM.%26aulast%3DAnnovazzi%26aufirst%3DL.%26aulast%3DCangemi%26aufirst%3DL.%26aulast%3DMuntoni%26aufirst%3DE.%26aulast%3DMiglio%26aufirst%3DG.%26aulast%3DDianzani%26aufirst%3DU.%26aulast%3DBattaglia%26aufirst%3DL.%26aulast%3DDianzani%26aufirst%3DC.%26atitle%3DSolid%2520Lipid%2520Nanoparticles%2520Carrying%2520Temozolomide%2520for%2520Melanoma%2520Treatment.%2520Preliminary%2520In%2520Vitro%2520and%2520In%2520Vivo%2520Studies%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26doi%3D10.3390%2Fijms19020255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emrick, T.</span></span> <span> </span><span class="NLM_article-title">Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma</span>. <i>Mol. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">5263</span>– <span class="NLM_lpage">5276</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.8b00766</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.8b00766" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFSiurbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=5263-5276&author=S.+M.+Wardauthor=M.+Skinnerauthor=B.+Sahaauthor=T.+Emrick&title=Polymer-Temozolomide+Conjugates+as+Therapeutics+for+Treating+Glioblastoma&doi=10.1021%2Facs.molpharmaceut.8b00766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma</span></div><div class="casAuthors">Ward, Sarah M.; Skinner, Matthew; Saha, Banishree; Emrick, Todd</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5263-5276</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of polymer-drug conjugates based on 2-methacryloyloxyethyl phosphorylcholine (MPC) was prepd. with the glioblastoma drug Temozolomide (TMZ) as pendent groups.  Random and block copolymers were synthesized by reversible addn.-fragmentation chain-transfer (RAFT) polymn. using a TMZ-contg. methacrylate monomer.  The soln. properties of the polyMPC-TMZ copolymers were investigated by dynamic light scattering and transmission electron microscopy, revealing well-defined nanostructures from the block copolymers.  Conjugation of TMZ to polyMPC enhanced drug stability, with decompn. half-life values ranging from 2- to 19-fold that of free TMZ.  The cytotoxicity of polyMPC-TMZ was evaluated in both chemosensitive (U87MG) and chemoresistant (T98G) glioblastoma cell lines.  Furthermore, the polyMPC-TMZ platform was expanded considerably by the prepn. of redox-sensitive polyMPC-TMZ copolymers utilizing disulfides as the polymer-to-drug linker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5xGQTVBKpHrVg90H21EOLACvtfcHk0lipnj6RRgwo8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFSiurbI&md5=02586adbb935033043345e533fd5a16c</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.8b00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.8b00766%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DS.%2BM.%26aulast%3DSkinner%26aufirst%3DM.%26aulast%3DSaha%26aufirst%3DB.%26aulast%3DEmrick%26aufirst%3DT.%26atitle%3DPolymer-Temozolomide%2520Conjugates%2520as%2520Therapeutics%2520for%2520Treating%2520Glioblastoma%26jtitle%3DMol.%2520Pharm.%26date%3D2018%26volume%3D15%26spage%3D5263%26epage%3D5276%26doi%3D10.1021%2Facs.molpharmaceut.8b00766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ananta, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulmurugan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massoud, T. F.</span></span> <span> </span><span class="NLM_article-title">Temozolomide-loaded PLGA Nanoparticles to Treat Glioblastoma Cells: A Biophysical and Cell Culture Evaluation</span>. <i>Neurol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1080/01616412.2015.1133025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1080%2F01616412.2015.1133025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=26905383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A280%3ADC%252BC28jjslSjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2016&pages=51-59&author=J.+S.+Anantaauthor=R.+Paulmuruganauthor=T.+F.+Massoud&title=Temozolomide-loaded+PLGA+Nanoparticles+to+Treat+Glioblastoma+Cells%3A+A+Biophysical+and+Cell+Culture+Evaluation&doi=10.1080%2F01616412.2015.1133025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Temozolomide-loaded PLGA nanoparticles to treat glioblastoma cells: a biophysical and cell culture evaluation</span></div><div class="casAuthors">Ananta Jeyarama S; Massoud Tarik F; Paulmurugan Ramasamy</div><div class="citationInfo"><span class="NLM_cas:title">Neurological research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  Current chemotherapies for brain glioblastoma do not achieve sufficient drug concentrations within tumors.  Polymeric nanoparticles have useful physicochemical properties that make them promising as nanoparticle platforms for glioblastoma drug delivery.  Poly[lactic-co-glycolic acid] (PLGA) nanoparticles encapsulating temozolomide (TMZ) could improve localized delivery and sustained drug release to glioblastomas.  METHODS:  We investigated three different procedures to encapsulate TMZ within PLGA nanoparticles.  We studied the biophysical features of optimized nanocarriers, including their size, shape, surface properties, and release characteristics of TMZ.  We evaluated the antiproliferative and cytotoxic effects of TMZ-loaded PLGA nanoparticles on U87 MG glioblastoma cells.  RESULTS:  A single emulsion technique using a TMZ saturated aqueous phase produced nanoparticles ≤200 nm in size allowing a maximal drug loading of 4.4% w/w of polymer.  There was a bi-phasic drug release pattern, with 80% of TMZ released within the first 6 h.  Nanoparticles accumulated in the cytoplasm after effective endocytosis.  There was no significant difference in cytotoxic effect of TMZ encapsulated within PLGA nanoparticles and free TMZ.  CONCLUSIONS:  PLGA nanoparticles are not suitable as carriers of TMZ for glioblastoma drug delivery on account of the overall high IC50 values of glioblastoma cells to TMZ and poor loading and encapsulation efficiencies.  Further biotechnological developments aimed at improving the loading of TMZ in PLGA nanoparticles or co-delivery of small molecule sensitizers to improve the response of human glioblastoma cells to TMZ are required for this approach to be considered and optimized for future clinical translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmgm9nomqNH3ELvajU9pjPfW6udTcc2ebDgfGiyrf7urntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jjslSjsA%253D%253D&md5=709de28142b312948221afa6d9694d31</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1080%2F01616412.2015.1133025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F01616412.2015.1133025%26sid%3Dliteratum%253Aachs%26aulast%3DAnanta%26aufirst%3DJ.%2BS.%26aulast%3DPaulmurugan%26aufirst%3DR.%26aulast%3DMassoud%26aufirst%3DT.%2BF.%26atitle%3DTemozolomide-loaded%2520PLGA%2520Nanoparticles%2520to%2520Treat%2520Glioblastoma%2520Cells%253A%2520A%2520Biophysical%2520and%2520Cell%2520Culture%2520Evaluation%26jtitle%3DNeurol.%2520Res.%26date%3D2016%26volume%3D38%26spage%3D51%26epage%3D59%26doi%3D10.1080%2F01616412.2015.1133025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patil, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portilla-Arias, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konda, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wawrowsky, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ljubimova, J. Y.</span></span> <span> </span><span class="NLM_article-title">Temozolomide Delivery to Tumor Cells by A Multifunctional Nano Vehicle Based on Poly(beta-<span class="smallcaps smallerCapital">l</span>-malic acid)</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2317</span>– <span class="NLM_lpage">2329</span>, <span class="refDoi"> DOI: 10.1007/s11095-010-0091-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1007%2Fs11095-010-0091-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=20387095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKntrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2010&pages=2317-2329&author=R.+Patilauthor=J.+Portilla-Ariasauthor=H.+Dingauthor=S.+Inoueauthor=B.+Kondaauthor=J.+Huauthor=K.+A.+Wawrowskyauthor=P.+K.+Shinauthor=K.+L.+Blackauthor=E.+Hollerauthor=J.+Y.+Ljubimova&title=Temozolomide+Delivery+to+Tumor+Cells+by+A+Multifunctional+Nano+Vehicle+Based+on+Poly%28beta-l-malic+acid%29&doi=10.1007%2Fs11095-010-0091-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Temozolomide Delivery to Tumor Cells by a Multifunctional Nano Vehicle Based on Poly(β-L-malic acid)</span></div><div class="casAuthors">Patil, Rameshwar; Portilla-Arias, Jose; Ding, Hui; Inoue, Satoshi; Konda, Bindu; Hu, Jinwei; Wawrowsky, Kolja A.; Shin, Paul K.; Black, Keith L.; Holler, Eggehard; Ljubimova, Julia Y.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2317-2329</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Temozolomide (TMZ) is a pro-drug releasing a DNA alkylating agent that is the most effective drug to treat glial tumors when combined with radiation.  TMZ is toxic, and therapeutic dosages are limited by severe side effects.  Targeted delivery is thus needed to improve efficiency and reduce non-tumor tissue toxicity.  Methods: Multifunctional targetable nanoconjugates of TMZ hydrazide were synthesized using poly(β-L-malic acid) platform, which contained a targeting monoclonal antibody to transferrin receptor (TfR), trileucine (LLL), for pH-dependent endosomal membrane disruption, and PEG for protection.  Results: The water-sol. TMZ nanoconjugates had hydrodynamic diams. in the range of 6.5 to 14.8 nm and ζ potentials in the range of -6.3 to -17.7 mV.  Fifty percent degrdn. in human plasma was obsd. in 40 h at 37°C.  TMZ conjugated with polymer had a half-life of 5-7 h, compared with 1.8 h for free TMZ.  The strongest redn. of human brain and breast cancer cell viability was obtained by versions of TMZ nanoconjugates contg. LLL and anti-TfR antibody.  TMZ-resistant cancer cell lines were sensitive to TMZ nanoconjugate treatment.  Conclusions: TMZ-polymer nanoconjugates entered the tumor cells by receptor-mediated endocytosis, effectively reduced cancer cell viability, and can potentially be used for targeted tumor treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9l3dXRdn_47Vg90H21EOLACvtfcHk0lhkA-Nm3clpmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKntrY%253D&md5=13d07834b0e25f339beab8e7a2b7749a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1007%2Fs11095-010-0091-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-010-0091-0%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DR.%26aulast%3DPortilla-Arias%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DInoue%26aufirst%3DS.%26aulast%3DKonda%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DWawrowsky%26aufirst%3DK.%2BA.%26aulast%3DShin%26aufirst%3DP.%2BK.%26aulast%3DBlack%26aufirst%3DK.%2BL.%26aulast%3DHoller%26aufirst%3DE.%26aulast%3DLjubimova%26aufirst%3DJ.%2BY.%26atitle%3DTemozolomide%2520Delivery%2520to%2520Tumor%2520Cells%2520by%2520A%2520Multifunctional%2520Nano%2520Vehicle%2520Based%2520on%2520Poly%2528beta-l-malic%2520acid%2529%26jtitle%3DPharm.%2520Res.%26date%3D2010%26volume%3D27%26spage%3D2317%26epage%3D2329%26doi%3D10.1007%2Fs11095-010-0091-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rekechenetskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ljubimova, J. Y.</span></span> <span> </span><span class="NLM_article-title">Nanomedicine Therapeutic Approaches to Overcome Cancer Drug Resistance</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1866</span>– <span class="NLM_lpage">1879</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2013.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.addr.2013.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=24120656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs12ktr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=1866-1879&author=J.+L.+Markmanauthor=A.+Rekechenetskiyauthor=E.+Hollerauthor=J.+Y.+Ljubimova&title=Nanomedicine+Therapeutic+Approaches+to+Overcome+Cancer+Drug+Resistance&doi=10.1016%2Fj.addr.2013.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Nanomedicine therapeutic approaches to overcome cancer drug resistance</span></div><div class="casAuthors">Markman, Janet L.; Rekechenetskiy, Arthur; Holler, Eggehard; Ljubimova, Julia Y.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">13-14</span>),
    <span class="NLM_cas:pages">1866-1879</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Nanomedicine is an emerging form of therapy that focuses on alternative drug delivery and improvement of the treatment efficacy while reducing detrimental side effects to normal tissues.  Cancer drug resistance is a complicated process that involves multiple mechanisms.  Here we discuss the major forms of drug resistance and the new possibilities that nanomedicines offer to overcome these treatment obstacles.  Novel nanomedicines that have a high ability for flexible, fast drug design and prodn. based on tumor genetic profiles can be created making drug selection for personal patient treatment much more intensive and effective.  This review aims to demonstrate the advantage of the young medical science field, nanomedicine, for overcoming cancer drug resistance.  With the advanced design and alternative mechanisms of drug delivery known for different nanodrugs including liposomes, polymer conjugates, micelles, dendrimers, carbon-based, and metallic nanoparticles, overcoming various forms of multi-drug resistance looks promising and opens new horizons for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt538MrygldrVg90H21EOLACvtfcHk0lhkA-Nm3clpmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs12ktr%252FM&md5=33cfbc666ad0d655232bf8d8f373a4e0</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2013.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2013.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DMarkman%26aufirst%3DJ.%2BL.%26aulast%3DRekechenetskiy%26aufirst%3DA.%26aulast%3DHoller%26aufirst%3DE.%26aulast%3DLjubimova%26aufirst%3DJ.%2BY.%26atitle%3DNanomedicine%2520Therapeutic%2520Approaches%2520to%2520Overcome%2520Cancer%2520Drug%2520Resistance%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2013%26volume%3D65%26spage%3D1866%26epage%3D1879%26doi%3D10.1016%2Fj.addr.2013.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Jong, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borm, P. J. A.</span></span> <span> </span><span class="NLM_article-title">Drug Delivery and Nanoparticles:Applications and Hazards</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.2147/IJN.S596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.2147%2FIJN.S596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=18686775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Wjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=133-149&author=W.+H.+De%0AJongauthor=P.+J.+A.+Borm&title=Drug+Delivery+and+Nanoparticles%3AApplications+and+Hazards&doi=10.2147%2FIJN.S596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Drug delivery and nanoparticles: applications and hazards</span></div><div class="casAuthors">De Jong, Wim H.; Borm, Paul J. A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-149</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1176-9114</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  The use of nanotechnol. in medicine and more specifically drug delivery is set to spread rapidly.  Currently many substances are under investigation for drug delivery and more specifically for cancer therapy.  Interestingly pharmaceutical sciences are using nanoparticles to reduce toxicity and side effects of drugs and up to recently did not realize that carrier systems themselves may impose risks to the patient.  The kind of hazards that are introduced by using nanoparticles for drug delivery are beyond that posed by conventional hazards imposed by chems. in classical delivery matrixes.  For nanoparticles the knowledge on particle toxicity as obtained in inhalation toxicity shows the way how to investigate the potential hazards of nanoparticles.  The toxicol. of particulate matter differs from toxicol. of substances as the composing chem.(s) may or may not be sol. in biol. matrixes, thus influencing greatly the potential exposure of various internal organs.  This may vary from a rather high local exposure in the lungs and a low or neglectable exposure for other organ systems after inhalation.  However, absorbed species may also influence the potential toxicity of the inhaled particles.  For nanoparticles the situation is different as their size opens the potential for crossing the various biol. barriers within the body.  From a pos. viewpoint, esp. the potential to cross the blood brain barrier may open new ways for drug delivery into the brain.  In addn., the nanosize also allows for access into the cell and various cellular compartments including the nucleus.  A multitude of substances are currently under investigation for the prepn. of nanoparticles for drug delivery, varying from biol. substances like albumin, gelatine and phospholipids for liposomes, and more substances of a chem. nature like various polymers and solid metal contg. nanoparticles.  It is obvious that the potential interaction with tissues and cells, and the potential toxicity, greatly depends on the actual compn. of the nanoparticle formulation.  This paper provides an overview on some of the currently used systems for drug delivery.  Besides the potential beneficial use also attention is drawn to the questions how we should proceed with the safety evaluation of the nanoparticle formulations for drug delivery.  For such testing the lessons learned from particle toxicity as applied in inhalation toxicol. may be of use.  Although for pharmaceutical use the current requirements seem to be adequate to detect most of the adverse effects of nanoparticle formulations, it can not be expected that all aspects of nanoparticle toxicol. will be detected.  So, probably addnl. more specific testing would be needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2ffgu7g8Mh7Vg90H21EOLACvtfcHk0ljD2GvHTBXhXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Wjt7w%253D&md5=db515c60ea3c5b6596b8802e82594c34</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.2147%2FIJN.S596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S596%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BJong%26aufirst%3DW.%2BH.%26aulast%3DBorm%26aufirst%3DP.%2BJ.%2BA.%26atitle%3DDrug%2520Delivery%2520and%2520Nanoparticles%253AApplications%2520and%2520Hazards%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2008%26volume%3D3%26spage%3D133%26epage%3D149%26doi%3D10.2147%2FIJN.S596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span> <span> </span><span class="NLM_article-title">pH-Sensitive Polymeric Micelles Triggered Drug Release for Extracellular and Intracellular Drug Targeting Delivery</span>. <i>Asian J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1016/j.ajps.2013.07.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.ajps.2013.07.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=159-167&author=Y.+Liuauthor=W.+Wangauthor=J.+Yangauthor=C.+Zhouauthor=J.+Sun&title=pH-Sensitive+Polymeric+Micelles+Triggered+Drug+Release+for+Extracellular+and+Intracellular+Drug+Targeting+Delivery&doi=10.1016%2Fj.ajps.2013.07.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.ajps.2013.07.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajps.2013.07.021%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26atitle%3DpH-Sensitive%2520Polymeric%2520Micelles%2520Triggered%2520Drug%2520Release%2520for%2520Extracellular%2520and%2520Intracellular%2520Drug%2520Targeting%2520Delivery%26jtitle%3DAsian%2520J.%2520Pharm.%2520Sci.%26date%3D2013%26volume%3D8%26spage%3D159%26epage%3D167%26doi%3D10.1016%2Fj.ajps.2013.07.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daniele, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zappelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trincavelli, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minutolo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, C.</span></span> <span> </span><span class="NLM_article-title">Lactate Dehydrogenase-A Inhibition Induces Human Glioblastoma Multiforme Stem Cell Differentiation and Death</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">15556</span> <span class="refDoi"> DOI: 10.1038/srep15556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1038%2Fsrep15556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=26494310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslans7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&author=S.+Danieleauthor=C.+Giacomelliauthor=E.+Zappelliauthor=C.+Granchiauthor=M.+L.+Trincavelliauthor=F.+Minutoloauthor=C.+Martini&title=Lactate+Dehydrogenase-A+Inhibition+Induces+Human+Glioblastoma+Multiforme+Stem+Cell+Differentiation+and+Death&doi=10.1038%2Fsrep15556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Lactate dehydrogenase-A inhibition induces human glioblastoma multiforme stem cell differentiation and death</span></div><div class="casAuthors">Daniele, Simona; Giacomelli, Chiara; Zappelli, Elisa; Granchi, Carlotta; Trincavelli, Maria Letizia; Minutolo, Filippo; Martini, Claudia</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15556</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Therapies that target the signal transduction and metabolic pathways of cancer stem cells (CSCs) are innovative strategies to effectively reduce the recurrence and significantly improve the outcome of glioblastoma multiforme (GBM).  CSCs exhibit an increased rate of glycolysis, thus rendering them intrinsically more sensitive to prospective therapeutic strategies based on the inhibition of the glycolytic pathway.  The enzyme lactate dehydrogenase-A (LDH-A), which catalyzes the interconversion of pyruvate and lactate, is up-regulated in human cancers, including GBM.  Although several papers have explored the benefits of targeting cancer metab. in GBM, the effects of direct LDH-A inhibition in glial tumors have not yet been investigated, particularly in the stem cell subpopulation.  Here, two representative LDH-A inhibitors (NHI-1 and NHI-2) were studied in GBM-derived CSCs and compared to differentiated tumor cells.  LDH-A inhibition was particularly effective in CSCs isolated from different GBM cell lines, where the two compds. blocked CSC formation and elicited long-lasting effects by triggering both apoptosis and cellular differentiation.  These data demonstrate that GBM, particularly the stem cell subpopulation, is sensitive to glycolytic inhibition and shed light on the therapeutic potential of LDH-A inhibitors in this tumor type.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeQln7yDbAH7Vg90H21EOLACvtfcHk0ljD2GvHTBXhXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslans7jO&md5=ee9925b21e5f1418f2ce668c5796d6db</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fsrep15556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep15556%26sid%3Dliteratum%253Aachs%26aulast%3DDaniele%26aufirst%3DS.%26aulast%3DGiacomelli%26aufirst%3DC.%26aulast%3DZappelli%26aufirst%3DE.%26aulast%3DGranchi%26aufirst%3DC.%26aulast%3DTrincavelli%26aufirst%3DM.%2BL.%26aulast%3DMinutolo%26aufirst%3DF.%26aulast%3DMartini%26aufirst%3DC.%26atitle%3DLactate%2520Dehydrogenase-A%2520Inhibition%2520Induces%2520Human%2520Glioblastoma%2520Multiforme%2520Stem%2520Cell%2520Differentiation%2520and%2520Death%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26doi%3D10.1038%2Fsrep15556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohd Omar, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soong, R.</span></span> <span> </span><span class="NLM_article-title">The Warburg Effect and Drug Resistance</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">970</span>– <span class="NLM_lpage">979</span>, <span class="refDoi"> DOI: 10.1111/bph.13422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1111%2Fbph.13422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=26750865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC28Xis1GjtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=970-979&author=B.+Bhattacharyaauthor=M.+F.+Mohd+Omarauthor=R.+Soong&title=The+Warburg+Effect+and+Drug+Resistance&doi=10.1111%2Fbph.13422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The Warburg effect and drug resistance</span></div><div class="casAuthors">Bhattacharya, Bhaskar; Mohd. Omar, Mohd Feroz; Soong, Richie</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">970-979</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The Warburg effect describes the increased utilization of glycolysis rather than oxidative phosphorylation by tumor cells for their energy requirements under physiol. oxygen conditions.  This effect has been the basis for much speculation on the survival advantage of tumor cells, tumorigenesis and the microenvironment of tumors.  More recently, studies have begun to reveal how the Warburg effect could influence drug efficacy and how our understanding of tumor energetics could be exploited to improve drug development.  In particular, evidence is emerging demonstrating how better modeling of the tumor metabolic microenvironment could lead to a better prediction of drug efficacy and the identification of new combination strategies.  This review will provide details of the current understanding of the complex interplay between glucose metab. and pharmacol. and discuss opportunities for utilizing the Warburg effect in future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMWLsbfrBry7Vg90H21EOLACvtfcHk0ljD2GvHTBXhXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xis1GjtrY%253D&md5=d7141e6ce6fd1ef30136a1f6ff944c1b</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1111%2Fbph.13422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13422%26sid%3Dliteratum%253Aachs%26aulast%3DBhattacharya%26aufirst%3DB.%26aulast%3DMohd%2BOmar%26aufirst%3DM.%2BF.%26aulast%3DSoong%26aufirst%3DR.%26atitle%3DThe%2520Warburg%2520Effect%2520and%2520Drug%2520Resistance%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D173%26spage%3D970%26epage%3D979%26doi%3D10.1111%2Fbph.13422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.</span></span> <span> </span><span class="NLM_article-title">Targeting Cellular Metabolism to Improve Cancer Therapeutics</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e532</span> <span class="refDoi"> DOI: 10.1038/cddis.2013.60</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1038%2Fcddis.2013.60" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=23470539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVyku7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&author=Y.+Zhaoauthor=E.+B.+Butlerauthor=M.+Tan&title=Targeting+Cellular+Metabolism+to+Improve+Cancer+Therapeutics&doi=10.1038%2Fcddis.2013.60"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cellular metabolism to improve cancer therapeutics</span></div><div class="casAuthors">Zhao, Y.; Butler, E. B.; Tan, M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">March</span>),
    <span class="NLM_cas:pages">e532</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The metabolic properties of cancer cells diverge significantly from those of normal cells.  Energy prodn. in cancer cells is abnormally dependent on aerobic glycolysis.  In addn. to the dependency on glycolysis, cancer cells have other atypical metabolic characteristics such as increased fatty acid synthesis and increased rates of glutamine metab.  Emerging evidence shows that many features characteristic to cancer cells, such as dysregulated Warburg-like glucose metab., fatty acid synthesis and glutaminolysis are linked to therapeutic resistance in cancer treatment.  Therefore, targeting cellular metab. may improve the response to cancer therapeutics and the combination of chemotherapeutic drugs with cellular metab. inhibitors may represent a promising strategy to overcome drug resistance in cancer therapy.  Recently, several review articles have summarized the anticancer targets in the metabolic pathways and metabolic inhibitor-induced cell death pathways, however, the dysregulated metab. in therapeutic resistance, which is a highly clin. relevant area in cancer metab. research, has not been specifically addressed.  From this unique angle, this review article will discuss the relationship between dysregulated cellular metab. and cancer drug resistance and how targeting of metabolic enzymes, such as glucose transporters, hexokinase, pyruvate kinase M2, lactate dehydrogenase A, pyruvate dehydrogenase kinase, fatty acid synthase and glutaminase can enhance the efficacy of common therapeutic agents or overcome resistance to chemotherapy or radiotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMC5ekN6_UhbVg90H21EOLACvtfcHk0ljD2GvHTBXhXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVyku7%252FJ&md5=fef8a7abec0d228e32fd03cfb85f3ca6</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2013.60&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2013.60%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DButler%26aufirst%3DE.%2BB.%26aulast%3DTan%26aufirst%3DM.%26atitle%3DTargeting%2520Cellular%2520Metabolism%2520to%2520Improve%2520Cancer%2520Therapeutics%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2013%26volume%3D4%26doi%3D10.1038%2Fcddis.2013.60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galluzzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kepp, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vander Heiden, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">Metabolic Targets for Cancer Therapy</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">829</span>– <span class="NLM_lpage">846</span>, <span class="refDoi"> DOI: 10.1038/nrd4145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1038%2Fnrd4145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=24113830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2nsr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=829-846&author=L.+Galluzziauthor=O.+Keppauthor=M.+G.+Vander+Heidenauthor=G.+Kroemer&title=Metabolic+Targets+for+Cancer+Therapy&doi=10.1038%2Fnrd4145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic targets for cancer therapy</span></div><div class="casAuthors">Galluzzi, Lorenzo; Kepp, Oliver; Vander Heiden, Matthew G.; Kroemer, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">829-846</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Malignant cells exhibit metabolic changes, when compared to their normal counterparts, owing to both genetic and epigenetic alterations.  Although such a metabolic rewiring has recently been indicated as yet another general hallmark of cancer, accumulating evidence suggests that the metabolic alterations of each neoplasm represent a mol. signature that intimately accompanies and allows for different facets of malignant transformation.  During the past decade, targeting cancer metab. has emerged as a promising strategy for the development of selective antineoplastic agents.  Here, we discuss the intimate relationship between metab. and malignancy, focusing on strategies through which this central aspect of tumor biol. might be turned into cancer's Achilles heel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWJB7NELP1nLVg90H21EOLACvtfcHk0lhPjB3_x0cxFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2nsr3M&md5=1c7d31d1d4494cfabe08604fbd44ffe0</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnrd4145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4145%26sid%3Dliteratum%253Aachs%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DKepp%26aufirst%3DO.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DMetabolic%2520Targets%2520for%2520Cancer%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D829%26epage%3D846%26doi%3D10.1038%2Fnrd4145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shingu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span> <span> </span><span class="NLM_article-title">Metabolic Alterations in Highly Tumorigenic Glioblastoma Cells: Preference for Hypoxia and High Dependency on Glycolysis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">32843</span>– <span class="NLM_lpage">32853</span>, <span class="refDoi"> DOI: 10.1074/jbc.M111.260935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1074%2Fjbc.M111.260935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=21795717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCisr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=32843-32853&author=Y.+Zhouauthor=Y.+Zhouauthor=T.+Shinguauthor=L.+Fengauthor=Z.+Chenauthor=M.+Ogasawaraauthor=M.+J.+Keatingauthor=S.+Kondoauthor=P.+Huang&title=Metabolic+Alterations+in+Highly+Tumorigenic+Glioblastoma+Cells%3A+Preference+for+Hypoxia+and+High+Dependency+on+Glycolysis&doi=10.1074%2Fjbc.M111.260935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis</span></div><div class="casAuthors">Zhou, Yunfei; Zhou, Yan; Shingu, Takashi; Feng, Li; Chen, Zhao; Ogasawara, Marcia; Keating, Michael J.; Kondo, Seiji; Huang, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">32843-32853, S32743/1-S32743/4</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Recent studies suggest that a small subpopulation of malignant cells with stem-like properties is resistant to chemotherapy and may be responsible for the existence of residual cancer after treatment.  We have isolated highly tumorigenic cancer cells with 100-fold increase in tumor initiating capacity from the tumor xenografts of human glioblastoma U87 cells in mice.  These cells exhibit stem-like properties and show unique energy metabolic characteristics including low mitochondrial respiration, increased glycolysis for ATP generation, and preference for hypoxia to maintain their stemness and tumor forming capacity.  Mechanistically, mitochondrial depression in the highly tumorigenic cells occurs mainly at complex II of the electron transport chain with a down-regulation of the succinate dehydrogenase subunit B, leading to deregulation of hypoxia-inducible factors.  Under hypoxia, the stem-like cancer cells are resistant to conventional anticancer agents but are sensitive to glycolytic inhibition.  Furthermore, combination of glycolytic inhibition with std. therapeutic agents is effective in killing the tumor-initiating cells in vitro and inhibits tumor formation in vivo.  Our study suggests that stem-like cancer cells prefer a low oxygen microenvironment and actively utilize the glycolytic pathway for ATP generation.  Inhibition of glycolysis may be an effective strategy to eradicate residual cancer stem cells that are otherwise resistant to chemotherapeutic agents in their hypoxic niches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowyx7mytI3hrVg90H21EOLACvtfcHk0lhPjB3_x0cxFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCisr7M&md5=c50be3969643e7e19aa239154db8c096</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.260935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.260935%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DShingu%26aufirst%3DT.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DOgasawara%26aufirst%3DM.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DKondo%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DP.%26atitle%3DMetabolic%2520Alterations%2520in%2520Highly%2520Tumorigenic%2520Glioblastoma%2520Cells%253A%2520Preference%2520for%2520Hypoxia%2520and%2520High%2520Dependency%2520on%2520Glycolysis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D32843%26epage%3D32853%26doi%3D10.1074%2Fjbc.M111.260935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minafra, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcino, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravatà, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaglio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanomi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amore, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cammarata, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Militello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoca, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baglio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbate, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacoviello, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelista, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilardi, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondì, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forte, G. I.</span></span> <span> </span><span class="NLM_article-title">Radiosensitizing Effect of Curcumin-Loaded Lipid Nanoparticles in Breast Cancer Cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">11134</span> <span class="refDoi"> DOI: 10.1038/s41598-019-47553-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1038%2Fs41598-019-47553-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=31366901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A280%3ADC%252BB3MvjsVejug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&author=L.+Minafraauthor=N.+Porcinoauthor=V.+Bravat%C3%A0author=D.+Gaglioauthor=M.+Bonanomiauthor=E.+Amoreauthor=F.+P.+Cammarataauthor=G.+Russoauthor=C.+Militelloauthor=G.+Savocaauthor=M.+Baglioauthor=B.+Abbateauthor=G.+Iacovielloauthor=G.+Evangelistaauthor=M.+C.+Gilardiauthor=M.+L.+Bond%C3%ACauthor=G.+I.+Forte&title=Radiosensitizing+Effect+of+Curcumin-Loaded+Lipid+Nanoparticles+in+Breast+Cancer+Cells&doi=10.1038%2Fs41598-019-47553-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Radiosensitizing effect of curcumin-loaded lipid nanoparticles in breast cancer cells</span></div><div class="casAuthors">Minafra Luigi; Porcino Nunziatina; Bravata Valentina; Gaglio Daniela; Cammarata Francesco Paolo; Russo Giorgio; Militello Carmelo; Savoca Gaetano; Baglio Margherita; Gilardi Maria Carla; Forte Giusi Irma; Gaglio Daniela; Bonanomi Marcella; Amore Erika; Bondi Maria Luisa; Abbate Boris; Iacoviello Giuseppina; Evangelista Giovanna; Gilardi Maria Carla</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11134</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In breast cancer (BC) care, radiotherapy is considered an efficient treatment, prescribed both for controlling localized tumors or as a therapeutic option in case of inoperable, incompletely resected or recurrent tumors.  However, approximately 90% of BC-related deaths are due to the metastatic tumor progression.  Then, it is strongly desirable to improve tumor radiosensitivity using molecules with synergistic action.  The main aim of this study is to develop curcumin-loaded solid nanoparticles (Cur-SLN) in order to increase curcumin bioavailability and to evaluate their radiosensitizing ability in comparison to free curcumin (free-Cur), by using an in vitro approach on BC cell lines.  In addition, transcriptomic and metabolomic profiles, induced by Cur-SLN treatments, highlighted networks involved in this radiosensitization ability.  The non tumorigenic MCF10A and the tumorigenic MCF7 and MDA-MB-231 BC cell lines were used.  Curcumin-loaded solid nanoparticles were prepared using ethanolic precipitation and the loading capacity was evaluated by UV spectrophotometer analysis.  Cell survival after treatments was evaluated by clonogenic assay.  Dose-response curves were generated testing three concentrations of free-Cur and Cur-SLN in combination with increasing doses of IR (2-9 Gy).  IC50 value and Dose Modifying Factor (DMF) was measured to quantify the sensitivity to curcumin and to combined treatments.  A multi-"omic" approach was used to explain the Cur-SLN radiosensitizer effect by microarray and metobolomic analysis.  We have shown the efficacy of the Cur-SLN formulation as radiosensitizer on three BC cell lines.  The DMFs values, calculated at the isoeffect of SF = 50%, showed that the Luminal A MCF7 resulted sensitive to the combined treatments using increasing concentration of vehicled curcumin Cur-SLN (DMF: 1,78 with 10 μM Cur-SLN.) Instead, triple negative MDA-MB-231 cells were more sensitive to free-Cur, although these cells also receive a radiosensitization effect by combination with Cur-SLN (DMF: 1.38 with 10 μM Cur-SLN).  The Cur-SLN radiosensitizing function, evaluated by transcriptomic and metabolomic approach, revealed anti-oxidant and anti-tumor effects.  Curcumin loaded- SLN can be suggested in future preclinical and clinical studies to test its concomitant use during radiotherapy treatments with the double implications of being a radiosensitizing molecule against cancer cells, with a protective role against IR side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwPdPrOAUoaXy-c-E1v-fmfW6udTcc2eaQwKiZnQUpc7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvjsVejug%253D%253D&md5=28edf721ecffd8220c6cdef2fbba1ae7</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-47553-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-47553-2%26sid%3Dliteratum%253Aachs%26aulast%3DMinafra%26aufirst%3DL.%26aulast%3DPorcino%26aufirst%3DN.%26aulast%3DBravat%25C3%25A0%26aufirst%3DV.%26aulast%3DGaglio%26aufirst%3DD.%26aulast%3DBonanomi%26aufirst%3DM.%26aulast%3DAmore%26aufirst%3DE.%26aulast%3DCammarata%26aufirst%3DF.%2BP.%26aulast%3DRusso%26aufirst%3DG.%26aulast%3DMilitello%26aufirst%3DC.%26aulast%3DSavoca%26aufirst%3DG.%26aulast%3DBaglio%26aufirst%3DM.%26aulast%3DAbbate%26aufirst%3DB.%26aulast%3DIacoviello%26aufirst%3DG.%26aulast%3DEvangelista%26aufirst%3DG.%26aulast%3DGilardi%26aufirst%3DM.%2BC.%26aulast%3DBond%25C3%25AC%26aufirst%3DM.%2BL.%26aulast%3DForte%26aufirst%3DG.%2BI.%26atitle%3DRadiosensitizing%2520Effect%2520of%2520Curcumin-Loaded%2520Lipid%2520Nanoparticles%2520in%2520Breast%2520Cancer%2520Cells%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26doi%3D10.1038%2Fs41598-019-47553-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liberti, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locasale, J. W.</span></span> <span> </span><span class="NLM_article-title">The Warburg Effect: How Does it Benefit Cancer Cells?</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1016/j.tibs.2015.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1016%2Fj.tibs.2015.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=26778478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGrtrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=211-218&author=M.+V.+Libertiauthor=J.+W.+Locasale&title=The+Warburg+Effect%3A+How+Does+it+Benefit+Cancer+Cells%3F&doi=10.1016%2Fj.tibs.2015.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The Warburg Effect: How Does it Benefit Cancer Cells?</span></div><div class="casAuthors">Liberti, Maria V.; Locasale, Jason W.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">211-218</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cancer cells rewire their metab. to promote growth, survival, proliferation, and long-term maintenance.  The common feature of this altered metab. is the increased glucose uptake and fermn. of glucose to lactate.  This phenomenon is obsd. even in the presence of completely functioning mitochondria and, together, is known as the 'Warburg Effect'.  The Warburg Effect has been documented for over 90 years and extensively studied over the past 10 years, with thousands of papers reporting to have established either its causes or its functions.  Despite this intense interest, the function of the Warburg Effect remains unclear.  Here, we analyze several proposed explanations for the function of Warburg Effect, emphasize their rationale, and discuss their controversies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql0YNvFw6E-7Vg90H21EOLACvtfcHk0ljqJz-NK_Ljpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGrtrvJ&md5=c693279b35f3942e9a10f130d375e6e2</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2015.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2015.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DLiberti%26aufirst%3DM.%2BV.%26aulast%3DLocasale%26aufirst%3DJ.%2BW.%26atitle%3DThe%2520Warburg%2520Effect%253A%2520How%2520Does%2520it%2520Benefit%2520Cancer%2520Cells%253F%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2016%26volume%3D41%26spage%3D211%26epage%3D218%26doi%3D10.1016%2Fj.tibs.2015.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gebregiworgis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhinderwala, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purohit, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaika, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, R.</span></span> <span> </span><span class="NLM_article-title">Insights into Gemcitabine Resistance and the Potential for Therapeutic Monitoring</span>. <i>Metabolomics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">156</span> <span class="refDoi"> DOI: 10.1007/s11306-018-1452-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1007%2Fs11306-018-1452-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=30830412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A280%3ADC%252BB3cbgtVOrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&author=T.+Gebregiworgisauthor=F.+Bhinderwalaauthor=V.+Purohitauthor=N.+V.+Chaikaauthor=P.+K.+Singhauthor=R.+Powers&title=Insights+into+Gemcitabine+Resistance+and+the+Potential+for+Therapeutic+Monitoring&doi=10.1007%2Fs11306-018-1452-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into gemcitabine resistance and the potential for therapeutic monitoring</span></div><div class="casAuthors">Gebregiworgis Teklab; Bhinderwala Fatema; Powers Robert; Bhinderwala Fatema; Powers Robert; Purohit Vinee; Chaika Nina V; Singh Pankaj K; Singh Pankaj K; Singh Pankaj K; Singh Pankaj K</div><div class="citationInfo"><span class="NLM_cas:title">Metabolomics : Official journal of the Metabolomic Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">156</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Gemcitabine is an important component of pancreatic cancer clinical management.  Unfortunately, acquired gemcitabine resistance is widespread and there are limitations to predicting and monitoring therapeutic outcomes.  OBJECTIVE:  To investigate the potential of metabolomics to differentiate pancreatic cancer cells that develops resistance or respond to gemcitabine treatment.  RESULTS:  We applied 1D (1)H and 2D (1)H-(13)C HSQC NMR methods to profile the metabolic signature of pancreatic cancer cells. (13)C6-glucose labeling identified 30 key metabolites uniquely altered between wild-type and gemcitabine-resistant cells upon gemcitabine treatment.  Gemcitabine resistance was observed to reprogram glucose metabolism and to enhance the pyrimidine synthesis pathway.  Myo-inositol, taurine, glycerophosphocholine and creatinine phosphate exhibited a "binary switch" in response to gemcitabine treatment and acquired resistance.  CONCLUSION:  Metabolic differences between naive and resistant pancreatic cancer cells and, accordingly, their unique responses to gemcitabine treatment were revealed, which may be useful in the clinical setting for monitoring a patient's therapeutic response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRc-0Sx9gELaEPI-fCgwosgfW6udTcc2eabUWU_BuzlR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbgtVOrsQ%253D%253D&md5=2d3318923654247500ab50a15a003e45</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1007%2Fs11306-018-1452-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11306-018-1452-7%26sid%3Dliteratum%253Aachs%26aulast%3DGebregiworgis%26aufirst%3DT.%26aulast%3DBhinderwala%26aufirst%3DF.%26aulast%3DPurohit%26aufirst%3DV.%26aulast%3DChaika%26aufirst%3DN.%2BV.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DPowers%26aufirst%3DR.%26atitle%3DInsights%2520into%2520Gemcitabine%2520Resistance%2520and%2520the%2520Potential%2520for%2520Therapeutic%2520Monitoring%26jtitle%3DMetabolomics%26date%3D2018%26volume%3D14%26doi%3D10.1007%2Fs11306-018-1452-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mendes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pais, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitorino, C.</span></span> <span> </span><span class="NLM_article-title">Targeted Theranostic Nanoparticles for Brain Tumor Treatment</span>. <i>Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">181</span> <span class="refDoi"> DOI: 10.3390/pharmaceutics10040181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.3390%2Fpharmaceutics10040181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFWktbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&author=M.+Mendesauthor=J.+J.+Sousaauthor=A.+Paisauthor=C.+Vitorino&title=Targeted+Theranostic+Nanoparticles+for+Brain+Tumor+Treatment&doi=10.3390%2Fpharmaceutics10040181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted theranostic nanoparticles for brain tumor treatment</span></div><div class="casAuthors">Mendes, Maria; Sousa, Joao Jose; Pais, Alberto; Vitorino, Carla</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">181</span>CODEN:
                <span class="NLM_cas:coden">PHARK5</span>;
        ISSN:<span class="NLM_cas:issn">1999-4923</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The poor prognosis and rapid recurrence of glioblastoma (GB) are assocd. to its fast-growing process and invasive nature, which make difficult the complete removal of the cancer infiltrated tissues.  Addnl., GB heterogeneity within and between patients demands a patient-focused method of treatment.  Thus, the implementation of nanotechnol. is an attractive approach considering all anat. issues of GB, since it will potentially improve brain drug distribution, due to the interaction between the blood-brain barrier and nanoparticles (NPs).  In recent years, theranostic techniques have also been proposed and regarded as promising.  NPs are advantageous for this application, due to their resp. size, easy surface modification and versatility to integrate multiple functional components in one system.  The design of nanoparticles focused on therapeutic and diagnostic applications has increased exponentially for the treatment of cancer.  This dual approach helps to understand the location of the tumor tissue, the biodistribution of nanoparticles, the progress and efficacy of the treatment, and is highly useful for personalized medicine-based therapeutic interventions.  To improve theranostic approaches, different active strategies can be used to modulate the surface of the nanotheranostic particle, including surface markers, proteins, drugs or genes, and take advantage of the characteristics of the microenvironment using stimuli responsive triggers.  This review focuses on the different strategies to improve the GB treatment, describing some cell surface mark.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqORBKqPBo3G7Vg90H21EOLACvtfcHk0ljqJz-NK_Ljpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFWktbbM&md5=e5021e6677458d42bc7c7370bb4a88be</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.3390%2Fpharmaceutics10040181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fpharmaceutics10040181%26sid%3Dliteratum%253Aachs%26aulast%3DMendes%26aufirst%3DM.%26aulast%3DSousa%26aufirst%3DJ.%2BJ.%26aulast%3DPais%26aufirst%3DA.%26aulast%3DVitorino%26aufirst%3DC.%26atitle%3DTargeted%2520Theranostic%2520Nanoparticles%2520for%2520Brain%2520Tumor%2520Treatment%26jtitle%3DPharmaceutics%26date%3D2018%26volume%3D10%26doi%3D10.3390%2Fpharmaceutics10040181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J. S.</span></span> <span> </span><span class="NLM_article-title">Mechanism of Temozolomide-Induced Antitumour Effects on Glioma Cells</span>. <i>J. Int. Med. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">172</span>, <span class="refDoi"> DOI: 10.1177/0300060513501753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=10.1177%2F0300060513501753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=24326954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Omt77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=164-172&author=W.+Shenauthor=J.+A.+Huauthor=J.+S.+Zheng&title=Mechanism+of+Temozolomide-Induced+Antitumour+Effects+on+Glioma+Cells&doi=10.1177%2F0300060513501753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of temozolomide-induced antitumour effects on glioma cells</span></div><div class="casAuthors">Shen, Wei; Hu, Jun-An; Zheng, Jie-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of International Medical Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">164-172, 9</span>CODEN:
                <span class="NLM_cas:coden">JIMRBV</span>;
        ISSN:<span class="NLM_cas:issn">0300-0605</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Objective: To investigate the mechanisms of action of the tumoricidal effects of temozolomide against the human glioma cell line U251 in vitro, and to provide preclin. proof-of-concept studies of the effects of temozolomide-contg. regimens.  Methods: U251 cells were exposed to 100 μmol/l temozolomide.  Morphol. alterations were monitored by light microscopy.  Cell viability was measured using the 3 -(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.  Cell cycle anal. and the rate of apoptosis were detd. using flow cytometry and the no. of acidic vesicular organelles stained with acridine orange were analyzed by fluorescence microscopy.  The scratch recovery test was used to measure cell migration.  Results: U251 cells that were treated with temozolomide displayed morphol. alterations indicative of a rounder shape and impaired cellular adhesion to the cell culture plate compared with control U251 cells.  Temozolomide reduced cell viability as measured by the MTTassay, caused cell cycle arrest in the gap 2/mitosis phase, inhibited cell migration and promoted autophagy in U251 cells.  Conclusion: Temozolomide induced autophagic, but not apoptotic processes, in U251 cells and thus reduced their viability and migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1pUre_1WsB7Vg90H21EOLACvtfcHk0lg85B7PuZ8Mhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Omt77P&md5=dcbb5da90767a03ff645c2f5c3eb710b</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1177%2F0300060513501753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0300060513501753%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DJ.%2BA.%26aulast%3DZheng%26aufirst%3DJ.%2BS.%26atitle%3DMechanism%2520of%2520Temozolomide-Induced%2520Antitumour%2520Effects%2520on%2520Glioma%2520Cells%26jtitle%3DJ.%2520Int.%2520Med.%2520Res.%26date%3D2014%26volume%3D42%26spage%3D164%26epage%3D172%26doi%3D10.1177%2F0300060513501753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i45"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00694">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_33682"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00694?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00694</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Chemical structure differences of temozolomide (TMZ), gemcitabine, and decitabine (DAC); stability of Hyb-D-PEG-AuNPs in DMEM as a function of time; UV–Vis loading spectra of TMZ and DAC at increasing known concentrations; normalized UV–Vis absorption of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="c387828083938684ee82b68d93b0">[email protected]</a> and <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="f4a0b9aed9b0b5b7b4a4b1b3d9b581baa487">[email protected]</a>; Raman spectra <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="e2b6afb8cfa6a3a1a2b2a7a5cfa397acb291">[email protected]</a> compared to free DAC as a control; drug release percentage of <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="51051c0b7c16141c110114167c10241f0122">[email protected]</a> versus time in PBS at pH = 5.0 or 6.0 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00694/suppl_file/jm0c00694_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00694/suppl_file/jm0c00694_si_001.pdf">jm0c00694_si_001.pdf (387.2 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00694&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-13%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00694%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00694" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799776eae12d18b","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
